<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> Advanced Accelerator Applications S.A. (Form: 20-F, Received: 04/29/2016 16:05:13) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_IDENTITY_OF_PERSONNEL **FIS_OFFER_STATISTICS **FIS_KEY_INFORMATION **FIS_INCOME_STATEMENT **FIS_COMPANY_INFORMATION **FIS_LEGAL_PROCEEDINGS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_OPERATING_AND_FINANCIAL_REVIEW **FIS_RESULTS_OF_OPERATIONS **FIS_INCOME_STATEMENT_2 **FIS_INCOME_STATEMENT_3 **FIS_LIQUIDITY_CAPITAL **FIS_CASH_FLOW **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_FINANCIAL_DATA **FIS_LISTING **FIS_ADDITIONAL_INFORMATION **FIS_MARKET_RISK **FIS_OTHER_SECURITIES **FIS_PART_II **FIS_DEFAULTS **FIS_MATERIAL_MODIFICATIONS **FIS_CONTROL_AND_PROCEDURES **FIS_AUDIT_COMMITTEE_EXPERT **FIS_CODE_OF_ETHICS **FIS_ACCOUNTANT_FEES **FIS_EXEMPTIONS_FROM_LISTING **FIS_PURCHASES_OF_EQUITY **FIS_CHANGE_IN_ACCOUNTANT **FIS_CORPORATE_GOVERNANCE **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_III **FIS_FINANCIAL_STATEMENTS **FIS_FINANCIAL_STATEMENTS_2 **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_INCOME_STATEMENT_4 **FIS_CASH_FLOW_2 **FIS_CASH_FLOW_3 **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_INCOME_STATEMENT_5 FIS_EXHIBIT_1 FIS_EXHIBIT_12 FIS_EXHIBIT_12_2 FIS_EXHIBIT_13 FIS_EXHIBIT_13_2 ">
<META NAME="DETECTED PAGES" CONTENT="253">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="DP65110_20F_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 3.5PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 14PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	UNITED STATES
<BR>
	SECURITIES AND EXCHANGE COMMISSION
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Washington, D.C. 20549
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 20%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 14PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM 20-F
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	(Mark One)
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	REGISTRATION
	STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OR
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9746;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ANNUAL
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
<BR>
<B>
	For the fiscal year ended December 31, 2015
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OR
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	TRANSITION
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
<BR>
<B>
	For the transition period from
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	to
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
	.
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	OR
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9744;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SHELL
	COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
<BR>
<B>
	Date of event requiring this shell company report
<U>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Commission
	file number: &#9;001-36826
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 14PT">
<B>
	Advanced
	Accelerator Applications S.A.
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
	(Exact name of Registrant as specified in its charter)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	France
</B>
<BR>
	(Jurisdiction of incorporation or organization)
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	20 rue
	Diesel
</B>
<BR>
<B>
	01630 Saint Genis Pouilly, France
</B>
<BR>
	(Address of principal executive offices)
<BR>
<B>
	Heinz M&auml;usli
</B>
<BR>
<B>
	+33 (0) 4 50 99 30 70
</B>
<BR>
	(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Copies to:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	John Crowley
</B>
<BR>
<B>
	Davis Polk &amp; Wardwell LLP
</B>
<BR>
<B>
	450 Lexington Avenue
</B>
<BR>
<B>
	New York, NY 10017
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Securities
	registered or to be registered pursuant to Section 12(b) of the Act:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57%">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Title
	of each class
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 43%">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Name
	of each exchange on which registered
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	American
	Depositary Shares, each representing 2 Ordinary Shares, par value &euro;0.10 per share
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	The NASDAQ
	Global Select Market
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	Ordinary
	Shares, par value &euro;0.10 per share
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	The NASDAQ
	Global Select Market*
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.15IN">
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Not listed for trading, only in connection
	with the listing of the American Depositary Shares on The NASDAQ Global Select Market.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Securities
	registered or to be registered pursuant to Section 12(g) of the Act:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	None
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Securities
	for which there is a reporting obligation pursuant to Section 15(d) of the Act:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	None
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Indicate the number of outstanding
	shares of each of the issuer&rsquo;s classes of capital or common stock as of the close of the period covered by the annual report:
	78,556,211&nbsp;Ordinary Shares, par value &euro;0.10 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Indicate by check mark if the
	registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Yes &#9744;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9746;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	If this report is an annual or
	transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of
	the Securities Exchange Act of 1934.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Yes &#9744;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	&#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Note
</B>
	&ndash; Checking
	the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange
	Act of 1934 from their obligations under those Sections.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Indicate by check mark whether
	the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
	the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
	to such filing requirements for the past 90 days.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Yes
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9746;
</FONT>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
	&#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	If applicable, place an X in
	the box to designate the appropriate rule provision relied upon in conducting this transaction:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Exchange
	Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) &#9744;
<BR>
	Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Indicate by check mark whether
	the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;accelerated
	filer and large accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT; TEXT-INDENT: 1.35PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Large Accelerated
	Filer&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9744;
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Accelerated Filer&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9744;
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT; TEXT-INDENT: 1.35PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-accelerated
	Filer&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9746;
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Indicate by check mark which
	basis of accounting the registrant has used to prepare the financial statements included in this filing:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 14%; TEXT-INDENT: 1.35PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;U.S.
	GAAP
</FONT>
</TD>
<TD STYLE="WIDTH: 74%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9746;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;International
	Financial Reporting Standards as issued by the International Accounting Standards Board
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-INDENT: 1.35PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	&#9;Other
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	If &ldquo;Other&rdquo; has been
	checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected
	to follow.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&#9744; Item
	17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9744; Item 18
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	If this is an annual report,
	indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Yes
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9744;
</FONT>
	&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9746;
</FONT>
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 1PT; MARGIN-BOTTOM: 1PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 3.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	Advanced
	Accelerator Applications S.A.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<A NAME="DP65110_20F_HTM_TOC">
</A>
<B>
	TABLE
	OF CONTENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
</B>
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 20%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<U>
	Page
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_PRESENTATIONOFFINANCIAL">
	PRESENTATION OF FINANCIAL AND OTHER INFORMATION
</A>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	iii
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_FORWARD-LOOKINGSTATEMENTS">
	FORWARD-LOOKING STATEMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	iv
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_ENFORCEMENTOFJUDGMENTS">
	ENFORCEMENT OF JUDGMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	vi
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12.25PT">
<A HREF="#DP65110_20F_HTM_PARTI">
	PART I
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM1">
	ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DIRECTORSANDSENIOR">
	A.&nbsp;&nbsp;&nbsp;Directors and Senior Management
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_ADVISERS">
	B.&nbsp;&nbsp;&nbsp;Advisers
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_AUDITORS">
	C.&nbsp;&nbsp;&nbsp;Auditors
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM2">
	ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_OFFERSTATISTICS">
	A.&nbsp;&nbsp;&nbsp;Offer Statistics
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_METHODANDEXPECTEDTIMETABLE">
	B.&nbsp;&nbsp;&nbsp;Method and Expected Timetable
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM3">
	ITEM 3. KEY INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SELECTEDFINANCIALDATA">
	A.&nbsp;&nbsp;&nbsp;Selected Financial Data
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	1
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_CAPITALIZATIONANDINDEBTEDNESS">
	B.&nbsp;&nbsp;&nbsp;Capitalization and Indebtedness
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	6
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_REASONSFORTHEOFFER">
	C.&nbsp;&nbsp;&nbsp;Reasons for the Offer and Use of Proceeds
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	6
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_RISKFACTORS">
	D.&nbsp;&nbsp;&nbsp;Risk Factors
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	6
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM4">
	ITEM 4. INFORMATION ON THE COMPANY
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	42
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_HISTORYANDDEVELOPMENT">
	A.&nbsp;&nbsp;&nbsp;History and Development of the Company
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	42
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_BUSINESSOVERVIEW">
	B.&nbsp;&nbsp;&nbsp;Business Overview
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	43
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_ORGANIZATIONALSTRUCTURE">
	C.&nbsp;&nbsp;&nbsp;Organizational Structure
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	95
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_PROPERTYPLANTANDEQUIPMENT">
	D.&nbsp;&nbsp;&nbsp;Property, Plant and Equipment
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	95
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM4A">
	ITEM 4A. UNRESOLVED STAFF COMMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	97
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM5">
	ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	97
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_OPERATINGRESULTS">
	A.&nbsp;&nbsp;&nbsp;Operating Results
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	97
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_LIQUIDITYANDCAPITALRESOURCES">
	B.&nbsp;&nbsp;&nbsp;Liquidity and Capital Resources
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	109
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_RESEARCHANDDEVELOPMENT">
	C.&nbsp;&nbsp;&nbsp;Research and Development, Patents and Licenses, etc.
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	118
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_TRENDINFORMATION">
	D.&nbsp;&nbsp;&nbsp;Trend Information
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	118
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_OFF-BALANCESHEET">
	E.&nbsp;&nbsp;&nbsp;Off-balance Sheet Arrangements
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	118
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_TABULARDISCLOSURE">
	F.&nbsp;&nbsp;&nbsp;Tabular Disclosure of Contractual Obligations
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	118
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SAFEHARBOR">
	G.&nbsp;&nbsp;&nbsp;Safe Harbor
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	118
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM6">
	ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	119
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DIRECTORSANDSENIOR">
	A.&nbsp;&nbsp;&nbsp;Directors and Senior Management
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	119
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_COMPENSATION">
	B.&nbsp;&nbsp;&nbsp;Compensation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	121
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_BOARDPRACTICES">
	C.&nbsp;&nbsp;&nbsp;Board Practices
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	125
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_EMPLOYEES">
	D.&nbsp;&nbsp;&nbsp;Employees
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	126
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SHAREOWNERSHIP">
	E.&nbsp;&nbsp;&nbsp;Share Ownership
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	126
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM7">
	ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	127
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MAJORSHAREHOLDERS">
	A.&nbsp;&nbsp;&nbsp;Major Shareholders
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	127
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_RELATEDPARTYTRANSACTIONS">
	B.&nbsp;&nbsp;&nbsp;Related Party Transactions
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	128
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_INTERESTSOFEXPERTS">
	C.&nbsp;&nbsp;&nbsp;Interests of Experts and Counsel
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	129
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM8">
	ITEM 8. FINANCIAL INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	130
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTS">
	A.&nbsp;&nbsp;&nbsp;Consolidated Statements and Other Financial Information
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	130
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SIGNIFICANTCHANGES">
	B.&nbsp;&nbsp;&nbsp;Significant Changes
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	130
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM9">
	ITEM 9. THE OFFER AND LISTING
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_OFFERING">
	A.&nbsp;&nbsp;&nbsp;Offering and Listing Details
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_PLANOFDISTRIBUTION">
	B.&nbsp;&nbsp;&nbsp;Plan of Distribution
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MARKETS">
	C.&nbsp;&nbsp;&nbsp;Markets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SELLINGSHAREHOLDERS">
	D.&nbsp;&nbsp;&nbsp;Selling Shareholders
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DILUTION">
	E.&nbsp;&nbsp;&nbsp;Dilution
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_EXPENSESOFTHEISSUE">
	F.&nbsp;&nbsp;&nbsp;Expenses of the Issue
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	131
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	i
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT; WIDTH: 90%">
<A HREF="#DP65110_20F_HTM_ITEM10">
	ITEM 10. ADDITIONAL INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; WIDTH: 10%">
	132
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SHARECAPITAL">
	A.&nbsp;&nbsp;&nbsp;Share Capital
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	132
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_ARTICLESOFASSOCIATION">
	B.&nbsp;&nbsp;&nbsp;Articles of Association
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	132
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MATERIALCONTRACTS">
	C.&nbsp;&nbsp;&nbsp;Material Contracts
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	148
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_EXCHANGECONTROLS">
	D.&nbsp;&nbsp;&nbsp;Exchange Controls
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	148
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_TAXATION">
	E.&nbsp;&nbsp;&nbsp;Taxation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	148
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DIVIDENDS">
	F.&nbsp;&nbsp;&nbsp;Dividends and Paying Agents
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	154
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_STATEMENTBYEXPERTS">
	G.&nbsp;&nbsp;&nbsp;Statement by Experts
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	154
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DOCUMENTSONDISPLAY">
	H.&nbsp;&nbsp;&nbsp;Documents on Display
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	154
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_SUBSIDIARYINFORMATION">
	I.&nbsp;&nbsp;&nbsp;Subsidiary Information
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	154
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM11">
	ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	155
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM12">
	ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	156
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DEBTSECURITIES">
	A.&nbsp;&nbsp;&nbsp;Debt Securities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	156
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_WARRANTSANDRIGHTS">
	B.&nbsp;&nbsp;&nbsp;Warrants and Rights
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	156
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_OTHERSECURITIES">
	C.&nbsp;&nbsp;&nbsp;Other Securities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	156
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_AMERICANDEPOSITARYSHARES">
	D.&nbsp;&nbsp;&nbsp;American Depositary Shares
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	156
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12.25PT">
<A HREF="#DP65110_20F_HTM_PARTII">
	PART II
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM13">
	ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DEFAULTS">
	A.&nbsp;&nbsp;&nbsp;Defaults
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_ARREARSANDDELINQUENCIES">
	B.&nbsp;&nbsp;&nbsp;Arrears and Delinquencies
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM14">
	ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MATERIALMODIFICATIONS">
	A.&nbsp;&nbsp;&nbsp;Material modifications to instruments
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MATERIALMODIFICATIONSTORIGHTS">
	B.&nbsp;&nbsp;&nbsp;Material modifications to rights
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_WITHDRAWALORSUBSTITUTIONOFASSETS">
	C.&nbsp;&nbsp;&nbsp;Withdrawal or substitution of assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_CHANGEINTRUSTEES">
	D.&nbsp;&nbsp;&nbsp;Change in trustees or paying agents
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_USEOFPROCEEDS">
	E.&nbsp;&nbsp;&nbsp;Use of proceeds
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	158
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM15">
	ITEM 15. CONTROLS AND PROCEDURES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	159
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_DISCLOSURECONTROLS">
	A.&nbsp;&nbsp;&nbsp;Disclosure Controls and Procedures
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	159
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_MANAGEMENTSANNUALREPORT">
	B.&nbsp;&nbsp;&nbsp;Management&rsquo;s Annual Report on Internal Control over Financial Reporting
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	159
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_ATTESTATIONREPORT">
	C.&nbsp;&nbsp;&nbsp;Attestation Report of the Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	159
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 0.5IN">
<A HREF="#DP65110_20F_HTM_CHANGESININTERNALCONTROL">
	D.&nbsp;&nbsp;&nbsp;Changes in Internal Control over Financial Reporting
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	159
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16">
	ITEM 16. [RESERVED]
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16A">
	ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16B">
	ITEM 16B. CODE OF ETHICS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16C">
	ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16D">
	ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16E">
	ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16F">
	ITEM 16F. CHANGE IN REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16G">
	ITEM 16G. CORPORATE GOVERNANCE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM16H">
	ITEM 16H. MINE SAFETY DISCLOSURE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	160
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12.25PT">
<A HREF="#DP65110_20F_HTM_PARTIII">
	PART III
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	161
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM17">
	ITEM 17. FINANCIAL STATEMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	161
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM18">
	ITEM 18. FINANCIAL STATEMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	161
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 23.75PT">
<A HREF="#DP65110_20F_HTM_ITEM19">
	ITEM 19. EXHIBITS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	161
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 9PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS">
	Index to Financial Statements
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-1
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	ii
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_PRESENTATIONOFFINANCIAL">
</A>
	PRESENTATION
	OF FINANCIAL AND OTHER INFORMATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Certain Definitions
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Unless otherwise indicated or the context
	otherwise requires, all references in this annual report on Form 20-F to &ldquo;AAA&rdquo; or the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
	&ldquo;our,&rdquo; &ldquo;ours,&rdquo; &ldquo;us&rdquo; or similar terms refer to Advanced Accelerator Applications S.A., together
	with its subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Financial Statements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our consolidated financial statements are
	presented in Euros. All references in this annual report on Form 20-F to &ldquo;$,&rdquo; &ldquo;US$,&rdquo; &ldquo;U.S. dollars,&rdquo;
	&ldquo;dollars&rdquo; and &ldquo;USD&rdquo; mean U.S. dollars and all references to &ldquo;&euro;&rdquo; and &ldquo;Euros&rdquo;
	mean Euros, unless otherwise noted. Throughout this annual report on Form 20-F references to ADSs mean ADSs or ordinary shares
	represented by ADSs, as the case may be.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	All references to &ldquo;U.S. dollars,&rdquo;
	&ldquo;dollars&rdquo; or &ldquo;$&rdquo; in this annual report on Form 20-F are to the U.S. dollar. All references to &ldquo;Euros&rdquo;
	or &ldquo;&euro;&rdquo; are to the Euro. Unless indicated otherwise, all U.S. dollar amounts are converted from Euros at the noon
	buying rate (as certified by the Federal Reserve Bank of New York) of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31, 2015. See
	&ldquo;Item 3. Key Information&mdash;A. Selected Financial Data&mdash;Exchange Rates&rdquo; for information regarding exchange
	rates for the Euro since 2010.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We maintain our books and records in Euros
	and prepare our consolidated financial statements in accordance with IFRS. The financial information contained in this annual report
	on Form 20-F includes our consolidated financial statements at and for the years ended December 31, 2015, 2014 and 2013, which
	have been audited by KPMG S.A., independent accountants as stated in their report appearing herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our fiscal year ends on December 31. References
	in this annual report to a fiscal year, such as &ldquo;fiscal year 2015,&rdquo; relate to our fiscal year ended on December 31
	of that calendar year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Market Share and Other Information
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Market data and certain industry forecast
	data used in this annual report on Form 20-F were obtained from internal reports and studies, where appropriate, the MEDraysintell
	2015 edition &ldquo;Nuclear medicine &ndash; World Market Report &amp; Directory&rdquo; an April 2014 report from Bio-Tech Systems,
	Inc. and data from published studies by doctors and medical professionals relating to clinical data, as well as estimates, market
	research, publicly available information and industry publications. Industry publications generally state that the information
	they include has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information
	is not guaranteed. However, we believe such data is accurate and agree that we are responsible for the accurate extraction of such
	information from such sources and its correct reproduction in this annual report on Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Rounding
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have made rounding adjustments to some
	of the figures included in this annual report on Form 20-F. Accordingly, numerical figures shown as totals in some tables or in
	certain discussions may not be an arithmetic aggregation of the figures that preceded them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	iii
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_FORWARD-LOOKINGSTATEMENTS">
</A>
	FORWARD-LOOKING
	STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This annual report on Form 20-F contains
	statements that constitute forward-looking statements. Many of the forward-looking statements contained in this annual report on
	Form 20-F can be identified by the use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo;
	&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
	&ldquo;potential,&rdquo; &ldquo;predict&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will&rdquo;
	and &ldquo;would,&rdquo; among others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Forward-looking statements appear in a
	number of places in this annual report on Form 20-F and include, but are not limited to, statements regarding our intent, belief
	or current expectations. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information
	currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially
	from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those
	identified under the section entitled &ldquo;Risk Factors&rdquo; in this annual report on Form 20-F. These risks and uncertainties
	include factors relating to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the timing of, and our ability to, obtain and/or maintain regulatory approvals for our products and product candidates and
	the rate and degree of market acceptance of our products and product candidates, including Lutathera;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to successfully commercialize Lutathera and our other product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our estimates regarding the market opportunity for our existing products, Lutathera and our other product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to maintain or expand sales of Gluscan and our other products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the clinical utility of Lutathera, Somakit, Annexin V-128 and our other product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the expected timeline of our completion of the required trial results analysis for Lutathera and other product candidates,
	including clinical trial milestones, analysis of primary endpoints, primary events, anticipated timing for conclusion of data analysis
	and related events;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to identify, develop and advance new targets to create additional product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the expected timeline of our development program for our product candidates, including statements about clinical trials and
	regulatory milestone dates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to maintain orphan drug status or otherwise gain or maintain other protection from competition for Lutathera and
	our other product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the occurrence of side effects or SAEs caused by or associated with diagnostic and therapeutic products and product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our plans to pursue R&amp;D in connection with our product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the extensive costs, time and uncertainty associated with new product development, including new and existing product development
	in cooperation with a development partner or partners;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to procure adequate quantities of necessary supplies and raw materials, including Lu-177 for Lutathera, and other
	chemical compounds that are acceptable for use in our manufacturing processes from our suppliers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to implement our growth strategy, including geographic and manufacturing expansion in the United States;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to sustain and create additional sales, marketing and distribution capabilities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to organize timely and safe delivery of our products and product candidates by third parties;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	iv
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	problems with the manufacture, quality or performance of our products and product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our belief that our relationships with our industry partners will continue without disruption;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our anticipation that we will generate higher sales as we diversify our sales base by increasing the number of products we
	offer;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our intellectual property and licensing position;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the success of operating initiatives, including advertising and promotional efforts and new product and concept development
	by us and our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to successfully identify, integrate and complete acquisitions and achieve expected synergies, and the reliability
	and quality of clinical data and products of our acquisition targets;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to compete and conduct our business in the future;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the impact of geographic and product mix on our total sales and net income (loss);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the availability of qualified personnel and our ability to motivate and retain such personnel;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in commodity costs, labor, distribution and other operating costs, or in our estimates of our D&amp;D costs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in government regulation and tax matters;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	legislation or regulation in countries where we sell our products and product candidates that affect product pricing, reimbursement,
	access or distribution channels;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	fluctuations in inflation and exchange rates in Europe, the United States, and elsewhere;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	general economic, political, demographic and business conditions in Europe, the United States and elsewhere;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	other factors that may affect our financial condition, liquidity and results of operations; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	other risk factors discussed under &ldquo;Item 3. Key Information&mdash;D. Risk Factors.&rdquo;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Forward-looking statements speak only as
	of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments
	or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence
	of unanticipated events except as required by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	v
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_ENFORCEMENTOFJUDGMENTS">
</A>
	ENFORCEMENT
	OF JUDGMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are a corporation organized under the
	laws of France. The majority of our directors are citizens and residents of countries other than the United States, and the majority
	of our assets are located outside of the United States. Accordingly, it may be difficult for investors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to obtain jurisdiction over us or our non-U.S. resident officers and directors in U.S. courts in actions predicated on the
	civil liability provisions of the U.S. federal securities laws;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to enforce judgments obtained in such actions against us or our non-U.S. resident officers and directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws against us
	or our non-U.S. resident officers or directors; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to enforce against us or our directors in non-U.S. courts, including French courts, judgments of U.S. courts predicated upon
	the civil liability provisions of the U.S. federal securities laws.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Nevertheless, a final judgment for the
	payment of money rendered by any federal or state court in the United States based on civil liability, whether or not predicated
	solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers
	that this judgment meets the French legal requirements concerning the recognition and the enforcement of foreign judgments and
	is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a
	foreign judgment without a review of the merits of the underlying claim, only if (1) the foreign court has indirect jurisdiction,
	based on the connection between the dispute and the court seized, (2) the judgment is not contrary to substantive and procedural
	international public policy and (3) the judgment is not tainted with fraud.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, French Law guarantees full
	compensation for the harm suffered but is limited to the actual damages, so that the victim does not suffer or benefit from the
	situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result, the enforcement, by U.S. investors,
	of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities
	law against us or members of our board of directors, officers or certain experts named herein who are residents of France or countries
	other than the United States would be subject to the above conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finally, there may be doubt as to whether
	a French court would impose civil liability on us, the members of our board of directors, our officers or certain experts named
	herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction
	in France against us or such members, officers or experts, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	vi
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_PARTI">
</A>
	PART I
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_IDENTITY_OF_PERSONNEL>
<A NAME="FIS_IDENTITY_OF_PERSONNEL"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM1">
</A>
	ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_DIRECTORSANDSENIORMANAGEMENT">
</A>
	A.&#9;Directors and Senior Management
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ADVISERS">
</A>
	B.&#9;Advisers
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_AUDITORS">
</A>
	C.&#9;Auditors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_IDENTITY_OF_PERSONNEL>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_OFFER_STATISTICS>
<A NAME="FIS_OFFER_STATISTICS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM2">
</A>
	ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_OFFERSTATISTICS">
</A>
	A.&#9;Offer Statistics
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_METHODANDEXPECTEDTIMETABLE">
</A>
	B.&#9;Method and Expected Timetable
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_OFFER_STATISTICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_KEY_INFORMATION>
<A NAME="FIS_KEY_INFORMATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM3">
</A>
	ITEM 3. KEY INFORMATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_SELECTEDFINANCIALDATA">
</A>
	A.&#9;Selected Financial Data
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The income statement and statement of financial
	position data as of and for the years ended December&nbsp;31, 2015, 2014 and 2013 for AAA are derived from our consolidated financial
	statements included elsewhere in this annual report on Form 20-F, which have been audited by KPMG S.A., an independent registered
	public accounting firm, as stated in their report appearing herein. We have derived our income statement and statement of financial
	position data as of and for the year ended December 31, 2012 from our Annual Consolidated Financial Statements not included in
	this annual report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We maintain our books and records in Euros
	and prepare our consolidated financial statements in accordance with IFRS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This financial information should be read
	in conjunction with &ldquo;Presentation of Financial and Other Information,&rdquo; &ldquo;Item 5. Operating and Financial Review
	and Prospects&mdash;A. Operating Results&rdquo; and our consolidated financial statements, including the notes thereto, included
	elsewhere in this annual report on Form 20-F. Our historical results are not necessarily indicative of results for future periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have not included selected consolidated
	financial data as of and for the year ended December 31, 2011 in the table below as we qualify as an emerging growth company under
	the Jumpstart Our Business Startups Act of 2012 or the JOBS Act and we make use of an existing accommodation for specified reduced
	reporting, requiring a minimum of two years of audited financial statements at the time of our initial public offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Year
	Ended December 31,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2013
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2012
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	US$(1)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	(US Dollars and Euros in thousands
	unless otherwise noted except share and per share amounts)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements
	of Income:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Sales&#9;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	96,227
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	88,615
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	69,865
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	53,806
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	40,834
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Raw materials and
	consumables used&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(19,909
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(18,335
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(14,597
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,185
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(6,296
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Personnel costs&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(32,056
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(29,520
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(21,089
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(16,265
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(13,259
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other operating expenses&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(48,265
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(44,447
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(35,015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(24,644
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(22,032
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other operating income&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,944
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,474
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,230
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,977
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,560
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Depreciation
	and amortization&#9;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12,294
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11,321
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11,993
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,545
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(6,495
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Operating
	loss&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,353
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,534
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(8,599
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,856
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(3,688
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Finance income (including
	changes in fair value of contingent consideration)&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,255
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,156
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	396
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	387
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	232
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Finance
	costs (including changes in fair value of contingent consideration)&#9;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(8,526
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(7,852
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(2,196
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,155
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(16,512
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Financial
	loss&#9;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(7,271
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(6,696
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,800
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,768
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(16,280
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Loss
	before income taxes&#9;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(17,624
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(16,230
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,399
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(11,624
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(19,968
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Income taxes&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(837
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(771
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(404
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,157
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(536
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Net
	loss for the period&#9;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(18,461
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(17,001
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(10,803
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12,781
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(20,504
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Attributable to owners
	of the company&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(18,461
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(17,001
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,499
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12,152
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(20,047
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-controlling interests&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(1,304
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(629
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(457
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Loss per share:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Basic (US$ and &euro; per share)&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.28
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.15
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.22
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.38
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Diluted (US$ and &euro; per share)&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.28
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.15
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.22
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(0.38
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Weighted average
	ordinary shares outstanding used in computing per share amounts
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Basic&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,943,481
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,943,481
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	61,884,911
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54,156,067
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	52,364,094
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Diluted&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,943,481
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	66,943,481
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	61,884,911
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	54,156,067
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	52,364,094
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Year
	Ended December 31,
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2013
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	2012
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	US$(1)
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	Euro
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	(US Dollars and Euros in thousands)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Financial Position:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Assets
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-current
	assets&#9;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	122,367
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	112,687
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	107,842
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	103,449
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	104,613
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Goodwill&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	24,609
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	22,662
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	21,377
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	21,252
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	22,285
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other intangible assets&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	34,623
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	31,884
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	32,410
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	30,581
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	33,845
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Property, plant and equipment&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	61,171
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	56,332
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	51,779
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	49,280
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	45,762
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Financial assets&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,642
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,512
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,959
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,336
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,721
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Deferred tax assets&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	322
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	297
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	317
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Current assets&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	175,281
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	161,416
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	78,672
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	40,028
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	38,543
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Inventories&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,458
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,105
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,363
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,278
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,833
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Trade and other receivables&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	25,654
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	23,625
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	20,053
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16,143
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,537
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other current assets&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16,071
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	14,800
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,160
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,997
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,107
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Cash and cash equivalents&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	129,098
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	118,886
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	45,096
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	13,610
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	14,066
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total assets&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	297,648
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	274,103
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	186,514
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	143,477
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	143,156
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Equity and liabilities
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Equity attributable
	to owners of the company&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	184,336
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	169,754
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	85,187
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	55,723
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	58,389
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Share capital&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,531
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	7,856
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6,323
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,415
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,244
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Share premium&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	232,363
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	213,982
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	118,421
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	76,594
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	69,650
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Reserves and retained earnings&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(38,097
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(35,083
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(30,058
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(14,134
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,542
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Net profit/(loss) for
	the period&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(18,461
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(17,001
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,499
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(12,152
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	(20,047
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-controlling interests&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	1,360
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,188
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total equity&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	184,336
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	169,754
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	85,187
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	57,083
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	60,577
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-current liabilities&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	74,211
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	68,341
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	70,709
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	62,052
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	56,447
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-current provisions&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	10,824
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,968
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	8,011
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6,029
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,592
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Non-current financial liabilities&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17,597
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	16,205
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	20,971
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	20,359
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	21,056
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Deferred tax liabilities&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	3,045
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	2,804
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,460
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,187
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,386
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other non-current liabilities&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	42,745
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	39,364
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	37,267
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	31,477
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	24,413
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Current liabilities&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	39,101
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	36,008
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	30,618
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	24,342
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	26,132
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Current provisions&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	128
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	115
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	300
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Current financial liabilities&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	6,038
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,560
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,915
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	5,458
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	4,012
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Trade and other payables&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,973
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	14,710
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12,156
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,218
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,857
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Other current liabilities&#9;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	17,090
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	15,738
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	12,419
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	9,551
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	11,963
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total liabilities&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	113,312
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	104,349
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	101,327
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	86,394
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	82,579
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Total Equity and liabilities&#9;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	297,648
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	274,103
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	186,514
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	143,477
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 10PT">
	143,156
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other Financial Metrics
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%">
	Adjusted EBITDA(2)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,941
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,787
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	3,394
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	7,689
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,807
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjusted EBITDA margin(3)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	To provide investors with additional information regarding our financial results, we have used Adjusted EBITDA, a financial
	measure not calculated in accordance with IFRS, within this annual report on Form 20-F. We define Adjusted EBITDA as net income
	(loss) calculated in accordance with IFRS plus: (i)&nbsp;finance income; (ii) finance costs (including changes in fair value of
	contingent consideration); (iii) income tax; and (iv) depreciation and amortization.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	We have included Adjusted EBITDA
	in this annual report on Form 20-F because it is a key measure used by our management and board of directors to understand and
	evaluate our core operating performance and trends, to prepare and approve our annual budget and to develop short- and long-term
	operational plans. In particular, we believe that the exclusion of the expenses eliminated in calculating Adjusted EBITDA can provide
	a useful measure for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides useful
	information to investors and others in understanding and evaluating our operating results in the same manner as our management
	and board of directors.
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	Although Adjusted EBITDA measures
	are frequently used by investors and securities analysts in their evaluations of companies, Adjusted EBITDA measures each have
	limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of our results
	of operations as reported under IFRS. Some of these limitations are:
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced
	in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital
	expenditure requirements;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	adjusted EBITDA does not reflect finance income or costs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to us; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently,
	which reduces its usefulness as a comparative measure.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	Because of these and other limitations,
	you should consider Adjusted EBITDA alongside IFRS-based financial performance measures, including various cash flow metrics, net
	income (loss) and our other IFRS financial results. Management addresses the inherent limitations associated with using Adjusted
	EBITDA through disclosure of such limitations, presentation of our financial statements in accordance with IFRS and reconciliation
	of Adjusted EBITDA to the most directly comparable IFRS measure, net income (loss). Further, management also reviews IFRS measures
	and measures such as our level of capital expenditures, R&amp;D expenditures, and interest expense, among other items.
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	We define Adjusted EBITDA margin as Adjusted EBITDA divided by sales.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table presents a reconciliation
	of Adjusted EBITDA to net income (loss), the most comparable IFRS measure, for each of the periods identified. It also presents
	the Adjusted EBITDA margin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-SIZE: 1PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net profit/(loss) for the period&#9;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(18,461
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(20,504
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Adjustments:
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Finance income (including changes in fair value of contingent consideration)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,255
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(387
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(232
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Finance costs (including changes in fair value of contingent consideration)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,526
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,852
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,196
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,512
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Income taxes&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	837
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	771
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	536
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Depreciation and amortization&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,294
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,993
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,545
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,495
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Adjusted EBITDA&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,941
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,787
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,394
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,689
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,807
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Sales&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	96,227
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	40,834
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Adjusted EBITDA margin &#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4.9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14.3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6.9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Exchange Rates and Exchange Controls
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table sets forth, for each
	period indicated, the low and high exchange rates for Euros expressed in U.S. dollars, the exchange rate at the end of such period
	and the average of such exchange rates on each day during a monthly period and on the last day of each month during quarterly and
	annual periods, based on the noon buying rate of the Federal Reserve Bank of New York for the Euro. As used in this document, the
	term &ldquo;noon buying rate&rdquo; refers to the rate of exchange for the Euro, expressed in U.S. dollars per Euro, as certified
	by the Federal Reserve Bank of New York.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of April 22, 2016, the noon buying rate
	of the Federal Reserve Bank of New York for the Euro was US$1.1239.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period-End
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Average&nbsp;for
<BR>
	Period
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	US$
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	US$
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	US$
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	US$
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(&euro; per $)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Year Ended December&nbsp;31:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	2011&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1.2973
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1.4002
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1.2926
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1.4875
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2012&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2909
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2062
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2013&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3779
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3302
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3816
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2014&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2188
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3235
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.3927
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0859
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Quarter Ended:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	March 31, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0741
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1246
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	June 30, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1069
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0582
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1428
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	September 30, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0848
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	December 31, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0859
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0954
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0562
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Month Ended:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	October&nbsp;31, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1042
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1228
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0963
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	November 30, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0562
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0727
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0562
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1026
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	December 31, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0859
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0889
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1025
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	January 31, 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0832
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0743
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0964
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	February 29, 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1092
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1362
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	March 31, 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1390
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.0845
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1390
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	April 30, 2016 (through April 22, 2016)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1239
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1349
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1239
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.1430
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CAPITALIZATIONANDINDEBTEDNESS">
</A>
	B.
</TD>
<TD>
	Capitalization and Indebtedness
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_REASONSFORTHEOFFER">
</A>
	C.
</TD>
<TD>
	Reasons for the Offer and Use of Proceeds
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_RISKFACTORS">
</A>
	D.
</TD>
<TD>
	Risk Factors
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	You should carefully consider the risks
	and uncertainties described below and the other information in this annual report on Form 20-F before making an investment decision
	regarding our securities, including our audited consolidated financial statements and the related notes appearing elsewhere in
	this annual report on Form 20-F. Our business, financial condition and results of operations could be materially and adversely
	affected if any of these risks materializes and as a result, the market price of our ADSs could decline and you could lose all
	or part of your investment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	This annual report on Form 20-F also
	contains forward-looking statements that involve risks and uncertainties. See &ldquo;Forward-Looking Statements.&rdquo; Our actual
	results could differ materially and adversely from those expressed or implied in these forward-looking statements as a result of
	certain factors, including the risks facing our Company described below and elsewhere in this annual report on Form 20-F.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Commercialization Risks
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our business currently depends significantly
	on sales of Gluscan, our most important PET product. Any adverse market event with respect to Gluscan could have a material adverse
	effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We rely heavily upon sales of our most
	important PET product, Gluscan. Sales from Gluscan comprised 47.5%, 46.8% and 51.6% of our total sales for the years ended December&nbsp;31,
	2015, 2014 and 2013, respectively. If our sales of Gluscan were to decrease significantly, or such sales were substantially or
	completely displaced in the market, we would lose a significant and material source of our total sales. Gluscan is our branded
	version of a generic FDG product, which is vulnerable to competition and also a decline in sales as a result of being a generic
	product. Gluscan faces competition from FDG products from other manufacturers, principally IBA Molecular, as well as larger healthcare
	companies and local competitors in geographic markets in Europe. See &ldquo;Item 4. Information on the Company&mdash;B. Business
	Overview&mdash;Our Competition.&rdquo; These competitors may create pressures on the price of, and margin that we are able to earn
	on, Gluscan, which could reduce our sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, if Gluscan or similar products
	from our competitors were to become the subject of litigation and/or an adverse governmental action requiring us or such competitors,
	as applicable, to cease sales of Gluscan, such an event could have a material adverse effect on our business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We depend heavily on the success of our
	lead product candidate, Lutathera, which we are developing for the treatment of inoperable progressive midgut NETs. If we are unable
	to commercialize Lutathera, or experience significant delays in doing so, our business will be materially harmed.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have invested a significant portion
	of our efforts and financial resources in the development of Lutathera for the treatment of inoperable progressive midgut NETs.
	Our ability to generate significant product revenues from sales of Lutathera will depend primarily on the successful development
	and commercialization of Lutathera, which depend on a number of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	obtaining regulatory approval for Lutathera from the Food and Drug Administration in the USA (FDA) and/or European
	Medicines Agency (EMA);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the establishment of an expanded international commercial infrastructure capable of supporting product sales, marketing and
	distribution of Lutathera;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	implementing marketing and distribution relationships with third parties in territories where we do not pursue direct commercialization
	of Lutathera;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	successful negotiation of favorable pricing and reimbursement in the countries which require such negotiation and in which
	we obtain regulatory approval for Lutathera;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the timing and scope of the commercial launch of Lutathera;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	acceptance of Lutathera by patients, the medical community and third-party payors; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Lutathera&rsquo;s ability to effectively compete with other therapies.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we do not achieve one or more of these
	factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize Lutathera,
	which would materially harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our business currently depends on sales
	of our products in the European Union, our most important geographic market. An adverse market event or deteriorating economic
	conditions in Europe or the European Union may have a significant impact on our overall sales and could have a material adverse
	effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We rely heavily upon sales in the European
	Union, which comprised 91.6%, 90.9% and 87.8% of our total sales for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.
	If our European Union sales were significantly impacted by either material changes to reimbursement regulations or private payor
	reimbursement in the European jurisdictions in which we operate, other regulatory developments, competition or other factors, this
	impact could have a material adverse effect on our business, financial condition and results of operations. Since our current PET
	and SPECT products are not proprietary, we are vulnerable to increased competition in the European PET and SPECT markets, and such
	competition may result in decreased sales or lower margins for our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	If we are unable to successfully introduce
	new products for clinical indications or fail to keep pace with advances in MNM or medical research or technology, our business,
	financial condition and results of operations could be adversely affected.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We operate in highly innovative businesses
	within the MNM field. We currently rely on sales of Gluscan for a significant portion of our total sales. However, our continued
	growth depends in large part on our ability to develop and obtain approval of new products and new indications for our products
	and product candidates. In particular, obtaining EMA market authorization and FDA approval for Lutathera is critical to our business
	plan. In addition, FDG products such as Gluscan are likely to face increasing competition from Gallium-labeled products in PET
	diagnostics that may offer advantages over existing FDG radiopharmaceuticals labeled with F-18. It will accordingly be important
	for us to successfully develop and seek approvals for Lutathera and our other product candidates, such as our Somakit products,
	which are PET product candidates for the production of Gallium-labeled diagnostic compounds. Failure to obtain regulatory approval
	of Lutathera or of any of our other product candidates or approval for additional indications, or failure to advance new formulations
	of PET, SPECT or other products and product candidates to meet new or changing demand could have a material adverse effect on our
	business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The development of innovative products
	and medical technologies that improve efficacy, safety, patients&rsquo; and clinicians&rsquo; ease of use and cost-effectiveness
	involves significant technical and business risks. The success of new product offerings will depend on many factors, including
	our ability to properly anticipate and satisfy customer needs, adapt to new technologies, obtain regulatory approvals on a timely
	basis, demonstrate satisfactory clinical results, manufacture products in an economic and timely manner, and differentiate our
	products from those of our competitors. If we cannot successfully introduce new products or product candidates, adapt to changing
	technologies or anticipate changes in our current and potential customers&rsquo; requirements, our products may become obsolete,
	which could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We face substantial competition in the
	commercialization of MNM products, which may result in others developing or commercializing products before or more successfully
	than we do.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There are numerous proprietary molecules
	for MNM products currently in development by other companies. We may face future competition with respect to our products, any
	products that we acquire, our current product candidates and any products or product candidates we may seek to develop or commercialize
	in the future from other pharmaceutical companies and governments, universities and other non-profit research organizations, which
	are increasingly aware of the commercial value of their research. Our competitors may develop products that are safer, more effective,
	more convenient or less costly than products that we may develop or market. Our competitors may devote greater resources to market
	or sell their products, adapt more quickly to new technologies and scientific advances, initiate or withstand substantial
	price competition more successfully than we can, or more effectively negotiate third-party licensing and collaborative arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We consider IBA Molecular, in the area
	of PET and SPECT diagnostics to be our main competitor in the European MNM market due to its significant know-how, manufacturing
	capacity and geographic presence. We also face competition in the field of PET diagnostic products from smaller suppliers who operate
	within specific geographic areas. While these smaller competitors may have more limited manufacturing infrastructure than we do,
	they may have greater experience than we do or a more established reputation than we do in such areas. We face competition in the
	field of SPECT diagnostic products from a greater number of SPECT manufacturers than we do in PET, given the more established and
	widespread use of SPECT imaging. Our competitors in SPECT include both large healthcare companies and smaller diagnostic imaging
	companies. In the field of MNT, we face competition from local companies and university hospitals that operate within specific
	geographic areas. While these competitors may have more limited manufacturing infrastructure than we do, they may have greater
	experience or a more established reputation in these geographic areas. Each of the above-mentioned competitors, in particular the
	larger healthcare companies, may have greater resources to devote to manufacturing, marketing or selling products than we do. Any
	reduction in demand for our products as a result of one or more competing products could lead to reduced sales, reduced margins,
	reduced levels of profitability or loss of market share for our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We commercialize almost all of our products
	without patent protection. Gluscan and our licensed products IASOflu, IASOdopa and IASOcholine are currently not covered by any
	issued patents. Moreover, the patents covering claims related to Lutathera expired in 2015 in the United States and are expected
	to expire in 2016 in Europe and various other jurisdictions. Without patent protection for these products and product candidates,
	we currently face competition from generic drug manufacturers and we may be unable to prevent additional generic drug manufacturers
	from developing, manufacturing or commercializing competing products. In addition, competition for our products may be affected
	by follow-on products in Europe and the United States and other jurisdictions. The existence of generic products may also result
	in decreased pricing for our products, which we have experienced in certain geographic areas in relation to Gluscan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Any or all of these competitive pressures
	could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We rely on maintaining orphan drug designation
	and obtaining market exclusivity for Lutathera and potentially for our Somakit products, Lutathera&rsquo;s companion PET diagnostic
	product candidates. Orphan drug designation may not ensure that we will obtain market exclusivity upon approval in a particular
	market. In addition, we may not obtain orphan drug market exclusivity if another drug containing the same active moiety is approved
	first, or we may lose market exclusivity if a later product demonstrates clinical superiority to Lutathera or the Somakit products.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera and the Somakit products, our
	leading therapeutic candidate and its companion diagnostic candidates, respectively, have been granted orphan drug designation
	by the FDA and the EMA. If Lutathera, the Somakit products or any of our other product candidates that receive orphan drug designation
	were to lose orphan drug designation or were to fail to obtain marketing exclusivity upon approval, our business, financial condition
	and results of operations could be materially adversely affected. Obtaining regulatory market exclusivity for Lutathera is particularly
	important due to the expiration of patents covering claims related to Lutathera in November 2015 for the United States and expected
	expiration in June 2016 for Europe and various other jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the United States, a product candidate
	with orphan drug designation qualifies for market exclusivity for up to seven years after FDA approval if it is approved for the
	designated use and no other product containing the same active moiety has existing market exclusivity. Thus, if Lutathera or the
	Somakit products are approved in the United States for the indication for which the applicable product has obtained orphan drug
	designation before any other product containing the same active moiety is approved and obtains market exclusivity, the FDA may
	not approve another product containing the same active moiety for the same indication during the market exclusivity period unless
	the second product is demonstrated to be clinically superior to Lutathera or the Somakit products. A product can demonstrate clinical
	superiority over another product if it is safer, more effective or makes a major contribution to patient care. In addition, a chemically
	dissimilar product would not be affected by Lutathera&rsquo;s or the Somakit products&rsquo; U.S. market exclusivity and could
	obtain approval and, if designated as an orphan drug, market exclusivity in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the European Union, EMA regulations
	provide marketing exclusivity for up to ten years for orphan drugs, subject to certain exceptions, including the demonstration
	of&thinsp; &ldquo;clinically relevant superiority&rdquo; by a similar medicinal product. EMA orphan marketing exclusivity applies
	to drug products for the same indication that use the same method of action but which can be chemically dissimilar. As a result,
	if Lutathera or the Somakit products obtain marketing authorization from the EMA before competing therapeutic candidates for the
	same indication that use the same method of action, the EMA may not grant marketing authorization to the competing therapeutic
	candidates for a period of up to ten years. However, if a competing therapeutic candidate is approved by the EMA before Lutathera
	or the Somakit products, that drug could end Lutathera&rsquo;s or the Somakit products&rsquo; market exclusivity in the European
	Union by demonstrating a clinically relevant advantage. We are pursuing registration and regulatory exclusivity for both Somakit-TATE
	and Somakit-TOC in the European Union and the United States. The loss of market exclusivity for Lutathera, the Somakit products
	or our other product candidates that we intend to commercialize in the European Union or the United States could have a material
	adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	The commercial success of our MNM products
	and product candidates will depend upon public perception of radiopharmaceuticals and the degree of their market acceptance by
	physicians, patients, healthcare payers and others in the medical community.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Adverse events in clinical trials of our
	product candidates or in clinical trials of others developing similar products and the resulting negative publicity, as well as
	any other adverse events in the field of MNM that may occur in the future, could result in a decrease in demand for our products
	or any product candidates that we may develop. If public perception is influenced by claims that MNM or specific therapies within
	MNM are unsafe, our products or product candidates may not be accepted by the general public or the medical community.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In particular, the continued or future
	commercial success of Gluscan, Lutathera and our other products and product candidates, as applicable, depends and will depend
	upon, among other things, these products and product candidates gaining and maintaining acceptance by physicians, patients, third-party
	payers and other members of the medical community as efficacious and cost-effective alternatives to competing products and treatments.
	If any of our products or product candidates does not achieve and maintain an adequate level of acceptance, we may not generate
	material sales of that product or product candidate or be able to successfully commercialize it. The degree of market acceptance
	of our products and product candidates will depend on a number of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our ability to provide acceptable evidence of safety and efficacy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the prevalence and severity of any side effects;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	availability, relative cost and relative efficacy of alternative and competing treatments;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the ability to offer our products for sale at competitive prices;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the relative convenience and ease of administration of our products and product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the willingness of the target patient population to try new products and product candidates and of physicians to prescribe
	these products and product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the strength of marketing and distribution support;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	publicity concerning our products and product candidates or competing products and treatments; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the sufficiency of coverage or reimbursement by third parties.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If our products or product candidates do
	not become widely accepted by potential customers, physicians, patients, third-party payers and other members of the medical community,
	such a lack of acceptance could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Reimbursement policies or a lack of reimbursement,
	changes in healthcare systems and third-party payer policies could result in a decline in our potential sales of our products.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the European Union, the United States
	and other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding such jurisdictions&rsquo;
	respective healthcare systems. These changes, particularly in the European Union and/or the United States, could prevent or delay
	EMA marketing authorization and/or FDA approval of our product candidates, restrict or regulate post-approval activities and affect
	our ability to profitably sell any products for which we obtain EMA marketing authorization and/or FDA approval, as applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the United States, there have been,
	and we expect that there will continue to be, a number of federal and state proposals to implement additional governmental controls
	over the healthcare system, including but not limited to efforts to control drug prices and overall healthcare costs. While we
	currently have a limited presence in the United States, recent U.S. legislation, rules and regulations instituted significant changes
	to the U.S. healthcare system that could have a material adverse effect on our business, financial condition and results of operations
	now or in the future as we consider expanding our U.S. business. We cannot predict what effects, if any, this legislation might
	have on us and our products, nor can we predict whether additional legislative or regulatory proposals may be adopted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, in the European Union, the
	United States and elsewhere, sales of therapeutic and other pharmaceutical products depend, in part, on the availability of reimbursement
	from third-party payers, such as governments and private insurance plans. Third-party payers are increasingly challenging the prices
	charged for medical products and services and they may limit access to radiopharmaceutical products through the use of prior authorizations.
	Any reimbursement granted may not be maintained, or limits on reimbursement available from third parties may reduce the demand
	for, or negatively affect the price and profitability, of those products. Third-party payers may pursue aggressive cost cutting
	initiatives such as comparing the effectiveness, benefits and costs of similar treatments, which could result in lower reimbursement.
	Policies that decrease reimbursement, or the loss of availability or lack of reimbursement from third-party payers, could harm
	our ability to successfully commercialize our products and product candidates, including Lutathera, as well as the demand for our
	products and product candidates, including Lutathera, which could have a material adverse effect on our business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In certain markets, reimbursement is dependent
	on budgets set by the government, which may place limits on reimbursements. For example, in many European countries, government
	healthcare entities that purchase PET products from us are constrained by budgetary limits, regardless of the demand for our PET
	products, such as Gluscan. In these and in other markets, if third-party payers are not willing or able to supply reimbursement
	to make up the difference between budget limits and demand for our products or product candidates, or if economic or other conditions
	cause governments or other reimbursing parties to revise their budgets for radiopharmaceutical products downward, our sales in
	that market could suffer significantly, which could have a material adverse effect on our business, financial condition and results
	of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	The implementation of the 2010 healthcare
	reform law in the United States may adversely affect our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our industry is highly regulated and changes
	in law may adversely impact our business. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care
	and Education Reconciliation Act of 2010 (collectively, the &ldquo;healthcare reform law&rdquo;), is a sweeping measure intended
	to expand healthcare coverage within the United States, primarily through the imposition of health insurance mandates on employers
	and individuals and expansion of the Medicaid program. While we do not currently conduct significant operations in the United States,
	several provisions of the new law, which have varying effective dates, may affect us as we seek to expand our presence in the United
	States and will likely increase certain of our costs. For example, an increase in the Medicaid rebate rate from 15.1% to 23.1%
	became effective as of January&nbsp;1, 2010, and the volume of rebated drugs was expanded to include beneficiaries in Medicaid
	managed care organizations, effective as of March&nbsp;23, 2010.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The reforms imposed by the new law will
	significantly impact the pharmaceutical industry; however, the full effects of the healthcare reform law cannot be known until
	these provisions are implemented and the Centers for Medicare and Medicaid Services and other federal and state agencies issue
	applicable regulations or guidance. Moreover, in the coming years, additional changes could be made to governmental healthcare
	programs that could impact the success of our products. We will continue to evaluate the healthcare reform law, as amended, and
	implementation of regulations or guidance related to various provisions of the healthcare reform law by federal agencies, as well as trends and changes that
	may be encouraged by the legislation and that may potentially impact our business over time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Manufacturing Risks
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our MNM products and product candidates
	are complex to manufacture and ship, which could cause us to experience delays in product manufacturing or development and resulting
	delays in sales.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Manufacturing MNM products and product
	candidates, especially in large quantities, is complex. The products and product candidates must be made consistently and in compliance
	with a clearly defined manufacturing process. In Europe, our production sites where we source manufacturing for European Union
	sales must comply with cGMP. The products and product candidates must also be delivered in accordance with local and international
	regulations applicable to the delivery of radioactive materials, in the case of our radiolabeled products and product candidates,
	and pharmaceuticals. Problems may arise during manufacturing for a variety of reasons, including problems with raw materials, equipment
	malfunctions and failures to follow specific protocols and procedures. In addition, slight deviations anywhere in the manufacturing
	process, including obtaining materials, filling, labeling, packaging, storage, shipping and quality control testing, may result
	in lot failures or manufacturing shut-down, delays in the release of product batches, product recalls, spoilage or regulatory action.
	Such deviations may require us to revise manufacturing processes or change suppliers or delivery mechanisms and may take significant
	time and resources to resolve. If unresolved, such deviations may affect manufacturing output and could cause us to fail to satisfy
	customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical
	trials, result in litigation or regulatory action against us or cause the EMA, the FDA or other regulatory bodies to cause us to
	cease releasing products until the deviations are explained and corrected. The design of the manufacturing and storage processes
	for our radioactive compounds may not completely eliminate the risk of exposure of our employees and others to radioactive materials
	and may need to be reworked in order to keep in compliance with national radio-protection laws in the jurisdictions in which we
	operate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Additionally, as our equipment ages, it
	will need to be replaced. Replacement of equipment has the potential to introduce variations in the manufacturing process that
	may result in lot failures or manufacturing shut-down, delay in the release of product batches, product recalls, spoilage or regulatory
	action. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and
	increase costs. In addition, the aging and eventual retirement of our cyclotrons will involve substantial costs associated with
	decontaminating and decommissioning the sites where they are used and regulatory risks in the event that the decontamination and
	decommissioning process is not done correctly or according to applicable regulatory requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Any of these risks could result in considerable
	financial or other harm that could be costly to us, damage our reputation and have a material adverse effect on our business, financial
	condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our MNM products and product candidates
	have limited shelf lives that make them susceptible to damage and loss, which could adversely affect our business, financial condition
	and operating results.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our PET products, including Gluscan, and
	our PET product candidates have a shelf life of approximately ten hours, and our therapy product candidates, such as Lutathera,
	have a shelf life of approximately three days. These products and product candidates accordingly require production facilities
	located in close proximity to their final customers and reliable transportation to avoid spoilage, damage and/or loss. The failure
	of third parties with whom we contract to deliver these products and product candidates within the scope of their limited shelf
	lives could result in the loss of a given shipment and the sales associated with it. In addition, for those products with radioactive
	elements, such as our F-18 PET products, any delay in shipment results in a loss of the radioactive dose as a result of radioactive
	decay, with the risk that the entire useful dose may be lost. Moreover, since each order is made individually or in small batches
	and delivered with dedicated transportation in compliance with local and international regulations applicable to the delivery of
	radioactive materials, we do not have readily available replacements to substitute for a lost delivery if circumstances beyond
	our control, such as delays or problems caused by weather changes or a failure in the transportation system operated by third parties
	that we hire, prevent the timely delivery of a batch, or if our facilities fail to distribute the ordered batch in a timely fashion
	in accordance with specifications. If such losses or failures were to occur, we could suffer harm to our reputation and a loss
	of customers and sales, which could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, if one or more of our facilities
	were to experience downtime, the limited shelf life of our products and product candidates, particularly those with radioactive
	components or elements, would make it difficult for us to replace such facilities&rsquo; production since the replacement product
	or product candidate may need to be delivered from a facility that is geographically distant from ordering customers. The logistical
	complexity of fulfilling such customer orders through an alternate, more geographically removed facility may make it impracticable
	or unduly costly to fulfill the orders of customers in a region where our facility or facilities are experiencing downtime. If
	we are unable to fulfill orders from our customers in such regions, we may lose such customers, which could have a material adverse
	effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We are expanding our production facilities,
	including through acquisitions, with a near-term focus on manufacturing and distribution of Lutathera in the United States and
	modifications to one or more production sites in Europe. Delay or failure to develop production capacity or delays or failures
	in obtaining regulatory approvals for any new production facilities could limit our ability to expand our sales.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In anticipation of potential FDA approval
	for Lutathera, we have purchased a Millburn, NJ facility that we are currently retrofitting with completion scheduled in the second
	quarter of 2016. We intend to start manufacturing operations at the Millburn facility in the first half of 2017 after receiving
	all necessary authorizations and licenses. This site, and any additional U.S. production site that we develop, as well as the execution
	of our plan to expand into the U.S. market for our products, and in particular Lutathera, will be important to our growth strategy.
	We also modified our F-18 production site in Zaragoza, Spain in order to enable it to produce Lutathera. The process for qualifying
	and validating one or more U.S. facilities and additional European facilities, obtaining associated regulatory approvals and complying
	with cGMP regulations or similar regulatory requirements for sales of our products or product candidates may be significant and
	may result in unanticipated delays or costs, which could limit our ability to expand sales and have a material adverse effect on
	our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Facilities that we own or that we may
	acquire are subject to risk of damage or interference and resulting delays, which could adversely affect our business and growth
	plans.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have experienced in the past, and may
	experience in the future, damage of or interference with the ongoing operations of production facilities that we own or may acquire.
	For example, a few days before we signed the acquisition agreement for a PET production site in Europe, the site experienced significant
	flooding that delayed the consummation of the transaction for several months while the problem was addressed. The resulting delay
	in our entrance into that geographic market limited our ability to compete in that market for product distribution in the market
	as other companies gained authorization to produce PET products and began selling it at low prices, which created more difficult
	competitive conditions for us. We also suffered fire damage to our Marseille, France facility that impeded the site&rsquo;s completion
	and accordingly delayed our ability to compete in the Marseille geographic market. In the event that our facilities or the third-party
	transportation infrastructure upon which we rely is damaged or disrupted as a result of natural conditions or other events or actions,
	our ability to manufacture and ensure the delivery of products to customers could be limited, which could have a material adverse
	effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In particular, we have two facilities,
	our laboratory near Ivrea, Italy and our laboratory in Meldola, Italy, that are approved by the
<I>
	Agenzia Italiana del Farmaco
</I>
	(the Italian Medicines Agency), or AIFA, to produce Lutathera, our lead product candidate. If either or both sites were to experience
	a shutdown or otherwise became unable to produce Lutathera, we do not currently have any other sites that would be able to cover
	for the lost production. While we may be able to secure approvals for other sites for the production of Lutathera in the future,
	we cannot assure you that we will be able to do so in a timely manner, as approvals of a facility or facilities in one country
	may not assure our ability to obtain similar approvals for other facilities or in other countries. In the event that we were to
	suffer a loss of capacity to produce Lutathera, and were unable to replace the lost capacity with production from other sites approved
	to manufacture Lutathera, our business, financial condition and results of operations could be materially adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	If we are unable to obtain supplies for
	the manufacture of Gluscan, Lutathera or our other products and product candidates in sufficient quantities and at an acceptable
	cost, our ability to manufacture Gluscan or Lutathera or to manufacture, develop and commercialize our other products and product
	candidates could be impaired, which could harm our sales, lead to a termination of one or more of our contracts, lead to delays
	in clinical trials or otherwise harm our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We depend on third parties for certain
	materials and services necessary for the manufacture of Gluscan, Lutathera and our other products and product candidates that we
	do not manufacture in our own facilities. These third parties include suppliers of Lu-177 radioisotope, consumable and vial suppliers,
	suppliers of certain precursor elements of radiopharmaceuticals and sterility subcontractors. A disruption in the availability
	of such materials or services from these and other suppliers could require us to qualify and validate alternative suppliers. If
	we are unable to locate or establish alternative suppliers, our ability to increase or maintain our current manufacturing levels
	for our products and product candidates could be adversely affected and could harm our sales, cause us to fail to satisfy contractual
	commitments, lead to the termination of one or more of our contracts or lead to delays in our clinical trials, any of which could
	be costly to us and otherwise have a material adverse effect on our business, financial condition and results of operations. We
	have however taken steps to mitigate the risk in particular in the supply of Lu-177 radioisotope, by acquiring the IDB Group in
	Holland, one of the leading producers of this product, at the beginning of January 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our business, and in particular the production
	of PET products and product candidates, requires substantial capital, including potential investments in large capital projects,
	to operate and grow.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Manufacturing and developing PET products,
	such as Gluscan, SPECT products and our product candidates, such as Lutathera, is capital-intensive and requires significant investments
	in manufacturing and distribution infrastructure, R&amp;D and facility maintenance. In order to obtain EMA, FDA and other regulatory
	approval for product candidates and new indications for existing products, we may be required to enhance the facilities in which,
	and processes by which, we manufacture existing products, to develop new product delivery mechanisms for existing products and
	to develop innovative product additions and conduct clinical trials. Any enhancements to our production facilities necessary to
	obtain EMA or FDA approval for product candidates or new indications for existing products could require large capital projects.
	In addition, if we acquire or build new facilities to manufacture any of our products or product candidates, we would need to obtain
	regulatory approval for the construction and operation of, and for such manufacturing at any new facility before we could begin
	marketing such product. We may also undertake capital projects in order to facilitate compliance with cGMP or expand capacity.
	Capital projects of these types involve technology and project management risks. Technologies that have worked well in a laboratory
	or in a pilot program may cost more or not perform as well, or at all, in full-scale operations. Projects may run over budget or
	be delayed. We cannot be certain that these projects will be completed in a timely manner or that we will comply with cGMP, and
	we may need to spend additional amounts to achieve compliance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Additionally, by the time these capital
	projects are completed, market conditions may differ significantly from our assumptions regarding competitors, customer demand,
	alternative therapies, reimbursement and public policy, and, as a result, capital returns may not be realized. At the same time,
	failure to invest in large capital projects may harm our competitive position and financial condition. In addition, to fund large
	capital projects, we may need to incur future debt or issue additional equity, and we may not be able to structure our debt obligations
	or issue equity on favorable economic terms, if at all. A failure to fund these activities, or a failure to realize capital returns
	in them, may harm our growth strategy, competitive position and quality compliance, and could have a material adverse effect on
	our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Research and Product Development Risks
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We depend in part on the success of Lutathera
	and our other product candidates. Certain of our product candidates are still in clinical and preclinical development. Clinical
	trials of our product candidates may not be successful. If we are unable to commercialize Lutathera and our other product candidates,
	or experience significant delays in doing so, our business, financial condition and results of operations could be materially adversely
	affected.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have invested a significant
	portion of our efforts and financial resources into the development of Lutathera and our other product candidates. While we
	have already begun generating sales from Lutathera in certain countries in Europe on a compassionate use and named patient
	basis, our ability to continue to generate sales from Lutathera and other product candidates will depend heavily on the
	successful development and eventual commercialization of Lutathera and our other product candidates. The success of Lutathera
	and our product candidates will depend on several factors, including the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	successful efforts in completing clinical trials of, receipt of regulatory approval for and commercialization of such product
	candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	for the product candidates to which we retain rights under relevant agreements, completion of preclinical studies and clinical
	trials of, receipt of marketing approvals for, establishment of commercial manufacturing capabilities for and successful commercialization
	of such product candidates; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	acceptance of our product candidates by patients, the medical community and third-party payers, effectively competing with
	other therapies, a continued acceptable safety profile following approval, and qualifying for, maintaining, enforcing and defending
	our intellectual property rights and claims.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we or the parties with whom we partner
	do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability
	to successfully commercialize Lutathera and our other product candidates, which could materially adversely affect our business,
	financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Because we are developing product candidates
	for the treatment of diseases in which there is limited clinical experience and, in some cases, using new methodologies, there
	is more risk that the outcome of our clinical trials will not be favorable or may not lead to approval of our product candidates.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There are currently few approved radiopharmaceutical
	therapeutic products. In addition, there has been limited historical clinical trial experience generally for the development of
	radiopharmaceutical therapeutics. As a result, the design and conduct of clinical trials for these drugs are uncertain and subject
	to increased risk.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may experience setbacks with our current
	or future clinical trials for our product candidates. We may not achieve the pre-specified endpoints with statistical significance
	in the trials of our product candidates, which would decrease the chance of obtaining, or could prevent, marketing approval for
	such product candidates, or the FDA may not determine that a given product candidate&rsquo;s clinical and other benefits outweigh
	its safety risks. We could also face similar challenges in designing clinical trials and obtaining regulatory approval for future
	product candidates, which could have a material adverse effect upon our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Clinical drug development involves a
	lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates, in
	particular those for Lutathera, are prolonged or delayed, we or any industry partners involved in the conduct of such trials may
	be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates on a timely
	basis or at all.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	To obtain the requisite regulatory approvals
	to market and sell any of our product candidates, we and/or our industry partners for such candidate typically must demonstrate
	through extensive preclinical and clinical trials that our product candidates are safe and effective in humans. The process for
	obtaining relevant governmental approvals to market our products is rigorous, time-consuming and costly. It is also impossible
	to predict the extent to which this process may be affected by legislative and regulatory developments. Due to these and other
	factors, our current product candidates or any of our other future product candidates could take a significantly longer time to
	gain regulatory approval than expected or may never gain regulatory approval. This could delay or eliminate any potential sales
	that we might earn from these product candidates due to the lost time before potential commercialization and potential changes
	in the competitive landscape by the time such product candidates are commercialized, if they are commercialized at all. We may
	also suffer reputational harm from such delays or failures that could affect our business more broadly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Clinical trials must be conducted in
	accordance with EMA, FDA and other applicable regulatory authorities&rsquo; legal requirements, regulations or guidelines,
	and are subject to oversight by these governmental agencies and Institutional Review Boards, or IRBs, at the medical
	institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our
	product candidates produced under cGMP and other requirements. We depend on our industry partners, including medical
	institutions and in particular Clinical Research Organizations, or CROs, to conduct clinical trials in compliance with Good
	Clinical Practice, or GCP, and in compliance with other applicable regulatory and technical requirements. To the extent they
	fail to do so, we may be affected by increased costs, program delays or both, which may harm our business. We have been
	affected in the past, and may be affected in the future, by technical issues on the part of industry partners in conducting
	clinical trials, including documentation failures that have resulted in, and may in the future result in, significant delays
	in product commercialization. We have also been affected in the past, and may be affected in the future, by difficulties in
	conducting our own trials that may require us to revise our protocol for such trials, revise patient enrollment targets and
	make other changes that have the effect of delaying completion of such trials and in turn the commercialization of our
	product candidates that depends upon such trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have recently completed a Phase 3
	clinical trial required for the approval of our lead product candidate, Lutathera. The trial concluded recruitment in
	February 2015, and we finalized the trial&rsquo;s database (confirming that all data contained therein is final) on September
	14, 2015 after verifying and ensuring incorporation of all trial data, and after confirming the occurrence of the predefined
	number of progression events required to conclude the trial to enable conclusive statistical analysis. We have submitted a
	New Drug Application (NDA) to the FDA, and a MAA to the EMA, for our Somakit products, our companion diagnostic
	product candidates to Lutathera, without conducting our own clinical trials. Our regulatory applications may be based on
	data published by third parties and, in the case of the MAA, our study in the United Kingdom, which is intended to
	supplement existing published data on product candidates similar to our Somakit products with further information, neither of
	which may be as reliable as data generated from our own clinical studies. In certain cases, obtaining marketing authorization
	following our trials for specific product candidates, or in the case of our Somakit products, based on existing study data
	for similar products, depends on satisfactory documentation that is largely controlled by third parties with whom we partner
	for such product candidates&rsquo; European and/or U.S. commercialization or by third parties with whom we have little or no
	direct involvement and whose documentation we have not independently verified. It is possible that upon review of these
	applications the FDA and EMA may nevertheless require us to conduct clinical trials for our Somakit products, thereby
	delaying their development. Certain of our other product candidates are in Phase 1/2 trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, the commencement and completion
	of clinical trials for other product candidates may be delayed, suspended or terminated as a result of many factors, including
	but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	negative or inconclusive results, which may require us to conduct additional preclinical studies or clinical trials or to abandon
	projects that we expected to be promising;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	safety or tolerability concerns that could cause us to suspend or terminate a trial if we find that the participants are being
	exposed to unacceptable health risks;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the delay or refusal of regulators or IRBs to authorize us to commence a clinical trial at a prospective trial site and changes
	in regulatory requirements, policies and guidelines;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including
	noncompliance with regulatory requirements;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial
	sites;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays resulting from the need to obtain regulatory approval of changes to existing trial protocols;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays in patient enrollment and variability in the number and types of patients available for clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the inability to enroll a sufficient number of patients in trials to ensure adequate statistical power to detect statistically
	significant treatment effects, including as a result of small eligible patient populations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	lower than anticipated retention rates of patients and volunteers in clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our third-party research contractors failing to comply with regulatory requirements or to meet their contractual obligations
	to us in a timely manner, or at all;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	difficulty in maintaining contact with patients after treatment, resulting in incomplete data;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	delays in establishing the appropriate dosage levels;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which
	may delay enrollment and reduce the power of a clinical trial to detect statistically significant results;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the quality or stability of a product candidate falling below acceptable standards;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the inability to produce or obtain sufficient quantities of a product candidate to complete clinical trials; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	exceeding budgeted costs due to difficulty in predicting accurately costs associated with clinical trials.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Even if we obtain regulatory approval,
	our product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on
	the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or
	desirable for the successful commercialization. In addition, if a product candidate produces unexpected side effects or safety
	issues, the EMA or the FDA may require the implementation of restrictive measures, or a comparable foreign regulatory authority
	may require the establishment of a similar strategy, that may, for instance, limit the distribution of such product candidate and
	impose burdensome implementation requirements on us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We anticipate that our expenses will
	increase substantially as compared to prior periods in connection with the completion of our Phase 3 clinical program for our lead
	product candidate, Lutathera, seeking approval for Lutathera from the FDA and EMA and building a commercialization infrastructure
	to support Lutathera&rsquo;s anticipated launch.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result of our continued investment
	in Lutathera, our expenses will increase substantially due to costs we will incur in connection with analyzing the Phase 3 trial
	data, expanding the results of the Phase 1 and 2 study with the most recent database update, seeking EMA marketing authorization
	and FDA approval for Lutathera for treatment of progressive midgut NETs in the European Union and the United States, respectively,
	and as a result of increased headcount, including management personnel, to support our clinical, manufacturing and sales activities.
	These costs will be in addition to those associated with our expanded infrastructure, increased legal, compliance, accounting and
	investor and public relations expenses associated with being a public company and increased insurance premiums, among other factors.
	We are party to agreements, including an acquisition agreement with BioSynthema, that impose royalty, milestone and earn-out payment
	obligations on us, in connection with our achievement of specific clinical, regulatory and commercial milestones with respect to
	Lutathera. We are also party to a related license agreement with Mallinckrodt,&nbsp;Inc., or Mallinckrodt, that requires us to
	pay a royalty payment to Mallinckrodt at percentage in the low teens of our net sales of Lutathera for each quarter until the first
	quarter of 2020, a letter of agreement with Erasmus Medical Center, or Erasmus, that requires us to pay Erasmus a low single-digit
	percentage royalty on net sales of Lutathera, which is capped based on the number of clinical trials required by the FDA, with
	a current maximum of&thinsp; &euro;2.0 million (US$2.2 million), and a license and royalty agreement for rights relating to a somatostatin
	analogue that requires us to pay a low single-digit percentage royalty on net sales of Lutathera. See &ldquo;Item 4. Information
	on the Company&mdash;B. Business Overview&mdash;Other Contracts&rdquo; for more information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Positive or timely results from preclinical
	trials do not ensure positive or timely results in late stage clinical trials or product approval by the EMA, the FDA or other
	regulatory authorities.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our product candidates that show positive
	preclinical, Phase 1, Phase 2 or Phase&nbsp;1/2 (if the trials are combined) results may not show sufficient safety or efficacy
	to obtain regulatory approvals and therefore fail in later-stage clinical trials. The EMA, the FDA and other regulatory authorities
	have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for
	any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising,
	such data may not be sufficient to support approval by the EMA, the FDA or any other regulatory authority.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The data obtained from Phase 1/2 trials
	we have completed may not be convincing and are not as reliable as late-stage clinical trials that are generally larger and conducted
	with more statistical rigor. For example, the Phase 1/2 trial for Lutathera was not controlled. As a result, the data obtained
	from the trial are not directly comparable to data from other products or other studies. In addition, because the trial was investigator-initiated,
	the trial did not have the proper controls or the proper level of homogeneity. The historical data to which we compare our Phase
	1/2 results vary in quality and are considered less reliable than other forms of data. These same concerns over reliability and
	comparability of data may arise in future clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, it is possible that the FDA
	may not consider the results of a single Phase 3 clinical trial of Lutathera to be sufficient for the approval of Lutathera. In
	general, two adequately designed, powered and well-controlled trials are required to demonstrate effectiveness sufficient for approval
	of a new drug. For example, the usual threshold level for statistical significance, consisting of a p-value of less than .05, or
	p&lt;.05, may not be sufficient for approval based on a single study, and a more robust showing of statistical significance may
	be required. Even with favorable results in the Phase 3 trial of Lutathera, the FDA may nonetheless require that we conduct additional
	clinical trials, possibly using a different design. If we are required to conduct an additional Phase 3 trial for Lutathera, we
	would incur significant additional clinical trial expenses. In addition, we could be delayed in obtaining regulatory approval for
	Lutathera and may not be able to quantify the delay, which would impact our commercialization strategy for Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	It is also possible that our product candidates
	will not complete clinical trials in the markets in which we intend to sell those product candidates. If this were to happen, we
	would not receive the regulatory approvals needed and neither we nor our industry partners would be able to market our product
	candidates in such markets. Significant clinical trial delays could also allow our competitors to bring products to market before
	we do, shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability
	to commercialize our product candidates, any of which may harm our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Approval by one regulatory authority does
	not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approval in any jurisdiction, the geographic
	market for our product candidates could be limited. Similarly, regulatory agencies may not approve the labeling claims that are
	necessary or desirable for the successful commercialization of our product candidates. Failure to obtain EMA marketing authorization,
	FDA approval, or other necessary regulatory approvals, as applicable, for our product candidates would result in our being unable
	to market and sell such product candidates on a commercial basis, which would materially adversely affect our business, financial
	condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	If serious adverse, undesirable or unacceptable
	side effects are identified during the development of our product candidates, we may need to abandon our development of such product
	candidates.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If our product candidates are associated
	with serious adverse, undesirable or unacceptable side effects, we may need to abandon their development or limit development to
	certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit
	perspective. Many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects
	that prevent or limit further development of the compound.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In a safety analysis performed in 615 patients
	in the Phase 1/2 trial for Lutathera, which we refer to as the Erasmus Study, the most common side effects observed, occurring
	within 24 hours of administration of the Lutathera injection, were transitory alopecia (38% of administrations), nausea (28% of
	administrations), vomiting (15% of administrations) and abdominal discomfort or pain (16% of administrations). The primary form
	of toxicity to patients treated with Lutathera was hematological, with 13% of the Erasmus Study patients experiencing one or more
	serious adverse effects, or SAEs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Erasmus Phase 1/2 trial continued after
	the first independent assessment conducted in 2011, and AAA resumed the data collection in 2015 with the objective of including
	an updated Clinical Study Report in the NDA submission. The second analysis includes follow-up data of the original 615 patients
	and an additional 599 patients who were enrolled in the study between March 2007 and December 2012. The safety analysis (SAF) dataset
	consisted of 1,214 patients; 629 (51.8%) experienced an adverse event, and 193 (15.9%) experienced a serious adverse event (SAE)
	at least possibly related to the study medication. Those with the highest frequencies were pancytopenia (8.0%), anemia (4.4%),
	diarrhea (4.7%); death (4.5%); abdominal pain (5.8%), vomiting (3.8%), nausea (3.2%) and thrombocytopenia (3.0%). See &ldquo;Item
	4. Information on the Company&mdash;B. Business Overview&mdash;Our Product Candidates in Clinical Development&mdash;Lead Therapeutic
	Candidate&mdash;Lutathera.&rdquo; There may also be potential long-term toxicity to certain patients&rsquo; bone marrow associated
	with treatment using Lutathera, with evidence of such toxicity observed in between 1% and 3% of the patients in our Phase 1/2 trial.
	An accurate assessment of this potential side effect has not yet been completed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that the safety profile
	of Lutathera in our pivotal Phase 3 trial is consistent with the safety information generated from the Erasmus Study, as
	the nature of, and percentage of patients experiencing, adverse events in the two trials were similar. The primary form
	of toxicity to patients treated with Lutathera in the Phase 3 trial was hematological, with 9% of the patients in the
	Lutathera arm of the trial experiencing one or more SAEs. See &ldquo;Item 4. Information on the Company&mdash;B.
	Business Overview&mdash;Our Product Candidates in Clinical Development&mdash;Lead Therapeutic
	Candidate&mdash;Lutathera&mdash;Phase 3 Trial&mdash;Initial Safety Analysis.&rdquo; However, a full safety analysis has yet
	to be completed and, depending on the results of the complete safety analysis, SAEs or side effects may be observed that
	could be raised by the EMA, the FDA and other regulatory authorities and could be an impediment to receipt of EMA marketing
	authorization or FDA approval, or physician or patient acceptance of Lutathera or our other product candidates because of
	concerns related to safety. As expected, the full safety analysis report of the NETTER-1 Phase 3 trial was available in
	the first quarter of 2016 and the clinical study report was finalized in April 2016. In the overall safety population (221
	patients), 129 patients (58.4%) experienced treatment emergent adverse events related to treatment (ADR), 95 (86%) in the
	Lutathera arm and 34 (31%) and in the Octreotide LAR arm. There were 683 ADR episodes, 611 for patients in the Lutathera arm
	and 72 for patients in the Octreotide LAR arm. The most frequent ADR episodes in the Lutathera are were &ldquo;nausea&rdquo;
	and &ldquo;vomiting&rdquo; (125 &ldquo;nausea&rdquo; episodes in the Lutathera arm vs 4 in the Octreotide LAR arm and 98
	&ldquo;vomiting&rdquo; episodes in the Lutathera arm vs 1 in the Octreotide LAR arm); in the Lutathera arm, the majority
	(about 75%) of these &ldquo;nausea&rdquo; and &ldquo;vomiting&rdquo; episodes were considered related to the amino acid
	co-infusion by the Investigators. Safety data are not available from the compassionate use and named patient programs in
	which Lutathera has been used. Our inability to timely market or sell Lutathera because of safety concerns or regulatory
	impediments could have a material adverse effect upon our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We may become exposed to costly and damaging
	liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability
	insurance may not cover all damages from such claims.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are exposed to potential product liability
	and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of radiopharmaceutical
	products. The current and future use of our existing products and our product candidates by us and our industry partners in clinical
	trials, and the sale of current products and any approved products in the future, may expose us to liability claims. These claims
	might be made by patients that use the product or product candidate, healthcare providers, pharmaceutical companies, our industry
	partners or others selling such products. Insurance against such claims is more expensive, in the case of our radioactive products,
	due to the increased potential for harm and the increased price of raw materials, relative to non-radioactive products. We maintain
	insurance policies on a country-by-country basis and typically insure ourselves against the following risks, among others:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks related to construction of production sites;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks related to the manufacture, distribution and use of our products and product candidates;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	director and officer liability risks;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	property damage risks; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks related to clinical trials.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We maintain liability insurance covering
	up to approximately &euro;79 million (US$85.8 million) in aggregate claims across the principal jurisdictions in which we operate,
	with varying amounts of coverage in specific jurisdictions depending on the extent of our operations in those jurisdictions and
	local law. A global liability insurance program has been implemented as of January 2015 with aggregate coverage as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in France, Portugal, Italy, Spain, Poland, Switzerland and the United States, an aggregate of approximately &euro;25 million
	(US$27.1 million) as part of a global master liability program;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in the United Kingdom, an aggregate of approximately &euro;30.0 million (US$32.6 million); and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in Germany, an aggregate of approximately &euro;10.0 million (US$10.9 million).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition to such global public and product
	liability insurance coverage, we maintain separate insurance coverage for our clinical trials covering our products and services.
	We believe our insurance coverage and related policy limits are customary for similarly situated companies and adequate to provide
	us with insurance coverage for foreseeable risks. However any claims against us, regardless of their merit, could be difficult
	and costly to defend and could result in:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	decreased demand for any product candidates or products that we may develop;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	termination of clinical trial sites or entire trial programs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	injury to our reputation and significant negative media attention;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	withdrawal of clinical trial participants;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	significant costs to defend the related litigation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	substantial monetary awards to trial subjects or patients;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	loss of sales;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	diversion of management and scientific resources from our business operations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the inability to commercialize any products that we may develop; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Although the clinical trial process is
	designed to identify and assess potential side effects, it is always possible that a product candidate, even after regulatory approval,
	may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials
	or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply
	with any warnings that identify known potential adverse effects and patients who should not use our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Although we maintain limited product liability
	insurance for our products and product candidates, it is possible that our liabilities could exceed our insurance coverage. We
	intend to expand our insurance coverage for the sale of commercial products to include additional product candidates, if any, for
	which we obtain EMA marketing authorization or FDA approval. However, we may not be able to maintain insurance coverage at a reasonable
	cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability
	claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not
	be sufficient to cover such claims and our business operations could be impaired.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Any of the events described above could
	have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Regulatory and Compliance Risks
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Failure to obtain or maintain regulatory
	approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We currently sell or intend to sell our
	products and product candidates in the European Union, the United States and around the world. To market our products elsewhere
	in Europe and other foreign jurisdictions, we may need to obtain separate regulatory approvals and comply with numerous and varying
	regulatory requirements. Approval by the EMA and/or FDA does not ensure approval by foreign regulatory authorities. The approval
	procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review. We and our industry
	partners may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and therefore we may be unable to
	commercialize our products in these countries and new markets, which may adversely impact our business, financial condition and
	results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Even if our product candidates obtain
	regulatory approval, they will be subject to continual regulatory review.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If EMA marketing authorization or FDA approval
	is obtained for any of our product candidates, the approved product will remain subject to continual review and therefore its approval
	could be subsequently withdrawn or restricted. We will be subject to ongoing obligations and oversight by regulatory authorities,
	including adverse event reporting requirements, requirements pertaining to advertising and promotion of our products, requirements
	to manufacture our products in accordance with cGMP and other post-marketing obligations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we, our product candidates or the manufacturing
	facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	issue warning letters or untitled letters;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	require us to enter into a consent decree, which can include the imposition of various fines, reimbursements for inspection
	costs and penalties for noncompliance, and require due dates for specific actions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	seek an injunction, impose civil penalties or monetary fines or pursue criminal prosecution;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	suspend or withdraw regulatory approval;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	suspend any ongoing clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	refuse to approve pending applications or supplements to applications filed by us;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	suspend or impose restrictions on operations, including costly new manufacturing requirements; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If any of these events occurs, our ability
	to sell such products may be impaired, and we may incur substantial additional expense to comply with regulatory requirements,
	which could materially adversely affect our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Regulatory approval for our products
	is limited by the EMA, the FDA and similar authorities in other jurisdictions to those specific indications and conditions for
	which clinical safety and efficacy have been demonstrated, and the prescription or promotion of off-label uses could adversely
	affect our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Any regulatory approval of our products
	is limited to those specific indications for which our products have been deemed safe and effective by the EMA, the FDA or similar
	authorities in other jurisdictions and therefore approved. In addition to the regulatory approval required for new formulations,
	any new indication for an approved product also requires regulatory approval. Once we distribute a therapy, PET or SPECT product
	or product candidate, we rely on physicians to prescribe and administer it for the indications described and as directed in the
	product&rsquo;s labeling. However, in certain cases physicians may prescribe a product for unapproved, or &ldquo;off-label&rdquo;
	uses, or in a manner that is inconsistent with the product&rsquo;s labeling, including its prescription information. To the extent
	such off-label uses and departures from the approved labeling become pervasive and produce results such as reduced efficacy or
	other adverse effects, the reputation of our products or product candidates in the marketplace may suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Furthermore, while physicians may choose
	to prescribe drugs for uses that are not described in the product&rsquo;s or product candidates&rsquo; labeling and for uses that
	differ from those approved by regulatory authorities, our ability to promote the products or product candidates is limited to those
	indications that are specifically approved by the EMA, the FDA or other regulators. Although regulatory authorities generally do
	not regulate the behavior of physicians, they do restrict communications by companies on the subject of off-label use. If our promotional
	activities fail to comply with these regulations or guidelines, we may be subject to warning or untitled letters from, or enforcement
	action by, these authorities. In addition, failure to follow EMA and FDA rules and guidelines relating to promotion and advertising
	can result in the EMA&rsquo;s or FDA&rsquo;s refusal to approve a product, the suspension or withdrawal of an approved product from
	the market, product recalls, fines, disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of
	which could have a material adverse effect upon our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our operations and the administration
	of certain of our products and product candidates, including Lutathera, involve the use of hazardous materials, and require us
	and third parties to comply with complex and stringent regulatory requirements and could expose us to significant potential liabilities.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our operations involve the use of hazardous
	materials, including radioactive materials, and may produce dangerous waste products. Accordingly, we, along with the third parties
	that conduct clinical trials for and manufacture our products and product candidates on our behalf, are subject to numerous local
	and foreign laws and regulations that govern, among other things, the use, manufacture, distribution, storage, handling, exposure,
	disposal and recordkeeping with respect to these materials. Third parties who administer our products and product candidates, including
	Lutathera, which is generally administered by radiation oncologists are also subject to such laws and regulations. Compliance with
	current or future laws and regulations can result in significant costs and we could be subject to substantial fines and penalties
	and other sanctions in the event of noncompliance. Past inspections of our facilities have noted certain deviations that required
	corrective and preventative action, though they did not result in any restrictions on our ability to produce or deliver radioactive
	products, and they did not result in any fines. We must also comply with special regulations relating to radioactive materials
	administered by national radioactive and pharmaceutical regulatory bodies, such as the
<I>
	Autorit&eacute; de Suret&eacute; Nucl&eacute;aire
</I>
	(French Nuclear Safety Authority), the
<I>
	Agence Nationale de S&eacute;curit&eacute; du M&eacute;dicament et des Produits de Sant&eacute;
</I>
	(National Security Agency of Medicines and Health Products) and AIFA, as well as similar agencies in the jurisdictions in which
	we operate
<B>
	.
</B>
	Any related cost or liability might not be fully covered by insurance, could exceed our resources and could
	have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We are required to comply with human
	health and safety and environmental laws and regulations, which could require us to incur significant costs or result in significant
	liabilities.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to a variety of human health
	and safety and environmental laws and regulations relating to, among other matters, the use, storage, treatment, discharge, transportation,
	handling and disposal of hazardous wastes and hazardous materials used to manufacture our products, including radioactive materials
	and gas, permitting and decommissioning and decontamination, or D&amp;D, obligations. As a result of our acquisition and retrofitting
	of a site in Millburn, NJ and our planned modifications to our F-18 production site in Zaragoza, Spain, we may be required to obtain
	permits or other authorizations under such laws, rules and regulations. Authorities in the relevant jurisdictions could, among
	other sanctions, impose fines, suspend production, alter our manufacturing processes or stop our operations if we do not comply
	with these laws or regulations. Environmental laws and regulations are becoming increasingly stringent and we may have to incur
	significant costs to comply with such laws and regulations in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The risk of contamination or injury from
	these hazardous and radioactive materials or wastes, including the disposal and transportation thereof, cannot be completely eliminated.
	In such event, we could be held liable for substantial damages or costs associated with the cleanup of, or exposure to, hazardous
	or radioactive materials or wastes. Our insurance policies may not fully cover any claims asserted against us in the future related
	to environmental contamination or required remediation. Any such costs or liability related to noncompliance or contamination would
	decrease our cash reserves and could harm our business or profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our use of facilities that use and produce
	radioactive materials subjects us to compliance with D&amp;D requirements when we close those facilities or at the end of the useful
	life of our cyclotrons, exposing us to potentially significant costs. Our products and product candidates are manufactured using
	radioactive components, such as the radioisotopes F-18 and Lu-177. When one of such facilities or a cyclotron reaches the end of
	its useful life or if we need to abandon such facility for any other reason, we are obligated under the laws and regulatory rules
	of the various jurisdictions in which we operate to decommission and decontaminate such facility or cyclotron. We have no experience
	with D&amp;D, and the costs of such D&amp;D may be substantial. Estimating the amount and timing of such future D&amp;D costs includes,
	among other factors, country-specific requirements and projections as to when a facility will retire or the useful life of a cyclotron.
	If we do not conduct D&amp;D properly at any of our sites, we may suffer significant additional costs to remediate any D&amp;D
	deficiencies, fines, regulatory or criminal charges or other sanction or legal action, any of which could have a material adverse
	effect upon our business, financial condition and results of operations. Although we have estimated our future D&amp;D costs and
	recorded a liability for such costs, there can be no assurances that we will not incur material D&amp;D costs beyond such estimates
	or our provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	The regulatory regimes to which we are
	subject may directly impact our management, members of whom may inadvertently become subject to enforcement actions or otherwise
	be distracted by regulatory actions.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to numerous and overlapping
	regulatory regimes in the jurisdictions in which we operate, many of which have stringent rules and regulations that may extend
	to our key executives and management. Our senior management has in the past had to devote time to addressing regulatory inquiries
	and demands, and may need to devote time and resources to inquiries, demands, investigations or regulatory actions in the future,
	including investigations or regulatory actions that result from inadvertent violations of certain regulations in particular jurisdictions,
	whether or not the member of management was directly involved or related to, or played any role in, such violations. The distraction
	or loss of time or resources caused by such instances may be significant and could result in a material adverse effect on our business,
	financial condition or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our international operations increase
	our risk of exposure to potential claims of bribery and corruption.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result of our international operations
	and commercialization efforts, we are subject to an increased risk of inadvertently conducting activities in a manner that violates
	the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act, or other similar foreign laws which prohibit corporations
	and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official,
	government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence
	a person working in an official capacity. In the course of establishing and expanding our commercial operations and seeking regulatory
	approvals in the European Union, the United States, and internationally, we will need to establish and expand business relationships
	with various third parties and will interact more frequently with foreign officials, including regulatory authorities and physicians
	employed by state-run healthcare institutions who may be deemed to be foreign officials under the FCPA or similar foreign laws.
	If our business practices are found to be in violation of the FCPA or similar foreign laws, we and our senior management may be
	subject to significant civil and criminal penalties, potential debarment from public procurement and reputational damage, which
	could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Intellectual Property, Licensing Dependence and Information
	Technology Risks
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our lead product candidate, Lutathera,
	will not be covered by any issued patents in the time before, during and/or after the period of its commercialization, and our
	competitors may be able to develop and commercialize similar or identical products, which could adversely affect our ability to
	successfully commercialize Lutathera.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The principal patent rights covering Lutathera
	that are licensed to us are expected to expire in June 2016 in Europe and various other jurisdictions. We have submitted the NDA
	to the FDA and the MAA to the EMA for Lutathera in April 2016. As a result, if we obtain marketing authorization for Lutathera
	but are not able to maintain regulatory marketing exclusivity through its orphan drug designation or other regulatory measures,
	we may not be able to exclude competitors from commercializing products similar or identical to ours if such competitors are able
	to obtain necessary marketing authorizations. The launch of a competing version of one of our products, including Lutathera if
	approved, would likely result in a substantial reduction in the demand for and sales attributable to such product, which could
	have a material adverse effect on our business, financial condition and results of operations. Due to the limited duration of
	our licensed patent rights covering Lutathera, we believe that you should not ascribe any material value to such patents.
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our business could be adversely affected
	if we are unable to gain access to relevant intellectual property rights of third parties, or if our licensing partners terminate
	our rights to license relevant intellectual property rights.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We currently rely, and may in the future
	rely, on certain intellectual property rights licensed from third parties to protect our technology. In particular, we are a party,
	through our wholly owned subsidiary AAA USA Inc. (formerly BioSynthema) to license agreements with Mallinckrodt and an additional
	party relating to rights that have been the basis of our R&amp;D related to Lutathera. We are also party to a license agreement
	with IASON GmbH, or IASON, covering our use of know-how and trademarks relating to our products IASOflu, IASOdopa and IASOcholine
	and a license agreement with respect to Annexin V-128. See &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Licensing.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under certain of our licenses from third
	parties, we have the responsibility to maintain and control the licensed intellectual property portfolio; however, to the extent
	our relevant counterparty is responsible for maintaining, controlling or enforcing the licensed intellectual property, we cannot
	ensure that the licensed rights will be adequately maintained, controlled and enforced by such counterparty. In addition, our licensed
	rights may expire or be suspended, terminated or otherwise lost in consequence of a breach of the agreements or due to other relevant
	facts and circumstances such as insolvency of the licensor. Our ability to comply with our contractual obligations may be affected
	by factors that we can only partially influence or control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The continuation of a good relationship
	with our licensing and distribution agreement counterparties and the ability to extend the agreements that we have in place is
	important to our business prospects. If our counterparties were to terminate their licenses with us or successfully challenge our
	use of their intellectual property, or if our licenses were to expire prior to the expiration of the rights granted under such
	licenses, we would be prevented from continuing our use of the relevant technology in clinical trials or, if our products are approved
	for marketing, from using the relevant technology in products that could be sold commercially. Because of the complexity of our
	product candidates and the patent rights we have licensed, determining the scope of the licenses and related obligations may be
	difficult and could lead to disputes between us and our licensor. The loss of rights under any such license could preclude us from
	further developing, manufacturing, commercializing and marketing our products, which could have a material adverse effect on our
	business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We rely on patents and other intellectual
	property rights to protect our products, product candidates and technologies, the maintenance, enforcement and defense of which
	may be challenging and costly. Failure to enforce or defend these rights adequately could harm our ability to compete and impair
	our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our commercial success depends in part
	on obtaining and maintaining patents and other forms of intellectual property rights for our products and product candidates, including
	the methods used to manufacture those products and the methods for treating patients using those products, as well as in-licensing
	such rights. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our
	products or product candidates in the relevant jurisdiction. Even if our owned and in-licensed patent applications do successfully
	issue, third parties may challenge their validity, scope, enforceability or ownership, which may result in such patents, or our
	rights to such patents, being narrowed or invalidated. Furthermore, even if our owned and in-licensed patents and patent applications
	are unchallenged, they may not adequately protect our intellectual property or prevent others from designing around our claims.
	For instance, others may be able to make and commercialize compounds that are the same as or similar to our product candidates
	but that are not covered by the claims of the patents that we own or have exclusively licensed. Others may also independently develop
	similar or alternative products or duplicate any of our technologies without infringing our intellectual property rights. Failure
	to protect or to obtain, maintain or extend adequate patent protection and other intellectual property rights could materially
	adversely affect our ability to develop and market our products and product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	To protect our competitive position, we
	may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights
	owned by or licensed to us, or to determine or challenge the scope, validity, enforceability or ownership of patents or other intellectual
	property rights of third parties. If we were to initiate legal proceedings against a third party to enforce a patent covering one
	of our products, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the
	United States and in Europe, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. The outcome following
	legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on
	a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection
	on one or more of our products or product candidates or certain aspects of our technology. Such a loss of patent protection could
	have a material adverse impact on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Third-party claims of intellectual property
	infringement may prevent or delay our development and commercialization efforts or otherwise affect our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There is a substantial amount of
	litigation involving patent and other intellectual property rights in the pharmaceutical industry, including patent
	infringement lawsuits, interferences, oppositions and
<I>
	inter partes
</I>
	reexamination, and
<I>
	inter partes
</I>
	review
	proceedings. Third parties have previously initiated, and may in the future initiate, such proceedings challenging our owned
	and in-licensed patents. Numerous European and U.S. issued patents and pending patent applications owned by third parties
	exist in the fields in which we and our collaborators are developing product candidates. As we gain greater visibility and
	market exposure as a public company, the risk increases that our products, product candidates and other business activities
	may be subject to claims of infringement of the patent and other proprietary rights of third parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Third parties may assert that we are employing
	their proprietary technology without authorization. We are aware of a U.S. patent owned by a third party that contains claims that
	could be found to cover our Somakit products. The owner of this patent may allege that our Somakit products infringe its patent
	rights, including by bringing a patent infringement lawsuit against us, which if successful could materially affect any commercialization
	of our Somakit products contemplated by us in the United States, if our Somakit products are approved. There may be other third-party
	patents or patent applications with claims that may relate to materials, formulations, methods of manufacture or methods of treatment
	related to the composition, use or manufacture of our products or product candidates. Because patent applications can take many
	years to issue, patent applications covering our products or product candidates could have been filed by others without our knowledge.
	Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner
	that could cover our products, product candidates or their use. The expiration dates of issued patents can be difficult to determine
	accurately and may be subject to extensions, which could expose us to the risk of unanticipated patent claims by third parties
	and delays in the development, manufacture, commercialization or marketing of our products and product candidates. The granting
	of orphan drug designation in respect of Lutathera, Somakit or any of our other product candidates does not guarantee our freedom
	to operate and is separate from our risk of possible infringement of third parties&rsquo; intellectual property rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If a third party were to assert a patent
	against us, we would potentially be required to challenge the validity of the patent or otherwise seek to license any rights to
	the patent necessary for the commercialization of our applicable product or product candidate in the relevant jurisdiction. There
	is no assurance that a court would find the asserted claims to be invalid or that we would be able to obtain a license to any necessary
	rights on reasonable terms, or at all. If any third-party patents are successfully asserted against us such that they are found
	to be valid and enforceable and infringed by our products or product candidates, we may not be able to successfully settle or otherwise
	resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required
	to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from, or experience substantial
	delays in, developing, manufacturing, commercializing or marketing our products or product candidates. In addition, there could
	be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts
	or investors perceive these results to be negative, such results could have a substantial adverse effect on the price of our ordinary
	shares and our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources
	available for development activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
	adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we
	can because of their substantially greater financial resources. If we fail in any such dispute, we may be subject to significant
	liability for damages, potentially including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed
	a patent. In addition to any such damages, we or our licensees may be temporarily or permanently prohibited from developing and
	commercializing any of our products and product candidates that are held to be infringing unless we obtain a license to such patents,
	which may not be available on commercially reasonable terms or at all. We might, if possible, also be forced to redesign products
	so that we no longer infringe the third-party intellectual property rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may also be subject to claims that we
	are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others,
	and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by
	others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Any of these
	events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we
	would otherwise be able to devote to our business. Uncertainties resulting from the initiation and continuation of intellectual
	property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We enjoy only limited geographical protection
	with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of intellectual
	property rights in those jurisdictions.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We generally file our first patent
	application (i.e., priority filing) at the European Patent Office, or EPO, or at a national patent office, such as the
	National Industrial Property Institute, or NIPI, in France. International applications under the Patent Cooperation Treaty,
	or PCT, are usually filed within twelve months of the priority filing. Based on the PCT filing, we may file national and
	regional patent applications in the United States, Australia, New Zealand, Japan, and Canada and all European Patent
	Convention, or EPC, member states by filing at the EPO and, depending on the individual case, also in any or all of, among
	other countries, China, India, Singapore and Israel. As yet, we have not filed for patent protection in all national and
	regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional
	patent applications before they ever issue as patents. Finally, the grant proceeding of each national/regional patent is an
	independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the
	relevant registration authorities, while granted by others. It is also quite common that, depending on the country, the scope
	of patent protection may vary for the same product candidate and/or technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The laws of some jurisdictions do not protect
	intellectual property rights to the same extent as the laws in the European Union and the United States, and many companies have
	encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter
	difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important
	for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from
	others in those jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Many countries have compulsory licensing
	laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
	of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies,
	which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties
	with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of
	operations may be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Changes in patent laws or patent jurisprudence
	could diminish the value of patents in general, thereby impairing our ability to protect our products.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As is the case with other pharmaceutical
	companies, our success is heavily dependent on intellectual property, particularly patents or licenses to patents necessary to
	develop product candidates and commercialize products. Obtaining and enforcing patents in the radiopharmaceutical industry involves
	both technological complexity and legal complexity. Therefore, obtaining and enforcing radiopharmaceutical patents is costly, time-consuming
	and inherently uncertain. In addition, the America Invents Act has been recently enacted in the United States, resulting in significant
	changes to the U.S. patent system. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the
	scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In
	addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
	uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts,
	and the U.S. Patent and Trademark Office, the laws and regulations governing patents could change in unpredictable ways that could
	weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly,
	the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system
	is relatively stringent with regard to the type of amendments that are allowed during prosecution. These changes could limit our
	ability to obtain new patents in the future that may be important for our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	In addition to patented technology, we
	rely on our unpatented proprietary technology, trade secrets, processes and know-how.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We rely on proprietary information (such
	as trade secrets, know-how and confidential information) to protect intellectual property that may not be patentable, or that we
	believe is best protected by means that do not require public disclosure. For example, our products Gluscan, IASOflu, IASOdopa
	and IASOcholine are not currently covered by any issued patents or pending patent applications in any jurisdiction, and we rely
	in part on owned and licensed know-how to maintain our competitive advantage with respect to these products. To protect this type
	of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors
	and advisors to agree to confidentiality provisions in employment agreements with us. Any new employee contract into which we enter
	contains confidentiality obligations and, for key personnel who will have access to our know-how and/or confidential information,
	a non-competition clause. We also typically execute confidentiality agreements with third parties before we initiate discussions
	relating to our know-how or proprietary information. However, trade secrets and/or confidential know-how are difficult to maintain
	as confidential. Current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our
	confidential information to competitors, and confidentiality
	agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a
	claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time-consuming
	and unpredictable. Moreover, the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have limited control over the protection
	of trade secrets used by our industry partners and suppliers and could lose future trade secret protection if any unauthorized
	disclosure of such information occurs. In addition, our proprietary information may otherwise become known or be independently
	developed by our competitors or other third parties, and such third parties may even apply for patent protection in respect of
	the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets, know-how
	and confidential information. Under certain circumstances, we may also decide to publish certain know-how to reduce the likelihood
	that others will obtain patent rights covering such know-how. To the extent that our employees, consultants, contractors, scientific
	advisors and other third parties use intellectual property owned by others in their work for us, disputes may arise as to the rights
	in related or resulting know-how and inventions. Costly and time-consuming litigation could be necessary to enforce and determine
	the scope of our proprietary rights, and failure to obtain or maintain protection for our proprietary information could adversely
	affect our competitive business position. Furthermore, laws regarding trade secret rights in certain markets where we operate may
	afford little or no protection to our trade secrets. Failure to obtain or maintain trade secrets and protection of know-how and
	other confidential information could adversely affect our competitive position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also rely on physical and electronic
	security measures to protect our proprietary information, but we cannot guarantee that these security measures will not be breached
	or provide adequate protection for our property. There is a risk that third parties may obtain and improperly utilize our proprietary
	information to our competitive disadvantage. We may not be able to detect or prevent the unauthorized use of such information or
	take appropriate and timely steps to enforce our intellectual property and other proprietary rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our information technology systems could
	face serious disruptions that could adversely affect our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our information technology and other internal
	infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic
	failure that could disrupt our operations. A significant disruption in the availability of our information technology and other
	internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our R&amp;D, which
	could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Risks Related to our Reliance on Third Parties
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We rely on third parties to deliver our
	products and these third parties may not perform.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We do not deliver our radiopharmaceutical
	products to hospitals and imaging centers ourselves. We depend, and we will likely depend in the future, on contracted third parties
	to deliver our products, which in many cases must be delivered in accordance with stringent local and international regulations
	applicable to the delivery of radioactive materials. Failure of these third parties to deliver our products to others in compliance
	with these regulations, whether inadvertent or intentional, could subject us to demands, investigations or regulatory actions in
	the future. Our ability to manufacture and ensure the delivery of products to customers could be limited in the event such actions
	were taken against us. In addition, if these third parties fail to deliver our products to our customers in a timely manner, we
	may suffer significant harm to our reputation and lose sales, which could have a material adverse effect on our business, financial
	condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, a portion of our sales is
	obtained through third parties. As a result, we rely on the commercialization strength of these distributors and the distribution
	channels through which they operate. We may not be able to retain these distribution relationships indefinitely and these distributors
	may not adequately support the sales, marketing and distribution efforts of our products in these significant markets. If third
	parties do not successfully carry out their contractual duties in maximizing the commercial potential of our products, or if there
	is a delay or interruption in the distribution of our products, it could negatively impact our sales of such products and could
	have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we choose not to rely on such third
	parties for distribution of our products in the future, for instance in the United States, where we are expanding our existing
	presence, we will have to distribute our products ourselves and will be directly subject to the same local and international regulations
	described above and risks associated with non-compliance. Our failure to establish appropriate
	distribution networks of our own in the United States or elsewhere or our failure to do so in a cost-effective manner or in a manner
	that satisfies such regulations could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We rely on third parties to provide services
	in connection with our preclinical and clinical development programs, in particular CROs. The inadequate performance by or loss
	of any of these service providers could negatively affect our product candidate development.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We rely on third parties, especially CROs,
	in connection with our preclinical and clinical development of certain product candidates, in particular for Lutathera. Although
	we do not exercise control over the day-to-day activities of our CROs, we are responsible for ensuring that our studies are conducted
	in accordance with applicable regulations and guidelines. Additionally, if these CROs or other third parties who help facilitate
	the development of our product candidates were to perform inadequately in their provision of services or conduct of preclinical
	or clinical activities, or if we were to lose the services of such third parties, the inadequate performance of or loss of such
	parties&rsquo; services could delay, undermine the reliability of, or otherwise negatively impact our preclinical or clinical trials,
	as well as the prospects for regulatory approval and commercialization of the relevant product candidates that depend upon the
	successful completion of such trials. The failure of a third party upon whom we depend to adequately provide such services may
	also result in exposure to liability, regulatory sanction and loss of reputation for us, any of which could have a material adverse
	effect upon our business, financial condition or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Related to our Business, Growth and Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We have experienced losses in the past
	and we may not become profitable in the future.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have incurred significant accumulated
	losses to date, in large part due to our investment in and costs relating to our R&amp;D activities and contingent financial liabilities
	relating to the acquisition of product candidates. Our financial results are significantly impacted by sales estimates of Lutathera,
	and in the future will be impacted by sales estimates of Annexin V-128 and related contingent consideration, licensing and royalty
	obligation estimates, which are accounted for in our consolidated financial statements as a liability under IFRS rules, and which
	may increase in the future if our estimates of future Lutathera and Annexin V-128 sales increase as well. We experienced a net
	loss of&thinsp; &euro;17.0 million (US$18.5 million), &euro;10.8 million (US$11.7 million) and &euro;12.8 million (US$13.9 million)
	for the years ended December 31, 2015, 2014 and 2013, respectively, and had an accumulated deficit of&thinsp; &euro;52 million
	(US$56.5 million) as of December&nbsp;31, 2015. Depending on our level of R&amp;D investment, the number of product candidates
	we undertake to develop, our sales and forecasts of our royalty obligations, we anticipate incurring continued net losses for the
	next three or more fiscal years. We also anticipate that our operating expenses will increase substantially in the foreseeable
	future as we continue to invest to grow our business and develop our product candidates, particularly Lutathera, while expanding
	geographically and complying with the requirements of being a public company. These efforts may prove to be more expensive than
	we currently anticipate, and we may not succeed in increasing our sales sufficiently to offset these higher expenses. Many of our
	efforts to generate sales from our product candidates are unproven or have yielded limited sales, and any failure to increase our
	sales or generate sales from new product candidates could prevent us from attaining profitability. If we are unable to effectively
	manage these risks and difficulties as we encounter them, we may suffer a material adverse effect on our business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We are dependent on the continued service
	of our senior management team, the loss or diminished performance of any member of which could have a material adverse effect on
	our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our performance is substantially dependent
	on our senior management, which includes Stefano Buono, our CEO, Heinz M&auml;usli, our CFO, and G&eacute;rard Ber, our COO. In
	addition, our success depends upon the continued contributions of our senior and other members of key management, scientific and
	technical personnel, many of whom have substantial experience with us or have been instrumental for us and our MNM therapy and
	related technologies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The loss of any member of senior management,
	managers in charge of overall operations in a specific country or senior scientists could delay our R&amp;D activities. In addition,
	the competition for qualified personnel in the radiopharmaceutical and pharmaceutical field is intense, and our future success
	depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face
	competition for personnel from other companies, universities,
	public and private research institutions and other organizations. Some of the entities with which we compete for management personnel
	have greater financial and other resources than we do or are located in geographic areas which may be considered by some to be
	more desirable places to live. We cannot be sure that any member of our senior management will remain with us or that any such
	member will not compete with us in the future. If our recruitment, retention and motivation efforts are unsuccessful in the future,
	it may be difficult for us to implement our business strategy, which could have a material adverse effect on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	In the past, we had identified material
	weaknesses in our internal control over financial reporting. If the since-implemented internal controls fail to be effective, such
	failure could result in material misstatements in our financial statements, cause investors to lose confidence in our reported
	financial and other public information and have a negative effect on the trading price of our shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Effective internal controls over financial
	reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
	are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
	implementation could cause us to fail to meet our reporting obligations. Section 404 of the Sarbanes-Oxley Act requires management
	of public companies to develop and implement internal controls over financial reporting and evaluate the effectiveness thereof.
	A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there
	is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely
	basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In connection with the preparation for
	our initial public offering and the 2015 annual financial statements, we identified material weaknesses in our internal controls
	related to our financial reporting and consolidation, as well as in our treasury functions. The specific weaknesses in our internal
	controls related to financial reporting and consolidation included, among other things, a lack of formal or written policies and
	procedures relating to various aspects of our financial reporting and consolidation process, the lack of a Company-wide accounting
	manual and standard reporting package model, as well as a lack of procedures for subsequent events reporting, reconciliation between
	local accounts and Company reporting, provisions for risks and charges and capitalization of R&amp;D expenditures. The specific
	weaknesses in our internal controls related to our treasury function included, among other things, a lack of formal or written
	procedures related to bank transactions and payment functions, and a failure to properly segregate duties (including access right
	segregation of duties in the newly implemented system) relating to these transactions and functions. We also identified a larger
	number of significant deficiencies in our internal controls.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have taken and continue to take actions
	to remediate these issues. We have strengthened our financial control and our accounting teams at the consolidated level by hiring
	additional experienced professionals and we also have reinforced the finance and accounting capabilities in several of our subsidiaries
	during the same period. In July&nbsp;2015 we hired an internal auditor who is also responsible for managing our SOX compliance
	project that we commenced in May&nbsp;2015. This project is supported by a team of external professionals experienced in SOX compliance
	matters. The project which includes a very thorough review and assessment of our processes and controls also revealed that we have
	deficiencies in certain processes and systems which required reinforcement with additional dedicated personal.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have also initiated a company-wide
	project to transfer all of our accounting to a single accounting software platform. Four AAA subsidiaries have been using this
	software for the closure of the 2015 financial statements, encountering difficulties and inefficiencies compared to the application
	of the previously used software packages. In January 2016 we have started to transfer two additional subsidiaries to this new
	accounting software platform. This has caused significant strain on the finance and accounting personnel in these subsidiaries
	and also on the personnel at headquarters and our external consultants, which are charged with rolling out and implementing this
	software across all units of AAA. The efficient and effective utilization of the software requires not only a significant learning
	effort but also a change of mentality, a new organization and a willingness to try new ways of doing things. The use of external
	experts of this accounting software allowed us to overcome to some extent resource constraints and technical problems. However
	language issues and a combination of particular local accounting standards, and specific customer and/or government requirements
	caused serious delays in implementing and utilizing the software in these two new subsidiaries. New software implementation, the
	initial public offering process and now being a publicly listed company cause a very significant workload
	for many of our employees who are now struggling to balance daily tasks and these added demands. The process of becoming a SOX
	compliant company is a complex one in our current context. Projects are interrelated at different levels and working sequentially
	or on one project in isolation is often not possible as there may be implications for other projects. We therefore have to apply
	a pragmatic approach to arrive at a balanced and workable solution. Our difficulties in implementing the accounting system cause
	delays in our efforts to resolve recognized deficiencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Beyond the before-mentioned issues we also
	encounter difficulties in recruiting qualified finance and accounting personnel. This means that we are forced to rely more on
	external consultants and are slower than planned in having the desired competences within AAA. We intend to take further steps
	to remediate the foregoing issues. However, if we fail to address these issues or should not manage to have effective internal
	controls in place, we may risk having material errors in our financial statements. This may result in the loss of investor confidence,
	possibly subject us to regulatory scrutiny and sanctions and reduce the company&rsquo;s market value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	If we fail to establish or maintain
	an effective system of internal controls, we may be unable to accurately report our financial results or prevent fraud, and investor
	confidence and the market price of the ADSs may, therefore, be adversely impacted.
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a public company, we will be
	required to maintain internal controls over financial reporting and to report any material weaknesses in such internal
	controls. In addition, beginning with our annual report for the year ending December&nbsp;31, 2016, we will be required to
	submit a report by management on the effectiveness of our internal controls over financial reporting pursuant to Section 404
	of the Sarbanes-Oxley Act. Given the appreciation of the value of our share price since the initial public offering, it
	is possible that we lose the &ldquo;emerging growth company&rdquo; status in 2016. We may be classified as a
	large accelerated filer and as such we would be obligated to have our auditor attest to the effectiveness of our internal
	controls over financial reporting pursuant to section 404(b) with the filing of our 2016 annual financial statements. We did
	not expect to be in a situation where we might be classified a large accelerated filer already in 2016. Our SOX
	compliance project, which we started in 2015 and which is a multi-year effort, may therefore be late and not get us in time
	to the expected level in the effectiveness of internal controls. This process is time-consuming, costly and strongly links to
	our new software implementation. If we identify material weaknesses in our internal controls over financial reporting, if we
	are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner or assert that
	our internal controls over financial reporting are effective, or if our independent registered public accounting firm is
	unable to express an unqualified opinion as to the effectiveness of our internal controls over financial reporting when
	required, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of the
	ADSs may be adversely impacted, and we could become subject to investigations by the stock exchange on which our securities
	are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We expect to hire a significant number
	of new employees and expand our development, regulatory and sales, marketing and distribution capabilities, and as a result, we
	may encounter difficulties in managing our growth, which could disrupt our operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We expect to experience significant growth
	in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs
	and sales, marketing and distribution as we work toward anticipated EMA market authorization and FDA approval for Lutathera, and
	as we expand our operations into the United States. To manage our anticipated future growth, we must continue to implement and
	improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
	personnel
<I>
	.
</I>
	We may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
	personnel
<I>
	.
</I>
	The expansion of our operations may lead to significant costs and may divert our management and business development
	resources
<I>
	.
</I>
	Any inability to manage growth could delay the execution of our business plans or disrupt our operations and
	have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Acquisitions that we have completed and
	any future acquisitions, strategic investments, partnerships or alliances could be difficult to integrate and/or identify, divert
	the attention of key management personnel, disrupt our business, dilute shareholder value and adversely affect our financial results,
	including impairment of goodwill and other intangible assets.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have acquired, and in the future
	may acquire or make, strategic investments in complementary businesses, radiopharmaceutical technologies or production and
	other services or enter into strategic partnerships or alliances with third parties to enhance our business or to expand into
	commercially attractive geographic markets. If we do identify suitable candidates, we may not be able to complete
	transactions on terms commercially acceptable to us, if at all. These types of transactions involve numerous risks,
	including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks associated with reorganizing acquisition targets to bring them to our manufacturing and quality standards; clinical trial
	data obtained by acquisition targets related to their products or product candidates that we acquire may be problematic or insufficient,
	requiring us to either conduct new trials or abandon the trials or the acquired product candidate;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	difficulties in integrating operations, technologies, accounting and personnel and achieving anticipated synergies;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	difficulties in supporting and transitioning clients of our acquired companies or strategic partners;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	diversion of financial and management resources from existing operations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risks of entering new markets;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential loss of key team members;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	failure to quickly and effectively leverage the increased scale, if any, resulting from such transactions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	inability to generate sufficient sales to offset transaction costs; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	unknown liabilities.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our organizational structure could make
	it difficult for us to efficiently integrate acquired businesses or technologies into our ongoing operations and assimilate employees
	of those businesses into our culture and operations. Accordingly, we might fail to realize the expected benefits or strategic objectives
	of any acquisition we undertake. Any such failure to integrate an acquired company or impairment of assets of any such company
	could have a material adverse impact on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	It is also possible that we may not identify
	suitable acquisition targets, strategic investments or partnerships or alliance candidates. Our inability to identify such opportunities,
	or our inability to complete such transactions, may negatively affect our competitiveness and growth prospects. Moreover, if we
	fail to properly evaluate acquisitions, alliances or investments, we may not achieve the anticipated benefits of any such transaction
	and we may incur costs in excess of what we anticipate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Historically, we have financed
	our acquisitions through a combination of cash and ordinary shares. As of December&nbsp;31, 2015, we had agreed to
	issue, pursuant to our acquisition agreements, as contingent consideration, shares having an aggregate market price of up
	to &euro;4.6 million (US$5.0 million), provided certain conditions are met, at market prices to be determined at the
	applicable date. We recently completed the acquisition of the IDB Group in January 2016. We financed the initial &euro;20
	million (US$21.7 million) purchase price with cash on hand and financed the net financial position (agreed to be current
	assets minus cash minus total liabilities) of &euro;0.3 million (US$0.3 million), the cash position of &euro;3.4 million (US$3.7
	million) and the first earn-out of a calculated &euro;1.7 million (US$1.8 million) with cash at hand in April 2016. The
	second earn-out payment of an expected &euro;3 million (US$3.3 million) due in April 2017 is also likely to be paid with cash
	at hand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Future acquisitions financed with our own
	cash could deplete the cash and working capital available to adequately fund our operations. We may also finance future transactions
	through debt financing, the issuance of our equity securities, existing cash, cash equivalents or investments or a combination
	of the foregoing. Acquisitions financed with the issuance of our equity securities in addition to those listed above could be further
	dilutive, which could further affect the market price of our ADSs. Acquisitions financed with debt could require us to dedicate
	a substantial portion of our cash flows to principal and interest payments and could subject us to restrictive covenants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our employees may engage in misconduct
	or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
	effect on our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are exposed to the risk of employee
	fraud or other misconduct. Misconduct by employees could include intentional failures to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	comply with EMA or FDA regulations or similar regulations of comparable foreign regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	provide accurate information to the EMA or the FDA or comparable foreign regulatory authorities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	comply with cGMP regulations and manufacturing standards that we have established, comply with applicable healthcare fraud
	and abuse laws and regulations in the jurisdictions in which we operate;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	report financial information or data accurately; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	disclose unauthorized activities to us.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In particular, sales, marketing and business
	arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing
	and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
	and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve
	the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious
	harm to our reputation. The precautions we take to detect and prevent this misconduct may not be effective in controlling unknown
	or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
	failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful
	in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations,
	including the imposition of significant fines or other sanctions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our failure to maintain certain tax benefits
	applicable to us as a French R&amp;D company may adversely affect our results of operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a French radiopharmaceutical company,
	we have benefited from certain tax advantages, including, principally, the French research tax credit (
<I>
	cr&eacute;dit d&rsquo;imp&ocirc;t
	recherche
</I>
	), or the CIR. The CIR is a French tax credit aimed at stimulating R&amp;D. The CIR can be offset against French corporate
	income tax due and the portion in excess (if any) may be refunded at the end of a three fiscal-year period. The CIR is calculated
	based on our claimed amount of eligible R&amp;D expenditures in France and represented income of &euro;4.2 million (US$4.6 million),
	&euro;3.3 million (US$3.6 million) and &euro;2.5&nbsp;million (US$2.7 million) in fiscal years 2015, 2014 and 2013, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The French tax authorities and the French
	Research and Technology Agency audit us on a regular basis. We were audited for the fiscal years 2007, 2008, 2009, 2011 and 2012
	and our CIR benefit determination was not challenged for those periods. Should the French tax authorities or the French Research
	and Technology Agency challenge our eligibility for, or our calculation of, certain tax reductions and/or deductions, including
	the CIR, in respect of our R&amp;D activities, we may be liable for additional corporate income tax and penalties and interest
	related thereto. Furthermore, the French Parliament may decide to eliminate, or reduce the scope or the rate of, the CIR benefit
	at any time. Any of these actions could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Dividends, if any, paid by us to ADR
	holders who are not U.S. residents for taxation purposes may be subject to French withholding tax at the domestic rate of 30%,
	regardless of whether these non-U.S.-resident holders are residents of a country that has entered into a double tax treaty with
	France.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Except for the double income tax treaty
	entered into between France and the United States on August&nbsp;31, 1994, as amended from time to time, none of the double tax
	treaties entered into by France and other jurisdictions contain provisions with respect to holders of U.S. ADSs. As a consequence,
	dividends, if any, that we would pay to the ADS Depositary for the benefit of non-U.S.-resident holders of ADSs would be subject
	to a French withholding tax levied at the domestic rate of 30%. U.S. resident holders of ADSs that are eligible for the income
	tax treaty between France and the United States would be subject to French withholding tax at the reduced treaty rate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Transfer pricing rules may adversely
	affect our corporate income tax expense.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Many of the jurisdictions in which we conduct
	business have detailed transfer pricing rules which require that all transactions with non-resident related parties be priced using
	arm&rsquo;s-length pricing principles. Contemporaneous documentation must exist to support this pricing. The tax authorities in
	these jurisdictions could challenge the propriety of our related party arm&rsquo;s-length transfer pricing policies and as a consequence
	the tax treatment of corresponding expenses and income. International transfer pricing is an area of taxation that depends heavily
	on the underlying facts and circumstances and generally involves a significant degree of judgment. If any of these tax authorities
	were successful in challenging our transfer pricing policies, we may be liable for additional corporate income tax, and penalties
	and interest related thereto, which may have a significant impact on our results of operations and future cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our results of operations could be materially
	adversely affected by fluctuations in foreign currency exchange rates.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We incur portions of our expenses and have
	sales in currencies other than the Euro, including the UK pound, Israeli Shekel, Japanese Yen, Swiss Franc and U.S. dollar. As
	a result, we are exposed to foreign currency exchange risk arising from future commercial transactions, recognized assets and liabilities
	and net investments in foreign operations. We currently do not engage in hedging transactions to protect against uncertainty in
	future exchange rates between particular foreign currencies and the Euro. Therefore, for example, an increase in the value of the
	Euro against the U.S. dollar could be expected to have a negative impact on our sales and earnings growth as U.S. dollar sales
	and earnings, if any, in the future, would be translated into Euros at a reduced value. We cannot predict the impact of foreign
	currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of
	operations and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We could be subject to strict restrictions
	on the movement of cash and the exchange of foreign currencies.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In some countries, we could be subject
	to strict restrictions on the movement of cash and the exchange of foreign currencies, which would limit our ability to use this
	cash across our global operations. This risk could increase to the extent that we continue our geographic expansion in emerging
	markets, which are more likely to impose these restrictions than more established markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	International hostilities, terrorist
	activities, natural disasters, pandemics and infrastructure disruptions could prevent us from effectively serving our clients and
	thus adversely affect our results of operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Acts of terrorist violence, political unrest,
	armed regional and international hostilities and international responses to these hostilities, natural disasters, global health
	risks or pandemics or the threat of or perceived potential for these events could have a negative impact on us. These events could
	adversely affect our customers and precipitate sudden significant changes in regional and global economic conditions and cycles.
	These events also pose significant risks to our people and to physical facilities and operations around the world, whether the
	facilities are ours or those of our alliance partners or customers. By disrupting communications and travel and increasing the
	difficulty of obtaining and retaining highly skilled and qualified personnel, these events could make it difficult or impossible
	for us to deliver our products and product candidates to our customers. Extended disruptions of electricity, other public utilities
	or network services at our facilities, as well as system failures at, or security breaches in, our facilities or systems, could
	also adversely affect our ability to serve our customers. We might be unable to protect our people, facilities and systems against
	all such occurrences. We generally do not have insurance for losses and interruptions caused by terrorist attacks, conflicts and
	wars. If these disruptions prevent us from producing our products or product candidates and delivering them to our customers, our
	business, financial condition and results of operations could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	In the past, we have not been, and in
	the future, we may not be, the sole owner of subsidiaries of ours that develop product candidates or conduct other activities that
	are important for our product pipeline. Therefore, we may not be able to control the timing of development efforts, associated
	costs, or important operations of such entities that we do not solely own.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Until December 2014, we were not the
	sole owner of certain subsidiaries of ours, including Atreus (of which we were previously a 50.1% owner), the developer of
	Annexin V-128, one of our lead product candidates. We may in the future participate in similar arrangements or make similar
	majority acquisitions of companies that develop product candidates that we believe will be beneficial for our product
	portfolio, or enter into acquisitions or joint ventures relating to other assets that we anticipate will create value for us.
	In such cases, we may be subject to agreements that allow other shareholders, entities or certain other subsidiaries to
	influence certain decisions and operations within those subsidiaries in ways with which we may not agree or which may be
	contrary to our own business strategy. These subsidiaries may in the future provide in these agreements for supermajority
	votes on important matters where even our majority interest may not be sufficient to cause the subsidiary to take certain
	actions, or take actions within certain timeframes which may include but are not limited to the pursuit of key trials and
	pursuit of approvals that are important to our business. Such parties&rsquo; interests may not be aligned with our own in
	certain cases and they may not agree with us as to particular actions. This limited ability to exercise control over the
	operations of future subsidiaries or in connection with future joint ventures may have a material adverse effect on our
	business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We are a multinational company that faces
	complex taxation regimes in various jurisdictions. Changes in our level of taxes, and audits, investigations and tax proceedings
	could have a material adverse effect on our business, results of operations and financial condition.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to income taxes in numerous
	jurisdictions. We calculate and provide for income taxes in each tax jurisdiction in which we operate. Tax accounting often involves
	complex matters and judgment is required in determining our worldwide provision for income taxes and other tax liabilities. We
	are subject to ongoing tax audits in various jurisdictions. Tax authorities have disagreed, and may in the future disagree, with
	our judgments, or may take increasingly aggressive positions with respect to the judgments we make. We regularly assess the likely
	outcomes of these audits in order to determine the appropriateness of our tax liabilities. However, our judgments might not be
	sustained as a result of these audits, and the amounts ultimately paid could be different from the amounts previously recorded.
	In addition, our effective tax rate in the future could be adversely affected by changes in the mix of earnings in countries with
	differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws. Tax rates
	in the jurisdictions in which we operate may change as a result of macroeconomic or other factors outside of our control. Increases
	in the tax rate in any of the jurisdictions in which we operate could have a negative impact on our profitability. In addition,
	changes in tax laws, treaties or regulations, or their interpretation or enforcement, including the French CIR, may be unpredictable,
	particularly in less developed markets, and could become more stringent, which could materially adversely affect our tax position.
	Any of these occurrences could have a material adverse effect on our results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	There can be no assurance that we will
	not be a passive foreign investment company, or PFIC, for any taxable year. If we are a PFIC for any taxable year, this could result
	in adverse U.S. federal income tax consequences to U.S. investors.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the Internal Revenue Code of 1986,
	as amended, or the Code, we will be a PFIC for any taxable year in which, after the application of certain &ldquo;look-through&rdquo;
	rules with respect to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of&thinsp; &ldquo;passive income,&rdquo;
	or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production
	of, &ldquo;passive income.&rdquo; Passive income generally includes interest, dividends, rents, certain non-active royalties and
	gains from the disposition of assets that produce passive income. Based upon the nature of our business and estimates of the valuation
	of our assets, including goodwill, which is based, in part, on the trading price of our ADSs, we do not believe that we were a
	PFIC for the year ended at December 31, 2015. However, because PFIC status depends on the composition of our income and assets
	and the relative fair market value of our assets from time to time, there can be no assurance that we will not be a PFIC for any
	taxable year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we are a PFIC for any taxable year during
	which a U.S. investor holds ordinary shares or ADSs, the U.S. investor may be subject to adverse tax consequences. See &ldquo;Item
	10. Additional Information&mdash;E. Taxation&mdash;U.S. Federal Income Tax Considerations for U.S. Holders&mdash;Passive foreign
	investment company rules.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our business is subject to the risks
	generally associated with international business operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We engage in business activities throughout
	Europe, in the United States and across the world. For the fiscal years ended December&nbsp;31, 2015, 2014 and 2013, we derived
	portions of our sales from the following countries: France, Italy, the United Kingdom, Germany, Switzerland, Spain, Portugal, Poland,
	Israel, the United States and Canada, among others. As a result, our business is and will continue to be subject to the risks generally
	associated with international business operations, including:
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in social, political and economic conditions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	transportation delays;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	limitations on foreign investment;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	restrictions on currency convertibility and volatility of foreign exchange markets;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	import-export quotas;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in local labor conditions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in tax and other laws and regulations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	expropriation and nationalization of our assets in a particular jurisdiction; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	restrictions on repatriation of dividends or profits.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Some of the countries in which we operate
	have been subject to social and political instability in the past, and interruptions in operations could occur in the future. Our
	sales could be adversely affected by any of the foregoing factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Risks Relating to the ADSs and Our Ordinary Shares
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	There has been no prior market for our
	ordinary shares or the ADSs, the market price for the ADSs may be volatile or may decline regardless of our operating performance,
	an active public trading market may not develop or be sustained, and you may not be able to resell the ADSs at or above the price
	you acquired.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There has been no public market for our
	ordinary shares or the ADSs prior to our initial public offering. An active or liquid market in the ADSs may not develop or, if
	it does develop, it may not be sustainable. The trading prices of the securities of pharmaceutical and biotechnology companies
	have been highly volatile. The market price of the ADSs may fluctuate significantly in response to numerous factors, many of which
	are beyond our control, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	results from our clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	actual or anticipated fluctuations in our sales and other results of operations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	changes in financial estimates by financial analysts, or any failure by us to meet or exceed any of these estimates, or changes
	in the recommendations of any financial analysts that elect to follow our ADSs or the shares of our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	announcements by us or our competitors of significant contracts or acquisitions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	future sales of our ordinary shares or ADSs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	lawsuits threatened or filed against us; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	investor perceptions of us and the industries in which we operate.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, the stock market in general
	has experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
	of particular companies affected. These broad market and industry factors may materially harm the market price of our ADSs, regardless
	of our operating performance. In the past, following periods of volatility in the market price of certain companies&rsquo; securities,
	securities class action litigation has been instituted against these companies. This litigation, if instituted against us, could
	adversely affect our financial condition or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	A significant percentage of our share
	ownership is concentrated in the hands of our principal shareholders and management, who will be able to exercise a significant
	influence on us.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our senior management, directors, current
	five percent or greater shareholders and affiliated entities together beneficially own approximately 41.74% of our ordinary shares
	outstanding as of December 31, 2015. As a result, these shareholders, acting together, will have significant influence over all
	matters that require approval by our shareholders, including the election of directors and approval of significant corporate transactions.
	Corporate action might be taken even if other shareholders oppose them. This concentration of ownership might also have the effect
	of delaying or preventing a change of control of our Company that other shareholders may view as beneficial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	If securities or industry analysts do
	not publish research or publish inaccurate or unfavorable research about our business, the price of our ordinary shares and the
	ADSs and trading volume could decline.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The trading market for the ADSs depends
	in part on the research and reports that securities or industry analysts publish about us or our business. If no or few securities
	or industry analysts cover our Company, the trading price for the ADSs would likely be negatively impacted. If one or more of the
	analysts who covers us downgrades the ADSs or publishes incorrect or unfavorable research about our business, the price of the
	ADSs would likely decline. If one or more of these analysts ceases coverage of our Company or fails to publish reports on us regularly,
	or downgrades the ADSs, demand for the ADSs could decrease, which could cause the price of the ADSs or trading volume to decline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We do not currently intend to pay dividends
	on our securities and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price
	of our ordinary shares and the ADSs. In addition, any distribution of dividends must be in accordance with the rules and restrictions
	applying under French law.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have never declared or paid any cash
	dividends on our ordinary shares and do not currently intend to do so for the foreseeable future. We currently intend to invest
	our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable
	future and the success of an investment in ADSs will depend upon any future appreciation in its value. Consequently, investors
	may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, as the only way to realize
	any future gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at
	which our shareholders have purchased the ADSs. Investors seeking cash dividends should not purchase the ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Further, under French law, the determination
	of whether we have been sufficiently profitable to pay dividends is made on the basis of our statutory financial statements prepared
	and presented in accordance with accounting principles generally accepted in France, or French GAAP. Moreover, pursuant to French
	law, we must allocate 5% of our unconsolidated net profit for each year, less any previous losses, to our legal reserve fund before
	dividends, should we propose to declare any, may be paid for that year, until the amount in the legal reserve is equal to 10% of
	the aggregate nominal value of our issued and outstanding share capital. In addition, payment of dividends may subject us to additional
	taxes under French law. See &ldquo;Item 10. Additional Information&mdash;B. Articles of Association&mdash;Key Provisions of Our
	By-laws and French Law Affecting Our Ordinary Shares&mdash;Rights, Preferences and Restrictions Attaching to Ordinary Shares&rdquo;
	for further details on the limitations on our ability to declare and pay dividends and the taxes that may become payable by us
	if we elect to pay a dividend. Therefore, we may be more restricted in our ability to declare dividends than companies not based
	in France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, exchange rate fluctuations
	may affect the amount of Euros that we are able to distribute, and the amount in U.S. dollars that our shareholders receive upon
	the payment of cash dividends or other distributions we declare and pay in Euros, if any. These factors could harm the value of
	the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We may need additional capital in the
	future to meet our financial obligations and to pursue our business objectives. Additional capital may not be available on favorable
	terms, or at all, which could compromise our ability to meet our financial obligations and grow our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that our existing cash
	and cash equivalents, including the net initial public offering proceeds, will enable us to fund our operating expenses and
	capital expenditure requirements for at least the next 24&nbsp;months. We have based this estimate on assumptions that may
	prove to be wrong, and we could use our capital resources sooner than we currently expect. We may require additional capital
	to finance acquisitions, to complete the clinical study and seek regulatory approval for Lutathera, development of
	Somakit, Annexin V-128 and other therapeutic and diagnostic candidates, expansion of our commercialization network for
	Lutathera, construction of a production site in Millburn, NJ, and potentially other such sites in the United States to
	produce Lutathera, development of an increasing presence within the United States and the recruitment and training of a
	significant number of employees in the middle to end of 2016 to be part of our U.S. sales force.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The maintenance and improvement of our
	business require successful development of experimental products for use in clinical trials, the design of clinical study protocols
	acceptable to the EMA, the FDA and other regulatory authorities, the successful outcome of clinical trials, scaling our manufacturing
	processes to produce commercial quantities or successfully transition technology, obtaining EMA, FDA and other regulatory approvals
	of our products or processes and successfully marketing an approved product or new product with our new process. To finance these
	various activities, we may need to incur future debt or issue additional equity, and we may not be able to structure our debt obligations
	or issue equity on favorable economic terms. A failure to fund these activities may harm our growth strategy, competitive position,
	quality compliance and could have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If adequate funds are not available on
	acceptable terms and on a timely basis, we may be required to delay, reduce the scope of or eliminate material parts of our business
	strategy, including forgoing development of existing and new product candidates. In addition, we may be unable to implement our
	business strategy and fund the expansion of our marketing, sales and R&amp;D efforts, increase working capital, take advantage
	of acquisition or other opportunities, or adequately respond to competitive pressures, which could seriously harm our business
	and results of operations. If we incur debt, the debt holders would have rights senior to shareholders to make claims on our assets,
	and the terms of any debt could restrict our operations, including our ability to pay dividends on our ordinary shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Furthermore, if we issue additional equity
	securities, shareholders will experience dilution, and we could issue securities with rights that are senior to those of our ordinary
	shares. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond
	our control, we cannot predict or estimate the amount, timing or nature of our future offerings. As a result, our shareholders
	bear the risk of our future securities offerings reducing the market price of the ADSs and diluting their interest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Future sales of our ordinary shares and
	the ADSs by existing shareholders or by us to raise capital could depress the market price of the ADSs.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If our existing shareholders sell, or
	indicate an intent to sell, substantial amounts of the ADSs in the public market after the 180-day contractual initial
	public offering lock-up, ending at May 8, 2016, and the other legal restrictions on resale discussed in this annual report on
	Form 20-F lapse, or if we indicate an intent to sell substantial amounts of our ordinary shares or ADSs to raise additional
	capital, the trading price of the ADSs could decline significantly and could decline below the initial public offering
	price.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	After the lock-up agreements pertaining
	to our initial public offering expire, and based on the number of ordinary shares outstanding at December 31, 2015, approximately
	33,886,906 additional ADSs (equivalent to 67,773,811 ordinary shares) will be eligible for sale in the public market, subject to
	any applicable volume limitations under Rule 144 under the Securities Act. In addition, the ordinary shares subject to our equity
	incentive plans and the shares reserved for future issuance under such plans will become eligible for sale in the public market
	in the future, subject to certain legal and contractual limitations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our Free Share Plans generally provide
	for a two-year vesting period for awards granted under the plans and an additional two-year holding period after vesting before
	free shares can be sold, except for certain beneficiaries who are non-French tax residents. When restrictions, if any, are lifted,
	ordinary shares issued under these plans may become eligible for sale in the public market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We intend to file one or more registration
	statements on Form S-8 with the SEC registering a number of ADSs for future issuance under our current and future equity incentive
	plans. Upon effectiveness of such registration statements, any ordinary shares subsequently issued under such plans will be eligible
	for sale in the public market, except to the extent that they are restricted by the lock-up agreements referred to above and subject
	to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the ordinary shares issued under these plans
	in the public market could have an adverse effect on the market price of the ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our by-laws and French corporate law
	contain provisions that may delay or discourage a takeover attempt.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Provisions contained in our by-laws and
	the corporate laws of France, the country in which we are incorporated, could make it more difficult for a third party to acquire
	us, even if doing so might be beneficial to our shareholders. In addition, provisions of our by-laws impose various procedural
	and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions
	include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	under French law, a non-resident of France may have to file an administrative notice with French authorities in connection
	with a direct or indirect investment in us, as defined by administrative rulings; see &ldquo;Item 10. Additional Information&mdash;B.
	Articles of Association&mdash;Limitations Affecting Shareholders of a French Company&rdquo;;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a merger (i.e., in a French law context, a share for share exchange following which our Company would be dissolved into the
	acquiring entity and our shareholders would become shareholders of the acquiring entity) of our Company into a company incorporated
	in the European Union would require the approval of our board of directors as well as a two-thirds majority of the votes held by
	the shareholders present, represented by proxy or voting by mail at the relevant meeting;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a merger of our Company into a company incorporated outside of the European Union would require 100% of our shareholders to
	approve it;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our shareholders may grant in the future our board of directors broad authorizations to increase our share capital or to issue
	additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors,
	including as a possible defense following the launching of a tender offer for our ordinary shares;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death of a director,
	subject to the approval by the shareholders of such appointment at the next shareholders&rsquo; meeting, which prevents shareholders
	from having the sole right to fill vacancies on our board of directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our board of directors can only be convened by our chairman (including upon request by a managing director to convene the board
	for a specific matter) or, when no board meeting has been held for more than two consecutive months, by directors representing
	at least one third of the total number of directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our board of directors meetings can only be regularly held if at least half of the directors attend either physically or by
	any other way, such as videoconference or teleconference, enabling the directors&rsquo; identification and ensuring their effective
	participation in the board&rsquo;s decisions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by mail at the
	relevant ordinary shareholders&rsquo; general meeting is required to remove directors with or without cause;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders&rsquo;
	meeting, except that a vote to remove and replace a director can be proposed at any shareholders&rsquo; meeting without notice;
	and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	pursuant to French law, the sections of our by-laws relating to the number of directors and election and removal of a director
	from office may only be modified by a resolution adopted by two-thirds of the votes of our shareholders present, represented by
	a proxy or voting by mail at the meeting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	You may not be able to exercise your
	right to vote the ordinary shares underlying your ADSs.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Holders of ADSs may exercise voting
	rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit
	agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the
	depositary will fix a record date for, among other things, the determination of ADS holders who shall be entitled to give
	instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall
	distribute to the holders as of the record date (1) the notice of the meeting or solicitation of consent or proxy sent by us;
	(2) a statement as to the manner in which instructions may be given by the holders and (3) a statement that the holders as of
	the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the
	underlying shares of the ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	You may instruct the depositary of your
	ADSs to vote the ordinary shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you
	withdraw the ordinary shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to
	withdraw those ordinary shares. If we ask for your instructions, the depositary, upon timely notice from us, will notify you of
	the upcoming vote and arrange to deliver our voting materials to you. We cannot guarantee you that you will receive the voting
	materials in time to ensure that you can instruct the depositary to vote your ordinary shares or to withdraw your ordinary shares
	so that you can vote them yourself. If the depositary does not receive timely voting instructions from you, it may give a proxy
	to a person designated by us to vote the ordinary shares underlying your ADSs. In addition, the depositary and its agents are not
	responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that
	you may not be able to exercise your right to vote, and there may be nothing you can do if the ordinary shares underlying your
	ADSs are not voted as you requested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Your right as a holder of ADSs to participate
	in any future preferential subscription rights or to elect to receive dividends in ordinary shares may be limited, which may cause
	dilution to your holdings.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	According to French law, if we issue additional
	securities for cash, current shareholders will have preferential subscription rights for these securities on a pro rata basis unless
	they waive those rights at an extraordinary meeting of our shareholders (by a two-thirds majority vote) or individually by each
	shareholder. However, our ADS holders in the United States will not be entitled to exercise or sell such rights unless we register
	the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements
	is available. In addition, the deposit agreement provides that the depositary need not make rights available to you unless the
	distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted
	from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive dividends
	in either cash or ordinary shares, under the deposit agreement the depositary may require satisfactory assurances from us that
	extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the
	option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights
	or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish
	an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings
	or to elect to receive dividends in ordinary shares and may experience dilution in their holdings. In addition, if the depositary
	is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will
	allow the rights to lapse, in which case you will receive no value for these rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	You may be subject to limitations on
	the transfer of your ADSs and the withdrawal of the underlying ordinary shares.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Your ADSs, which may be evidenced by ADRs,
	are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when
	it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register
	transfers of your ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary
	think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the
	deposit agreement, or for any other reason subject to your right to cancel your ADSs and withdraw the underlying ordinary shares.
	Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary
	has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting
	at a shareholders&rsquo; meeting or we are paying a dividend on our ordinary shares. In addition, you may not be able to cancel
	your ADSs and withdraw the underlying ordinary shares when you owe money for fees, taxes and similar charges and when it is necessary
	to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of
	ordinary shares or other deposited securities. There is currently no market for our underlying ordinary shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	As a FPI, we are exempt from a number
	of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company; our ordinary
	shares are not listed, and we do not currently intend to list our ordinary shares, on
	any market in France, our home country. This may limit the information available to holders of the ADSs.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are a &ldquo;foreign private issuer,&rdquo;
	as defined in the SEC&rsquo;s rules and regulations and, consequently, we are not subject to all of the disclosure requirements
	applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange
	Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations
	applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act.
	We are also exempt from Regulation FD, which regulates selective disclosures of material information by issuers. In addition, our
	officers and directors are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions of Section 16 of
	the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we expect to submit
	quarterly interim consolidated financial data to the SEC on Form 6-K, we are not be required to file periodic reports and financial
	statements with the SEC as frequently or as promptly as U.S. public companies and are not be required to file quarterly reports
	on Form 10-Q or current reports on Form 8-K under the Exchange Act. Furthermore, our ordinary shares are not listed, and we do
	not currently intend to list our ordinary shares, on any market in France, our home country. As a result, we are not subject to
	the reporting and other requirements of listed companies in France. In addition, we are not required to publish quarterly or semiannual
	financial statements in France. Accordingly, there will be less publicly available information concerning our Company than there
	would be if we were a U.S. public company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	As a FPI, we are permitted to adopt certain
	home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing
	standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate
	governance listing standards.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a FPI listed on the Nasdaq Global Select
	Market, we are subject to corporate governance listing standards. However, rules permit a FPI like us to follow the corporate governance
	practices of its home country. Certain corporate governance practices in France, which is our home country, may differ significantly
	from corporate governance listing standards. For example, neither the corporate laws of France nor our by-laws require a majority
	of our directors to be independent and our independent directors would not necessarily hold regularly scheduled meetings at which
	only independent directors are present. Currently, we intend to comply with the corporate governance listing standards of Nasdaq
	relating to a majority independent board to the extent possible under French law. However, if we choose to change such practice
	to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise would have
	under corporate governance listing standards applicable to U.S. domestic issuers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We may lose our FPI status in the future,
	which could result in significant additional cost and expense.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	While we currently qualify as a FPI, the
	determination of FPI status is made annually on the last business day of an issuer&rsquo;s most recently completed second fiscal
	quarter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the future, we would lose our FPI status
	if we fail to meet the requirements necessary to maintain our FPI status as of the relevant determination date. For example, if
	more than 50% of our securities are held by U.S. residents or more than 50% of our executive officers or members of our board of
	directors are residents or citizens of the United States, we could lose our FPI status.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The regulatory and compliance costs to
	us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a FPI. If we are not a
	FPI, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which
	are more detailed and extensive in certain respects than the forms available to a FPI. We would be required under current SEC rules
	to prepare our financial statements in accordance with U.S. GAAP, rather than IFRS, and modify certain of our policies to comply
	with corporate governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S.
	GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate
	governance requirements on U.S. stock exchanges that are available to FPIs such as the ones described above and exemptions from
	procedural requirements related to the solicitation of proxies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	U.S. investors may have difficulty enforcing
	civil liabilities against our Company and directors and senior management and the experts named in this annual report on Form 20-F.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Most of our directors and certain members
	of senior management, those of certain of our subsidiaries and the experts named in this annual report on Form 20-F are non-residents
	of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside of the
	United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments
	obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally,
	it may be difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Foreign
	courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most appropriate forums in which to
	bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which
	the foreign court resides, and not U.S. law, is applicable to the claim.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Further, if U.S. law is found to be applicable,
	the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters
	of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. In particular, there is
	some doubt as to whether French courts would recognize and enforce certain civil liabilities under U.S. securities laws in original
	actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions
	brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages under the U.S. securities
	laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered but is intended to
	punish the defendant. The enforceability of any judgment in France will depend on the particular facts of the case as well as the
	laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition
	and enforcement of judgments (other than arbitration awards) in civil and commercial matters. See &ldquo;Enforcement of Judgments.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	The rights of shareholders in companies
	subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the
	United States.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are a French company with limited liability.
	Our corporate affairs are governed by our by-laws and by the laws governing companies incorporated in France. The rights of shareholders
	and the responsibilities of members of our board of directors are in many ways different from the rights and obligations of shareholders
	in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our board of directors
	is required by French law to consider the interests of our Company, which also includes the interests of our shareholders, our
	employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties
	will have interests that are different from, or in addition to, your interests as a holder of ADSs. See &ldquo;Item 6. Directors,
	Senior Management and Employees&mdash;C. Board Practices&mdash;Corporate Governance Practices&rdquo; and &ldquo;Item 10. Additional
	Information&mdash;B. Articles of Association.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Transformation into a public company
	will increase our costs and disrupt the regular operations of our business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our initial public offering had a significant
	and transformative effect on us. Our business historically has operated as a privately owned company, and we expect to incur significant
	additional legal, accounting, reporting and other expenses as a result of having publicly traded ADSs. We will also incur costs
	which we have not incurred previously, including, but not limited to, costs and expenses for directors&rsquo; fees, increased director
	and officer liability insurance, investor relations expenses and various other costs of a public company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also anticipate that we will incur costs
	associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented
	by the SEC and Nasdaq. We expect these rules and regulations to increase our legal and financial compliance costs and make certain
	management and corporate governance activities more time-consuming and costly, particularly after we are no longer an &ldquo;emerging
	growth company.&rdquo; These rules and regulations may make it more difficult and more expensive for us to obtain director and
	officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher
	costs to obtain the same or similar coverage. This could have an adverse impact on our ability to recruit independent board members.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The additional demands associated with
	being a public company may disrupt regular operations of our business by diverting the attention of some of our senior management
	team away from sales-producing activities to management and administrative oversight, adversely affecting our ability to attract
	and complete business opportunities and increasing the difficulty in both retaining professionals and managing and growing our
	businesses. Any of these effects could harm our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	We are an &ldquo;emerging growth company&rdquo;
	and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the ADSs less
	attractive to investors.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are an &ldquo;emerging growth company,&rdquo;
	as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are
	applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being
	required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We cannot predict if
	investors will find the ADSs less attractive because we will rely on these exemptions. If some investors find our ADSs less attractive
	as a result, there may be a less active trading market for our ADSs and our ADS price may be more volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For as long as we are an &ldquo;emerging
	growth company&rdquo; under the recently enacted JOBS Act, our independent registered public accounting firm will not be required
	to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act.
	We could be an emerging growth company for up to five fiscal years following the date of our initial public offering. Furthermore,
	after the date we are no longer an emerging growth company, our independent registered public accounting firm will only be required
	to attest to the effectiveness of our internal control over financial reporting depending on our market capitalization. Even if
	our management concludes that our internal controls over financial reporting are effective, our independent registered public accounting
	firm may still decline to attest to our management&rsquo;s assessment, or may issue a report that is qualified, if it is not satisfied
	with our controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant
	requirements differently from us. In addition, in connection with the implementation of the necessary procedures and practices
	related to internal controls over financial reporting, we may identify deficiencies that we may not be able to remediate in time
	to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. Failure to comply with
	Section 404 could subject us to regulatory scrutiny and sanctions, impair our ability to increase sales, cause investors to lose
	confidence in the accuracy and completeness of our financial reports and negatively affect our share price and the price of the
	ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_KEY_INFORMATION>
<!-- FIELD: /PAGE -->
<EFX_COMPANY_INFORMATION>
<A NAME="FIS_COMPANY_INFORMATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM4">
</A>
	ITEM 4. INFORMATION ON THE COMPANY
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_HISTORYANDDEVELOPMENT">
</A>
	A.
</TD>
<TD>
	History and Development of the Company
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our legal and commercial name is Advanced
	Accelerator Applications S.A. We were incorporated as a s
<I>
	oci&eacute;t&eacute; anonyme
</I>
	, or S.A., under the laws of the French
	Republic on March&nbsp;29, 2002. We are registered on the Registry of Commerce and Companies of Bourg-en-Bresse under the number
	441 417 110. Our principal executive offices are located at 20 Rue Diesel 01630 Saint Genis Pouilly, France, and our telephone
	number is +33 (0) 4 50 99 30 70.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our website is www.adacap.com. The information
	contained on our website is not a part of this annual report on Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We were founded in 2002 by Mr. Buono, our
	CEO and a physicist who had previously worked at CERN with Nobel Physics Prize winner Carlo Rubbia, Paolo Pom&eacute;, a private
	equity firm partner, G&eacute;rard Ber, our COO and a pharmacist with 18 years&rsquo; experience in pharmaceutical and MNM sales
	and marketing, and Enrico de Maria, an engineer and the current CEO of our Italian subsidiary. In 2003 we constructed our first
	radiopharmaceutical laboratory in Saint-Genis-Pouilly, Rh&ocirc;ne-Alpes, France, the first of six laboratories that we constructed
	between 2003 and 2009. In December 2004 we obtained our first marketing authorization from Swiss authorities to commercialize Gluscan
	in Switzerland. We began production of Gluscan at our Saint-Genis-Pouilly site and have since added production sites in France
	and Italy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In December 2008, we acquired Gipharma,
	an Italian pharmaceutical contract manufacturer for small-volume injectable and freeze-dried solutions, specializing in SPECT radiopharmaceuticals.
	In 2010 we made an initial equity investment in Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company
	headquartered in Ottawa, Canada, to help progress its leading compound Annexin V-128 into a Phase 1/2 trial for early diagnosis
	of rheumatoid arthritis. In 2010, we also acquired BioSynthema, which specialized in MNM discovery, and with it Lutathera, our
	lead therapeutic product candidate, which we have advanced through a pivotal Phase 3 trial for the treatment of progressive midgut
	NETs that has produced positive initial results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Over the last several years, we have expanded
	our European MNM manufacturing network, entering new markets and strengthening our position in existing territories. Highlights
	of our expansion include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in January 2016, acquiring 100% of the shares of the IDB Group, or IDB. IDB is a leading manufacturer of Lu-177. IDB produces,
	markets and sells Lu-177 under the brand name LuMark&reg;, which it has established as the leading brand of Lu-177 worldwide. LuMark&reg;
	is the only Lu-177 product to have received European marketing authorization. We believe that, in line with our vertical integration
	strategy, acquiring IDB will enable AAA to obtain a reliable supply of Lu-177 for production of Lutathera and certain of our future
	potential product candidates.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in July 2015, acquiring a production site in Millburn, NJ that we are currently retrofitting to develop manufacturing capacity
	to support our commercialization of Lutathera in the United States. We expect to complete construction at the facility in the second
	quarter of 2016, and intend to start manufacturing operations there in the first quarter of 2017 after receiving all necessary
	authorizations and licenses;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in May and June 2015, successfully completing private placements through which we raised a total of&thinsp; &euro;23.1 million
	(US$25.1 million), providing additional financing for clinical development of our portfolio of MNM diagnostic and therapeutic products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in December 2014, acquiring the remaining 49.9% of Atreus to become its sole owner. The complete ownership of Atreus facilitates
	our R&amp;D efforts for Annexin V-128 and, if we are successful in obtaining market authorization, we believe it will allow us
	to better exploit the commercial potential of Annexin V-128;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in December 2014, acquiring the remaining 49.9% of AAA Germany GmbH (formerly Umbra), a German radiopharmaceutical company,
	to become its sole owner. We had initially acquired a 50.1% stake in Umbra, giving us our first direct presence in Germany, in
	February 2012. We paid &euro;1.2 million (US$1.3 million) in cash for the purchase price for the remaining share ownership;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in the third quarter of 2014, entering into an agreement with GE Healthcare to acquire its Italian FDG PET imaging agent business,
	GE Healthcare S.r.L., for &euro;0.7 million (US$0.8 million) in cash over the next two years and &euro;0.6 million (US$0.7 million)
	in estimated royalty payments to be made between September 2015 and September 2017. The acquisition reinforces our position as
	one of the leading companies in the PET market in Italy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in the second quarter of 2014, expanding into the United States and establishing an office in New York as part of our early
	efforts to build a commercialization platform for Lutathera in the United States;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in February 2014, successfully completing a capital increase of&thinsp; &euro;41.1 million (US$46.0 million), allowing us to
	accelerate our international expansion, including an increased presence in the United States, and helping us to finance the clinical
	development of our portfolio of MNM diagnostic and therapeutic products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in February 2014, acquiring 100% of IEL, a privately held UK distributor of nuclear medicine products and technologies. The
	acquisition gives us our first direct presence in the United Kingdom and Ireland, expanding our existing services and expertise
	in nuclear medicine and providing us with an established manufacturing and commercialization platform. IEL generated sales of approximately
	&euro;10.3 million (US$11.5 million) for the year ended December 31, 2013, an increase of 51% over the previous year; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	entering the Polish market in January 2013 following a long-term collaboration agreement with the University of Warsaw. We
	are managing the University&rsquo;s Radiopharmaceutical Production and Research Centre and began manufacturing Gluscan for hospitals
	in Poland in October 2014.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_BUSINESSOVERVIEW">
</A>
	B.
</TD>
<TD>
	Business Overview
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are an innovative radiopharmaceutical
	company that develops, produces and commercializes MNM products. MNM is a medical specialty that uses trace amounts of radioactive
	compounds to treat diseases such as cancer and create functional images of organs and lesions. Our lead therapeutic product candidate,
	Lutathera, is a novel MNM compound that we are currently developing for the treatment of NETs, a significant unmet medical need.
	Lutathera is a Lu-177 labeled somatostatin analogue peptide that has received orphan drug designation from the EMA and FDA. Lutathera
	was also granted Fast-Track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. The FDA
	provides Fast-Track designation to product candidates that treat serious conditions and fill an unmet medical need in order to
	facilitate their development and expedite their review. In a pivotal Phase 3 trial for the treatment of inoperable progressive
	midgut NETs, Lutathera combined with Octreotide LAR has produced favorable initial results compared to the current standard of
	care, treatment with Octreotide LAR alone. Lutathera is also currently administered on a compassionate use and named patient basis
	for the treatment of NETs in ten European countries, and we estimate that Lutathera has been used in over 3,000 patients to date.
	We have also built a leadership position in nuclear medicine diagnostics in Europe by manufacturing and commercializing our broad
	portfolio of six diagnostic products for a number of clinical indications, and by selectively acquiring and integrating complementary
	businesses and assets. We leverage our leadership position, industry experience, and know-how to pursue targeted development strategies
	to enable promising pathways to product approval. Our total sales have grown from &euro;69.9 million (US$75.9 million) for the
	year ended December&nbsp;31, 2014 to &euro;88.6 million (US$96.2 million) for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are advancing the MNT branch of
	our MNM business, with our novel lead therapeutic candidate, Lutathera, a Lu-177-labeled somatostatin analogue peptide having
	undergone a pivotal Phase 3 trial for patients with inoperable progressive midgut NETs. NETs are a heterogeneous group of
	tumors originating in the neuroendocrine cells of the body, and approximately two thirds of NETs arise in the
	gastro-entero-pancreatic tract. Somatostatin is an important regulator of the endocrine system and somatostatin analogues
	have been approved for symptomatic treatment of NETs since 1987. There are currently no approved radiopharmaceutical
	treatments for most NETs, representing a significant unmet medical need in an orphan indication for which we believe
	Lutathera shows significant promise. The Phase 3 trial concluded recruitment in February 2015, and we have finalized the
	trial&rsquo;s database (confirming that all data contained therein is final) after verifying and ensuring incorporation of
	all trial data, and after confirming the occurrence of the predefined number of progression events required to conclude the
	trial to enable conclusive statistical analysis. Upon finalizing the trial database we completed an analysis of the
	trial&rsquo;s primary endpoint of PFS. We presented the results of our analysis in an Oral Presentation at the Presidential
	Session on September 27, 2015 at the ESMO conference. This presentation related to the efficacy results for the primary endpoint of PFS and
	two secondary endpoints of objective response rate and overall survival. Updated information was also presented at the
	North American Neuroendocrine Tumor Society (NANETS) conference in October 2015, the Gastrointestinal Cancers Symposium of
	ASCO (American Society for Clinical Oncology) conference in January 2016 and the European Neuroendocrine Tumor Society
	(ENETS) conference in March 2016. As expected, the complete safety and efficacy analysis for the trial was available in the
	first quarter of 2016, and the clinical study report has been finalized in April 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Phase 3 trial is a multi-center,
	randomized, comparator-controlled, parallel-group study evaluating the efficacy and safety of Lutathera combined with
	Octreotide LAR 30 mg compared to Octreotide LAR 60 mg alone. Lutathera demonstrated a significant improvement in the primary
	endpoint, assessing PFS. There were 23 confirmed progression event deaths in the Lutathera arm and 68 confirmed progression
	event deaths in the Octreotide LAR 60 mg arm. The median PFS for the Octreotide LAR 60 mg arm was 8.4 months while the median
	PFS for the Lutathera arm had not yet been reached by the time of the analysis, meaning that more than 50% of the patients in
	the Lutathera arm had survived without any progression event at that time. For a more detailed description of the results of
	the Phase 3 trial, see &ldquo;&mdash;&thinsp;Our Product Candidates in Clinical Development&mdash;Lead Therapeutic
	Candidate&mdash;Lutathera&mdash;Phase 3 Trial.&rdquo; We have submitted the NDA to the FDA and the MAA to the EMA for
	Lutathera in April 2016. In addition, on the basis, in part, of positive initial safety and efficacy results in earlier
	trials for both midgut NETs and NETs in general, physicians treating NET patients have sought and have received authorization
	to use Lutathera on a compassionate use and named patient basis in ten European countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have formulated Lutathera with a three-day
	shelf life, which we believe will enable us to efficiently produce and distribute it in the European Union through our European
	manufacturing and commercialization infrastructure. To further support our production of Lutathera and future product candidates,
	we acquired the IDB Group in January 2016, providing us with what we believe to be a reliable production source of Lu-177. In the
	United States, we have begun construction of a production facility for Lutathera in New Jersey that will provide the U.S. supply
	of Lutathera. If approved, we intend to commercialize Lutathera in the United States with a targeted oncology-focused sales force,
	which we are currently establishing. Additionally, in June 2015 we entered into an exclusive distribution and license agreement
	for Lutathera in Japan with FRI, a leading in-country distributor of nuclear medicine and diagnostic imaging products. Our agreement
	calls for FRI to finance and conduct its own bridging study, and then to submit its findings to the applicable regulatory authorities
	in Japan for approval. We intend to support this process by manufacturing Lutathera for FRI&rsquo;s study and providing supplementary
	data from our previous clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are also a strong European player in
	MNM diagnostics with a portfolio of six diagnostic PET and SPECT products. PET and SPECT are imaging techniques in MND with applications
	in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Our leading diagnostic product is Gluscan, our
	branded FDG PET imaging agent. Gluscan assists in the diagnosis of serious medical conditions, primarily in oncology, by assessing
	glucose metabolism. We are building on our diagnostics foundation by developing additional MND product candidates to further strengthen
	our existing portfolio. We have submitted a MAA to the EMA for Somakit-TOC and have submitted a NDA to the FDA for Somakit-TATE,
	which are Lutathera&rsquo;s companion PET diagnostic candidates. Both Somakit products have received orphan drug designation in
	the European Union and the United States. We have implemented a strategy of developing these two similar, but structurally different,
	Somakit products to help ensure regulatory exclusivity for one or both Somakit products in the European Union and the United States.
	In addition, we have initiated Phase 1/2 clinical trials for Annexin V-128 a SPECT product candidate for the imaging of apoptotic
	and necrotic lesions with applications in a broad range of indications such as assessment of rheumatoid arthritis and spondyloarthritis,
	diagnosis of atherosclerosis and atherosclerosis advanced lesions, and assessment of chemotherapy-induced cardiotoxicity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We manufacture a majority of our products
	at our 17 production sites as of end of March 2016. We also have two other sites under construction, including one in Millburn,
	NJ that we are retrofitting to enable it to produce Lutathera and one in Murcia, Spain that we acquired for purposes of manufacturing
	PET products. The Millburn site is expected to be operational in first half of 2017, the one in Murcia site in the second half
	of 2016. Our PET production sites are strategically positioned close to our customers. We sell our products through our sales
	and marketing network. We employ 441 employees as of end of March 2016 throughout Europe, North America and Israel. We have a
	direct sales and marketing presence in eight countries and generate sales in 19 countries (excluding markets where IDB is selling).
	This platform enables us to secure production and sales from partnerships of choice with global healthcare players, including
	large pharmaceutical companies, for whom we manufacture MNM products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The global MNM market was estimated at
	approximately US$4.3 billion as of December&nbsp;31, 2014 (with 92% of sales in MND and 8% of sales in MNT) according to MEDraysintell.
	While the market is largely concentrated in MND, where we believe we have a leading position in Europe, MNT represents a fast-growing
	field in MNM. MEDraysintell projects that MNT sales may constitute up to US$13.0 billion of total MNM sales of US$24.0 billion
	by 2030, representing a compound annual growth rate of 30%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Strengths
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	A late-stage radiopharmaceutical therapeutic candidate targeting midgut NETs:
</B>
	&nbsp;&nbsp;Lutathera is an innovative
	therapeutic candidate with orphan drug status in the United States and the European Union and Fast-Track designation in the United
	States. We received positive data in the fourth quarter of 2015 from a pivotal Phase 3 trial evaluating the efficacy and safety
	of Lutathera combined with Octreotide LAR 30 mg compared to Octreotide LAR 60 mg alone. In an analysis of the trial&rsquo;s primary
	endpoint of PFS assessment, completed by the Company in September 2015, the Lutathera arm demonstrated a significant improvement
	in PFS compared to the PFS for Octreotide LAR 60 mg arm. As of December&nbsp;31, 2015, Lutathera has been administered to over
	3,400 NET patients in various studies and has received approval for use in compassionate use and named patient programs in ten
	countries in Europe. As of March 31, 2016, Lutathera has been administered to over 1,180 patients in over 59 centers across Europe
	under such programs, for which we have delivered, through third parties, over 2,980 doses of Lutathera. An Expanded Access Program
	for Lutathera has also been activated in the United States in March 2016. Moreover, Lutathera is the only PRRT product candidate
	to have gone through a Phase 3 clinical trial. PRRT is an emerging form of treatment for patients with inoperable somatostatin-receptor-positive
	NETs that involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides, and has been incorporated into
	the treatment guidelines for NETs published by ENETS, NANETS and ESMO. We believe Lutathera has the potential to become a new paradigm
	for the treatment of midgut NETs and of NETs more broadly, since up to 80% of NETs are somatostatin-receptor-positive.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Leveraging our leadership position and vertical integration to produce differentiated MNM products:
</B>
	&nbsp;&nbsp;We have
	developed significant expertise and established an integrated R&amp;D, manufacturing and commercialization infrastructure to become
	a leading player in the growing MNM market. We believe our leading position in European MNM is underpinned by our (i)&nbsp;pan-European
	presence, (ii) proximity to our more than 200 principal customers through our PET production facilities, a key advantage given
	the short half-life of PET and other MNM products, (iii) scalable and modular manufacturing, (iv) extensive scientific know-how
	and (v)&nbsp;ongoing interaction with the healthcare field through hospitals, universities and research centers. We have R&amp;D
	teams based in seven of our production facilities (in addition to our dedicated R&amp;D facility in Nantes, France), which allows
	them to link practical manufacturing know-how to pipeline product candidate development to maximize the opportunity for commercial
	success. This setup allows us to exploit synergies between manufacturing and R&amp;D and enabled us to advance Lutathera with a
	new formulation targeting midgut NETs soon after we acquired it.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Diversified, attractive product candidate development pipeline:
</B>
	&nbsp;&nbsp;We leverage our successful diagnostics business
	to invest in multiple avenues of growth by developing product candidates across the therapy, PET and SPECT categories of radiopharmaceuticals,
	including mid- and late-stage product candidates. In addition to Lutathera, we are advancing diagnostic and therapeutic product
	candidates that are currently in clinical trials and preclinical studies. Our Somakit products (which we also refer to, together,
	as Somakit), our companion PET diagnostic product candidates for Lutathera, are novel kits in development for radiolabeling somatostatin
	analogue peptides to help diagnose somatostatin-receptor-positive NET lesions, and each kit has been designated as an orphan drug
	by the EMA and the FDA. The Somakit products have the potential to offer a standardized procedure for producing diagnostic compounds
	that reduces customers&rsquo; need for expensive equipment and quality control testing. The NDA for Somakit-TATE was filed with
	the FDA on July 1, 2015 and we plan to file a MAA with the EMA in the first half of 2018. Depending on the exclusivity afforded
	by the orphan protection of Somakit TATE in the US we may submit an NDA for Somakit-TOC to the FDA and have submitted the MAA to
	the EMA in October 2015. In the United States, Europe, and Canada, we are also developing Annexin V-128, a SPECT diagnostic candidate
	for apoptosis and necrosis, which are present in a number of pathological conditions in oncology and
	cardiovascular diseases, as well as in autoimmune disorders. Annexin V-128 is currently in Phase 1/2 clinical trials to evaluate
	its safety, pharmacokinetics and dosimetry in patients with rheumatoid arthritis or ankylosing spondylitis. Two Phase 2 clinical
	trials have been initiated in April 2016, one in artherosclerotic carotid plaque indication, and one in early detection of chemotherapy-induced
	cardiotoxicity in breast cancer patients. 177Lu-PSMA-SR6 and 68Ga-PSMA-SR6 are in development to treat, image, monitor and stage
	prostate cancer. 177Lu-PSMA-SR6 will be aimed at treating and monitoring prostate cancer and 68Ga-PSMA-SR6 should act as its companion
	diagnostic and help diagnose and stage the disease. AAA has signed an exclusive license agreement with Johns Hopkins University
	in Baltimore, Maryland to develop and market PSMA-SR6, in prostate cancer. A proof-of-concept study in humans is planned for 2016.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Established MNM platform in a market characterized by significant barriers to entry:
</B>
	&nbsp;&nbsp;The MNM market is characterized
	by logistical, manufacturing and regulatory complexities that make entry into the market difficult. We believe that, to be successful,
	a prospective entrant into the market must develop advanced manufacturing know-how, invest significant time and considerable resources
	into the construction of a production infrastructure subject to stringent regulatory requirements, operate on a scale that enables
	the cost-effective manufacture and sale of complex products and efficiently arrange for the distribution of these products. We
	believe that we have overcome these barriers with a network of 16 production facilities across Europe, all of which we believe
	operate in conformity with cGMP, including two recently added facilities in Bonn, Germany and Warsaw, Poland that began operations
	in July&nbsp;2014. We also have two other sites under construction, including one in Millburn, NJ that we are retrofitting to enable
	it to produce Lutathera and one in Murcia, Spain that we acquired for purposes of manufacturing PET products. Both sites are expected
	to be operational in early 2017. This network provides the basis for our advanced manufacturing capacity, cost-efficient production
	and organization of reliable product distribution. Our network has a longstanding track record of supplying high-quality products
	to our customers. The combination of our pan-European platform, our production infrastructure and our proven and reliable logistical
	capabilities has enabled us to secure significant customer loyalty and establish our position as a partner for global players,
	such as GE&nbsp;Healthcare and Eli Lilly, for the production of their molecular diagnostic products.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Highly qualified and experienced management team with a proven track record of launching innovative products and successfully
	integrating acquired companies:
</B>
	&nbsp;&nbsp;Our senior management team combines extensive experience in the MNM market with
	continuity of leadership. Our founding members still direct our strategy and development 14 years after our inception, and our
	senior management team has combined MNM industry experience of more than 50 years. To complement our organic growth, we have acquired,
	in a series of eleven transactions since 2009, businesses and promising product candidates that further leverage our logistical
	infrastructure, as well as manufacturing facilities to expand our existing network and enter into new markets. We carry over our
	commitment to leadership continuity into our acquisition strategy by retaining key management and other personnel in acquired companies
	while executing our plan to integrate these acquisitions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Strategy
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Obtain approval for Lutathera in the United States and Europe:
</B>
	&nbsp;&nbsp;We believe Lutathera is a promising
	therapeutic candidate, initially for progressive midgut NETs, a significant unmet medical need, and potentially for related
	indications. In light of the initial positive results of Lutathera&rsquo;s pivotal Phase 3 trial, we were allowed by the FDA
	to submit the NDA in a rolling fashion. In April 2016, we have completed the NDA submission to the FDA and submitted the MAA
	to the
	EMA for
	Lutathera. The FDA and the EMA have historically allowed approval based on a single Phase 3
	trial where the trial is well-designed, well-conducted and internally consistent, and provides statistically persuasive
	efficacy findings such that confirmation of the trial results in a second trial would be ethically or practically
	impossible.
	We believe
	that our Phase 3 trial results will meet this threshold based upon (i) our discussions with the FDA and the EMA
	regarding the allowance of market access based upon a single trial (if successful), (ii) our Phase 3 trial&rsquo;s large
	randomized patient pool, which has allowed us to demonstrate what we believe to be a significant improvement in primary
	endpoint PFS, as well as improvement in overall survival, compared to the current standard of care, (iii) the current lack
	of available
	therapy for patients in Lutathera&rsquo;s targeted indication and (iv) Lutathera&rsquo;s receipt of Fast-Track
	designation from the FDA.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Commercialize Lutathera in the United States and Europe:
</B>
	&nbsp;&nbsp;In order to support the launch of Lutathera, we
	built and currently operate two manufacturing facilities in Italy and we have modified our production site at Zaragoza in Spain
	in 2015. We estimate that these sites may be sufficient to produce the expected global commercial supply of Lutathera. Additionally,
	we have purchased a Millburn, NJ facility that we are currently retrofitting with completion scheduled in the second quarter of
	2016. We intend to start manufacturing operations at the Millburn facility in the first half of 2017 after receiving all necessary
	authorizations and licenses to optimize our commercialization efforts in the U.S. market. We intend to commercialize Lutathera
	with our own sales force in the United States, as well as in the EU5 (France, UK, Spain, Italy and Germany). Because midgut NET
	is an orphan indication with a limited number of available treatment options, patient populations are often highly organized, including
	through the formation of patient advocacy groups, which can facilitate our identification of and access to patients. The midgut
	NET indication&rsquo;s orphan disease designation also means that treatment trends are heavily influenced by key opinion leaders
	located in a limited number of centers of excellence. We have identified approximately 50 nuclear medicine centers in the United
	States that we believe treat over 80% of midgut NET patients in the United States. Similarly, we have identified approximately
	80 nuclear medicine centers in the EU5 that we believe treat over 80% of midgut NET patients in the EU5. We believe we can efficiently
	target these nuclear medicine centers with a specialty sales force of approximately 13 sales representatives and three field-based
	market access specialists in the United States and approximately 30 sales representatives in the EU5. Our commercial leadership
	team is already in place and we are currently in the early stages of establishing our commercial infrastructure, including sales
	representatives, medical affairs, marketing, market access, market research, sales force effectiveness and strategic planning.
	We anticipate commencing marketing for Lutathera in these geographic areas soon after FDA and/or EMA approval. Outside of the United
	States and EU5 we intend to contract with select partners to commercialize Lutathera. For example, in June 2015 we entered into
	an exclusive distribution and license agreement for Lutathera in Japan with FRI to finance and conduct its own bridging study,
	and then to submit its findings to the applicable regulatory authorities in Japan for approval.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Maximize the value of our diagnostic portfolio and advance our diagnostic product pipeline:
</B>
	&nbsp;&nbsp;We aim to leverage
	our pan-European presence and R&amp;D capabilities to drive further growth of our existing products and successfully develop new
	product candidates. First, we intend to broaden our customer base by entering into new manufacturing and licensing agreements in
	our existing markets, targeting hospitals with whom we do not currently have relationships and marketing our diagnostic MNM products
	in new markets. Second, we intend to use our know-how to increase efficiencies in the production of our key products by reducing
	costs, improving processes and increasing profitability margins. Finally, we are working to advance our diagnostic candidates,
	including Somakit and Annexin V-128, through important clinical and preclinical phases of development, in addition to seeking the
	requisite regulatory approvals for their future commercialization. 177Lu-PSMA-SR6 and 68Ga-PSMA-SR6 are in development to treat,
	image, monitor and stage prostate cancer. 177Lu-PSMA-SR6 will be aimed at treating and monitoring prostate cancer and 68Ga-PSMA-SR6
	should act as its companion diagnostic and help diagnose and stage the disease. AAA has signed an exclusive license agreement with
	Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, in prostate cancer. A proof-of-concept study in
	humans is planned for 2016.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Pursue strategic acquisitions:
</B>
	&nbsp;&nbsp;We have a track record of identifying, acquiring and integrating businesses
	and assets into our Company that we believe hold strategic value to us, having acquired and integrated seven commercial-stage companies,
	two development-stage companies, one promising product candidate, a manufacturing and distribution business and one manufacturing
	facility since 2009. We expect to continue to target acquisitions that will further build our product pipeline and expand our production
	capacity and geographic coverage. We have augmented our product pipeline in part by acquiring companies that are already developing
	product candidates that we believe will be successful, as we did by purchasing BioSynthema to acquire rights to Lutathera, and
	by acquiring Atreus to develop Annexin V-128 in Europe and Canada. We also target acquisitions that will enable us to better vertically
	integrate key components of the radiopharmaceutical production chain as we did by acquiring IDB Group in early 2016. In the case
	of each acquisition, we take a disciplined approach to analyzing the target&rsquo;s compatibility with our existing development,
	manufacturing and commercialization infrastructure. More broadly, our aim in targeting specific acquisitions is to further consolidate
	our position as a leading pan-European nuclear diagnostics company while exploring additional product pipeline
	opportunities and avenues for expansion in the United States and outside Europe.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
	Leverage our platform to pursue additional strategic partnerships:
</B>
	&nbsp;&nbsp;We plan to explore new opportunities to
	work with global pharmaceutical companies that would supplement our current production of their diagnostic products and strengthen
	our business relationships. In addition, we intend to pursue a three-pronged strategy for establishing important new industry partnerships.
	First, we intend to leverage our manufacturing expertise to in-license additional compounds. Second, we intend to capitalize on
	our R&amp;D efforts and healthcare industry connections to strategically out-license our products to others. Third, we plan to
	use our expertise in manufacturing diagnostics to explore the potential for working with pharmaceutical companies to develop companion
	diagnostics with those companies. We believe that these efforts will further enhance our reputation as a leading European MNM company
	while broadening our industry experience.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Industry
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	MNM is a medical specialty that involves
	the use of trace amounts of radioactive substances called radiopharmaceuticals or radiotracers to create functional images of the
	body and its organs (MND) and to treat various diseases, such as cancer (MNT). Radiopharmaceuticals injected into patients before
	a MND procedure leave a radioactive trace that is detected by special PET and SPECT cameras, which utilize different processes
	in tandem with computers to provide detailed functional images of the areas of the body being investigated. These images allow
	physicians to see the body&rsquo;s internal workings and to analyze its chemical and biological processes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Nuclear medicine procedures can identify
	abnormalities very early in the progress of a disease&mdash;often before many medical problems become apparent with conventional
	imaging such as radiological imaging or ultrasound. MND procedures provide what we believe are significant advantages over traditional
	diagnostic imaging because they:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	enable drug tracing and provide functional images of molecular-level physiological functions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	provide an alternative to more invasive procedures such as biopsy or surgery;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	enable cost savings and improve patient comfort versus invasive procedures;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	provide support in the development of new treatments and in the monitoring of patients; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	provide support to the physicians in the disease management process (treatment algorithm decision process).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The global MNM market was estimated at
	approximately US$4.3 billion as of December&nbsp;31, 2014 (with 92% of sales in MND and 8% of sales in MNT) according to MEDraysintell.
	While the market is largely concentrated in MND, where we believe we have a leading position in Europe, MNT represents a fast-growing
	field in MNM. MEDraysintell projects that MNT sales may constitute up to US$13.0 billion of total MNM sales of US$24.0 billion
	by 2030, representing a compound annual growth rate of 30%. New indications are increasingly being evaluated for MNM radiopharmaceuticals,
	particularly in the diagnosis and treatment of cognitive diseases, which are a growing medical burden across many countries due
	to the aging global population.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The World Nuclear Association estimates
	that approximately 10 million and 15 million diagnostic procedures are undertaken annually in Europe and the United States, respectively,
	according to an April&nbsp;2014 Bio-Tech Systems, Inc. report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Below is a graph showing the worldwide
	sales forecast for MNM products in PET and SPECT diagnostics and in therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_001.JPG" ALT="" STYLE="HEIGHT: 330PX; WIDTH: 511PX">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Source:&nbsp;&nbsp;&nbsp;MEDraysintell 2014 report &mdash;
	Opportunities in nuclear medicine &mdash; radioisotopes, radiopharmaceuticals
</I>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Therapeutics
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	MNT is an innovative therapeutic modality
	that combines two approaches: tumor targeting and radiation. Tumor targeting allows drugs to selectively enter unhealthy cells
	due to the affinity between the drug and certain receptors expressed by the diseased cells. The few MNT products registered as
	of December&nbsp;31, 2015 are anti-cancer drugs. Unlike traditional chemotherapy drugs, which target both cancerous and healthy
	cells, this approach can enable a more tailored and effective treatment with minimal side effects. Two types of radiation can be
	emitted by these products: a gamma ray, used to make SPECT images, or a beta particle, an energetic electron that destroys the
	DNA of the tumor.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The MNT market is projected to be a significant
	long-term growth driver of the MNM market with an expected average annual growth of 30% between 2013 and 2030, according to MEDraysintell.
	MNT has the potential to generate high margins as costs for therapeutic products can be reimbursed at a rate of up to 100 times
	the cost of diagnostic products. Most of the MNT products in development are found at smaller companies. We believe that there
	are currently three notable radiopharmaceutical products in the market:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Xofigo
<SUP>
	&reg;
</SUP>
	, from Bayer Pharmaceuticals (acquired from Algeta), indicated for the treatment of patients with castration-resistant
	prostate cancer, symptomatic bone metastases and no known visceral metastatic disease;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Zevalin
<SUP>
	&reg;
</SUP>
	, from Spectrum Pharmaceuticals, a radiolabeled antibody for the treatment of relapsed or refractory
	low grade, follicular, or transformed B-cell non-Hodgkin&rsquo;s lymphoma, including patients with Rituxan refractory follicular
	NHL; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Bexxar
<SUP>
	&reg;
</SUP>
	, from GSK, indicated for the treatment of patients with CD20-positive relapsed or refractory, low grade,
	follicular, or transformed non-Hodgkin&rsquo;s lymphoma.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Product Candidates in Clinical Development
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Lead Therapeutic Candidate &mdash; Lutathera
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera is a ready-to-inject solution
	of a Lu-177-labeled analogue of somatostatin, a hormone that acts as an important regulator of the endocrine system. Somatostatin
	analogues are synthetic versions of this hormone and have been approved for symptomatic treatment of NETs since 1987. Many radiolabeled
	analogues have been used in past published studies to treat NETs expressing somatostatin receptors. A radiolabeled analogue is
	a peptide that carries a radioactive isotope such as Lu-177 within its overall structure. Lutathera has three components:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the somatostatin analogue Octreotate (the peptide targeting the NET cells);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	DOTA, a compound able to combine metals (such as Lu-177) into complexes through a ring structure; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Lu-177, a radioisotope.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera is the first ever PRRT radiopharmaceutical
	product candidate to have completed a Phase 3 trial for the treatment of progressive midgut NETs. Existing approaches to treatment
	of progressive midgut NETs, described below, are associated with serious side effects and low-to-moderate efficacy and there are
	currently no approved radiopharmaceutical treatments available for progressive midgut NETs (a subgroup of all NETs).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Accordingly, we believe that Lutathera
	addresses a significant unmet medical need, a belief supported by the FDA&rsquo;s grant of Fast-Track designation to Lutathera
	in April 2015. Fast-Track is a designation that the FDA provides when a product candidate treats a serious condition and fills
	an unmet medical need in order to facilitate the product candidate&rsquo;s development and expedite review. Similarly, Lutathera
	has been granted an Authorization for Temporary Use from the
<I>
	Agence Nationale de S&eacute;curit&eacute; du M&eacute;dicament
</I>
	in France in order to facilitate its development and expedite review, as well as provide immediate access to patients while we
	are in the process of preparing the relevant regulatory submissions in the European Union. We also believe that Lutathera&rsquo;s
	potential to provide imaging data at the same time as it treats progressive midgut NETs is an advancement toward tailored treatment
	of patients, as it would allow physicians to monitor each patient&rsquo;s responsiveness to the therapy throughout the treatment
	process, should they wish to do so. Lutathera has been approved on a compassionate use and named patient basis in ten European
	countries not only for the treatment of midgut NETs, but for all NETs expressing somatostatin receptors (approximately 80% of all
	NETs).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The table below shows overall incidence
	of NETs versus all malignant neoplasms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_002.JPG" ALT="" STYLE="HEIGHT: 359PX; WIDTH: 575PX">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Source:&nbsp;&nbsp;&nbsp;Yao et al., One hundred years after
	&ldquo;carcinoid&rdquo;: epidemiology of and prognostic factors for NET in 35,825 cases in the US. J. Clinical Oncology 26:3063-3072;
	SEER: National Cancer Institute&rsquo;s Surveillance, Epidemiology and End Results.
</I>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	The Treatment Opportunity
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	NETs are rare, heterogeneous tumors originating
	from dispersed neuroendocrine cells that are distributed throughout the body. The term &ldquo;neuroendocrine&rdquo; relates to
	the ability of these cells to synthesize, store and secrete neuro-hormones, neuro-transmitters or neuro-modulators, which are produced
	by both the endocrine and the nervous systems. NETs arising in the neuroendocrine cells of the gastro-entero-pancreatic tract are
	the second most common type of gastrointestinal malignancy in the United States. It is estimated that approximately two thirds
	of all NETs are NETs located in the gastro-entero-pancreatic tract. The age-adjusted incidence rate, representing the number of
	new cases in the United States for the years 2003&thinsp;&ndash;&thinsp;2007, for NETs is 5.76 per 100,000 inhabitants, according
	to data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database, as presented in an article
	in the Journal of Clinical Endocrinology &amp; Metabolism in 2011. Based on U.S. Census data and European Union census data, we
	estimate the incidence for NETs for the combined populations of the United States and the European Union in 2013 was approximately
	47,300. Midgut NETs, which are those NETs that arise in the small bowel and the first portion of the colon (the midgut), make up
	approximately 20.47% of patients from the SEER database of all NETs for 2000&thinsp;&ndash;&thinsp;2007. Based on U.S. Census data
	and European Union census data, we estimate that the number of patients in the combined populations of the United States and European
	Union was approximately 9,690 in 2013. According to an article published in the European Journal of Nuclear Medicine and Molecular
	Imaging, 96% of midgut NETs over-express SSTR2 (which is the target receptor for our diagnostic and therapeutic product candidates).
	As a result, we estimate, based on U.S. Census data and European Union census data, that approximately 9,300 patients had SSTR2-positive
	midgut NETs in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Because midgut NETs are generally slow-growing
	tumors, the number of existing patients is significantly larger than the yearly incidence number. According to an article published
	in the Journal of Clinical Oncology in 2008 that analyzes SEER data from 1973&thinsp;&ndash;&thinsp;2004, we estimate the prevalence
	of midgut NETs today to be approximately 58,900 patients in total in the United States and the European Union, of which approximately
	56,500 over-express SSTR2 receptors. No anti-proliferative treatments are currently available in the midgut NET indication, meaning
	that Lutathera has the potential to be used in treatment of a significant number of midgut NET patients. We believe that, in addition
	to the incidence of midgut NETs increasing, the number of patients diagnosed with midgut NETs is also increasing due to better diagnostic tools
	and other factors leading to more frequent identification of these tumors in patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a product candidate designed to treat
	these tumors, Lutathera has received orphan drug designation in the United States and in the European Union from the FDA and the
	EMA, respectively, for all NETs. In the United States, orphan drugs are defined as drugs that treat diseases or conditions that
	affect 200,000 or fewer individuals in the country. In the European Union, orphan drugs are defined as medicinal products that
	are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not
	more than five out of 10,000 individuals in the European Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that there are significant benefits
	to orphan drug designation, particularly where, as is the case for Lutathera and the Somakit products, product candidates have
	limited patent protection. If EMA marketing authorization and FDA approval are granted to an orphan drug, subject to certain exceptions,
	the drug will be entitled to up to ten years of marketing exclusivity in the European Union and up to seven years of marketing
	exclusivity in the United States, respectively, with such protection being independent of the patent status of the drug. As a result,
	we are pursuing registration and regulatory exclusivity for both Somakit-TATE and Somakit-TOC in the European Union and the United
	States. In addition, if an orphan drug demonstrates compelling results, it may be possible to obtain EMA marketing authorization
	or FDA approval based on a single pivotal Phase 3 trial, instead of the two pivotal Phase 3 trials generally required for approval
	by regulatory agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Existing Treatments in NETs
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Most patients with NETs do not exhibit
	symptoms and their tumors are discovered only upon unrelated surgery or exams. Although functioning NETs that produce certain hormones
	and other chemicals often cause patients to exhibit symptoms, the non-specific nature of these symptoms can lead to delayed diagnosis.
	By the time patients with NETs are diagnosed, their cancer has usually metastasized, with regional or distant metastasis observed
	in approximately 50% of cases. Once they have metastasized, NETs cannot be effectively treated by surgery alone and generally are
	not curable. As a result, there is a significant need for non-surgical treatments of metastatic NETs, given that patients with
	NETs often exhibit cancer symptoms only after the tumors have metastasized and surgery can no longer be an effective solution by
	itself.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	NETs are typically considered slow-growing
	tumors and therefore treatments employing standard chemotherapeutic agents (which attack both healthy and malignant cells) have
	been of limited value in treating inoperable, metastatic NETs, with historic response rates (partial and complete) of approximately
	20% (calculated as the mean value of partial and complete responses), as shown in Table 1 below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Table 1 below, drawn from a study in the
	Journal of Clinical Oncology, summarizes the published efficacy data from numerous historical studies for treatment of NET patients
	under various regimens, including the 310 evaluable NET patients that were treated with Lutathera between January&nbsp;2000 and
	August&nbsp;2006 in the Erasmus Study. There are two criteria that need to be met in order to meaningfully compare patient populations
	from different studies: (1) the patient populations must be similar, as is the case below, where the matched subgroup is selected
	from the Erasmus Study NET patient population treated with Lutathera and (2) tumor response rates must be measured by CT or magnetic
	resonance imaging according to standardized criteria and not solely by physical examination, palpation or biochemical markers.
	A subgroup of Erasmus patients that met these criteria was used for the comparison shown in Table 1. Where the data for certain
	responses to particular treatment regimens was insufficiently robust or was not reported (and therefore could not be used for the
	comparison), the relevant space in the table is marked with a &ldquo;N/A,&rdquo; for &ldquo;not applicable.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The figures may differ from those reported
	in other tables within this section that refer to the same Erasmus Study, as those figures were obtained after a separate, retrospective
	independent data analysis performed in 2011 that analyzed slightly different patient subgroups.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 1:&nbsp;&nbsp;&nbsp;Response to
	treatments:&nbsp;&nbsp;&nbsp;Partial Response (PR)/Complete Response (CR), progression-free survival (PFS) and overall survival
	(OS) of NET patients treated with chemotherapy regimens or with Lutathera.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 30%; PADDING-RIGHT: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Regimen(1)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Type
	of Tumor(1)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 8%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Number
	of Patients
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 8%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	PR/CR
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Median
<BR>
	PFS
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 10%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Median
	Overall Survival
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 19%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Study
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	(%)
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	(months)
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	(months)
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	(year)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	STZ + DOX&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Cheng (1999)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	DAC&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	56
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Bukowski (1994)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	DAC&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Ritzel (1995)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	FU + IFN-&alpha;&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc/NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	21
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	23
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Andreyev (1995)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	MIT&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc/NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Neijt (1995)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	PAC&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc/NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Ansell (2001)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	STZ + FU + DOX&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	84
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	39
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Kouvaraki (2004)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	DOX + FU&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	85
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	13
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Sun (2005)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	STZ + FU&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	78
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Sun (2005)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	IRI + FU&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc/NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Ducreux (2006)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	OXA + CAP&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Well-diff NET
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	27
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	N/A
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	40
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Bajetta (2007)
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	Lutate (Lutathera)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Carc/NEP
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	310
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	32
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	46
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	Kwekkeboom (2008)
</TD>
</TR>
</TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 20.15PT">
	(1)
</TD>
<TD>
	STZ, Streptozocin; DOX, Doxorubicin; DAC, Dacarbazine; FU, 5-Fluorouracil; IFN-&alpha; Interferon-&alpha;; MIT, Mitoxantron;
	PAC, Paclitaxel; IRI, Irinotecan; OXA, Oxaliplatin; CAP, Capecitabine; Lutate, Lu-177 Dotatate; Carc, carcinoids; NEP, neuroendocrine
	pancreatic tumors (Kwekkeboom et al., 2008). Dr. Kwekkeboom held 12,384 ordinary shares of AAA as of April 2016, which is equivalent
	to 0.016% of our outstanding ordinary shares. Dr. Kwekkeboom became one of our shareholders in 2010 when we acquired BioSynthema.
	He was previously a BI Shareholder and a portion of the acquisition consideration consisted of newly issued ordinary shares of
	ours. Dr. Kwekkeboom received his shares as part of the acquisition and he also provides certain consulting services for us on
	an arm&rsquo;s length basis.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As shown in Table 1 above, tumor response
	rates, PFS and overall survival, or OS, time data for Lutathera generally compared favorably to other chemotherapeutic drugs. There
	are limitations on the usefulness of the above data because, in clinical development, a retrospective study (such as the one from
	which the above table is derived) will review data already available, while a prospective study will generate the data that will
	be analyzed to support a hypothesis. From a methodological perspective, data from a prospective study is generally considered preferable
	for the generation of robust data, and sources of error due to confounding factors and bias are more common in retrospective studies
	than in prospective studies. Nevertheless, we believe that the above data reflects promising potential benefits of treatment with
	Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Within the field of NET treatment,
	somatostatin analogues such as Sandostatin
<SUP>
	&reg;
</SUP>
	, from Novartis, are used to control certain clinical syndromes
	(collectively referred to as carcinoid syndrome) such as severe diarrhea and flushing episodes associated with metastatic
	carcinoid tumors. Most NETs overexpress somatostatin receptors, which are protein receptors within human cells that sense
	molecules outside of the cell and activate cellular responses to somatostatin, a short-lasting endogenous hormone.
	Somatostatin is an important regulator of the endocrine system, and somatostatin analogues mimic its activity with more
	potent inhibition of growth hormone, glucagon and insulin, which are often produced by carcinoid tumors. The presence of the
	outsized number of these somatostatin receptors in NET cancer cells provides a specific target for nuclear medicine. In 2014,
	Novartis reported US$1.7 billion of sales of Sandostatin
<SUP>
	&reg;
</SUP>
	, its somatostatin analogue treatment for carcinoid
	syndrome. However, treatment of carcinoid syndrome is distinct from treating metastatic NETs themselves. For treatment of
	NETs themselves, Ipsen S.A.&rsquo;s, or Ipsen&rsquo;s, Somatuline
<SUP>
	&reg;
</SUP>
	Depot
<SUP>
	&reg;
</SUP>
	(lanreotide)
	Injection 120 mg, or Somatuline
<SUP>
	&reg;
</SUP>
	, was approved by the FDA in December 2014 for the treatment of adult patients
	with unresectable, well-differentiated or moderately-differentiated, locally advanced or metastatic NETs in the
	gastro-entero-pancreatic tract. According to Ipsen, Somatuline
<SUP>
	&reg;
</SUP>
	was approved based on a demonstration of
	improved PFS in Ipsen&rsquo;s placebo controlled study, which enrolled 204 patients with unresectable, well- or
	moderately-differentiated (WHO G I-II, Ki-67 &lt;10%), locally advanced or metastatic, non-functioning NETs in the
	gastro-entero-pancreatic tract. According to Ipsen, the median PFS in the Somatuline
<SUP>
	&reg;
</SUP>
	arm of the study had not
	been reached at the time of the study&rsquo;s final analysis, and was therefore determined to be greater than 22 months,
	while the median PFS in the placebo arm was 16.6 months. The aim of the study, according to an article discussing the study
	that was published in The New England Journal of Medicine, was to introduce Somatuline
<SUP>
	&reg;
</SUP>
	as early as possible
	in the management of the patients&rsquo; condition, since the patients&rsquo; tumors were non-functioning
	(and accordingly mostly asymptomatic) and such patients were potentially in a deferred treatment condition (known as a &ldquo;wait
	and see&rdquo; policy). At baseline, the disease was stable for a total of 96% of the patients in this seven-year study, according
	to Ipsen.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the treatment of pNETs, chemotherapeutic
	agents have become the standard of care. Response rates vary according to tumor aggressiveness but are estimated to be between
	approximately 30% and 50%. Two targeted therapies have been approved for the second line treatment of progressive non-functioning
	pNETs, with limited PFS:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Afinitor
<SUP>
	&reg;
</SUP>
	(everolimus), a mammalian target of the rapamycin (mTOR) inhibitor, was approved by the FDA for the
	treatment of adult patients with pNETs with unresectable, locally advanced or metastatic disease on the basis of PFS of 11 months
	observed in Phase 3 trials. Recently, it was approved in the USA for the treatment of adult patients with progressive, well-differentiated,
	non-functional NETs of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease. Afinitor
<SUP>
	&reg;
</SUP>
	is also approved for the treatment of other cancer indications such as HER2-negative breast cancer and renal cell carcinoma. In
	2014, Novartis reported &euro;1.4 billion (US$1.6 billion) of sales of Afinitor
<SUP>
	&reg;
</SUP>
	in all of its five approved indications.
	Treatment with Afinitor
<SUP>
	&reg;
</SUP>
	may cause severe skin and gastrointestinal disorders, kidney and liver toxicity and bone
	marrow damage.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Sutent
<SUP>
	&reg;
</SUP>
	(sunitinib), a multi-targeted receptor tyrosine kinase inhibitor, or RTK, was approved by the FDA and
	the EMA for the treatment of unresectable or metastatic, well-differentiated pNETs with disease progression in adults on the basis
	of PFS of 11.4 months observed in Phase 3 trials. Sutent
<SUP>
	&reg;
</SUP>
	is also approved for the treatment of gastrointestinal
	stromal tumors and metastatic renal cell carcinoma. In 2013, Pfizer reported &euro;870.9 million (US$960.4 million) of sales of
	Sutent
<SUP>
	&reg;
</SUP>
	in all of its indications. Treatment with Sutent
<SUP>
	&reg;
</SUP>
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
	may
	cause severe side effects such as renal failure, heart failure, gastrointestinal disorders, hemorrhages and hematological disorders
	(e.g., neutropenia, thrombocytopenia, and anemia), which are among its most common adverse drug reactions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Our Solution: Lutathera
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In light of the current limited options
	and effectiveness for treatment of NETs overall and the lack of treatments for progressive midgut NETs specifically, we believe
	Lutathera can meet a significant medical need by potentially improving patient outcomes in the treatment of progressive midgut
	NETs, as well as other somatostatin-receptor-positive tumors. We acquired the rights to Lutathera, which was initially developed
	by BioSynthema under an exclusive worldwide license from Mallinckrodt, as part of our 2010 acquisition of BioSynthema and have
	reworked it into its current formulation. Lutathera treats certain NETs by selectively binding to SSTR2 receptors that are overexpressed
	in those NET cells. Lutathera then destroys NET cells in a targeted fashion by delivering a local emission of high-energy electrons.
	Because Lutathera also emits gamma radiation, we believe it will also function as a disease management tool, as the gamma radiation
	it emits can be captured with a SPECT camera. We believe this diagnostic potential will allow the treating physician to monitor
	the efficacy of the treatment concurrently with its administration to the patient, should the physician wish to do so.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Phase 3 Trial
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In September 2015 we obtained positive
	data from Lutathera&rsquo;s pivotal Phase 3 trial for the treatment of inoperable progressive midgut NETs following an analysis
	of the data in the trial database that was finalized in September 2015. The Phase 3 trial is a multi-center, randomized, comparator-controlled,
	parallel-group study evaluating the efficacy and safety of Lutathera (using total cumulative administered radioactivity of 29.6
	GBq) combined with Sandostatin
<SUP>
	&reg;
</SUP>
	LAR 30 mg intramuscular injections compared to Sandostatin
<SUP>
	&reg;
</SUP>
	LAR 60
	mg intramuscular injections (referred to by its generic name, Octreotide LAR, in the table below). We administered Lutathera every
	eight weeks to patients with inoperable, progressive, somatostatin-receptor-positive, midgut NETs under Sandostatin
<SUP>
	&reg;
</SUP>
	LAR 30 mg. The structure of the trial is represented below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_003.JPG" ALT="" STYLE="HEIGHT: 192PX; WIDTH: 586PX">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The trial, which commenced in
	September 2012, enrolled a total of 229 randomized patients across 36 European sites and 15 American sites, each of whom was
	assigned to open-label treatment. The primary endpoint of the trial was the assessment of PFS, with additional endpoints
	assessing objective response rate, overall survival, time to tumor progression, safety and quality of life. A dosimetry,
	pharmacokinetics and electrocardiography assessment was also conducted in a subset of 20 patients at selected sites to
	provide a more complete assessment of the safety profile of Lutathera. The Phase 3 trial concluded recruitment in February
	2015, and we finalized the trial database (confirming that all data contained therein is final) after verifying and ensuring
	incorporation of all trial data, and after confirming the occurrence of the predefined number of progression events required
	to conclude the trial to enable conclusive statistical analysis. Upon finalizing the trial database in September 2015 we
	completed an analysis of the trial primary endpoint of PFS. The statistical analysis was performed on the entire patient
	population, also known as the Intent-To-Treat, or ITT, population, which accordingly did not yet exclude those patients who
	had significant deviations from the protocol. Patients who had significant deviations from protocol consist of those patients
	who did not comply sufficiently with the underlying treatment model (for example, by failing to have a CT scan taken in the
	prescribed window) and thereby impacted the reliability of the observed efficacy or safety profile of the treatment for such
	patients. As expected, a complete safety and efficacy analysis for the trial was available in the first quarter of 2016, and the
	clinical study report has been finalized in April 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Study Population
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The studied population included patients
	who fulfilled the following criteria:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the patient must be 18 years of age or older;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the patient must have metastatic or locally advanced, inoperable, histologically proven, midgut NETs, with a Ki67 index &lt;20%.
	Ki67 is a tumoral marker used to define an index of tumor proliferation, and a Ki67 index value of less than or equal to 20% corresponds
	to Grade 1-2 tumors. Tumoral markers are biological markers found in the blood, urine, or body tissues that can be modified or
	abnormal in cancer patients; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the patient must have somatostatin-receptor-positive disease with a progressive on uninterrupted fixed dose of Octreotide LAR
	(20-30 mg every 3-4 weeks).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The population included patients with functioning
	and non-functioning NETs. A functioning NET is a NET that shows symptoms of carcinoid syndrome, including increased hormone secretion,
	inducing diarrhea and flushing, and eventually secondary restrictive cardiomyopathy. Table&nbsp;2 below presents the population
	characteristics at enrollment:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 2:&nbsp;NETTER-1 population characteristics
	at enrollment. BMI refers to Body Mass Index.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 78%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<SUP>
	177
</SUP>
	Lu-Dotatate
	(n=116)
</P>
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Octreotide
	LAR 60mg (n=113)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Gender
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Male&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	53&thinsp;(46%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	60&thinsp;(53%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Female&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	63&thinsp;(54%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	53&thinsp;(47%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Age
</B>
	(years), mean (SD)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	63&thinsp;(&plusmn;9)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	64&thinsp;(&plusmn;10)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	BMI
</B>
	(Kg/sgm), mean (SD)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	25&thinsp;(&plusmn;5)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	26&thinsp;(&plusmn;7)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Primary tumor site
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Jejunum&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	6&thinsp;(5%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	9&thinsp;(8%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Ileum&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	86&thinsp;(74%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	82&thinsp;(73%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Appendix&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(1%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2&thinsp;(2%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Right colon&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	3&thinsp;(3%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(1%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Other&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	20&thinsp;(17%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	19&thinsp;(17%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Site of metastasis
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Liver&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	97&thinsp;(84%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	94&thinsp;(83%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Lymph nodes&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	77&thinsp;(66%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	65&thinsp;(58%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Bone&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	13&thinsp;(11%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	12&thinsp;(11%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Lungs&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	11&thinsp;(10%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5&thinsp;(4%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Other (*)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	40&thinsp;(35%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	37&thinsp;(33%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	(*)&#9;Mainly peritoneal and mesenteric.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Tumor characteristics in terms of NET tumoral
	markers and somatostatin receptor imaging were also identical in the two treatment groups, as shown in Table 3 and Table 4 below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 3:&nbsp;&nbsp;&nbsp;NET tumoral
	markers in the NETTER-1 population. SRS refers to Somatostatin Receptor Scintigraphy, which is an imaging procedure to visualize
	somatostatin receptors in human tissue, using specialized cameras to detect a radionuclide bound to a targeting agent. Krenning
	Scale refers to a scale indicating the uptake of Octreoscan, an imaging product used for the SRS (1: Lowest (worst), 4: Highest
	(best)). Chromogranin-A refers to a neuroendocrine protein secreted in the body that is used as a marker to gauge NET proliferation
	and is detected in the blood. 5-HIAA refers to 5-hydroxyindolacetic acid, which is detected in larger amounts in the urine of patients
	with NETs.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=116)
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=113)
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<B>
	Ki67
</B>
	, n (%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	ENETS G1/G2&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	76/40&thinsp;(66/34%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	81/32&thinsp;(72/28%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<B>
	SRS, Krenning scale
</B>
	, n (%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	Grade 2&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13&thinsp;(11%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14&thinsp;(12%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
	Grade 3&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34&thinsp;(29%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32&thinsp;(28%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	Grade 4&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69&thinsp;(60%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	67&thinsp;(59%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<B>
	Chromogranin A (ug/L)
</B>
	, mean (SD)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	649&thinsp;(420)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	670&thinsp;(422)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<B>
	5-HIAA (mg/24h)
</B>
	, mean (SD)*&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100&thinsp;(183)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77&thinsp;(83)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 4:&nbsp;&nbsp;&nbsp;NET tumoral
	markers in the NETTER-1 population. Tissue markers: Synaptophysin and Chromogranin-A are neuroendocrine secretory proteins used
	as markers of NET proliferation.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=116)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=113)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Synaptophysin
</B>
	, n (%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	0% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(0.9%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	0&thinsp;(0.0%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	1 &ndash; 50% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	3&thinsp;(2.6%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4&thinsp;(3.5%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	&gt;50% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	111&thinsp;(95.7%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	108&thinsp;(95.6%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Not evaluable &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(0.9%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(0.9%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Chromogranin A, n (%)
</B>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	0% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2&thinsp;(1.7%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(0.9%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	1 &ndash; 50% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5&thinsp;(4.3%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5&thinsp;(4.4%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	&gt;50% positive cells &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	107&thinsp;(92.2%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	106&thinsp;(93.8%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Not evaluable &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2&thinsp;(1.7%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(0.9%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 5:&nbsp;&nbsp;&nbsp;Overall Tumor
	Burden in the NETTER-1 population.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=116)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=113)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
	Overall tumor burden, n (%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Limited &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	99 (85.3%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	98 (86.7%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Moderate &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	13 (11.2%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	13 (11.5%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Extensive &#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4 (3.4%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2 (1.8%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Table 6, Table 7 and Table 8 below respectively
	show that (i) prior treatments, (ii) times since first diagnosis, disease progression and diagnosis of metastasis and (iii) reasons
	for ending prior treatment were similar in the case of the two treatment groups.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 6:&nbsp;&nbsp;&nbsp;Prior treatments
	in the NETTER-1 population.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=116)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=113)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Prior resection
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	90&thinsp;(78%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	93&thinsp;(82%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Prior ablation
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	6&thinsp;(5%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	11&thinsp;(10%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Chemo-embolization
</B>
	, n (%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	14&thinsp;(12%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	11&thinsp;(10%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Time since last intervention
</B>
	, yrs (SD)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4.7&thinsp;(&plusmn;3.3)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5.7&thinsp;(&plusmn;3.6)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Type of previous treatment
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Radiotherapy&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7&thinsp;(4%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	8&thinsp;(5%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	PRRT&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(1%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	0&thinsp;(0%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Chemotherapy&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	47&thinsp;(27%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	51&thinsp;(30%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Other&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	48&thinsp;(28%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	40&thinsp;(24%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 7:&nbsp;&nbsp;&nbsp;Times since
	first diagnosis, first disease progression and diagnosis of metastasis in the NETTER-1 population.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 64%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=116)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=113)
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 12%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Statistical
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Significance
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Time since first diagnosis (years)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5.13
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5.93
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	NS&thinsp;(p=0.09)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Time since first disease progression (years)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2.73
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2.93
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	NS&thinsp;(p=0.42)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Time since diagnosis of metastasis (years)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4.28
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	4.97
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	NS&thinsp;(p=0.30)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 8:&nbsp;&nbsp;&nbsp;Reasons for
	end of treatment in the NETTER-1 population.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT; WIDTH: 70%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<SUP>
	177
</SUP>
	Lu-Dotatate
	(n=116)
</P>
</TD>
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Octreotide
	LAR 60mg (n=113)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Reason for end of treatment phase
</B>
	n (%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Consent withdrawal&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	9&thinsp;(8%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	9&thinsp;(8%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Best subject interest&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	10&thinsp;(9%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	9&thinsp;(8%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Adverse event&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7&thinsp;(6%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7&thinsp;(6%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Disease progression&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	19&thinsp;(16%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	58&thinsp;(51%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Efficacy Analysis
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the efficacy analysis that we completed,
	Lutathera demonstrated a significant improvement in the primary endpoint, assessing PFS. There were 23 confirmed progression event
	deaths in the Lutathera arm and 68 confirmed progression event deaths in the Octreotide LAR 60mg arm. The median PFS for the Octreotide
	LAR 60mg arm was 8.4 months while the median PFS for the Lutathera had not yet been reached. Median PFS is calculated as the amount
	of time after which 50% of patients in a trial arm have progressed, or died, and 50% have survived without any progression event.
	The improvement in median PFS in the Lutathera arm was statistically significant (p &lt;0.0001) with a hazard ratio of 0.21 (95%
	Confidence Interval (CI): 0.13-0.33). A hazard ratio is a measure of the probability of a patient experiencing death due to a progression
	event and enables estimates as to the risk of death for a set of patients relative to a study&rsquo;s control group. The hazard
	ratio in the Phase 3 study demonstrates a risk reduction of 79% in the likelihood of a death due to a progression event for patients
	treated with Lutathera and Octreotide LAR together versus a treatment with a double-dose of Octreotide LAR (the control group).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As shown in Table 9 below, at the time
	of the conclusion of the Phase 3 study, the Octreotide LAR arm had already demonstrated a median PFS of 8.4 months. Patients in
	the Lutathera arm, however, did not experience an aggregate number of progression events sufficient to result in a median PFS,
	meaning that more than 50% of the patients in the Lutathera arm had survived without any progression event as of the conclusion
	of the study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 9:&nbsp;&nbsp;&nbsp;Kaplan-Meier
	function for Progression Free Survival in the NETTER-1 study: Final analysis.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_004.JPG" ALT="" STYLE="HEIGHT: 390PX; WIDTH: 503PX">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Within the current evaluable patient dataset
	for tumor responses, consisting of 201 patients, the objective response rate, or ORR, based upon the number of complete tumoral
	responses, or CR, and partial tumoral responses, or PR, was 18 (18%) in the Lutathera arm and 3 (3%) in the Octreotide LAR 60 mg
	arm. This improvement was statistically significant (p=0.0008), with a p-value much lower, and therefore more robust, than the
	usually accepted threshold of p&lt;0.05. Table 10 below shows the range of tumoral responses for each arm of the trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 10:&nbsp;&nbsp;&nbsp;Tumoral responses
	in the NETTER-1 population assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST). Exclude patients with
	no post-baseline scans or central response available.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 70%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<SUP>
	177
</SUP>
	Lu-Dotatate
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=101)
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Octreotide
	LAR 60mg
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	(n=100)
</P>
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Complete Response (n)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	0
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Partial Response (n)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	17
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Objective Response Rate (CI 95%)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;18 (10-25)%
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	3&thinsp;(0&ndash;6)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Progressive Disease (n, %)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	6&thinsp;(5%)
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	27&thinsp;(24%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Complete Response (CR) above indicates
	disappearance of all target lesions, while Partial Response (PR) indicates at least a 30% decrease in the sum of the diameters
	of the target lesions. Progressive Disease (PD) indicates at least a 20% increase in the sum of diameters of the target lesions,
	and an absolute increase of at least 5 mm, while Stable Disease (SD) indicates neither sufficient shrinkage to suggest Partial
	Response nor sufficient increase to suggest Progressive Disease. Objective Response measures the sum of CR and PR, while Objective
	Response Rate the percentage of objective responses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At the time of the analysis prior to finalizing
	the clinical study report for the submission to the FDA and the EMA, the number of deaths was 14 in the Lutathera arm and 26 in
	the Octreotide LAR 60 mg arm (p=0.004 at interim analysis) with a hazard ratio of 0.40 (95% CI: 0.21 &ndash; 0.77), which suggests
	an improvement in OS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 11:&nbsp;&nbsp;&nbsp;Kaplan-Meier
	function for Overall Survival in the NETTER-1 study: Interim analysis.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_005.JPG" ALT="" STYLE="HEIGHT: 404PX; WIDTH: 528PX">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Initial Safety Analysis
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The safety profile for Lutathera that we
	initially observed in the study was consistent with that observed in the Phase I-II Erasmus Study. A complete a full analysis of
	the safety profile was available in April 2016. The total number of patients experiencing adverse events in each arm is shown in
	Table 12 below. Adverse events are any undesired harmful effect resulting from a medication or other interventions related to the
	use of a medicinal product, such as significant change in the blood cell count or another physiological parameter. In the Phase
	3 trial, a significant number of these adverse events consisted of vomiting and nausea related to the use of an amino acid co-injection
	that was administered alongside Lutathera to help protect against renal injury from exposure to the treatment. We are considering
	GMP manufacturing of, and obtaining marketing authorization for, an amino acid co-injection that we believe is significantly improved
	and which we believe will reduce the number of events of vomiting and nausea in Lutathera patients when co-injected, while continuing
	to help protect patients against renal injury. We believe this improved amino acid co-injection formulation is eligible for orphan
	drug designation in the United States and European Union and we planned to file a MAA by the end of the second quarter of 2016
	and a NDA by the end of 2016 with the EMA and FDA, respectively, for this solution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 12:&nbsp;&nbsp;&nbsp;Number of
	patients experiencing adverse events in each arm (safety dataset includes patients who received at least one administration of
	studied products).
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 78%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<SUP>
	177
</SUP>
	Lu-Dotatate
	(n=111)
</P>
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Octreotide
	LAR 60mg (n=110)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Any adverse event
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	106&thinsp;(96%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	95&thinsp;(86%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Related to treatment&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	95&thinsp;(86%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	34&thinsp;(31%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Serious adverse events
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	29&thinsp;(26%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	26&thinsp;(24%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Related to treatment&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	10&thinsp;(9%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1&thinsp;(1%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Withdrawals due to adverse events
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	7&thinsp;(6%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	10&thinsp;(9%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Related to treatment&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5&thinsp;(5%)
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	0&thinsp;(0%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our adverse event assessment was performed
	according to the grading system of the National Cancer Institute&rsquo;s Common Terminology Criteria for Adverse Events. The number
	of adverse event episodes in these patients are shown in Table 13 below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 13:&nbsp;&nbsp;&nbsp;Number and
	grading of treatment emergent adverse event episodes in patients experiencing adverse events and who received at least one administration
	of product in each arm.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 78%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Maximal
	Severity, number of episodes
</P>
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<SUP>
	177
</SUP>
	Lu-Dotatate
	(n=111)
</P>
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Octreotide
	LAR 60mg
<BR>
	(n=110)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Grade 1 (mild)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	861
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	437
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Grade 2 (moderate)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	339
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	170
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Grade 3 (severe)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	78
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	47
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Grade 4 (threatening / disabling)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
	Grade 5 (death)&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	8
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
	Missing&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The SAEs reported in the Lutathera arm
	that were related to treatment are presented in Table 14 below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 14:&nbsp;&nbsp;Serious adverse
	events reported in the Lutathera arm that were related to treatment.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 89%; FONT-SIZE: 8PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	SAE
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Blood &amp; lymphatic system
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Lymphocytopenia&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Thrombocytopenia&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Neutropenia&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Pancytopenia&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Bicytopenia&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Renal &amp; urinary disorders
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Acute kidney injury&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Renal failure&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 10PT">
<B>
	Vascular disorders
</B>
	&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-LEFT: 0.125IN">
	Portal hypertension&#9;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-RIGHT: 10PT">
	1
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The adverse events reported in the Phase
	3 study are presented in the following Table:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 15:&nbsp;&nbsp;Percentages and
	grading of adverse events reported in at least 10% of patients treated with Lutathera vs patients receiving Octreotide LAR 60 mg
	(SAF dataset, n=221).
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD COLSPAN="2" STYLE="BORDER-TOP: WHITE 1PT SOLID; BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 3PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-TOP: WHITE 1PT SOLID; BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 3PT SOLID; PADDING: 3PT; BACKGROUND-COLOR: #A1D862; TEXT-ALIGN: CENTER">
<B>
<SUP>
	177
</SUP>
	Lu-Dotatate
</B>
<BR>
<B>
	(N=111)
</B>
</TD>
<TD COLSPAN="2" STYLE="BORDER-TOP: WHITE 1PT SOLID; BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 3PT SOLID; PADDING: 3PT; BACKGROUND-COLOR: #A1D862; TEXT-ALIGN: CENTER">
<B>
	Octreotide LAR 60 mg
</B>
<BR>
<B>
	(N=110)
</B>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD COLSPAN="2" STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	All grades
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Grade 3-4
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	All grades
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Grade 3-4
</B>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="WIDTH: 31%; BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	System Organ Class
</B>
</TD>
<TD STYLE="WIDTH: 21%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT; BORDER-RIGHT: WHITE 1PT SOLID">
<B>
	Preferred Term
</B>
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT; BORDER-RIGHT: WHITE 1PT SOLID">
<B>
	%
</B>
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT; BORDER-RIGHT: WHITE 1PT SOLID">
<B>
	%
</B>
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT; BORDER-RIGHT: WHITE 1PT SOLID">
<B>
	%
</B>
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT; BORDER-RIGHT: WHITE 1PT SOLID">
<B>
	%
</B>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD ROWSPAN="5" STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Gastrointestinal disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Nausea
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	59%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	4%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	12%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Vomiting
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	47%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	7%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	10%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Diarrhea
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	29%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	3%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	19%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Abdominal pain
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	26%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	3%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	26%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Abdominal distension
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	13%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	14%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD ROWSPAN="2" STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	General disorders &amp; administration site conditions
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Fatigue / asthenia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	40%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	25%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Edema peripheral
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	14%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	7%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD ROWSPAN="5" STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Blood and lymphatic system disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Thrombocytopenia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	25%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Lymphopenia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	18%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	9%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Anemia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	14%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Leukopenia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	10%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Neutropenia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Musculoskeletal &amp; connective tissue disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Musculoskeletal pain
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	29%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	20%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Metabolism &amp; nutrition disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Decreased appetite
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	18%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	8%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	3%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD ROWSPAN="2" STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Nervous system disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Headache
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	16%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Dizziness
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	11%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Vascular disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Flushing
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	13%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	1%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	9%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Skin &amp; subcutaneous tissue disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Alopecia
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	11%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	2%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #F2F2F2">
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; BORDER-LEFT: WHITE 1PT SOLID; PADDING: 3PT">
<B>
	Respiratory, thoracic &amp; mediastinal disorders
</B>
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	Cough
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	11%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	5%
</TD>
<TD STYLE="BORDER-RIGHT: WHITE 1PT SOLID; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING: 3PT">
	0%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the overall SAF population (221 patients),
	129 patients (58.4%) experienced treatment emergent adverse events related to treatment (ADR), 95 (86%) in the Lutathera arm and
	34 (31%) and in the Octreotide LAR arm. There were 683 ADR episodes, 611 for patients in the Lutathera arm and 72 for patients
	in the Octreotide LAR arm. The most frequent ADR episodes in the Lutathera are were &ldquo;nausea&rdquo; and &ldquo;vomiting&rdquo;
	(125 &ldquo;nausea&rdquo; episodes in the Lutathera arm vs 4 in the Octreotide LAR arm and 98 &ldquo;vomiting&rdquo; episodes in
	the Lutathera arm vs 1 in the Octreotide LAR arm); in the Lutathera arm, the majority (about 75%) of these &ldquo;nausea&rdquo;
	and &ldquo;vomiting&rdquo; episodes were considered related to the amino acid co-infusion by the Investigators.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The treatment exposure to Lutathera was
	assessed in all patients. The patients who have not received the full treatment have either progressed or withdrawn from the study,
	and therefore their treatment was interrupted. Most of the patients (74%) received a full Lutathera treatment (four administrations
	of 200 mCi, one every eight weeks, for a total dose of 800 mCi). Table 16 below presents the exposure data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 16:&nbsp;&nbsp;&nbsp;Lutathera
	dose exposure (n=111).
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 86%; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Nb
<BR>
	of Patients
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<B>
	Drug exposure
</B>
	, n (%)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	600 - 800 mCi&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	82&thinsp;(74%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
	400 &ndash; 600 mCi&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10&thinsp;(9%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	200 &ndash; 400 mCi&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11&thinsp;(10%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
	200 mCi&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3&thinsp;(3%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	Not recorded &#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5&thinsp;(5%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<B>
	Number of administrations
</B>
	, n (%)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	4&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79&thinsp;(71%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
	3&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12&thinsp;(11%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	2&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13&thinsp;(12%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN">
	1&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6&thinsp;(5%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN">
	0&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1&thinsp;(1%)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	During treatment with Lutathera, a dose
	reduction can be performed within the frame of the Dose Modifying Toxicity, or DMT, scheme, a set of guidelines to address toxicity
	directly related to the amount of treatment administered, and which requires a 50% dose reduction in case of certain adverse events,
	primarily Grade 2 events for blood platelet count, or Grade 3 or 4 hematological toxicity or any other Grade 3 or 4 toxicity. These
	toxicity events are of particular concern due to their impact on an oncology product&rsquo;s safety for patients. The DMT scheme
	may also apply if the administration of Lutathera is thought to severely and clinically significantly worsen the applicable patient&rsquo;s
	lymphocyte count and liver function. During the Phase 3 trial, the dose had to be reduced for toxicity events in six patients,
	or 5% of the 111 treated patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Preliminary Findings
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that the initial results described
	above indicate a clinically meaningful and statistically significant increase in PFS, the primary endpoint of the Phase 3 study,
	as well as in ORR, and suggests a survival benefit in patients with advanced midgut NETs who are treated with Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have submitted the NDA to the FDA and
	the MAA to the EMA for Lutathera in April 2016.&nbsp;The long-term follow-up for patients treated with Lutathera will continue
	after any approval and will include further assessment on OS, long-term toxicity to critical organs such as bone marrow and the
	kidneys, hematology, biochemistry and urine analyses, every six months for five years after the end of the study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Commercialization Plans for Lutathera
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We intend to commercialize Lutathera with
	our own sales force in the United States, as well as in the EU5. Because midgut NET is an orphan indication with a limited number
	of available treatment options, patient populations are often highly organized, including through the formation of patient advocacy
	groups, which may facilitate our identification of and access to patients. The midgut NET indication&rsquo;s orphan disease designation
	also means that treatment trends are heavily influenced by key opinion leaders located in a limited number of centers of excellence.
	We have identified approximately 50 nuclear medicine centers in the United States that we believe treat over 80% of midgut NET
	patients in the United States. Similarly, we have identified approximately 80 nuclear medicine centers in the EU5 that we believe
	treat over 80% of midgut NET patients in the EU5. We believe we can efficiently target these nuclear medicine centers with a specialty
	sales force of approximately 13 sales representatives and three field-based market access specialists in the United States and
	approximately 30 sales representatives in the EU5. Our commercial leadership team is already in place and we are currently in the
	early stages of establishing our commercial infrastructure, including sales representatives, medical affairs, marketing, market
	access, market research, sales force effectiveness and strategic planning. We anticipate commencing marketing for Lutathera in
	these geographic areas soon after FDA and/or EMA approval. Outside of the United States and EU5 we intend to contract with select
	partners to commercialize Lutathera. We have already contracted with many partners in Europe to provide access to Lutathera on
	a compassionate use and named patient basis, and in June 2015 we entered into an exclusive distribution and license agreement for
	Lutathera in Japan with FRI to finance and conduct its own bridging study, and then to submit its findings to the applicable regulatory
	authorities in Japan for approval. We intend to support this process by manufacturing Lutathera for FRI&rsquo;s study and providing
	supplementary data from our previous clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Supply chain &mdash; Lutathera
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For Lutathera, we have the capability to
	supply the U.S. market from multiple European sites and have verified this capability during the course of the past two years as
	we plan for Lutathera&rsquo;s potential U.S. launch. However, to improve the efficiency of our supply chain for the U.S. market,
	we have acquired a Millburn, NJ facility that we are currently retrofitting to produce Lutathera principally for the market in
	North America. We plan to finish retrofitting the site in the second quarter of 2016 and immediately begin qualification of the
	site in order to achieve FDA authorization for the site and start manufacturing operations in the first half of 2017 after receiving
	all necessary authorizations and licenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	From Europe initially, and soon after from
	Millburn, NJ, we will ship Lutathera to hospitals around North America, typically by plane, for injection within 24 to 48 hours
	after production. We have experience shipping F-18-labeled products that are typically injected two to four hours after production
	due to such products&rsquo; significantly shorter half-lives. Because of this prior experience, we believe that we will be able
	to facilitate reliable delivery of Lutathera during the time windows within which it must be delivered to its clinical destinations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have further strengthened our Lutathera
	supply chain by acquiring, at the beginning of January 2016, the IDB Group in Holland, one of the leading producers of the Lu-177
	radioisotope.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Other Studies Involving Lutathera
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera is also being studied in three
	ongoing investigator-sponsored studies in a total of 202 patients to explore its potential use in additional indications. We believe
	there are several indications, including different somatostatin-receptor-positive tumor types such as pNETs, glioblastomas and
	medulloblastomas, with significant unmet medical needs for which Lutathera may have future applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Based on the favorable safety and efficacy
	profile observed in previous clinical studies, Lutathera was also made available for compassionate use and on a named patient basis
	to treatment programs in Austria, Denmark, Estonia, Finland, France, Greece, Portugal, Spain, Switzerland and the United Kingdom.
	As of July 31, 2015, we provided 2,121 doses of Lutathera to these programs in approximately 48 centers, of which eight are currently
	participating in Lutathera&rsquo;s Phase 3 trial for patients with inoperable progressive midgut NETs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, Lutathera is the only Phase
	3 therapeutic candidate utilizing PRRT, which has been incorporated into the treatment guidelines for NETs published by ENETS since
	2009. As a consequence of its inclusion into the ENETS guidelines, in 2010 ESMO included PRRT in its therapeutic algorithm, suggesting
	the use of PRRT in the event that existing approaches or registered products were ineffective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Phase 1/2 Study
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera&rsquo;s Phase 1/2 Erasmus Study
	started in January 2000 as an open, single arm study. At the start of the study, a biodistribution and dosimetry assessment was
	performed in order to evaluate the kidney protection benefit of amino acid co-infusion and to provide a first estimate for the
	maximum safe dose for treatments. The biodistribution and dosimetry assessment was followed by an ascending dose study to determine
	if observed toxicities from the single administered dose and resulting cumulative administered radioactivity remained below acute
	toxicity limits to the critical organs (bone marrow and kidneys). From these studies the maximum activity to be administered was
	determined at a cumulative administration of 800 millicuries, or &ldquo;mCi,&rdquo; a standard radiation measurement, with four
	intravenous administrations of 200 mCi of Lutathera at four to 13 week intervals. The primary endpoints were tumor responses, disease
	progression, OS, quality of life and safety.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Phase I-II Erasmus study data have
	been analyzed in two separate time periods:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	1. The first analysis was conducted in
	2011 and included 615 patients who were enrolled in the study between January 2000 and March 2007 (follow-up cut-off date as of
	February 2010). The results of the source data verification and analyses conducted at that time were provided to the FDA at the
	time of the IND submission and before the initiation of the pivotal Phase III NETTER-1 study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	2. The Erasmus Phase 1/2 trial continued
	after this first independent assessment and AAA resumed the data collection in 2015 with the objective of including an updated
	Clinical Study Report in the NDA and MAA submission. The second analysis includes follow-up data of the original 615 patients and
	an additional 599 patients who were enrolled in the study between March 2007 and December 2012.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera generated positive safety and
	efficacy data for the 1,214 patients in the Phase 1/2 study. Clinical data collected over this period were retrospectively reviewed
	by an independent clinical research organization in order to assess and verify the source data and perform a statistical analysis
	of the study results. In this independent reassessment of data, special attention was paid to patients with the same diagnosis
	as proposed for our Phase 3 trial. We believe the results of this comprehensive analysis should be considered as reliable and supportive
	of the results of our pivotal Phase 3 trial, and we expect to be able to rely on the observations relating to efficacy from this
	analysis in seeking regulatory approvals for Lutathera because it was conducted by trained radiologists and data management professionals.
	The results of the review indicated that Lutathera may prolong PFS and OS as compared to the treatments listed in Table 1 above,
	while improving patients&rsquo; self-assessed quality of life. Both acute and late adverse events after treatment with Lutathera
	were generally milder for these patients than other treatments to which Lutathera was compared (i.e., the treatments listed in
	Table 1 above). This favorable safety profile was also supported by the retrospective analyses performed on all 615 patients included
	in the Phase 1/2 study.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Due to the lack of available treatment
	for the NET family of tumors, the 1,214 patients included in the Phase 1/2 study are a mixed population in terms of tumor type.
	All such patients were included in the safety evaluation performed at the completion of the study. A retrospective efficacy evaluation
	was performed on certain of the 404 patients diagnosed with NET tumors. From this group of 404 patients, 265 patients with NETs
	met specific evaluation criteria for tumor type and severity and were included in the retrospective efficacy analysis. These 265
	selected patients were those who had received at least one treatment with Lutathera and had at least one valid primary efficacy
	variable measurement after their entry into the Phase 2 study to measure the effects of Lutathera. The patients all had NETs, including
	foregut and hindgut carcinoid tumors, and an Octreoscan tumor uptake score of&thinsp; &ge; 2 in order to confirm adequate tumor
	uptake by target tumoral lesions expressing somatostatin 2 receptor uptake.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Subgroup analyses of tumor response (the
	primary endpoint) and PFS (as a secondary endpoint) have been performed on various subgroups specified in the overall retrospective
	analysis with different tumor types, the results of which are described below. The results for objective tumor response (combining
	complete response, or CR, partial response, or PR, and minor response, or MR) to treatment with Lutathera according to standardized
	criteria are summarized in Table 17 below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 17:&nbsp;&nbsp;Objective tumor
	Response (CR, PR and MR) to Lutathera by main tumor types according to RECIST&nbsp;1.1 standardized criteria (Full Analysis dataset,
	n=575).
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	Patients
</TD>
<TD COLSPAN="2" STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	NE
</TD>
<TD COLSPAN="4" STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	ORR* 95% CI
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1PT SOLID">
	Tumor Type
</TD>
<TD STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID">
	N
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID">
	N
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID">
	%
</TD>
<TD STYLE="WIDTH: 7%; BORDER-BOTTOM: BLACK 1PT SOLID">
	N
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PT SOLID">
	%
</TD>
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1PT SOLID">
	Lower
</TD>
<TD STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1PT SOLID">
	Upper
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Pancreatic NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	168
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	10
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	6.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	100
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	59.5
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	21.7
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	78.3
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Foregut NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	12
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	50.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	26.8
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	39.3
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Hindgut NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	13
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	7.7
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	46.2
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	19.1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	73.3
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Unknown NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	86
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	5
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	5.8
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	35
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	40.7
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	52.1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	67.0
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Bronchial NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	21
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	4.8
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	7
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	33.3
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	13.2
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	53.5
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Midgut NET
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	218
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	10
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	4.6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	72
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	33.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	30.3
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	51.1
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Other
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	19
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	5.3
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	31.6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	0.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	25.6
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Thyroid Carcinoma
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	20
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	5.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	3
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	15.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	0.0
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	30.7
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
	Paraganglioma
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	18
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	5.6
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	2
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	11.1
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	10.7
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	52.5
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	*
</TD>
<TD>
	Objective Response Rate: ORR (Complete Response + Partial Response), CR: Complete Response; PR: Partial Response; NE: Non-Evaluable
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	PFS rates are shown in Table 18 below.
	The overall median PFS was 28 months with a 95% CI of 25 &thinsp;&ndash;&thinsp;30 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Table 18:&nbsp;&nbsp;&nbsp;Summary statistics
	of median PFS (months) by tumor type/overall (FAS, n=575)
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="3" STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Nb. of Patients
</TD>
<TD NOWRAP COLSPAN="3" STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Median Progression Free Survival - 95% CI
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
	&nbsp;
</TD>
<TD NOWRAP STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Total
</TD>
<TD NOWRAP STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Events
</TD>
<TD NOWRAP STYLE="WIDTH: 11%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	%
</TD>
<TD NOWRAP STYLE="WIDTH: 15%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Months
</TD>
<TD NOWRAP STYLE="WIDTH: 16%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Lower
</TD>
<TD NOWRAP STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	Upper
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP>
	Overall
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	575
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	369
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	64.2
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	28.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	25.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	30.3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	Pancreatic NET
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	168
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	95
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	56.6
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	30.8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	25.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	36.2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP>
	Hindgut NET
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	13
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	61.5
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	29.3
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	22.3
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	39.0
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	Unknown NET
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	86
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	54
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	62.8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	29.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	24.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	36.9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP>
	Midgut NET
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	218
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	154
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	70.6
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	28.8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	24.1
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	33.7
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	Paraganglioma
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	18
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	6
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	33.3
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	24.8
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	15.4
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP>
	Bronchial NET
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	21
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	15
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	71.4
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	18.3
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	10.3
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	25.4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	Other
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	19
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	17
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	89.5
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	14.5
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	11.9
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	25.0
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP>
	Thyroid carcinoma
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	20
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	16
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	80.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	9.6
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	8.0
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	28.9
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	Foregut NET
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	12
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	4
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	33.3
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	21.2
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A subset of 51 patients diagnosed with
	midgut progressive NETs (the same indication that is being evaluated in our Phase 3 trial for Lutathera) was further evaluated
	for PFS, OS and tumor response. Within this retrospective analysis, we only included patients with the same diagnosis that would
	qualify them for enrollment in the Phase 3 trial for Lutathera. Two different standardized criteria were used for this analysis:
	the Southwest Oncology Group, or SWOG, criteria, a standard evaluation method based on tumor dimension, and the Response Evaluation
	Criteria in Solid Tumors, or RECIST, criteria, which is the most widely accepted current standard. The median PFS of these subjects
	was:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	45 months (95% CI 22&thinsp;&ndash;&thinsp;57 months) according to RECIST criteria; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	39 months (95% CI 18&thinsp;&ndash;&thinsp;57 months) according to SWOG criteria; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	The median OS estimate was 47.3 months with a 95% CI of 27.7&thinsp;&ndash;&thinsp;75.3 months.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The findings of the Phase 1/2 study indicated
	that there may be a substantial anti-tumor effect in NET patients treated with Lutathera. The treatment resulted in a significant
	improvement in clinical endpoint responses (PFS and OS) as compared to the responses reported in the literature for NET patients
	treated with the current standard of care, Sandostatin
<SUP>
	&reg;
</SUP>
	, though no statistical analysis comparing them could be
	conducted due to the data for Sandostatin
<SUP>
	&reg;
</SUP>
	and Lutathera being reported from different studies. Furthermore, the
	treatment with a cumulative administered dose of 29.6 GBq (GBq refers to a gigabecquerel, a unit of radiation measurement) of Lutathera
	was shown to be safe relative to other therapies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the Phase 1/2 trial, the endpoints were
	defined as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Time to progression, or TTP, was calculated from the first day of treatment to the day of documented progression. Deaths were
	not included in the TTP analyses.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	PFS was defined as the time from first treatment until objective tumor progression or death from any cause.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	OS was calculated from the first day of treatment until the day of death or until the last date of follow-up for patients who
	were lost to follow-up.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Objective tumor response was the sum of complete, partial and minor tumoral responses according to SWOG criteria.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The safety profile of Lutathera was supported
	by both by serum and urine analyses performed during the study. The evaluation of the dosimetry data collected on all treated patients
	indicated that there was no correlation between creatinine clearance loss per year (as indicator of kidney function) and the administration
	of Lutathera. In the overall population, the incidence of both nausea and vomiting increase from baseline after the first and after
	each subsequent administrations but declined down to levels below baseline thereafter. Malaise was the highest reported symptom
	at baseline (60.1%), decreasing after each treatment to reach 25.3% at 6-month follow-up before gradually increasing again (41.2%
	at 30-month follow-up). The number of patients reporting pain decreased for the duration of treatment but increased afterwards
	being maximum and higher than baseline at the 30-month follow-up (48.5% versus 42.6%). The number of subjects experiencing hair
	loss increased from 10% at baseline to just over 40% after each of the first 3 treatments but started reducing thereafter, returning
	back to baseline levels at the 3-month follow-up (9.4%). The incidence of diarrhea showed a gradual decrease over time whereas
	that of flushes fluctuated between 26.7% and 36.8% with no correlation with treatment. The incidence of stomatitis and hand and
	foot syndrome remained low throughout. The SAEs with the highest frequencies were in decreasing order: pancytopenia (8.0%), anemia
	(4.4%), diarrhea (4.7%); death (4.5%); abdominal pain (5.8%), vomiting (3.8%), nausea (3.2%) and thrombocytopenia (3.0%). The evaluation
	of both acute and late adverse events of Lutathera in comparison with literature data supports a favorable safety profile of the
	treatment. The side effects of Lutathera treatment were generally milder than those induced by other anti-tumor agents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	An update on the safety profile of
	Lutathera was presented in an Oral Presentation at the Presidential Session on September 27, 2015 at the ESMO conference.
	Updated information was also presented at the North American Neuroendocrine Tumor Society (NANETS) conference in October
	2015, the Gastrointestinal Cancers Symposium of ASCO (American Society for Clinical Oncology) conference in January 2016, and
	will be presented at the European Neuroendocrine Tumor Society (ENETS) conference in March 2016. See
	&ldquo;&mdash;&thinsp;Our Product Candidates in Clinical Development&mdash;Lead Therapeutic
	Candidate&mdash;Lutathera&mdash;Phase 3 Trial&mdash;Initial Safety Analysis.&rdquo; As expected, the complete safety analysis
	for the trial was available in the first quarter of 2016, and the clinical study report has been finalized in April 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Overview of Radioisotopes
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our products contain radioisotopes, which
	are radioactive elements that enable the creation of diagnostic images and can be used to treat diseases. A radioisotope is an
	unstable form of a chemical element that emits radiation (a process also known as radioactive decay) to achieve stability. Such
	radiation can consist of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	gamma rays, which are high-energy photons that allow SPECT imaging;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	positrons, which are antiparticles of the electrons that allow PET imaging; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	electrons, which are particles used for many years in external radiotherapy to treat diseases.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Radioisotopes are obtained by using specialized
	equipment to excite the nucleus of atoms and altering the number of protons or neutrons in the target nuclei. When this process
	artificially produces a combination of neutrons and protons that does not already exist in nature, the atom is unstable, resulting
	in a radioactive isotope or radioisotope. The radioisotope&rsquo;s decay and resulting emission of one of the three forms of radiation
	described above enables MNM procedures. MNM radioisotopes decay over a time span ranging from a few seconds to several days, allowing
	the radioactivity from radioisotopes in our products and product candidates to completely disappear after use. The radioactive
	decay process is typically measured in half-lives, the time needed for half of the excited atoms in the unstable element to return to stability.
	The half-life of our PET products is approximately two hours. In general, after ten half-lives all MNM products are considered
	to no longer be radioactive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Radioisotopes can be manufactured in several
	ways. A common method is by neutron activation in a nuclear reactor. This involves the capture of a neutron by the nucleus of the
	target atom, resulting in an excess of neutrons, as in the case of Lu-177, the radioisotope used for Lutathera. We do not operate
	a nuclear reactor and obtain radioisotopes for Lu-177 production through sub-contract with third parties. The acquisition in January
	2016 of the IDB Group allowed us to reduce our reliance on third-party supply of Lu-177. We will continue sourcing some of our
	Lu-177 needs from third-party suppliers to ensure production reliability. The radioisotopes that we manufacture are produced in
	our particle accelerators, known as cyclotrons, as in the case of the F-18 that we use in Gluscan and our other PET products, described
	below. To make F-18, the Oxygen-18 (O-18) contained in water is bombarded by protons in our cyclotrons. Protons can knock out neutrons
	from O-18 atoms, transforming them into F-18. On average, after approximately two hours the F-18 decays, emitting a positron, which
	can be used for PET imaging via detection of the positron with a PET camera. Each of our PET manufacturing sites has at least one
	cyclotron to produce F-18.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition to their incorporation of a
	radioactive element such as F-18 to enable imaging, MNM products and procedures require a mechanism for effective disease targeting.
	This can be achieved by designing molecules to selectively reach unhealthy cells by using molecular pathways or by targeting receptor
	expressions specific to diseased cells. Radiopharmaceuticals are a combination of these molecular entities that target diseases,
	also known as vectors, and radioactive atoms, which are attached to or combined with a relevant vector.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	When the decay of a radioisotope results
	in both an electron and a gamma ray (or positron) being emitted, it is possible to treat and image a particular disease at the
	same time. We believe Lutathera has the potential to achieve such simultaneous treatment and imaging of NETs using SPECT cameras.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Overview of PET Products
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	PET products or tracers are injected into
	patients to enable high-quality imaging by PET cameras. PET is a state-of-the-art diagnostic technique in MND that is mainly used
	in clinical oncology, cardiology and neurology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	PET scans with FDG have been a significant
	breakthrough in cancer treatment. Because FDG is a radiopharmaceutical molecule that accumulates in many tumors, it allows physicians
	to more accurately determine the precise stage of many tumors, localize unknown metastases and monitor therapeutic efficacy or
	the reoccurrence of cancers. We produce and sell FDG under the brand name of Gluscan. FDG is produced by attaching the short-lived
	radioactive tracer F-18 to glucose, or sugar, molecules, which are then immediately injected into patients. Certain cancer cells
	and other inflammatory cells are hyperactive and hungry for sugar molecules, so they easily absorb FDG. Once inside these cells,
	FDG releases positrons that collide with the electrons in the body, producing energy in the form of opposite rays. These rays are
	detected by a PET camera, which produces a high-quality image of the lesion. Most PET cameras are now coupled with a computerized
	tomography, or CT, scan to facilitate better tumor/lesion localization by combining the functional imaging of PET with the morphological
	imaging of CT. Other PET radiopharmaceuticals use different molecular pathways to accumulate in lesions, but the imaging mechanism
	is the same as for FDG.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	F-18 has a half-life of approximately two
	hours. PET products with F-18 have a useful life that expires after five or six half-lives. After the expiration of these half-lives,
	the injections containing F-18 lose too much of their radioactive element to be an effective diagnostic in normal doses. Gluscan
	has a shelf life of approximately ten hours, consistent with other F-18 PET products. As a result of this limitation, the distribution
	of PET products involves complex logistics. Manufacturing sites for the products must be located within a practical distance from
	nuclear medicine facilities, such as those within hospitals, that allows for their delivery to occur within a very limited timeframe
	of less than ten hours. Because the products include radioactive materials, each customer order must be delivered using dedicated
	transportation in accordance with local regulations applicable to the handling and transportation of hazardous and/or radioactive
	materials in each country. The required capital-intensive infrastructure and logistical complexity of distributing PET products
	in a safe and timely manner create significant barriers to entry into the PET market for potential competitors. At the same time,
	the PET market is an attractive one for us, as it has enjoyed a double-digit growth rate, according to data from MEDraysintell.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This strong growth has been driven by the
	increased imaging quality and technological advancement of PET-CT imaging, and has resulted in most diagnostics-related radiopharmaceutical
	research being concentrated in PET during the past 15 years. We believe there are as many as 42 PET tracers worldwide in different
	stages of development (from preclinical to Phase 3), compared with only 12 tracers in SPECT.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Overview of SPECT Products
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The majority of SPECT products have a different
	manufacturing process from that used for PET products and as a result are sold according to a different business model. SPECT products
	are often sold in what are known as &ldquo;cold&rdquo; kits (because they are not radioactive, or &ldquo;hot&rdquo;), to be labeled,
	or fused with, the radioisotope Tc-99. Tc-99 has a half-life of approximately six hours, but it is extracted by generators that
	are sold separately to the end-user, thus allowing the Tc-kits to have a longer shelf life.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Tc-99 generators have a shelf life
	of one week. We do not sell these generators; in Europe, third parties sell them directly to the MNM departments within particular
	hospitals and, in the United States, to specialized radiolabeling facilities called radiopharmacies, where they are labeled and
	distributed into syringes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Although in the United States hospitals
	can have departments acting as radiopharmacies, more than 95% of syringes in the United States containing radiolabeled products
	are prepared through external third-party facilities and delivered daily to hospitals&rsquo; and other entities&rsquo; MNM departments.
	By contrast, in Europe, the use of external radiopharmacies is available only in the Netherlands, Spain and the United Kingdom,
	so the MNM departments in most hospitals or clinics label their SPECT products internally.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Because our SPECT products are all &ldquo;cold&rdquo;
	kits to be labeled with Tc-99 at the end-user&rsquo;s facilities, they are not subject to delivery-related restrictions such as
	Dangerous Goods Regulations, which apply to radioactive goods and products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Lead PET Product Candidate &mdash; Somakit
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Somakit is a novel, patent-pending, sterile
	and easy-to-use freeze-dried, or lyophilized reconstitution kit that we have developed for the direct Gallium-68, or Ga-68, labeling
	of somatostatin analogue peptides (Dotatate and Dotatoc) for the localization of primary and/or metastatic lesions of NETs. As
	a product candidate designed to initially diagnose the presence of somatostatin-receptor-positive NETs, we believe that Somakit
	is a promising companion diagnostic agent for Lutathera, with which it shares similar chemical features.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Somakit products radioactive Ga-68
	Dotatate and Ga-68 Dotatoc peptides have a strong affinity for SSTR2, which the majority of NETs overexpress. As a result, these
	peptides bind to SSTR2 receptors in NETs and allow imaging of NETs by emitting localized radiation that PET cameras can detect
	and translate into diagnostic images. In addition, we believe Somakit will provide gains in efficiency for hospitals and other
	customers. Somakit-TATE can be prepared using our kit, for which we have a patent pending, which would be reconstituted in hospital
	radiopharmacies without the use of a radiochemistry module, thus making the product available to all hospitals, even those that
	do not have a fully equipped cGMP-compliant radiopharmacy unit. This feature would limit the need for expensive equipment and procedures
	such as synthetic modules and high-performance liquid chromatography, and could lead to a reduced number of confirmatory local
	quality control tests since all specification tests would be performed on Somakit at the manufacturing facility before it is delivered
	to the end-user. Additionally, we believe that Somakit may improve on existing exams by potentially reducing the timeframe during
	which the diagnostic exam must be conducted from 24 hours (for current approved procedures) to two hours.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We received orphan drug designation for
	Somakit-TATE from the FDA in December 2013 and from the EMA in February 2014 for its use as a diagnostic agent for GEP NETs, and
	orphan designation for Somakit-TOC from the EMA in March 2015 and FDA in July 2015. We have implemented a strategy of developing
	these two similar, but structurally different, Somakit products to help ensure regulatory exclusivity for one or both Somakit products
	in the European Union and the United States. We anticipate that our next stage of the Somakit products&rsquo; development will
	involve ongoing consultation with the EMA and FDA on clinical development programs, with a goal of seeking EMA marketing authorization
	and FDA approval beginning in 2017. We prepared and filed the IND submission for Somakit-TATE in the United States in October 2014.
	Following FDA recommendations, the NDA for Somakit-TATE was submitted on July 1, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the European Union, we filed a MAA of
	Somakit TOC to the EMA on the basis of a bibliographic review. The safety study involving 20 patients is also ongoing in the United
	Kingdom, which has been designed to supply additional data that the EMA may require beyond that provided in the bibliographic review.
	Depending on the exclusivity afforded by the orphan protection of Somakit TATE in the US we may submit an NDA for Somakit-TOC to
	the FDA and have submitted the MAA to the EMA in October 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Supply chain &mdash; Somakit
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For Somakit, our kit approach significantly
	simplifies the requirements to produce an injectable dose by eliminating the need for a chemistry synthesis process and many complex
	quality control steps. By reducing the process to less than 20 minutes, with what we believe are easy-to-follow instructions, we
	believe that Somakit can be used directly by any hospital that chooses to purchase a small Ga-68 generator.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There are already more than 10 sites in
	the United States operating Ga-68 generators for the purposes of research and expanded access programs. We believe this already
	represents a significant portion of the U.S. centers treating most neuroendocrine tumor patients. However, to further ensure availability
	of doses, we intend to partner with local radiopharmacies across the country that will reconstitute doses and deliver them to hospitals
	within a one-hour radius of major metropolitan areas. We have already entered our first agreement in early 2016 with two radiopharmacy
	networks, including Zevacor Molecular.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Lead SPECT Product Candidate &mdash;
	Annexin V-128
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Annexin V-128, which is labeled with Technetium-99m
	(Tc-99m), is a SPECT radiopharmaceutical product candidate that aims to detect early cell stress and apoptosis to assess programmed
	cell death in many pathological conditions, including rheumatoid arthritis. Annexin V-128 was developed by Atreus in Canada through
	an exclusive worldwide license from a third party. In December 2014, we became the sole owner of Atreus and have an exclusive option
	to sublicense rights to Annexin V-128 for marketing and distribution in the territories of the European Union. We are responsible
	for conducting pivotal studies and for regulatory approval in the European Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Based on the results of previous trials,
	including multiple published human trials using other forms of Annexin and published in peer-reviewed international scientific
	journals, we believe that there is significant promise in the use of Annexin V-128 for the imaging of cellular apoptosis and necrosis.
	Cellular apoptosis and necrosis are associated with a variety of debilitating or fatal medical conditions including rheumatoid
	arthritis, Crohn&rsquo;s disease, Alzheimer&rsquo;s disease, myocarditis, cardiac transplant rejection, acute myocardial infarction
	and unstable atherosclerotic carotid artery disease. In addition, we believe Annexin V-128 could be effective in evaluating patient
	responses to treatment for lymphoma and lung cancer. We also believe we may be able to overcome difficulties that have hampered
	the development of other forms of Annexin, including manufacturing issues, such as difficulties in lyophilization of the product
	and limitations related to the biodistribution of the agent due to challenges in targeting its uptake to specific organs (which
	interferes with the detection of apoptosis in the targeted area). Drawing on our R&amp;D expertise and manufacturing know-how,
	we believe we have met some of these challenges by developing and manufacturing a single-vial lyophilized kit with an extended
	shelf life and reduced cost of manufacture, and an improved formulation with better biodistribution in animal and human testing
	compared to other forms of Annexin due to the specific properties of Annexin V-128.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Specifically, the previous forms of Tc-99m-labeled
	Annexin relied on a chelator, or &ldquo;linker,&rdquo; called hydrazinonicotinamide, or &ldquo;Hynic.&rdquo; The inclusion of Hynic
	proved to be an impediment to optimizing the lyophilization process and the product ultimately needed to be shipped frozen. The
	current formulation of Annexin V-128, by contrast, has an endogenous Tc-99m binding site and as a result does not need a linker,
	allowing us to successfully lyophilize the product. This makes it simpler to ship and prepare, and extends its shelf life. Further,
	in the previous formulation the inclusion of the Hynic resulted in the prior formulation staying in the kidneys longer rather than
	being distributed through the body. This negative effect on biodistribution increased the radiation dose to the patient and interfered
	with imaging performance. By omitting the Hynic in our formulation, we believe we have been able to create superior biodistribution
	of Annexin V-128.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other forms of Annexin have been
	widely-used in at least 29 clinical studies, including sponsored trials (e.g., previous trials sponsored by the Theseus
	Corporation) and non-sponsored, or spontaneous, trials, having been studied extensively in both animals and humans. These
	compounds were based on a previous version of Annexin that was not optimized in terms of formulation or technical performance
	based upon preclinical and clinical studies of Annexin. We have developed Annexin V-128 in a new recombinant form that allows
	direct Tc-99m labeling and possesses what we believe are favorable characteristics for commercialization and imaging
	performance. In December 2014, we completed a Phase 1 trial to assess its safety, tolerability, biodistribution and dosimetry
	in Canada at the Ottawa Heart Institute and are currently analyzing the results of the study. In addition, we have begun a
	Phase 1/2 clinical trial at Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland designed to assess its safety,
	tolerability biodistribution and dosimetry, as well as the ability of Annexin V-128 to evaluate the presence of lesions
	before and after drug treatment in patients with rheumatoid arthritis or ankylosing spondylitis. We have begun patient
	enrollment in this Phase 1/2 clinical trial, where a total of 20 patients will be enrolled to receive two doses of Annexin
	V-128, one at baseline (before drug treatment) and one after drug treatment. We anticipate that our next stage of Annexin
	V-128&rsquo;s development will be the successful completion of these trials, with the goal of beginning Phase 3 trials in
	2017.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We had a pre-IND meeting regarding
	Annexin V-128 with the FDA on June 2, 2011 regarding its development program through Phase 1 and 2 (or Phase 1/2) trials. Two
	Phase 2 clinical trials have been initiated in April 2016, one in artherosclerotic carotid plaque indication, and one in
	early detection of chemotherapy-induced cardiotoxicity in breast cancer patients. Besides, a Phase II study is ongoing to
	assess the imaging potential in infective endocarditis and atrial thrombus indication. This trial is sponsored by the French
	National Institute of Health and Medical Research (INSERM). If initial safety, tolerability and efficacy data from our Phase
	1/2 trials for Annexin V-128 are positive, we plan to submit our initial results to the EMA and the FDA and seek their
	scientific advice in the second half of 2017 in order to finalize the proposed indication for Annexin V-128 and design an
	appropriate Phase 3 trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Our Research and Development Efforts
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our R&amp;D team is committed to the development
	of new product candidates. With more than 10% of our employees in R&amp;D and significant expertise located in both Europe and
	the United States, this team has implemented a strategy with five integrated prongs:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	identification of new diagnostic and therapeutic candidates to address unmet medical needs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	support of existing therapeutic product areas with external strategic collaborations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	development of innovative formulations for both reconstituted kits and ready-to-inject solutions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	early identification of promising candidate molecules through the integration of radiochemistry, pharmacology, dosimetry, and
	Proof of Concept (PoC) in humans; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	pursuit of an approach for unmet medical needs that combines diagnostic and therapeutic aspects.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that in-depth imaging expertise
	is key to the development of innovative imaging technologies and product candidates. We have accordingly established a multi-imaging
	solution platform, Ephoran Multi Imaging Solutions, to cover imaging techniques ranging from those techniques used extensively
	in preclinical settings and in clinics (e.g., MRI, PET, CT, SPECT, US) to optical imaging (OI, visible light and near-infra-red).
	We believe this platform can also be used to partner with external companies to improve and accelerate their product development.
	In addition, we believe our platform is uniquely positioned in preclinical and clinical imaging, allowing for serial/longitudinal
	imaging experiments during pharmacology and toxicology animal studies, and it is closely connected to and works with the Centre
	of Excellence in Preclinical Imaging at the University of Turin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The R&amp;D group assumes leadership of
	our efforts in the identification and development of promising new candidates that target orphan diseases and unmet medical needs
	in the field of oncology, cardiology, neurology and inflammation. By integrating diagnostics and therapy, we work toward targeted
	and personalized medicine that tailors treatments to individual patient needs. Through our R&amp;D senior management group we direct
	the overall strategy for developing our pipeline of product candidates while strictly adhering to international radiopharmaceutical
	regulations and guidelines. The R&amp;D management group has significant expertise and know-how across the entire product development
	chain and is supported by experienced staff in radiochemistry, pharmaceutical, preclinical and clinical development. In addition,
	we maintain continuous interactions with the healthcare field through hospitals, universities and research centers of excellence
	as a part of our strategy to foster a robust R&amp;D pipeline.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Commercial Products
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The table below summarizes our principal
	PET and SPECT products:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28%; PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 0.5PT SOLID; TEXT-INDENT: -0.25IN">
	Product
</P>
</TD>
<TD STYLE="WIDTH: 23%; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Description
</P>
</TD>
<TD STYLE="WIDTH: 24%; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Applications
</P>
</TD>
<TD STYLE="WIDTH: 25%; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Marketing
	Authorizations
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	Gluscan/Gluscan 500/ Barnascan&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<BR>
	Our brand names for FDG (concentration = 600MBq*/ml and 500MBq*/ml at calibration time for Gluscan and Gluscan 500, respectively; 3,000MBq*/ml for Barnascan at calibration time)
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<BR>
	PET tracer for oncology, cardiology, neurology and infectious/inflammatory diseases
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
<BR>
	Gluscan: Belgium, France, Italy, Luxembourg, Switzerland
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	Gluscan 500: France, Germany, Poland, Portugal, Spain
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	Barnascan: Spain
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	IASOflu&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our licensed brand name for Sodium Fluoride-18
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	PET tracer used as a bone imaging agent in defining areas of altered osteogenic activity
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Belgium, France, Germany, Italy, Luxembourg, Poland *
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	IASOdopa&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our licensed brand name for 6-fluoro-(18F)-L-DOPA, a DOPA analogue
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	PET tracer for diagnostic use, with key applications in neurology and oncology
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	France, Germany, Italy *
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
	DOPAVIEW
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our brand name for 6-fluoro-(18F)-L-DOPA, a DOPA analogue
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	PET tracer for diagnostic use, with key applications in neurology and oncology
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	France
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	IASOcholine&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our licensed brand name for 18F-choline (FCH)
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma (liver cancer)
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Belgium, France, Germany, Italy, Luxembourg, Poland *
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	AAACholine
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our brand name for 18F-choline (FCH)
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	PET tracer for detecting metastasis of prostate cancer and hepatocellular carcinoma (liver cancer)
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	France
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	MIBITEC/Adamibi&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Our brand names for a generic version of a widely-used SPECT cardiac imaging agent
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	SPECT tracer for myocardial exploration, localization of parathyroid tissue and breast cancer diagnosis
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	MIBITEC: Austria, France, Germany, Luxembourg, Poland,
	Slovenia
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.1IN">
	Adamibi: Greece, Italy&nbsp;
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 6PT 10PT 6PT 0.125IN; TEXT-INDENT: -0.125IN">
	Leukokit&#9;
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Medical device for the separation and labeling of autologous leukocytes
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Identifies sites of infection or inflammation in the body
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	CE mark: can be commercialized throughout Europe
</TD>
</TR>
</TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	* only countries to which AAA delivers the products are listed
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Leading PET Product &mdash; Gluscan
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Gluscan, which includes Gluscan 500 and
	Barnascan, is our leading PET product. Its active ingredient is FDG, the most widely used PET tracer. Gluscan contains a radioactive
	marker that enables the detection of a number of conditions in oncology, neurology, cardiology and inflammatory and infectious
	disease. We have marketing authorizations for Gluscan in Belgium, France, Germany, Italy, Luxembourg, Poland, Portugal, Spain and
	Switzerland.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We manufacture and organize distribution
	for Gluscan from our production sites in France, Italy, Portugal and Spain. Gluscan addresses a growing market in Europe and is
	currently our top-selling product, accounting for approximately 70.3% of the sales from our PET portfolio and 47.5% of total sales
	for the year ended December&nbsp;31, 2015 and 66.8% of the sales from our PET portfolio and 46.8% of total sales for the year ended
	December&nbsp;31, 2014. We are a leading supplier of FDG in Europe, and develop, manufacture and distribute our FDG products in
	an integrated fashion through our operating facilities, enabling reliable production, service and delivery to nuclear medicine
	end-users.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Because the market for PET products is
	growing and is expected to continue to grow, we expect to increase our capacity to produce Gluscan to meet potentially increasing
	demand at a local level and to possibly address new geographical markets. We are in the process of qualifying a new production
	site in Murcia (Spain), which is expected to be operational in the second half of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other PET Products
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also manufacture and market IASOflu,
	which images bone metastases; IASOdopa, which can help diagnose Parkinson&rsquo;s disease and tumors in certain indications; and
	IASOcholine, which can help diagnose prostate cancer. Each of these products is under an exclusive license from IASON, an Austrian
	manufacturer of F-18 products. We manufacture these three F-18 molecules at production sites in France and/or Italy. Our license
	agreement with IASON covers France, Spain, Belgium, Luxembourg, the Netherlands and parts of Switzerland and Italy. This license
	agreement is further described under &ldquo;&mdash;Licensing&mdash;IASON Know-How and Trademark License Agreement.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have developed our own F-18 DOPA product,
	DOPAVIEW, as well as our own FCH product. They both received regulatory approval in France on September 16, 2015 and have been
	submitted for approval in Switzerland. Our plan is to gradually submit both product candidates for approval in all other European
	countries where we have production sites.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We intend to reinforce our strong position
	in the growing PET market in Europe by adding to our portfolio of PET products and extending our geographical coverage through
	both internal growth and selective acquisitions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	SPECT Products
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	MIBITEC and Adamibi
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	MIBITEC and Adamibi are our brand names
	for a generic version of a widely-used SPECT cardiac imaging agent, Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate.
	They are approved for myocardial exploration, localization of parathyroid tissue and breast cancer diagnosis. MIBITEC was first
	launched in France in late 2010 and its marketing authorization has been extended to Austria, Germany, Poland, Luxembourg and Slovenia.
	We also market it in Greece and Italy under the name Adamibi. We intend to expand our sales of MIBITEC and Adamibi by selling them
	in new markets and are currently seeking marketing authorizations for MIBITEC and Adamibi in other European countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Leukokit
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Leukokit is a registered single-use medical
	device that contains all the necessary materials (with the exception of the radiopharmaceutical agent) to carry out separation
	and labeling of autologous leukocytes. The resulting labeled leukocytes are administered to patients to identify sites of infection
	or inflammation in the body. The use of Leukokit simplifies the procedure for identifying such sites and improves the operator&rsquo;s
	safety and the microbiological quality of the labeled cell preparation. Its use only requires a bench centrifuge, basic equipment
	often present in laboratories, enabling radiolabeling without expensive equipment. Leukokit meets the essential requirements of all relevant European Medical
	Device Directives and carries the CE-mark, a legal requirement permitting the marketing of a medical device throughout the European
	Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Strategic Relationships
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We manufacture several diagnostic products
	and product candidates for third parties, including GE&nbsp;Healthcare and Eli Lilly in Europe. These contract manufacturing agreements
	enable us to optimize our production capacity and leverage our core strengths in the manufacture of radiopharmaceuticals and our
	experience in organizing their distribution. These relationships demonstrate that our expertise and the strength of our production
	network position us as a key MNM player in Europe, and we intend to build on these relationships to explore additional opportunities
	with these partners. We also intend to seek new partners in the pharmaceutical industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also work with Bracco to advance Cardiogen,
	an existing product in the Bracco portfolio that is already approved for the U.S. market, through the trials and regulatory approvals
	required to commercialize Cardiogen in new markets in Europe. On September 18, 2015, we received a positive opinion from Swiss
	regulatory authorities on the last variation needed to commercialize this product in the territory.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Marshall Isotopes Enriched Water
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We acquired Marshall Isotopes Ltd., or
	Marshall, as part of a cost control and vertical integration strategy, since Marshall was one of only seven suppliers of enriched
	water &mdash; an essential component in the production of radiopharmaceuticals &mdash; in the world. We have recently increased
	the capacity of Marshall&rsquo;s enriched water production facilities to 150 kilograms as of July&nbsp;31, 2015, from 90 kilograms
	in June&nbsp;2011 when we first acquired the company. This capacity expansion was achieved through an investment program of&thinsp;
	&euro;1.2 million (US$1.3 million) by building two new lines of production. We sell all excess production that we do not require
	for our own radiopharmaceutical production pursuant to short-term and long-term contracts in Australia, Canada, China, Hong Kong,
	Japan, New Zealand, Singapore, South Korea, the United States and several countries in the European Union. We expect to continue
	to sell excess enriched water in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	IDB GroupLutetium 177
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	We acquired
	the IDB Group in January 2016 as part of cost-control and vertical integration strategy, since IDB was one of our two providers
	of Lu-177 for Lutathera. The IDB Group includes is a leading manufacturer of Lutetium 177&nbsp;(Lu-177). IDB produces, markets
	and sells Lu-177 under the brand name LuMark&reg;, and has established this product as the leading brand of Lutetium 177 worldwide.
	LuMark&reg; is the only Lu-177 product to have received European Marketing Authorization. Owning the IDB Group will help AAA maintain
	a reliable supply of Lu-177 for the production of Lutathera and AAA&rsquo;s future product candidates. The current capacity of
	the IDB is a weekly production yield of 7 TBq (5 production days and 2 targets per day for 10 targets per week). The facility operates
	today on average at 30% of its production capacity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Competition
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are engaged in sectors of the radiopharmaceutical
	and pharmaceutical industry that are competitive and rapidly changing. Large pharmaceutical, specialty pharmaceutical, radiopharmaceutical
	and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are
	commercializing or pursuing the development of products that aim to diagnose and treat serious conditions affecting patients. The
	diagnostic and therapeutic products and product candidates that they develop and/or produce may target the same conditions and
	cancers our products and product candidates aim to diagnose and/or treat. Our products face competition in the field of MNM and
	we expect our product candidates, if approved, to face significant and increasing competition as new products enter the MNM market
	from competitors that have been or will be able to overcome the MNM market&rsquo;s barriers to entry, and as advanced technologies
	become available.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our product candidates are expected to
	face competition based on their safety and effectiveness, the timing and scope of regulatory approvals, the availability and cost
	of supply, our marketing, sales and service capabilities, reimbursement coverage, price, patent position and other factors. Our
	competitors may succeed in developing competing products before we do, obtaining regulatory approval for products or gaining acceptance
	for the same markets that we are targeting. If one or more of our competitors is &ldquo;first to market&rdquo; with a product that
	competes with one of our product candidates, such as Lutathera or Somakit, our competitive position could be compromised because
	it may be more difficult for us to obtain marketing approval for that product candidate and/or successfully market that product candidate as a second
	product to market, in particular because we will not benefit from orphan drug market protections.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Therapeutics
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our lead therapeutic candidate, Lutathera,
	is the first ever radiopharmaceutical product candidate to have completed an European and U.S. Phase 3 clinical trials for the
	treatment of progressive midgut NETs. However, Lutathera faces competition from existing cancer treatments, including standard
	chemotherapy treatments that are not approved for the midgut NET indication. Competing drugs that target the same or similar NETs
	targeted by Lutathera (though they are not approved for the same indication as Lutathera) include Sandostatin
<SUP>
	&reg;
</SUP>
	and
	Afinitor
<SUP>
	&reg;
</SUP>
	, both from Novartis, Somatuline
<SUP>
	&reg;
</SUP>
	from Ipsen and Sutent
<SUP>
	&reg;
</SUP>
	from Pfizer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may also face competition in midgut
	NET treatment from conventional oncology therapies and existing approaches, such as cytotoxic therapy and molecular targeted therapy
	from established healthcare and pharmaceutical companies, such as Ipsen (Somatuline
<SUP>
	&reg;
</SUP>
	), Novartis (Sandostatin LAR
<SUP>
	&reg;
</SUP>
	,
	Afinitor
<SUP>
	&reg;
</SUP>
	), Pfizer (Sutent
<SUP>
	&reg;
</SUP>
	), Roche (Avastin
<SUP>
	&reg;
</SUP>
	, Octreolin
<SUP>
	&reg;
</SUP>
	) and Lexicon
	(LX1032
<SUP>
	&reg;
</SUP>
	). We will compete with such companies both in terms of efficacy and on the basis of price. While we believe
	our therapeutic approaches have significant advantages compared to conventional approaches, we may still face competition from
	conventional approaches for reasons of cost or familiarity of hospitals and doctors with existing treatments. However, if approved,
	we believe that Lutathera would be the first product indicated for the treatment of progressive midgut NETs where existing treatments
	fail to halt patient progression.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	PET
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Because PET products have a short shelf
	life of approximately ten hours, our competition is limited to companies and organizations with manufacturing infrastructure located
	within a distance that allows for rapid delivery to nuclear medicine facilities. We face competition in the field of PET from other
	manufacturers of PET products, principally IBA Molecular, our main competitor in the European MNM market due to its significant
	know-how, manufacturing capacity and geographic presence. We also face competition in the field of PET diagnostic products from
	smaller suppliers who operate within specific geographic areas.
<FONT STYLE="BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	SPECT
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We face competition in the field of SPECT
	from a greater number of SPECT manufacturers than we do in PET, given the more established and widespread use of SPECT imaging.
	Our competitors include both large healthcare companies such as GE Healthcare and IBA Molecular, and smaller diagnostic imaging
	companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Licensing
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have entered into various licensing
	agreements related to certain of our products and product candidates. We summarize the principal licensing agreements below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Somatostatin Analogue License Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In June&nbsp;2007, we entered into the
	Somatostatin Analogue License Agreement, pursuant to which we received a worldwide, irrevocable, non-exclusive license to develop,
	make, use, sell and distribute certain products related to patents pertaining to labeled somatostatin analogues. We may sublicense
	our rights under the agreement, subject to the counterparty&rsquo;s right to disapprove and block a proposed sublicense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are obligated to pay a low single-digit
	royalty on net sales of Lutathera for the longer of&thinsp; (i) the period that the use or sale of Lutathera is covered by a valid
	patent licensed under the agreement, or (ii) ten years from first commercial sale, in each case on a country-by-country basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, we are obligated in turn to
	pay Erasmus a low single-digit percentage royalty on net sales of Lutathera in exchange for the exclusive rights to use certain
	data of Erasmus relating to Lutathera. This royalty is capped based on the number of clinical trials required by the FDA (if the
	FDA was to require more than one pivotal Phase 3 trial for Lutathera), with a current maximum of&thinsp; &euro;2.0 million (US$2.2
	million).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Supply Obligations
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the event that Lutathera is approved
	for patient use by Erasmus, we are required to supply Lutathera for all of Erasmus&rsquo; product needs at the best price at which
	the product is sold in the European Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Term and Termination
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The agreement, unless terminated earlier
	by either party, will remain in effect on a country-by-country basis until our payment obligations expire for each applicable country.
	The agreement provides that either party may terminate the agreement if the other party willfully breaches the agreement and does
	not cure such breach within 90 days, or such additional time as may be reasonably necessary to rectify the breach, after receiving
	written notice of such breach. Additionally, only if required by law, either party may terminate the agreement in the event of
	the other party&rsquo;s insolvency, bankruptcy or related events or proceedings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Mallinckrodt License Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are party to a license agreement with
	Mallinckrodt under which we have an exclusive, worldwide license (with the right to sublicense) to patents owned by Mallinckrodt
	to develop, manufacture and commercialize a Lu-177 radiolabeled somatostatin peptide analogue compound for radio-therapeutic and
	dosimetric use in the field of oncology. We are currently developing our product candidate Lutathera under this Mallinckrodt license.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are obligated to make quarterly royalty
	payments to Mallinckrodt calculated at a percentage in the low teens of our net sales of Lutathera for the preceding quarter through
	January&nbsp;1, 2020. We will not have to make royalty payments on sales of Lutathera in any country where a court of competent
	jurisdiction has ruled that the licensed Mallinckrodt patents are invalid.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Diligence and Manufacturing Obligations
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We must use commercially reasonable efforts
	to develop and commercialize Lutathera and are responsible for manufacturing Lutathera in accordance with good manufacturing practices
	to meet the requirements for development and patient use following the first commercial sale of Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Term and Termination
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The license agreement, unless terminated
	earlier by either party, will remain in effect through January&nbsp;1, 2020. The agreement provides that either party may terminate
	the agreement in the event of the other party&rsquo;s insolvency, bankruptcy or related events or proceedings, or if the other
	party materially breaches the agreement and does not cure such breach within 90 days after receiving written notice of such breach.
	Upon expiration or termination of the license agreement, our license to Mallinckrodt&rsquo;s patents will terminate and will revert
	to Mallinckrodt.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the event that Mallinckrodt terminates
	the agreement pursuant to its terms, we must assign Mallinckrodt our rights to third-party sublicenses under the agreement and,
	at Mallinckrodt&rsquo;s election, transfer certain inventory and packaging at cost, as well as marketing authorizations and data
	related to Lutathera. We must also grant Mallinckrodt an exclusive royalty-bearing, worldwide license, and right to sublicense,
	in and to certain intellectual property rights, know-how and clinical data owned or licensed by us relating to a Lu-177 radiolabeled
	somatostatin peptide analogue for radio-therapeutic and dosimetric use in the field of oncology and a right of first offer within
	90 days after the termination on the sale of our Lutathera-related manufacturing assets, including related intellectual property
	and, if exercised, a right to better any subsequent third-party offer for a period of 12 months following the date of termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	IASON Know-How and Trademark License
	Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In January&nbsp;2009, we entered into a
	license agreement with IASON under which we received an exclusive license to use:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	IASON&rsquo;s know-how relating to IASOcholine, IASOflu and IASOdopa, or the Licensed Products, for the purpose of manufacturing
	and selling the Licensed Products in France, Spain, Belgium, Luxembourg, the Netherlands, certain areas of Switzerland and certain
	areas of Italy (except for IASOcholine, which is not licensed to us in Italy, and IASOflu, which is licensed to us on a non-exclusive
	basis in certain regions of Italy); and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	certain of IASON&rsquo;s trademarks in relation thereto.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the terms of the license grant, we
	may not sublicense any of our licensed rights, manufacture the Licensed Products for sale outside the territories described above
	or sell the Licensed Products outside such territories without the prior consent of IASON. IASON is entitled to manufacture, commercialize
	or use any Licensed Products manufactured through the use of any improvements to IASON&rsquo;s know-how made by us, by way of a
	nonexclusive, worldwide, royalty-free license.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	IASON also provided us with certain pharmaceutical
	and technical information and documentation and support in the installation of technical equipment necessary for the production
	of the Licensed Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the agreement, we currently pay IASON
	royalties for every batch of the Licensed Products that we produce. The fee per batch varies by product, with a maximum of&thinsp;
	&euro;600 (US$662). Payment is to be made within 60 days following the end of every quarter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Diligence and Manufacturing Obligations
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We must produce escalating minimum quantities
	of each of the licensed products within the agreed territory for each year of the agreement. We must also use our best efforts
	to exercise our license right to start production without delay and to carry out appropriate advertising and marketing activities
	to promote the sales of the Licensed Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Term and Termination
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The license agreement, unless terminated
	earlier by either party, will remain in effect for an initial period of five years and thereafter for successive periods of one
	year each. Either party may terminate the agreement by the end of the initial period or any subsequent period by giving the other
	party nine months&rsquo; notice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, IASON may terminate the agreement
	without prior notice in the event that we do not achieve the agreed minimum quantities described above, have lost our legal basis
	for pharmaceutical production, do not fulfill essential obligations under the agreement despite a written warning, file a nullity
	suit against a contractual property right or are subject to insolvency proceedings. The agreement also provides that either party
	may terminate the agreement if the other party breaches the agreement and does not cure such breach within 30 days after receiving
	notice of such breach.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Upon termination of the agreement for any
	reason, our license from IASON to make and sell the Licensed Products will terminate, except that we are entitled, for a period
	not to exceed six months after the termination date of the agreement, to manufacture the Licensed Products to the extent necessary
	to satisfy contractual obligations with customers that we accepted prior to termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Intellectual Property
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our success depends in part on our
	ability to obtain and maintain proprietary protection for our products, product candidates, technology and know-how, to
	operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. We
	seek to protect the products, product candidates, proprietary processes and other inventions that we believe are important to
	the development of our business by, among other methods, filing patent applications and maintaining, defending and enforcing
	issued patents in Europe, the United States and various other foreign jurisdictions. We also rely on trade secrets, know-how,
	continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position. For more
	information, please see &ldquo;Item 3. Key Information&mdash;D. Risk Factors&mdash;Intellectual Property, Licensing
	Dependence and Information Technology Risks.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	With respect to our products Gluscan, IASOflu,
	IASOdopa and IASOcholine, we rely on a combination of marketing authorization and owned and licensed know-how, technology and trademarks
	to maintain our competitive advantage. We hold a trademark registration for GLUSCAN in France and as an international registration
	under the Madrid system. We also license trademark registrations for IASOFLU, IASODOPA and IASOCHOLINE in Austria, Germany, France,
	Hungary, Italy and the Czech Republic. These products are not currently covered by any issued patents or pending patent applications
	in any jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of March 2016, we owned or exclusively
	licensed a total of approximately 73 issued patents and 15 patent applications covering certain aspects of Lutathera, Annexin V-128
	and Somakit in various jurisdictions throughout the world, including original filings, continuations and divisional applications.
	Our owned and licensed patents and patent applications relating to these key product candidates are described below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Lutathera.
</I>
</B>
	&nbsp;&nbsp;&nbsp;Our exclusively-licensed patents related to Lutathera, including 34 patents in various
	jurisdictions throughout the world, excluding the United States and including the European Union, Canada and Japan, cover radiolabeled
	peptide compositions targeting somatostatin receptors for the therapeutic treatment of tumors and are expected to expire on June&nbsp;6,
	2016. Due to the limited duration of our licensed patent rights covering Lutathera, we believe that you should not ascribe any
	material value to such patents.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Annexin.
</I>
</B>
	&nbsp;&nbsp;&nbsp;Our licensed patents related to Annexin V-128, including 5 U.S. patents and 12 patents
	in various other jurisdictions throughout the world, including the European Union and Japan, cover an
<I>
	in vivo
</I>
	method of
	imaging pain and cell death by use of a radioisotope-labeled Annexin and are expected to expire between April&nbsp;29, 2018 and
	October&nbsp;5, 2029 in the United States and between April&nbsp;28, 2018 and April&nbsp;3, 2022 in all other jurisdictions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<B>
<I>
	Somakit.
</I>
</B>
	&nbsp;&nbsp;&nbsp;Our 22 issued patents and 12 patent applications in various other jurisdictions throughout
	the world (including one U.S. patent application) related to Somakit, if issued, would cover a process wherein the Ga-68 is effectively
	complexed by a chelator-functionalized molecule in an aqueous buffer of formic acid/format and in the presence of compounds capable
	of chelating metal cations. The issued patents are expected to expire between August 12, 2031 and August 10, 2032, and the patent
	applications, if issued, would be expected to expire in 2032.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition to Lutathera, Annexin V-128
	and Somakit, our portfolio includes approximately 24 families of patents and patent applications covering certain aspects of our
	other MNM products, product candidates and discovery programs. Each patent family typically consists of patents and patent applications
	in the European Union, as well as broadly equivalent patents and patent applications in various other key jurisdictions, including,
	for example, the United States, France, the United Kingdom, Italy, Spain, Poland, Portugal, Switzerland, Germany and Canada. We
	expect these other issued patents and patent applications, if issued and if the appropriate maintenance, renewal, annuity and other
	government fees are paid, to expire between 2020 and 2034, before taking into account any potential adjustments, terminal disclaimers,
	extensions or other market exclusivity that may be available to us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The term of individual patents depends
	upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent
	term is 20 years from the earliest date of filing a non-provisional patent application. The term of a European patent is 20 years
	from its filing date. In the United States, a patent&rsquo;s term may be shortened if a patent is terminally disclaimed over another
	patent or as a result of delays in patent prosecution by the patentee, and a patent&rsquo;s term may be lengthened by patent term
	adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0.25IN">
	The
	term of a European patent covering a product or method of manufacture or use that requires national marketing authorization is
	subject to extensions on a country-by-country basis among the contracting states under the EPC. In general, only the specific
	molecule that receives marketing authorization (and the formulation of which is well-described in its patent) can receive extended
	protection. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for patent term extension,
	which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug
	Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five
	years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug or
	biologic is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years
	from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available
	in other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive
	marketing authorization, we expect to apply for patent term extensions on patents covering those products. We anticipate that
	some of our issued patents may be eligible for patent term extensions. For more information, please see &ldquo;&mdash;Regulation&mdash;United
	States&mdash;Hatch-Waxman Amendments to the FDCA&rdquo; and &ldquo;&mdash;&thinsp;Regulation&mdash;European Union.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may rely, in some circumstances, on
	trade secrets and know-how to protect our technology. However, trade secrets can be difficult to preserve. We seek to protect our
	proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors
	and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
	security of our premises and physical and electronic security of our information technology systems.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Customers
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The customers for our products include
	public and private hospitals, universities, third-party research laboratories, clinical centers and pharmaceutical companies. None
	of our customers accounts for 10% or more of our sales, with our most significant customer accounting for 3.2% and 4.2% of our
	sales and our top ten customers accounting for a combined total of 16.0% and 18.3% of our sales for the year ended December&nbsp;31,
	2015 and for the year ended December&nbsp;31, 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of December&nbsp;31, 2015, we had over
	200 unique PET customers, representing over 67% of our sales. We also have over 200 customers for SPECT and other MNM products.
	Our radiopharmaceutical customers are handled by key account managers who accompany them and act as advisers for hospital personnel
	and any others involved in patient management.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other Contracts
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	BioSynthema Sale and Purchase Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We acquired BioSynthema in 2010, pursuant
	to a sale and purchase agreement with the BI Shareholders, under which we acquired 100% of BioSynthema&rsquo;s shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The acquisition price is primarily performance-based.
	The initial consideration consisted of a cash payment of&thinsp; &euro;0.4 million (US$0.4 million) and payment of ordinary shares
	having an aggregate market value of&thinsp; &euro;2.3 million (US$2.5 million), as well as three potential milestone payments.
	Each milestone payment consists of&thinsp; &euro;0.4 million (US$0.4 million) in cash and ordinary shares having an aggregate market
	value of&thinsp; &euro;2.3 million (US$2.5 million), for a total possible acquisition price of&thinsp; &euro;1.5 million (US$1.6
	million) in cash and &euro;9.2 million (US$10.0 million) in ordinary shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We made the first milestone payment in
	October&nbsp;2012 when the FDA and the EMA approved the initiation of Phase 3 clinical trials for Lutathera. The second milestone
	is payable when Lutathera has obtained both EMA market authorization and FDA approval. The final milestone is payable when the
	global aggregate commercial net sales of Lutathera or a substitute product, each as defined in the agreement, have reached &euro;10
	million (US$10.9 million). The number of our ordinary shares to be issued in the remaining two milestone payments is calculated
	by dividing the payment owed by the market price of our ordinary shares when payment is due.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The agreement also requires that we pay
	an additional contingent consideration (consisting of a royalty) to the BI Shareholders calculated at a low- to mid-single-digit
	percentage of annual net sales of Lutathera, if our gross profit margin (with respect to sales of Lutathera or a substitute product),
	as defined in the agreement, within that year exceeds 30%. The percentage paid depends on the amount of net sales, and will be
	paid until the earlier of&thinsp; (i) ten years following our first commercial sale (as defined by the FDA and/or the EMA) of Lutathera
	or (ii) ten years following the first commercial sale of any substitute product that we manufacture. Payment is due within 90 days
	following the end of each fiscal year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	IEL Share Purchase Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We purchased IEL in February&nbsp;2014
	pursuant to a share purchase agreement with IEL Holdco, or the Seller, and its warrantors, or the IEL Warrantors, under which we
	acquired 100% of the share capital of IEL.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In connection with the agreement, we paid
	294,743 of our ordinary shares having an aggregate market value of &euro;1.5 million (US$1.6 million) to the Seller, and paid &euro;0.4
	million (US$0.4 million) in cash in May&nbsp;2014 to the Seller to compensate the Seller for IEL&rsquo;s positive net financial
	position at a specified date. There are no further payments to be made to the Seller.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Other Provisions
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In order for us to retain the important
	services of senior executives at IEL, the agreement provides for the continued service of certain IEL executives in their existing
	roles for a minimum period of one to three and a half years, depending upon the particular executive. In addition, under the agreement,
	the Seller agreed that it will not sell, transfer or otherwise dispose of or encumber any of our ordinary shares issued to it in
	satisfaction of the purchase price for 24 months without our prior written consent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Atreus Purchase Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In December 2014, we acquired the remaining
	49.9% of Atreus that we did not already own to become its sole owner pursuant to a share purchase agreement with Atreus Holdco.
	We paid an upfront cash payment for the acquisition and are obligated to pay additional anniversary payments to Atreus Holdco,
	as well as milestone payments in connection with obtaining potential EMA marketing authorizations or FDA approvals for Annexin
	V-128. If we obtain such marketing authorization or approval, respectively, we will be obligated to pay a low single-digit percentage
	royalty on global sales of Annexin V-128 for ten years thereafter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Pierrel Service Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are party to a service agreement with
	Pierrel Research Italy S.p.A., or Pierrel (now part of Therametrics holding AG, or Therametrics), pursuant to which Pierrel provides
	us with clinical research services, in particular packaging and logistics, in support of our pivotal Phase 3 trial for Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Financial Terms
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are obligated to pay Pierrel according
	to a cost grid provided in the agreement for the various packaging and logistic services that Pierrel provides, depending on the
	service and subject to certain assumptions, on an ongoing basis through the completion date of our Phase 3 trial. In connection
	with this agreement and raw materials provided by Pierrel, we paid Pierrel &euro;6.3 million (US$6.8&nbsp;million) during the year
	ended December&nbsp;31, 2015, &euro;5.1 million (US$5.5&nbsp;million) during the year ended December&nbsp;31, 2014 and &euro;2.6
	million (US$2.8 million) during the year ended December&nbsp;31, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	FRI License Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We entered into an exclusive license agreement
	with FRI in June 2015, under which we provided FRI and its affiliates an exclusive, royalty-bearing license, without the right
	to sublicense, under certain patent rights, know-how and trademarks to develop, commercialize and sell Lutathera in Japan for the
	treatment of tumors bearing somatostatin receptors, including NETs, for an initial term that commenced in June 2015 and will continue
	until ten years after the granting of the first marketing authorization for Lutathera in Japan. Pursuant to the license agreement,
	we are eligible to receive a royalty on net sales, at a percentage ranging from the low single digits to the low teens. We are
	also eligible to receive under the agreement milestone payments in an aggregate of up to &euro;4.5 million (US$ 4.9 million) depending
	upon receipt of marketing authorization for Lutathera in Japan and based upon FRI reaching specified levels of annual sales of
	Lutathera in Japan. During the initial term, either party may terminate upon prior written notice upon the other party&rsquo;s
	material breach, insolvency, or failure to achieve certain diligence obligations. We can terminate the agreement upon prior written
	notice in the event of change of control in FRI under certain circumstances. After the initial term, the agreement will be automatically
	renewed for successive two year periods unless either party gives written notice of
	termination a specified number of days prior to the expiration of the then-current term or terminated by either party upon prior
	written notice for breach, subject to a cure period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Regulation
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our business is subject to extensive government
	regulation. Regulation by governmental authorities in the United States, the European Union and other jurisdictions is a significant
	factor in the development, manufacture and marketing of any drugs and in ongoing R&amp;D activities. Our products are subject to
	rigorous preclinical and clinical trials and other pre-marketing approval requirements by the FDA, the EMA and other regulatory
	authorities in the United States, the European Union and in other jurisdictions. A process of managing a product during the course
	of its life cycle is performed after any approval in order to keep up to date any EMA marketing authorization and/or FDA approval,
	touching on three focus areas: quality, safety and efficacy. Our departments of regulatory affairs, pharmacovigilance, quality
	and medical information are dedicated to monitoring post-marketing activities in line with the safety profiles of our products
	and the applicable regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	United States
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the United States, the FDA regulates
	drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and regulations implemented by the agency. If we fail to comply
	with the applicable United States requirements at any time during the product development process, including non-clinical testing,
	clinical testing, the approval process or after approval, we may become subject to administrative or judicial sanctions. These
	sanctions could include, but are not limited to, the FDA&rsquo;s refusal to allow us to proceed with clinical testing, refusal
	to approve pending applications, withdrawal of an approval, warning letters, adverse publicity, product recalls, product seizures,
	total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Approval of Drugs
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The process required by the FDA before
	a drug may be marketed in the United States generally involves satisfactorily completing each of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&rsquo;s Good
	Laboratory and Good Manufacturing Practice regulations, as applicable;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials
	may begin;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed
	indication, conducted in accordance with federal regulations and GCPs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submission of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the
	product in clinical development and proposed labeling;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submission to the FDA of a NDA;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties,
	at which the product is produced to assess compliance with strictly enforced cGMP;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential FDA audit of the non-clinical and clinical trial sites that generated the data in support of the NDA; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	FDA review and approval of the NDA before any commercial marketing, sale or shipment of the product.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The testing, collection and submission
	of data and the preparation of necessary applications are expensive and time-consuming. The FDA may not act quickly or favorably
	in reviewing these applications, and we may encounter significant difficulties or costs in our efforts to obtain FDA approvals
	that could delay or preclude us from marketing our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Preclinical Studies and IND Application
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Preclinical tests include laboratory evaluations
	of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess
	the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing
	must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information
	and analytical data, are submitted to the FDA as part of an IND application. The IND becomes effective 30 days after receipt by
	the FDA, unless the FDA raises concerns or questions about the conduct of the proposed clinical trial, including concerns that
	human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any
	outstanding FDA concerns before the clinical trial can begin. Submission of the IND may result in the FDA not allowing the trials
	to commence or not allowing the trial to commence on the terms originally specified in the IND. If the FDA raises concerns or questions
	either during this initial 30 day period, or at any time during the IND process, the FDA may choose to impose a partial or complete
	clinical hold. This order issued by the FDA would delay either a proposed clinical study or cause suspension of an ongoing study,
	until all outstanding concerns have been adequately addressed and the FDA have notified the company that investigations may proceed.
	This could cause significant delays or difficulties in completing planned clinical studies in a timely manner.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Clinical Trials
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Clinical trials involve the administration
	of the investigational product to human subjects under the supervision of qualified investigators. Clinical trials are conducted
	under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and
	the effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. An IRB must also review
	and approve the clinical trial before it can begin and monitor the study until it is completed. The IRB will consider, among other
	things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects and the possible liability
	of the institution. The FDA, the IRB or the sponsor may suspend or discontinue a clinical trial at any time or impose sanctions
	for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or
	the subjects are being exposed to an unacceptable health risk. Clinical trials must be conducted in compliance with federal regulations,
	including regulations related to informed consent and in compliance with GCP, an international standard meant to protect the rights
	and health of patients and to define the roles of clinical trial sponsors, administrators and monitors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Clinical trials typically are conducted
	in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
<U>
	Phase 1
</U>
</I>
	clinical trials are
	initially conducted in a limited population to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution
	and excretion in healthy humans or, on occasion, in patients, such as cancer patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
<U>
	Phase 2
</U>
</I>
	clinical trials are
	generally conducted in a limited patient population to identify possible adverse effects and safety risks, determine the efficacy
	of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical
	trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trial.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
<U>
	Phase 3
</U>
</I>
	clinical trials proceed
	if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety
	profile. Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number
	of patients, typically at geographically dispersed clinical trial sites, to permit FDA to evaluate the overall benefit-risk relationship
	of the drug and to provide adequate information for the labeling of the drug. In most cases FDA requires two adequate and well-controlled
	Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be
	sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a statistically
	very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with
	a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In some cases, the FDA may condition approval
	of a NDA for a product candidate on the sponsor&rsquo;s agreement to conduct additional clinical trials to further assess the drug&rsquo;s
	safety and effectiveness after NDA approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These
	studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document
	a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a
	company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical
	trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials could
	result in withdrawal of approval for products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	New Drug Application
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The results of product candidate development,
	preclinical testing and clinical trials are submitted to the FDA as part of a NDA. The NDA also must contain extensive manufacturing
	information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee.
	The FDA has 60 days from its receipt of a NDA to determine whether the application will be accepted for filing based on the agency&rsquo;s
	threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for
	filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription
	Drug User Fee Act, or the PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard
	NDA and respond to the applicant, and six months from the filing date for a priority NDA. The FDA does not always meet its PDUFA
	goal dates for standard and priority NDAs. The review process is often significantly extended by FDA requests for additional information
	or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests, or the NDA sponsor
	otherwise provides additional information or clarification regarding information already provided in the submission within the
	last three months before the PDUFA goal date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Before approving a NDA, the FDA will typically
	inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities
	at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA
	contains data that provide substantial evidence that the drug is safe and effective in the indication studied.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At the conclusion of the FDA&rsquo;s review,
	it will issue either an approval letter or a complete response letter. If the FDA&rsquo;s evaluations of the NDA and the clinical
	and manufacturing procedures and facilities are favorable and there are no outstanding issues, the FDA will issue an approval letter.
	If the application is not approved, the FDA will issue a complete response letter, which generally outlines the deficiencies in
	the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application.
	Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response to the issues
	identified by the FDA. Such resubmissions are classified under PDUFA as either Class 1 or Class 2. The classification of a resubmission
	is based on the information submitted by an applicant in response to an action letter. Under the goals and policies agreed to by
	the FDA under PDUFA, the FDA has two months to review a Class 1 resubmission and six months to review a Class 2 resubmission. The
	FDA will not approve an application until issues identified in the complete response letter have been addressed. If, or when, those
	deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The FDA may also refer the NDA to an advisory
	committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the
	recommendation of the advisory committee, but it generally follows such recommendations. The FDA may withdraw a drug approval if
	ongoing regulatory requirements are not met or if safety problems occur after the drug reaches the market. In addition, the FDA
	may require further testing, including Phase 4 clinical trials, and surveillance programs to monitor the effect of approved drugs
	which have been commercialized. The FDA has the power to prevent or limit further marketing of a drug based on the results of these
	post-marketing programs. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved
	labeling. Further, if there are any modifications to a drug, including changes in indications, labeling or manufacturing processes
	or facilities, a sponsor is required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development
	of additional data or the conduct of additional preclinical studies and clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Breakthrough Therapy Designation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Breakthrough therapy designation is intended
	to expedite the development and review of products for serious and life-threatening conditions. Preliminary clinical evidence must
	demonstrate the drug may have substantial improvement over other available therapy. This designation conveys all of the same features
	of fast track designation, as well as more intensive FDA guidance throughout the development program. This guidance can include
	meetings throughout the development cycle, providing timely advice to ensure both the nonclinical and clinical programs are as
	efficient as practicable, and includes involvement of senior managers and experienced staff in cross-disciplinary and collaborative
	reviews. In general, sponsors must apply for breakthrough therapy designation, although the FDA may suggest to the sponsor that
	they consider submitting a request for the designation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Fast Track Designation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The FDA&rsquo;s fast track program is intended
	to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening
	condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the
	condition. Under the fast track program, the sponsor of a new product candidate may request the FDA to designate the product candidate
	for a specific indication as a fast track drug concurrent with or after the filing of the IND for the product candidate. The FDA
	must determine if the product candidate qualifies for fast track designation within 60 days of receipt of the sponsor&rsquo;s request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If fast track designation is obtained,
	the FDA may initiate review of sections of a NDA before the application is complete. This rolling review is available if the applicant
	provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user
	fees. However, the time period specified in the PDUFA, which governs the time period goals the FDA has committed to reviewing an
	application, does not begin until the complete application is submitted. Additionally, the fast track designation may be withdrawn
	by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera has been granted Fast-Track designation
	by the U.S. Food and Drug Administration. Fast-Track is designed to facilitate the development of and expedite review of, product
	candidates that treat serious conditions and fill an unmet medical need.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In some cases, either a breakthrough therapy
	or a fast-track-designated product candidate may also qualify for one or more of the following programs:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Priority Review.&nbsp;&nbsp;&nbsp;
</I>
	Under
	FDA policies, a product candidate is eligible for priority review, or review within six months from the time a complete NDA is
	accepted for filing, if the product candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis
	or prevention of a disease. Under PDUFA, the FDA is further entitled to take 60 days to determine that an application is sufficiently
	complete to allow the filing, therefore a priority review timetable may be 60 days before acceptance plus review. We cannot guarantee
	any of our product candidates will receive a priority review designation, or, if such a priority designation is received, that
	review or approval will be faster than conventional FDA procedures, or that the FDA will ultimately grant approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Accelerated Approval.&nbsp;&nbsp;&nbsp;
</I>
	Under
	the FDA&rsquo;s accelerated approval regulations, the FDA is authorized to approve product candidates that have been studied for
	their safety and effectiveness in treating serious or life-threatening illnesses, and that provide meaningful therapeutic benefit
	to patients over existing treatments based upon either a surrogate endpoint that is reasonably likely to predict clinical benefit
	or on the basis of an effect on a clinical endpoint other than patient survival. In clinical trials, surrogate endpoints are alternative
	measurements of the symptoms of a disease or condition that are substituted for measurements of observable clinical symptoms. A
	product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion
	of Phase 4 or post-approval clinical trials to validate the surrogate endpoint or confirm the effect on the clinical endpoint.
	Failure to conduct required post-approval studies, or to validate a surrogate endpoint or confirm a clinical benefit during post-marketing
	studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates
	approved under accelerated regulations are subject to prior review by the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	When appropriate, we intend to seek breakthrough
	therapy, fast track designation, priority review or accelerated approval for our products. We cannot predict whether any of our
	products will obtain a breakthrough therapy, fast track designation, priority review or accelerated
	approval or the ultimate impact, if any, of these programs on the approval process, on the timing, or the likelihood of FDA approval
	of any of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Orphan Drug Designation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Orphan drug designation in the United States
	is designed to encourage sponsors to develop drugs intended for rare diseases or conditions. In the United States, a rare disease
	or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects
	more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing
	and making available the drug for the disease or condition will be recovered from sales of the drug in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Orphan drug designation qualifies a company
	for tax credits and market exclusivity for seven years following the date of the drug&rsquo;s marketing approval if granted by
	the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval
	to market the product. The Office of Orphan Products Development, or OOPD, at the FDA is responsible for designating drugs as orphan
	drugs based on acceptable confidential requests made under the regulatory provisions. The drug must then go through the new drug
	approval process like any other drug. Orphan drug designations are decided solely by the OOPD staff, but the OOPD occasionally
	will request opinions from the Center for Drug Evaluation and Research, especially when dealing with issues such as the appropriateness
	of the requested indication or the scientific rationale described by the sponsor.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A sponsor may request orphan drug designation
	of a previously unapproved drug or new orphan indication for an already marketed drug. In addition, a sponsor of a drug that is
	otherwise the same drug as an already approved drug may seek and obtain orphan drug designation for the subsequent drug for the
	same rare disease or condition if it can present a plausible hypothesis that its drug may be clinically superior to the first drug.
	Clinical superiority can be demonstrated on the basis of superior safety, superior efficacy, or a major contribution to patient
	care. More than one sponsor may receive orphan drug designation for the same drug for the same rare disease or condition, but each
	sponsor seeking orphan drug designation must file a complete request for designation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Lutathera, 68Ga-DOTATATE and 68Ga-DOTATOC
	were each granted orphan drug designation in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The period of exclusivity begins on the
	date that the marketing application is approved by the FDA and applies only to the indication for which the drug has been designated.
	The FDA could approve a second application for the same drug for a different use or a second application for a clinically superior
	version of the drug for the same use. The FDA cannot, however, approve the same drug made by another manufacturer for the same
	indication during the market exclusivity period absent a demonstration of clinical superiority unless it has the consent of the
	sponsor or the sponsor is unable to provide sufficient quantities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Hatch-Waxman Amendments to the FDCA
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, under the FDCA, as amended
	by the Hatch-Waxman Amendments, a drug can be classified as a new chemical entity if the FDA has not previously approved any other
	new drug containing the same active moiety. Under sections 505(c)(3)(D)(ii) and 505(j)(5)(D)(ii) of the FDCA, as amended by the
	Hatch-Waxman Amendments, the first applicant to gain approval of a NDA for a new chemical entity may, in the absence of patent
	protections, be eligible for five years of market exclusivity in the United States following regulatory approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	During the five-year exclusivity period,
	the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA, submitted by a competitor for
	another version of such drug, where the applicant does not own or have a legal right of reference to all the data required for
	approval. Protection under the Hatch-Waxman Amendments will not prevent the filing or approval of another full NDA, but the applicant
	would be required to conduct its own adequate and well-controlled clinical trials to demonstrate safety and effectiveness. The
	Hatch-Waxman Amendments also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplements to existing
	NDAs if new clinical investigations are essential to the approval of the applications, for new indications, dosages, or strengths
	of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and
	does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs filed by competitors for drugs containing the original active
	agent or uses not protected by the exclusivity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Hatch-Waxman Amendments also permits
	a patent restoration term of up to five years as compensation for the portion of a drug&rsquo;s patent term lost during product
	development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
	beyond a total of 14 years. The patent term restoration period is generally one-half the time between the effective date of an
	IND, and the submission date of a NDA, plus the time between the submission date of a NDA and the approval of that application.
	Only one patent applicable to an approved drug is eligible for the extension and it must be applied for prior to expiration of
	the patent. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for
	any patent term extension or restoration. In the future, we may consider applying for restorations of patent term for some of our
	currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected length of
	clinical trials and other factors involved in the filing of the relevant NDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Post-approval Regulation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If regulatory approval for marketing of
	a product or new indication for an existing product is obtained, a manufacturer is required to comply with all regular post-approval
	regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. Manufacturers
	are required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information
	and comply with requirements concerning advertising and promotional labeling requirements. Drug manufacturers and certain of their
	subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic
	unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP,
	which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, NDA holders and third-party
	manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance
	with cGMP and other regulatory requirements. Discovery of problems with a product after approval for marketing may result in restrictions
	on a product, manufacturer, or holder of an approved NDA, including withdrawal of the product from the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	European Union
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The process regarding approval of medicinal
	products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily
	completing each of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good
	Laboratory Practice regulations;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submission to the relevant national authorities of a clinical trial application, or CTA, which must be approved before human
	clinical trials may begin;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed
	indication;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	submission to the relevant competent authorities of a MAA, which includes the data supporting safety and efficacy and proposed
	indications as well as detailed information on the pharmaceutical development, manufacturing process and controls;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities,
	including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the
	product.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Pharmaceutical development and Preclinical
	Studies
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Pharmaceutical development activities include
	laboratory evaluations of product chemistry, formulation and stability. Preclinical tests include studies to evaluate pharmacology,
	pharmacokinetics and toxicology in animal models, in order to assess the potential safety and efficacy of the product and gather
	essential data required for first-in-human studies. The conduct of the preclinical
	tests and formulation of the compounds for testing must comply with the relevant EU regulations and requirements. The results of
	the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Clinical Trial Application
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Pursuant to the Clinical Trials Directive
	2001/20/EC, as amended, a system for the approval of clinical trials in the European Union has been implemented through national
	legislation of the member states. Under this system, approval must be obtained from the competent national authority of a European
	Union member state in which a study is planned to be conducted. To this end, a CTA is submitted, which must be supported by an
	investigational medicinal product dossier, or IMPD, and further supporting information prescribed by the Clinical Trials Directive
	and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has
	issued a favorable opinion on the CTA in that country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Efforts are being made by the regulators
	and related stakeholders to implement the new clinical trial regulation (Regulation EU No 536/2014) which will become applicable
	not earlier than May 28, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Clinical drug development is often described
	as consisting of four temporal phases (Phase 1&thinsp;&ndash;&thinsp;4), see EMA&rsquo;s note for guidance on general considerations
	for clinical trials (CPMP/ICH/291/95).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 1 (Most typical kind of study:&nbsp;Safety and Pharmacokinetics);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 2 (Most typical kind of study:&nbsp;Therapeutic Exploratory);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 3 (Most typical kind of study:&nbsp;Therapeutic Confirmatory); and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Phase 4 (Variety of Studies:&nbsp;Therapeutic Use).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Studies in Phase 4 are all studies (other
	than routine surveillance) performed after drug approval and related to the approved indication.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The phase of development provides an inadequate
	basis for classification of clinical trials because one type of trial may occur in several phases. The phase concept is a description,
	not a set of requirements. The temporal phases do not imply a fixed order of studies since for some drugs in a development plan
	the typical sequence will not be appropriate or necessary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Manufacturing of investigational products
	is subject to the holding of authorization and must be carried out in accordance with cGMP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Health Authority Interactions
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	During the development of a medicinal product
	and life cycle management of a product, frequent interactions with the EU regulators are vital to make sure all relevant input
	and guidelines/regulations are taken into account in the overall program. We have established an ongoing dialogue with the EMA
	and certain national authorities by making use of the mechanisms that exist for interaction and input. We also manage the timing
	and communication about any process improvement, production site additions or safety variations, which is crucial for our business
	in addition to being important information to provide to patients and/or stakeholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Available Authorization Procedures
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Authorization to market a product in the
	European Union member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition
	procedure, a decentralized procedure or a national procedure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Centralized authorization procedure
</I>
	.&nbsp;&nbsp;&nbsp;Certain drugs, such as those defined as medicinal products developed
	by means of biotechnological processes, must undergo the centralized authorization procedure for marketing authorization, which,
	if granted, is automatically valid in all European Union member states. The EMA and the European Commission administer the centralized
	authorization procedure.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Pursuant to Regulation 726/2004, this procedure is mandatory for:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	medicinal products developed by means of one of the following biotechnological processes:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	recombinant DNA technology;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed
	mammalian cells; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	hybridoma and monoclonal antibody methods;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	advanced therapy medicinal products as defined in Article 2 of Regulation 1394/2007 on advanced therapy medicinal products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	medicinal products for human use containing a new active substance which, on the date of entry into force of this Regulation,
	was not authorized in the European Union, for which the therapeutic indication is the treatment of any of the following diseases:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	acquired immune deficiency syndrome;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	cancer;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	neurodegenerative disorder;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	diabetes;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	auto-immune diseases and other immune dysfunctions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 1IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	viral diseases; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	medicinal products that are designated as orphan medicinal products pursuant to Regulation 141/2000.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	The centralized authorization procedure is optional
	for other medicinal products if they contain a new active substance or if the applicant shows that the medicinal product concerned
	constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization is in the interest
	of patients at a European Community level.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	Under the centralized authorization procedure, the
	CHMP serves as the scientific committee that renders opinions about the safety, efficacy and quality of human products on behalf
	of the EMA. The CHMP is composed of experts nominated by each member state&rsquo;s national drug authority, with one of them appointed
	to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the Committee
	acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP
	has 210 days, to adopt an opinion as to whether a marketing authorization should be granted. In practice the process takes longer
	as additional information is requested, which triggers clock-stops in the procedural timelines. The process is complex and involves
	extensive consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed,
	a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds on
	which this conclusion was reached. The opinion produced by the CHMP is sent to the European Commission and used in reaching the
	final decision.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	In general, if the centralized procedure is not followed,
	there are three alternative procedures. If marketing authorization in only one member state is preferred, an application can be
	filed to the national competent authority of a member state. The other two options are a mutual recognition by European Union member
	states and the decentralized procedure, both under Directive 2001/83. A marketing authorization may be granted only to an applicant
	established in the European Union.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 94 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Mutual recognition procedure.&nbsp;&nbsp;&nbsp;
</I>
	If an authorization has been granted by one member state, or the Reference
	Member State, an application may be made for mutual recognition in one or more other member states, or the Concerned Member State(s).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Decentralized procedure
</I>
	.&nbsp;&nbsp;&nbsp;The third option is the decentralized procedure. The decentralized procedure
	may be used to obtain a marketing authorization in several European member states when the applicant does not yet have a marketing
	authorization in any country.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	National procedure
</I>
	.&nbsp;&nbsp;&nbsp;Applicants following the national procedure will be granted a marketing authorization
	that is valid only in a single member state. Furthermore, this marketing authorization is not based on recognition of another marketing
	authorization for the same product awarded by an assessment authority of another member state. The national procedure can also
	serve as the first phase of a mutual recognition procedure.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	It is not always possible for applicants to follow
	the national procedure. In the case of medicinal products in the category for which the centralized authorization procedure is
	compulsory, that procedure must be followed. In addition, the national procedure is not available in the case of medicinal product
	dossiers where the same applicant has already obtained marketing authorization in one of the other European Union member states
	or has already submitted an application for marketing authorization in one of the other member states and the application is under
	consideration. In the latter case, applicants must follow a mutual recognition procedure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	After a drug has been authorized and launched, it
	is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be
	kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme
	cases, the authorization may be revoked, resulting in withdrawal of the product from sale.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Accelerated Assessment Procedure
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	When appropriate, we may seek accelerated
	assessment for our products being submitted under centralized procedure. When an application is submitted for a marketing authorization
	in respect of a drug for human use which is of major interest from the point of view of public health and in particular from the
	viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to article 14, paragraph
	9 of Regulation 726/2004.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Conditional Approval
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As per Regulation EC 726/2004, Art. 14(7),
	a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be
	granted a conditional marketing authorization on the basis of less complete clinical data than are normally required, subject to
	specific obligations being imposed on the authorization holder. These specific obligations are to be reviewed annually by the EMA.
	The list of these obligations shall be made publicly accessible. Such an authorization shall be valid for one year, on a renewable
	basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Exceptional Circumstances
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As per Regulation EC 726/2004, Art. 14(8),
	products for which the applicant can demonstrate that comprehensive data (in line with the requirements laid down in Annex I of
	Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation) might be eligible for
	marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess the risk-benefit
	balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under exceptional
	circumstances is aimed at the provision of information on the safe and effective use of the product and will normally not lead
	to the completion of a full dossier/approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We cannot predict which of our products
	will obtain any of such designations or predict the ultimate impact, if any, of such designations on the timing, conditions or
	likelihood of EMA authorization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 95 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Period of Authorization and Renewals
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Marketing authorization shall be valid
	for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of
	the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization
	holder shall provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and
	efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing
	authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the
	Commission or the competent authority decides, on justified grounds, to proceed with one additional five-year renewal. Any authorization
	which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of
	the authorizing member state within three years after authorization shall cease to be valid (the so-called sunset clause).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Orphan Drug Designation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Regulation 141/2000 states that a drug
	shall be designated as an orphan drug if its sponsor can establish:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	(a)(i) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
	affecting not more than five in ten thousand persons in the European Community when the application is made, or;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	(a)(ii) that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious
	and chronic condition in the European Community and that without incentives it is unlikely that the marketing of the drug in the
	European Community would generate sufficient return to justify the necessary investment; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	(b) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been
	authorized in the European Community or, if such method exists, the drug will be of significant benefit to those affected by that
	condition.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Regulation 847/2000 holds criteria for
	the designation of orphan drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	An application for designation as an orphan
	product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization
	for an orphan drug leads to a ten-year period of market exclusivity. This period may, however, be reduced to six years if, at the
	end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, perhaps because
	the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected
	cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration
	of&thinsp; &ldquo;clinically relevant superiority&rdquo; by a similar medicinal product, or, after a review by the Committee for
	Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation
	criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant to Regulation 141/2000 shall
	be eligible for incentives made available by the European Community and by the member states to support research into, and the
	development and availability of, orphan drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have applied for and been granted orphan
	status in the European Union for Lutathera, 68 Ga-DOTATATE and 68 Ga-DOTATOC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Regulatory Data Protection
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Without prejudice to the law on the protection
	of industrial and commercial property, all full applications for marketing authorization following Article 8(3) of the Directive
	2001/83/EC as amended receive an 8+2+1 protection regime.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This regime consists of a regulatory data
	protection period of eight years commencing on the date of marketing authorization with a concurrent market exclusivity of ten
	years plus an additional market exclusivity of one further year if, during the first eight years of those ten years, the marketing
	approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to
	their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current
	rules, a third party may reference the preclinical and clinical data
	of the original sponsor beginning eight years after first approval, but the third party may market a generic version after only
	ten (or eleven) years have lapsed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As indicated, additional data protection
	can be applied for when an applicant has complied with all requirements as set forth in an approved PIP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Manufacturing
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The manufacturing of authorized drugs,
	for which a separate manufacturer&rsquo;s license is mandatory, must be conducted in strict compliance with European cGMP requirements
	and comparable requirements of other regulatory bodies, which mandate the methods, facilities and controls used in manufacturing,
	processing and packing of drugs to assure their safety and identity. The EMA enforces its cGMP requirements through mandatory registration
	of facilities and inspections of those facilities. The EMA may have a coordinating role for these inspections while the responsibility
	for carrying them out rests with the member states competent authority under whose responsibility the manufacturer falls. Failure
	to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost sales, and could subject
	the applicant to potential legal or regulatory action, including but not limited to warning letters, suspension of manufacturing,
	seizure of product, injunctive action or possible civil and criminal penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Marketing and Promotion
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The marketing and promotion of authorized
	drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or
	the general public, are strictly regulated in the European Community notably under Directive 2001/83 in the European Community
	code relating to medicinal products for human use as amended by Directive 2004/27. The applicable regulation aims to ensure that
	information provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately reflects
	the safety and efficacy claims authorized by the EMA or by the competent authority of the authorizing member state. Failure to
	comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and
	criminal penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Life Cycle Management of a Marketed Product
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	After receiving marketing authorization
	approval, various aspects of the life cycle of a product with marketing authorization must be managed and properly undertaken.
	These include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	variations (single or grouping type IA, IB, II variations);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	extension applications;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	annual reassessments (in case of conditional approval or approval under exceptional circumstances);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	certain post-authorization measures (such as post-authorization efficacy or safety studies, or PAES or PASSs, if any);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	renewal of marketing authorization (after five years in the European Union);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Article 46 pediatric study submissions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	periodic safety update reports, or PSURs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	marketing and cessation notifications, where required;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	sunset clause monitoring; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	product information review and confirmation.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 97 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Pharmacovigilance
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The pharmacovigilance system in the European
	Union operates with the management and involvement of regulatory authorities in member states, the European Commission and the
	EMA. In some member states, regional centers are in place under the coordination of the national competent authority.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Within this system, the EMA&rsquo;s role
	is to coordinate the EU pharmacovigilance system and to ensure the provision of advice for the safe and effective use of medicines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Updated pharmacovigilance legislation (Regulation
	(EU) No 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December&nbsp;2010.
	The legislation was the biggest change to the regulation of human medicines in the European Union since 1995. It has significant
	implications for applicants and holders of EU marketing authorizations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The EMA, the EU member states and the European
	Commission are responsible for implementing much of the new legislation, which has been effective since July&nbsp;2012. The EMA
	plays a key role in coordinating activities relating to the authorization and supervision of medicines, including safety monitoring,
	across this network.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The EMA is working with a wide range of
	stakeholders, including the European Commission, pharmaceutical companies, national medicines regulatory authorities, patients
	and healthcare professionals, to ensure effective implementation. Most of the legislation had to be implemented by July&nbsp;2012.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Background to the New Legislation
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A strong factor in the development of the
	new Directive and Regulation is the incidence of so-called adverse drug reactions, which are responses to a medicine that are &ldquo;noxious
	and unintended.&rdquo; Adverse drug reactions are estimated to cause 197,000 deaths per year in the European Union. A strengthened
	European safety monitoring system aims to reduce the number of adverse drug reactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The European Commission began a review
	of the European system of safety monitoring in 2005, including an independent study sponsored by the European Commission and extensive
	public consultation in 2006 and 2007. The resulting legislation was adopted by the European Parliament and Council of Ministers
	in December&nbsp;2010.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The new legislation forms part of a three-piece
	&ldquo;pharmaceutical package&rdquo; and amends existing pharmacovigilance legislation contained in Directive 2001/83/ EC and Regulation
	(EC) No. 726/2004.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	Impacts of the New Legislation on Marketing
	Authorization Holders
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Marketing authorization applicants and
	holders are impacted by the legislation in a number of key areas. The legislation aims to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	make roles and responsibilities clear;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	minimize duplication of effort;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	free up resources by rationalizing and simplifying PSURs and adverse drug reaction reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	establish a clear legal framework for post-authorization monitoring.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Examples of impacts on marketing authorization
	holders and applicants include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	EudraVigilance/adverse drug reaction reporting
</I>
	:&nbsp;&nbsp;Following a successful audit, marketing authorization holders
	submit adverse drug reaction reports only into EudraVigilance. Previously, reports went via the individual national competent authority,
	including reporting of medication errors that resulted in an adverse reaction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Simplified safety monitoring:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	PSURs have a single assessment for the same active substance or a combination of active substances;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 98 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	routine PSUR reporting is no longer necessary for products with low risk or for old or established products unless concerns
	arise;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	PSUR reporting is electronic following the establishment of an EU repository. PSURs are sent directly to the EMA;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	there is a strengthened legal basis for requesting post-authorization safety studies, or PASSs, and post-authorization efficacy
	studies, or PAESs from the pharmaceutical industry; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	risk management systems are required for all newly authorized medicines.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Referrals
</I>
	:&nbsp;&nbsp;All pharmacovigilance referrals are discussed by the Pharmacovigilance Risk Assessment Committee,
	or PRAC, and the Committee for Medicinal Products for Human Use, or CHMP, or the Coordination Group for Mutual Recognition and
	Decentralised Procedures &mdash; Human, or CMDh. Opinions are adopted as a result.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Inspections and pharmacovigilance systems
</I>
	:&nbsp;&nbsp;Marketing authorization holders are required to maintain a pharmacovigilance
	system master file, or PSMF permanently available for submission or inspection by the national competent authority. The PSMF replaced
	the detailed description of the pharmacovigilance system, or DDPS.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<I>
	Supply of medicinal product information to the EMA
</I>
	:&nbsp;&nbsp;Regulation 1235/2010 states that by July&nbsp;2, 2012,
	marketing authorization holders must have submitted information to the EMA on medicinal products for human use authorized or registered
	in the European Union using an electronic format provided by the EMA. Marketing authorization holders are also responsible for
	maintaining this information once submitted.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have also organized a governance system
	to facilitate the respect of ethical standards and the safety, well-being and health of volunteers and patients engaged in medical
	activities related to the conduct of clinical trials. These activities include clinical development, commercialization or any other
	related activity such as R&amp;D, investigator-sponsored trials, investigator medicinal grants or compassionate use. The pharmacovigilance
	system promotes patients&rsquo; safety when using medicinal products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Within the pharmaceutical business sector,
	market authorization holders and other competent authorities are responsible for ensuring that a structure is in place so that
	individual case safety reports are captured at a local level and properly reported into central functions. Ongoing monitoring and
	evaluation of reported cases are diligently performed to timely detect any early safety signals. Appropriate corrective measures
	are applied whenever necessary, and are covered by various quality tools, templates, record-keeping mechanisms, and other functions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have established multidisciplinary teams
	and pharmacovigilance officers and committees to oversee first-in-man studies, evaluate and decide upon amendments to clinical
	study protocols, assess the benefit-risk ratio of studies and other courses of action as well as major medical or medical-device-related
	safety matters. The latter are also addressed within the ambit of specific customer complaint quality documentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Quality Assurance for Radiopharmaceuticals
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have established various interrelated
	and controlled activities in order to work effectively and efficiently. We try to ensure that all processes required for the delivery
	of products by third parties and services are identified and planned. We perform and control the following tasks in connection
	with any project, service or production:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	identify key processes that define the critical path of any project/service/production;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	define their interaction, if any, supported by a risk assessment analysis;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	ensure and assess their performance and controllability based on measurable indicators;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	render them uniquely traceable through assigned and controlled documentation; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	seek to continually enrich/improve their content and performance.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 99 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Common features of our processes and sub-processes
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	defined and agreed starting point;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	processed inputs based on outputs from organizations such as suppliers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	sequence of activities that are logically and or chronologically related;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	processed outputs that generate added value for us and our partners;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	defined ending point, which becomes the next input for a subsequent process;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	assessment of process output by defining markers (e.g., key performance indicators); and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	assignment of a process owner and clear roles and responsibilities.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Following those common features, processes
	are usually designed along a process chain which may be formulated throughout a product life cycle according to the research and
	development of a new radiopharmaceutical product; within those processes, technology transfer activities are also covered by quality
	control systems.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our board of directors assumes the leadership
	of quality control and continual improvement as a strategic pillar of our business by establishing a corporate-level quality control
	structure and its implementation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Customer satisfaction and compliance with
	regulatory requirements are the most fundamental aspects that our quality control systems aim to serve. By maintaining close contact
	with customers and interested third parties, we work to meet expectations (business contractual, technical and quality expectations)
	on consistent basis. Direct and indirect gauging of customer satisfaction and complaints also assists us in defining metrics and
	maintaining and enhancing trust and performance between all parties. Feedback from customers, informal escalation or formal complaints
	are all treated with care and diligence.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Dangerous Goods Transportation
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	All radiopharmaceutical products (except
	&ldquo;cold&rdquo; kit radiopharmaceuticals, such as certain SPECT products) are considered dangerous goods and have to respect
	specific regulation to be transported. Our products are transported in a specific package named package type A (UN2915) generally
	by road to the end-user, or by air.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Legislation governing the carriage of dangerous
	goods by road in particular countries and throughout Europe, adopted by 46 countries worldwide, is based on the Agreement Concerning
	the International Carriage of Dangerous Goods by Road. The structure is consistent with that of the United Nations Recommendations
	on the Transport of Dangerous Goods, Model Regulations, and the Technical Instructions for the Safe Transport of Dangerous Goods
	by Air (of the International Civil Aviation Organization). This agreement has been in place for over 50 years, and is amended every
	two years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The law in relation to the carriage of
	dangerous goods by road sets out duty holders/participants with certain responsibilities. The participants with specific legal
	duties are the consignor, carrier, driver and vehicle crew, packer, filler, loader, unloader, tank-container/portable tank operator,
	consignee and the Dangerous Goods Safety Adviser, or DGSA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Seasonality
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Historically, we have not experienced material
	fluctuations in our sales over any quarterly period in the year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Environmental, Health and Safety Issues
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to various environmental,
	health and safety laws, rules and regulations, including those relating to the use, storage, treatment, release, transportation
	and disposal of radioactive and hazardous materials and wastes, and permitting and D&amp;D obligations. As a result of our planned
	construction or acquisition of a full-scale manufacturing facility in the United States, we may be required to obtain permits or
	other authorizations under such laws, rules and regulation. Except as discussed below in connection with D&amp;D, we believe that
	compliance with these laws, rules and regulations will not
	materially affect our results of operations or our position with respect to our competitors. However, we can provide no assurance
	of the effect that any possible future environmental laws, rules or regulations will have on our business, operating results or
	financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Some of these laws and regulations provide
	for liability in the event of contamination at our facilities or in connection with the transportation of our products. We could
	be held liable for the costs of cleanup or be subject to third-party claims, including claims for personal injury or property damage,
	should contamination of the environment or exposure to radioactive or hazardous materials occur. We could also be subject to, among
	other sanctions, significant fines for failure to comply with applicable environmental, health and safety laws and regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our facilities where cyclotrons are installed
	and our cyclotrons eventually will need to be decommissioned and decontaminated, and such facilities must be returned to their
	original state at the end of a facility&rsquo;s useful life. In connection with this process, we will incur D&amp;D costs and we
	have recorded a liability for such costs. We estimate the costs associated with D&amp;D for a cyclotron-equipped production site
	to be approximately &euro;0.6 million (US$0.7 million) per cyclotron. This estimate may differ based on factors such as country-specific
	requirements. Estimating the amount and timing of such future D&amp;D costs includes, among other factors, making projections as
	to when a facility will retire or the useful life of a cyclotron.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Environmental, health and safety laws and
	regulations are complex, change frequently and have become more stringent over time. We cannot assure you that our costs of complying
	with current or future environmental, health and safety laws and regulations will not exceed our estimates or adversely affect
	our results of operations and financial condition. Further, we cannot assure you that we will not be subject to environmental,
	health and safety claims in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal Proceedings
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	From time to time we may become involved
	in legal proceedings that arise in the ordinary course of business. As of the date of this annual report on Form 20-F, there are
	no material ongoing litigation, regulatory or other proceedings and we have no knowledge of any investigations by governmental
	or regulatory authorities in which we are a target that could have a material adverse effect on our current business. During the
	period covered by the audited and approved financial statements contained herein, we have not been a party to or paid any damages
	in connection with litigation that has had a material adverse effect on our financial position. No assurance can be given that
	future litigation will not have a material adverse effect on our financial position.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dividends and Dividend Policy
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have not declared or paid any cash dividends
	on our ordinary shares and do not currently intend to pay cash dividends on our ordinary shares in the foreseeable future. We intend
	to retain all available funds and any future earnings to fund the development and expansion of our business. Dividends, if any,
	on our outstanding ordinary shares, will be proposed by our board of directors and must be approved by our shareholders. Even if
	our board of directors decides to propose dividends in the future, the form, frequency and amount of such dividends will depend
	upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions
	and other factors our board of directors may deem relevant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Subject to the requirements of French law,
	dividends may only be distributed from our statutory retained earnings. Moreover, we must allocate 5% of our unconsolidated net
	profit for each year to our legal reserve fund before dividends, should we propose to declare any, may be paid for that year, until
	the amount in the legal reserve is equal to 10% of the aggregate nominal value of our issued and outstanding share capital. See
	&ldquo;Item 10. Additional Information&mdash;B. Articles of Association&mdash;Key Provisions of Our By-laws and French Law Affecting
	Our Ordinary Shares&mdash;Rights, Preferences and Restrictions Attaching to Ordinary Shares&rdquo; for further details on the limitations
	on our ability to declare and pay dividends. Dividend distributions, if any, will be made in Euros and converted into U.S. dollars
	with respect to the ADSs, as provided in the deposit agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_ORGANIZATIONALSTRUCTURE">
</A>
	C.
</TD>
<TD>
	Organizational Structure
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We were incorporated as a
<I>
	soci&eacute;t&eacute;
	anonyme
</I>
	, or S.A., under the laws of the French Republic in 2002. Prior to our initial public offering, we were a privately
	owned company. We are registered in Bourg en Bresse, France. Our principal executive offices are located at 20 rue Diesel, 01630
	Saint Genis Pouilly, France and our telephone number at this address is +33 (0) 4 50 99 30 70.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	The subsidiaries as of December 31, 2015 are
	listed below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 77%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Entity
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Registered office in
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications SA
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	France
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications Unipessoal Lda
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Portugal
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications Polska sp zoo
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Poland
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications (Italy) Srl
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Italy
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	G.I. Pharma Srl
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Italy
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications International SA
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Switzerland
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications (Switzerland) SA
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Switzerland
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications GmbH (Ex - Umbra Medical AG)
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Germany
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications Ib&eacute;rica S.L.
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Spain
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications USA, Inc. (Ex - Biosynthema Inc.)
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	USA
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Marshel (R.R) Investments Ltd
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Israel
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Marshall Isotopes Ltd
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Israel
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Catalana De Dispensacion
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Spain
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Barnatron SA
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Spain
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Advanced Accelerator Applications Canada Inc.
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Canada
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Atreus Pharmaceuticals Corporation (Merged with Advanced&nbsp;Accelerator&nbsp;Applications&nbsp;Canada Inc.)
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Canada
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Eifel Property GmbH
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Germany
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	Imaging Equipment Ltd
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 1PT; PADDING-BOTTOM: 1PT">
	UK
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_PROPERTYPLANTANDEQUIPMENT">
</A>
	D.
</TD>
<TD>
	Property, Plant and Equipment
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have developed a pan-European manufacturing
	network with 16 production facilities (including seven with R&amp;D capabilities) and one facility dedicated exclusively to R&amp;D
	in Nantes, France. We also have two other sites under construction, including one in Millburn, NJ that we are retrofitting to enable
	it to produce Lutathera and one in Murcia, Spain that we acquired for purposes of manufacturing PET products. The Millburn site
	is expected to be operational in the first half of 2017 and the one in Murcia in the second half of 2016.Our sales and distribution
	network is based in 8 countries and reaches markets in 19 countries excluding IDB markets. We have a total of 25 production and
	R&amp;D sites and office locations (we house two of our entities at the same offices in Geneva, Switzerland), in 14 countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 102 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 46%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Location
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Offices
	Only
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	PET
	Production
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	SPECT
	Production
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Enriched
	Water Production
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Therapy
</P>
</TD>
<TD STYLE="WIDTH: 9%; PADDING-RIGHT: 10PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	R&amp;D
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Saint-Genis-Pouilly, France (Headquarters)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Troyes, France&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	B&eacute;thune, France&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Nantes, France&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	St. Cloud, Paris, France&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Marseille, France&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Colleretto Giacosa, Italy&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Saluggia, Italy (Gipharma)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Meldola, Italy&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Pozzilli, Italy&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Almuna de Dona Godina, Spain&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Barcelona, Spain (Barnatron)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Barcelona, Spain (Cadisa)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Madrid, Spain&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Porto, Portugal&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Lisbon, Portugal&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Geneva, Switzerland (AAA Switzerland/AAA&nbsp;International)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Bonn, Germany&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Warsaw, Poland&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Baarle-Nassau, The Netherlands&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Ravels, Belgium&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Beer Tuvia, Israel (Marshall Isotopes)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Chilcompton, United Kingdom (IEL)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	New York, USA&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 10PT">
	Ottawa, Canada (Atreus)&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	x
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that all of our laboratories
	operate according to cGMP in accordance with European regulations. In addition, two of our Italian plants, in the Ivrea and Meldola
	areas, have obtained approval from AIFA to produce Lutathera, qualifying them as the first industrial pharmaceutical laboratories
	in the world to receive approval from a central authority to produce an injectable nuclear molecular therapeutic product. These
	two laboratories are expected to be our main Lutathera production sites for all of Europe. Our other production sites develop,
	manufacture and/or sell our other existing products and product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our production capacity and extent of utilization
	of our facilities is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	PET production facilities:&nbsp;&nbsp;&nbsp;all sites combined are generally capable of producing up to 52 batches (at six
	curies of FDG, or 60&thinsp;&ndash;&thinsp;100 doses) per day, or between 12,000 and 13,000 batches per year, of F-18 products,
	with actual production estimated at approximately 75% of capacity, or approximately 9,000 to 10,000 batches. Due to the short half-life
	of F-18, exact capacity and utilization in terms of doses can differ significantly as a further delivery distance and more time
	(with resulting decay of the FDG) results in a higher dosage of FDG required in each batch produced.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	SPECT production facilities:&nbsp;&nbsp;&nbsp;all sites combined are capable of producing approximately 5&nbsp;million vials
	of SPECT product per year, with an average utilization rate of approximately 44% during the past five years, or approximately 2.2
	million vials actually produced.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Enriched water:&nbsp;our enriched water facilities have a production capacity of 150 kilograms of water per year. Any enriched
	water which we do not immediately sell or use can be stored for short-term future sale.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	The current capacity of the IDB facility, the company which we acquired in January 2016, is a weekly production yield of 7
	TBq (5 production days and 2 targets per day for 10 targets per week). The facility operates today on average at 30% of its production
	capacity.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our production and R&amp;D resources represent
	what we believe to be one of our key competitive strengths, as they allow us to develop, manufacture and sell therapeutic and diagnostic
	products in all significant European markets while positioning us as a licensing and manufacturing partner for companies such as
	GE Healthcare and Eli Lilly that require qualified manufacturers for their existing and new PET products. Our manufacturing footprint
	is scalable. We currently manufacture Lutathera at two facilities in Italy where we have the capacity to produce commercial-scale
	supplies of Lutathera. We are modifying our facility in Zaragoza, Spain, in order to have an additional production site for Lutathera
	before the end of 2016. In order to support the commercial launch of Lutathera and to simplify our manufacturing logistics, we
	purchased and are currently retrofitting a site in Millburn, NJ at a cost of approximately &euro;10.0 million (US$11.0 million),
	to produce Lutathera in the United States. We intend to commercialize Lutathera with our own sales force in France, Germany, Italy,
	Spain, Portugal, Switzerland, The Netherlands, Belgium, Canada, Poland, the United Kingdom and the United States, and with partners
	in other countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_LEGAL_PROCEEDINGS>
</EFX_COMPANY_INFORMATION>
<!-- FIELD: /PAGE -->
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM4A">
</A>
	ITEM 4A. UNRESOLVED STAFF COMMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="FIS_OPERATING_AND_FINANCIAL_REVIEW"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM5">
</A>
	ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	The following discussion of our financial
	condition and results of operations should be read in conjunction with our audited consolidated financial statements and the notes
	thereto, included elsewhere in this annual report on Form 20-F, as well as the information presented under &ldquo;Presentation
	of Financial and Other Information&rdquo; and &ldquo;Item 3. Key Information&mdash;A. Selected Financial Data.&rdquo;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	The following discussion contains forward-looking
	statements that involve risks and uncertainties. Our actual results may differ materially from those expressed or implied in the
	forward-looking statements as a result of various factors, including those set forth in &ldquo;Forward-Looking Statements&rdquo;
	and &ldquo;Item 4. Information on the Company&mdash;D. Risk Factors&rdquo; and elsewhere in this annual report on Form 20-F.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_OPERATINGRESULTS">
</A>
	A.
</TD>
<TD>
	Operating Results
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Overview
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are an innovative radiopharmaceutical
	company that develops, produces and commercializes MNM products. MNM is a medical specialty that uses trace amounts of radioactive
	compounds to treat diseases such as cancer and create functional images of organs and lesions. Our lead therapeutic product candidate,
	Lutathera, is a novel MNM compound that we are currently developing for the treatment of midgut NETs, a significant unmet medical
	need. Lutathera is a Lu-177 labeled somatostatin analogue peptide that has received orphan drug designation from the EMA and the
	FDA. Lutathera was also granted Fast-Track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut
	NETs. The FDA provides Fast-Track designation to product candidates that treat serious conditions and fill an unmet medical need
	in order to facilitate their development and expedite their review. In a pivotal Phase 3 trial for the treatment of inoperable
	progressive midgut NETs, Lutathera combined with Octreotide LAR has produced favorable initial results compared to the current
	standard of care, treatment with Octreotide LAR alone. Lutathera is also currently administered on a compassionate use and named
	patient basis for the treatment of NETs in ten European countries, and we estimate that Lutathera has been used in over 3,000 patients
	to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Key Metrics
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands except percentages)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-STYLE: ITALIC">
	Financial metrics
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%">
	Sales&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	96,227
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Year-over-year percentage increase&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating income/(loss)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,353
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss for the period&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	Adjusted EBITDA(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,941
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,787
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,394
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjusted EBITDA margin(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash from operating activities&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,796
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,363
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,367
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash and cash equivalents&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	129,098
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Adjusted EBITDA and Adjusted EBITDA margin are not calculated in accordance with IFRS. A reconciliation of these non-IFRS measures
	to their most directly comparable IFRS-based measures along with a summary of the measures and their material limitations are included
	in &ldquo;Item 3. Key Information&mdash;A. Selected Financial Data&mdash;Other Financial Metrics.&rdquo;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We monitor the key financial and operating
	metrics set forth in the preceding table to help us evaluate trends, establish budgets, measure the effectiveness and efficiency
	of our operations and gauge our cash generation. We discuss sales and the components of net income (loss) in &ldquo;&mdash;A. Results
	of Operations,&rdquo; Adjusted EBITDA and Adjusted EBITDA margin in footnotes 2 and 3, respectively, in &ldquo;Item 3. Key Information&mdash;A.
	Selected Financial Data&mdash;Other Financial Metrics&rdquo; and cash flows provided by operating activities in &ldquo;&mdash;B.
	Liquidity and Capital Resources&rdquo; below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	IFRS Financial Statements
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We operate in a single segment. Under IFRS,
	income and expenses must be classified by their nature or by their function in the consolidated statements of income. We present
	our consolidated statements of income by nature. As a result, income and expenses are aggregated in the consolidated statements
	of income according to their nature, and are not reallocated among functions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Factors Affecting Our Results of Operations
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Growing Demand and Sales
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Over the past few years, we have seen an
	increase in demand for MNM products as a result of an increased focus on tailored patient treatment. Improvements in PET and SPECT
	technology, as well as our manufacturing expertise and know-how, have enabled us to innovate in our development of molecular nuclear
	diagnostics for and molecular nuclear therapeutic treatment of serious conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We realize sales from our PET and SPECT
	products, enriched water and product candidates, including Lutathera. We also realize sales of products and product candidates
	we manufacture for third parties. Sales are recognized when the following conditions are met: there is an agreement between the
	parties; the goods have been delivered or the services rendered; the price is fixed or can be reliably measured; and it is probable
	that future economic benefits from the transaction will flow to us. Rebates and discounts granted to customers are deducted from
	the corresponding sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our total sales were &euro;88,6 million
	(US$96.2 million) for the year ended December&nbsp;31, 2015, &euro;69.9 million (US$75.9 million) for the year ended December&nbsp;31,
	2014, and &euro;53.8 million (US$58.4 million) for the year ended December&nbsp;31, 2013. Historically, we have derived most of
	our sales from the sale of Gluscan, which represented 47.5%, 46.8% and 51.6% of our total sales in fiscal years 2015, 2014 and
	2013, respectively. We expect that sales of Gluscan and our other PET products will grow over the coming years as we seek new markets,
	obtain new customers for Gluscan and obtain marketing approval for IASOflu, IASOdopa and IASOcholine in additional European countries.
	In addition, with one of the largest manufacturing networks and one of the broadest product portfolios in the European market,
	we expect to be able to successfully compete to manufacture and/or distribute new proprietary third-party products that are expected
	to enter the PET market and to increase our sales by working with the owners of these products. We expect sales of our SPECT products
	to grow modestly as we continue to develop or seek to acquire products or promising product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that Lutathera, our principal
	therapeutic MNM candidate, will generate demand with significant growth potential due to its potential ability to provide improved
	patient outcomes in the treatment of midgut NETs, a significant unmet medical need. We have submitted the NDA to the FDA and the
	MAA to the EMA for Lutathera in April 2016. We expect to commence commercial
	sales of Lutathera as soon as practicable following FDA approval or EMA marketing authorization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Costs of Raw Materials
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The costs of our raw materials are generally
	subject to price fluctuations. Historically, however, other than enriched water, we have not experienced significant price fluctuations
	from our principal suppliers, although we can provide no assurance on price fluctuations or the lack thereof in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result of experiencing significant
	price fluctuations for enriched water, a key component in our radiopharmaceutical manufacturing, we acquired Marshall in 2011 to
	secure our own price-stable source of enriched water. We may take similar actions in the future to in-source other raw materials
	for our manufacturing. To date, we have been able to mitigate raw material cost
	increases due to our significant scale and the resulting efficiencies in our supply chain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 105 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	98
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Raw materials for the production of Lutathera
	historically represented a high percentage of sales in the early stages of our compassionate use and named patient basis programs,
	but this percentage has decreased due to the increase in sales volume and our implementation of a new pricing policy for Lutathera.
	We expect these costs to further decrease in percentage terms primarily due to the recent acquisition of IDB, the lower cost of
	sourcing of Lutetium and the expected sales price of Lutathera once we will be able to sell following the required Marketing Authorization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	R&amp;D Costs and Investments
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Since our founding, we have focused on
	building a broad portfolio of MNM products. Building this portfolio requires significant up-front costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As discussed above, our financial statements
	are presented by nature and not by function. We therefore do not present R&amp;D costs as a single line item in our financial statements.
	Instead, R&amp;D costs are recorded in our consolidated statements of income by their nature: in personnel costs, raw materials
	and consumables used and other operating expenses. Expenditure incurred during research phases is expensed as incurred. Expenditure
	incurred during development phases is capitalized as intangible assets if it meets certain criteria. Such criteria are considered
	not to have been met until a regulatory filing has been made in a major market and approval is considered highly probable. As a
	result of this policy, no development costs have been capitalized to date. See &ldquo;&mdash;&thinsp;Critical Accounting Policies&mdash;Internally
	Generated Intangible Assets.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our R&amp;D costs include clinical trials
	to obtain regulatory approvals, personnel costs for our R&amp;D team and the acquisition of specific R&amp;D materials and manufacturing
	equipment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Total expenditures on R&amp;D for fiscal
	year 2015 were &euro;14.7 million (&euro;10.5 million and &euro;7.3 million for fiscal years 2014 and 2013 respectively), primarily
	related to the development of Lutathera. These consist of personnel costs, including share-based payments for R&amp;D personnel,
	of&thinsp;&euro;2.2 million, for fiscal year 2015 (&euro;2.4 million for each of the fiscal years 2014 and 2013), and other operating
	costs amounting to &euro;12.5 million for fiscal year 2015 (&euro;8.1 million and &euro;4.9 million for fiscal years 2014 and 2013
	respectively).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December 31, 2014, R&amp;D costs recorded
	in our statement of financial position as other intangible assets consisted of acquired in-process R&amp;D for &euro;16.1 million
	principally resulting from the acquisitions of Atreus and BioSynthema in 2010. The carrying value of these intangible assets increased
	to &euro;17 million at December&nbsp;31, 2015, primarily due to exchange rate fluctuations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	R&amp;D costs may fluctuate from period
	to period, as our product candidates enter various stages of development. For example, for the years ended December&nbsp;31, 2015,
	2014 and 2013, we incurred significant development costs related to our Phase 3 trial for Lutathera. We expect to continue to incur
	development costs related to Lutathera, as well as other planned or future clinical trials for the other products candidates in
	our pipeline. See &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Our Product Candidates in Clinical
	Development.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Changes in Fair Value of Contingent Consideration
	and Their Effects on Financial Results
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The change in fair value of contingent
	consideration is recorded in financial results and primarily represents the variation and adjustment relating to our valuation
	of other long-term liabilities due to the former shareholders of BioSynthema, or the BI Shareholders, and former shareholders of
	Atreus, or the Atreus Shareholders, which results from our earn-out obligations to such former shareholders of these acquired companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For fiscal year ended December&nbsp;31,
	2015, we recorded a net financial loss of &euro;6.7 million, consisting of finance income of&thinsp; &euro;1.2 million and finance
	costs of&thinsp; &euro;7.9 million. &euro;5.3 million of these finance costs were related to an increase of our other long-term
	liabilities, following the update of contingent consideration amounts due principally to the BI&nbsp;Shareholders and Atreus Shareholders
	described below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For fiscal year 2014, we recorded a net
	financial loss of &euro;1.8 million, consisting of finance income of&thinsp; &euro;0.4 million and finance costs of&thinsp; &euro;2.2
	million. &euro;1.1 million of these finance costs were primarily related to a change in our other long-term liabilities of contingent
	consideration due to the BI Shareholders described below. For fiscal year 2013, we recorded a financial loss of&thinsp;
	&euro;9.8 million, consisting of finance income of &euro;0.4&nbsp;million and finance costs of&thinsp; &euro;10.2 million. &euro;7.4
	million of these finance costs were related to a change in our other long-term liabilities of contingent consideration due to the
	BI Shareholders described below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 106 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	99
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the BioSynthema sale and purchase
	agreement, we are required to pay a variable royalty amount to the BI Shareholders, consisting of a low single-digit percentage
	of annual net sales of Lutathera, if our gross profit margin with respect to sales of Lutathera, as defined in the agreement, within
	that year exceeds 30%. This consideration is payable annually for ten years following EMA market authorization or FDA approval
	for Lutathera.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The aggregate variable and fixed
	milestone payments due to the BI Shareholders pursuant to the BioSynthema sale and purchase agreement are considered to be a
	liability classified contingent consideration under IFRS-3. The fair value of this contingent consideration was recognized
	initially as part of the consideration transferred, measured at its acquisition date fair value. The contingent consideration
	liability is remeasured to fair value at each reporting date until the contingency is resolved. Changes in the fair value of
	this contingent consideration liability are recognized in the income statement as finance cost or income. For the fiscal
	years 2014 and 2013, our principal assumption for purposes of determining the net present value of this financial obligation
	was, other than sales forecasts, a 67% probability of successfully commercializing Lutathera and obtaining reimbursement,
	estimated by us based on the stage of Lutathera&rsquo;s development at period end. At December 31, 2015, we have revised this
	probability to 80% following the substantial completion of Lutathera&rsquo;s pivotal Phase 3 trial and based on the current
	stage of the product development at that date. As a result, the contingent liability owed to the BI Shareholders has increased
	to &euro;33.8 million at December 31, 2015. If the probability of successfully bringing Lutathera to commercialization
	with reimbursement were to be increased to 100%, our contingent consideration would have amounted to &euro;42.2 million
	at December 31, 2015. We also applied a discount rate of 10% to the expected cash outflows to reflect the time value of
	money and the estimated risks to realizing the future cash flows. An increase or decrease of 1% in the discount rate would
	lead to a decrease of &euro;1.9 million or an increase of &euro;2 million, respectively. An increase or decrease of 5% in
	foreign currencies against the euro would lead to an increase of &euro;1.2 million or a decrease of &euro;1.1 million,
	respectively. Other items could have an impact on the contingent consideration such as the timing of market authorization in
	the various jurisdictions or the future selling prices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For the change in the fair value of the
	BioSynthema contingent consideration liability, we recorded finance costs of&thinsp;&euro;3.9 million for fiscal year 2015. This
	charge is mainly due to the increase in the liability resulting from the increase of the probability of occurrence from 67% to
	80% as the Company had substantially completed Lutathera phase 3 development at December 31, 2015, the exchange rate fluctuations
	between the U.S. dollar and the euro, and the unwinding of the discount. Those impacts are partially offset by the updating of
	the business plan on future sales of Lutathera. The Company revised the business plan of future sales of Lutathera to take into
	account some modified assumptions. These consist primarily of a revised sales launch schedule for some countries in Europe compared
	to the previously assumed single launch date for all the major European countries. The respective finance costs related to the
	change in the BI Shareholder contingent consideration for fiscal years 2014 and 2013 were &euro;0.9 million and &euro;7.4 million.
	The total contingent consideration liability amounted to &euro;33.8 million, &euro;29.8 million and &euro;28.9 million at December&nbsp;31,
	2015, 2014 and 2013 respectively. The change over this three-year period from the end of fiscal year 2013 to the end of fiscal
	year 2015 is mainly due to the increase in the probability of occurrence from 67% to 80%, the updating of the business plan on
	future sales of Lutathera and the unwinding of the discount.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the Atreus sale and purchase agreement
	which was concluded on December 18, 2014, we are required to pay fixed anniversary and milestone payments prior to having obtained
	marketing authorization for Annexin V-128. We are also required to pay a low single digit percentage royalty on sales for a duration
	of ten years following receipt of the first market authorization. Our principal assumptions at December 31, 2015 were that (1)
	we would obtain such regulatory approvals in 2019 (assumed 2018 in our 2014 financial statements) (2) with a probability of occurrence
	of 100% for 2016 anniversary payments and milestones payments, 60% for 2017 and 2018 anniversary payments and milestones payments,
	and then 30% for further anniversary payments and milestone payments and for royalty payments (3) a discount rate of 10% on expected
	cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 107 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	100
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0.25IN">
	The
	contingent consideration based on our business case and the above assumptions amounted to &euro;6.3 million and
	&euro;6.0 million at December&nbsp;31, 2015 and 2014, respectively. The increase in the contingent consideration is driven by
	a finance charge of &euro;0.6 million for the period ended at December 31, 2015 mainly due to the updating of the business
	plan on future sales of Annexin, updating the probability of occurrence of payments of anniversary and milestone payment and
	the exchange rate variation of the Canadian dollar to the euro, partially offset by a payment of &euro;0.3 million made to
	former Atreus owners. The Company revised the business plan on future sales of Annexin. The changes are primarily due to the
	fact that a first potential indication for Annexin was replaced with a different, more promising indication. This results in
	a delayed start of sales with a Marketing Authorization and a higher amount of royalties to pay over the contractually
	relevant period.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	If the probability of successfully bringing
	Annexin V-128 to commercialization with reimbursement were to be increased to 100%, our contingent consideration would have
	amounted to &euro;19.7 million at December 31, 2015. An increase or decrease of 1% in the discount rate would result in a
	decrease of &euro;0.5 million or an increase of&thinsp; &euro;0.6 million in the contingent consideration liability. An
	increase or decrease of 5 percentage point in the value of the Canadian dollar against the euro would result in a decrease
	or an increase of &euro;0.3 million in the contingent consideration liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The remaining contingent consideration
	liability to former owners of acquired companies mainly consists of&thinsp;&euro;2.3 million, &euro;2.7 million and &euro;3.6 million
	at December&nbsp;31, 2015, 2014 and 2013, respectively, related to the acquisition of Cadisa and Barnatron in 2012 and to the acquisition
	of the Steripet Business of GE Healthcare S.r.L.in Italy in June&nbsp;2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Acquisitions
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our results of operations are significantly
	affected by our past acquisitions. We incorporate an acquired business into our results of operations on the date we acquire the
	business, which affects the comparability of sales for such period with prior periods. In particular, our results for the year
	ended December&nbsp;31, 2014 may not be directly comparable to those for the year ended December&nbsp;31, 2013, which do not reflect
	the effect on our results of operations of the acquisition of IEL on February&nbsp;14, 2014. The acquisition of the GE Healthcare
	Steripet business in Italy at the end of the third quarter of 2014 had no significant impact on the results of 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Part of our strategy is to acquire and
	consolidate complementary businesses and assets, such as promising product candidates. Any future acquisitions could limit year-to-year
	comparisons of our results of operations. We may also incur substantial debt, issue additional equity securities or use other funding
	sources to fund future acquisitions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Personnel Costs, Including Share-Based
	Compensation
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Personnel costs consist of compensation
	for employees in all functions (including salaries, social charges such as pension and medical plans and share-based compensation).
	We expect our personnel costs to increase in absolute Euros and as a percentage of sales as we continue to expand our operations
	in Europe and the United States and hire additional personnel, particularly since we intend to establish our own sales and distribution
	network in the United States for Lutathera and potentially other product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also expect our personnel costs to increase
	as we hire more personnel to transition from being a private company to a public company. In addition, we incurred additional personnel
	costs related to our initial public offering in the second half of 2015 as a result of bonuses to be paid to management and certain
	employees totaling approximately &euro;1.2 million and a &euro;1.0 million one-time payment to the chairman of our board upon the
	completion of such offering which has been recorded as other operating expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Share-based compensation consists of grants
	of rights to acquire free shares pursuant to our Free Share Plans and also of stock options and warrants. Share-based compensation
	expense is measured based on the estimated fair value of the awards on the date of grant. The fair value of the share price at
	the date of the grant is determined by reference to the subscription price used for the most recent share capital increase that
	occurred prior to the date of the grant. The fair value of the stock options and the warrants has been determined by using the
	Black-Scholes option pricing model. For a summary of our capital raises, see &ldquo;Item 10. Additional Information&mdash;B. Articles
	of Association&mdash;History of Securities Issuances.&rdquo; There are only service-based vesting conditions. Based on historical
	trends, we have assumed that 95% of the free shares allocated pursuant to our Free Share Plans will eventually be acquired by our
	employees. We have also assumed that 95% of the stock options allocated will be exercised and 100% of the warrants. The warrants
	were granted to 6 non-executive board members and we assumed that 100% of these warrants will be used and exchanged into shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Share-based compensation expense is recorded
	under personnel costs and is recognized over the service period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 108 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	101
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Subsidies, Including the Cr&eacute;dit
	d&rsquo;Imp&ocirc;t Recherche (Research Tax Credit) (CIR)
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We benefit from subsidies, primarily from
	the CIR in France. The CIR is calculated on our claimed amount of eligible R&amp;D expenditures in the European Union and represented
	income of&thinsp; &euro;4.2 million (US$4.6 million), &euro;3.3 million (US$3.6 million) and &euro;2.5&nbsp;million (US$2.7 million)
	in fiscal years 2015, 2014 and 2013 respectively. Our R&amp;D costs in the European Union with public and private institutions
	are determined by
<I>
	L&rsquo;Agence Nationale de la Recherche
</I>
	(The French Research and Technology Agency). We record these
	subsidies in our consolidated statement of income under &ldquo;Other operating income&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other Components of Our Results of Operations
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other Operating Expenses
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other operating expenses principally consist
	of third-party transport costs of PET products delivered to our customers, consulting and other professional services, such as
	legal services, operating lease expenses and various administrative expenses, repairs and maintenance of production equipment and
	the buildings in which such equipment is located, non-inventoried purchases, travelling expenses and communication costs and services
	relating to R&amp;D provided by external experts and companies. As a result of being a public company, we expect to incur additional
	expenses related to outside legal counsel, accounting and auditing activities, compliance with public company reporting and corporate
	governance requirements, increased insurance requirements and enhancing our internal control environment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Depreciation and Amortization
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Depreciation and amortization primarily
	corresponds to depreciation of tangible assets, including property, plants and equipment and amortization of intangible assets,
	such as patents and customer relationships. It also includes impairment to goodwill and other assets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Finance Income and Finance Costs
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finance income and finance costs primarily
	relate to the change in fair value of contingent consideration relating to our valuation of long-term liabilities due to the BI
	Shareholders and the Atreus Shareholders. See &ldquo;&mdash;&thinsp;Factors Affecting Our Results of Operations&mdash;Changes in
	Fair Value of Contingent Consideration and Their Effects on Financial Results.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Income Taxes
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to income taxes in France
	and in other jurisdictions in which we operate. We do not have the ability to offset the taxes we are required to pay across borders.
	Our operations are taxed in each country in which we operate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period Attributable
	to Owners of the Company
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period attributable to
	owners of the company reflects net loss for the period less non-controlling interest. Our non-controlling interests consisted primarily
	of the 49.9% interest we did not own in each of Atreus and Umbra until December 2014. We acquired the non-controlling interests
	in Umbra and Atreus in the last quarter of 2014 and as a consequence do not show any non-controlling interest in the financial
	statements at and for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 109 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	102
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Year ended December 31, 2015 compared
	to year ended December 31, 2014
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table summarizes certain
	of our financial and operating data for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	% Change from prior year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands unless otherwise noted
<BR>
	except share and per share amounts)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Consolidated Statements of Income:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Sales&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	96,227
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	26.8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Raw materials and consumables used&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,909
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,335
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Personnel costs&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(32,056
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(29,520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Other operating expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(48,265
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(44,447
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(35,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Other operating income&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,944
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,474
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Depreciation and amortization&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,294
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(11,321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(11,993
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Operating loss&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,353
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Finance income (including changes in fair value of contingent consideration)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,255
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	191.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Finance costs (including changes in fair value of contingent consideration)&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,526
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,852
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	257.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Financial Loss&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,271
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,696
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,800
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	271.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Loss before income taxes&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17,624
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(16,230
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,399
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	56.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Income taxes&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(837
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(771
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net loss for the period&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Attributable to owners of the company&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Non-controlling interests&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<B>
	&mdash;
</B>
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(100.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Loss per share:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Basic (US$ and &euro; per share)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Diluted (US$ and &euro; per share)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Weighted average ordinary shares outstanding used in computing per share amounts:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Basic&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,943,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,943,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Diluted&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,943,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,943,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Sales
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Sales increased 26.8%, or &euro;18.7 million,
	from &euro;69.9 million for the year ended December 31, 2014 to &euro;88.6 million for the year ended December 31, 2015. The increase
	was due to changes in our product mix and increased volumes as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	&euro;10.9 million resulted from increased PET sales, including Gluscan, to new and existing customers, with &euro;1.9 million
	of such sales resulting from an increase in sales of IASOcholine; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the remainder resulted from increased sales of Lutathera on both a named patient and compassionate use basis and increased
	sales of other products to existing and new customers
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	The increase in our product sales resulted primarily from our retention and development of existing and new client relationships,
	as well as increased demand for PET products in the markets in Europe where we market and sell our products.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 110 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	103
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Raw Materials and Consumables Used
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Raw materials and consumables used increased
	25.6% from &euro;14.6 million for the year ended December 31, 2014 to &euro;18.3 million for the year ended December 31, 2015.
	The change was mainly the result of an increase in sales and changes to our product mix.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Personnel Costs
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Personnel costs increased 40% from &euro;21.1
	million for the year ended December 31, 2014 to &euro;29.5 million for the year ended December 31, 2015, primarily due to an increase
	in the number of employees from 332 employees at December 31, 2014 to 403 employees at December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Also, in preparation for the
	potential launch of Lutathera in the United States and in the European Union we hired senior personnel and in general
	personnel at higher than our previous average salary costs. Furthermore the adoption and use of a new Stock Option Plan in
	2015 resulted in costs that we did not have previously. The expense recognized for stock options in the consolidated
	statement of income (loss) for the year ended December 31, 2015 was &euro;0.6 million. We also incurred one-time costs due to
	the award of an initial public offering bonus (IPO Bonus) of &euro;1.2 million to senior management and certain of our
	employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other Operating Expenses
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other operating expenses increased 26.9%
	from &euro;35.0 million for the year ended December 31, 2014 to &euro;44.4 million for the year ended December 31, 2015, primarily
	as a result of&thinsp; (1) external R&amp;D services (an increase of&thinsp; &euro;3.2 million), (2) lease and other administrative
	expenses (an increase of&thinsp; &euro;1.2 million), (3) communication (an increase of&thinsp; &euro;1.2 million), (4) use of consulting
	and other professional services (an increase of&thinsp; &euro;1.0 million), (5) third-party transportation expenses (an increase
	of&thinsp; &euro;1.0 million), principally attributable to increased sales, (6) travel expenses (an increase of&thinsp; &euro;0.5
	million) and (7) taxes (an increase of&thinsp; &euro;0.5 million).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other Operating Income
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other operating income increased 29.4%
	from &euro;4.2 million for the year ended December 31, 2014 to &euro;5.5 million for the year ended December 31, 2015, primarily
	as a result of increased income from the CIR, and an increase in subsidies received in France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Depreciation and Amortization
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Depreciation and
	amortization decreased 5.6%, from &euro;12.0 million for the year ended December 31, 2014 to &euro;11.3 million for the year
	ended December 31, 2015. Of the &euro;0.7 million total decrease, &euro;1.7 million is attributable to the decrease in
	Portugal assets impairment charge partly offset by &euro;1.0 million increase in depreciation mainly in France (&euro;0.3
	million), Italy (&euro;0.2 million) and due to a new production site in Germany (&euro;0.3 million).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Operating Loss
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result of the above, we had an operating
	loss of&thinsp; &euro;9.5 million for the year ended December 31, 2015, compared to an operating loss of&thinsp; &euro;8.6 million
	for the year ended December 31, 2014, an increase in loss of &euro;0.9 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Finance Income (Including Changes in
	Fair Value of Contingent Consideration)
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finance income increased 191.7% from &euro;0.4
	million for the year ended December 31, 2014 to &euro;1.2 million for the year ended December 31, 2015. The increase is primarily
	due to the gain on derivatives related to the foreign exchange contracts concluded by the Company in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 111 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	104
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Finance Costs (Including Changes in Fair
	Value of Contingent Consideration)
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finance costs increased 257.5% from
	&euro;2.2 million for the year ended December 31, 2014 to &euro;7.9 million for the year ended December 31, 2015. The
	increase of&thinsp; &euro;5.7 million is primarily due to an increase of&thinsp; &euro;3 million in the charge for a change
	in value of the contingent consideration related to our acquisition of BioSynthema, an increase of &euro;0.8 million in the
	charge for a change in value of contingent consideration related to our acquisition of the steripet Business of GE Healthcare
	and an increase of&thinsp; &euro;0.6 million in the charge for a change in value of the contingent consideration related to
	our acquisition of Atreus for the year ended December 31, 2015 compared to the year ended December 31, 2014. See
	&ldquo;&mdash;&thinsp;Factors Affecting Our Results of Operations&thinsp;&mdash;&thinsp;Changes in Fair Value of Contingent
	Consideration and Their Effects on Financial Results.&rdquo; Finance costs are also impacted by a &euro;1.4 million increase
	in foreign exchange loss mostly due to foreign currencies fluctuations against the EUR with main impacts in France on USD
	cash assets and in Israel on EUR loans to affiliates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Income Taxes
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Income taxes expenses increased 91.0% at
	&euro;0.8 million for the year ended December 31, 2015 compared to &euro;0.4 million for the year ended December 31, 2014. The
	income tax rate in most of the countries in Europe in which we operate is between 15% and 35%. Our entities in France, the United
	States, Canada, Poland and Germany did not generate taxable income for the year ended December 31, 2015 or for the year ended December
	31, 2014. The current income tax expense was mainly generated in Italy, Spain and UK.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period increased &euro;6.2
	million from &euro;10.8 million for the year ended December 31, 2014 to &euro;17.0 million for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period Attributable
	to Owners of the Company
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period attributable to
	owners of the company increased &euro;7.5 million from &euro;9.5 million for the year ended December 31, 2014 to &euro;17.0 million
	for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period Attributable
	to Non-Controlling Interests
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period attributable to
	non-controlling interests was &euro;1.3 million for the year ended December&nbsp;31, 2014. There is no further loss attributable
	to non-controlling interests for the year ended December&nbsp;31, 2015 as we acquired the remaining non-controlling interest in
	Umbra and Atreus at the end of 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 112 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	105
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Year ended December 31, 2014 compared
	to year ended December 31, 2013
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table summarizes certain
	of our financial and operating data for the years ended December 31, 2014 and 2013:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	% Change from prior year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands unless otherwise noted
<BR>
	except share and per share amounts)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Consolidated Statements of Income:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Sales&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	78,207
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	29.8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Raw materials and consumables used&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16,340
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,185
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Personnel costs&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(23,607
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16,265
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	29.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Other operating expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(39,196
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(35,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(24,644
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Other operating income&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,735
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,977
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Depreciation and amortization&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,425
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(11,993
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,545
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Operating loss&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,626
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	363.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Finance income (including changes in fair value of contingent consideration)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	443
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	387
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Finance costs (including changes in fair value of contingent consideration)&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,458
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(78.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Financial Loss&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,800
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,768
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(81.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Loss before income taxes&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(11,641
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,399
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(11,624
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Income taxes&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(452
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(65.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net loss for the period&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,093
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Attributable to owners of the company&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,633
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Non-controlling interests&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,460
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(629
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	107.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Loss per share:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Basic (&euro; per share)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(31.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Diluted (&euro; per share)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(31.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Weighted average ordinary shares outstanding used in computing per share amounts:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Basic&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	54,156,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Diluted&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,884,911
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	54,156,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.1194 at August&nbsp;31, 2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Sales
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Sales increased 29.8%, or &euro;16.1 million,
	from &euro;53.8 million for year ended December&nbsp;31, 2013 to &euro;69.9 million for the year ended December&nbsp;31, 2014.
	Of the total &euro;16.1 million increase, &euro;9.6 million, or 59.6%, was due to the acquisition of IEL on February&nbsp;14, 2014.
	The remaining &euro;6.5 million, or 40.4%, was due to changes in our product mix and increased volumes as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	&euro;6.8 million resulted from increased PET sales, including Gluscan, to new and existing customers, with &euro;1.5 million
	of such sales resulting from an increase in sales of IASOcholine; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	&euro;0.3 million net decrease in SPECT, Therapy and other product sales.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The increase in our product sales resulted
	primarily from our retention and development of existing and new client relationships, as well as increased demand for PET products
	in the markets in Europe where we market and sell our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 113 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	106
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Raw Materials and Consumables Used
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Raw materials and consumables used increased
	58.9% from &euro;9.2 million for the year ended December&nbsp;31, 2013 to &euro;14.6 million for the year ended December&nbsp;31,
	2014. The change was mainly the result of an increase of&thinsp;&euro;3.7 million in raw materials and consumables used related
	to the acquisition of IEL.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Personnel Costs
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Personnel costs increased 29.7% from &euro;16.3
	million for the year ended December&nbsp;31, 2013 to &euro;21.1 million for the year ended December&nbsp;31, 2014. Of the total
	&euro;4.8 million increase, &euro;4.7 million was due to an increase in the number of employees from 275 employees at December&nbsp;31,
	2013 to 333 employees at December&nbsp;31, 2014. &euro;3.7 million of the &euro;4.7 million was due to the hiring of additional
	employees as part of our organic growth, while the remaining &euro;1.0 million resulted from the addition of 17 IEL employees as
	part of the acquisition of IEL on February&nbsp;14, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The increase in the number of employees
	resulted in increased salaries and social charges and other benefits. Social charges and other benefits, such as retirement and
	healthcare plans, which are generally subject to inflation, are paid according to industry conventions and/or national guidelines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other Operating Expenses
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other operating expenses increased 42.1%
	from &euro;24.6 million for the year ended December&nbsp;31, 2013 to &euro;35.0 million for the year ended December&nbsp;31, 2014,
	primarily as a result of&thinsp; (1) charges related to our preparations for an initial public offering and listing on Nasdaq (&euro;2.8
	million), (2) R&amp;D expenses (an increase of&thinsp; &euro;2.1 million), (3) rents and other administrative charges (an increase
	of&thinsp; &euro;0.9 million), (4) use of consulting and other professional services (an increase of&thinsp; &euro;0.8 million),
	(5) third-party transportation expenses (an increase of &euro;1.4 million), principally attributable to increased sales, (6) repairs
	and maintenance (an increase of &euro;0.6 million) and (7) royalties (an increase of&thinsp; &euro;0.5 million). In addition, &euro;1.4
	million was attributable to our acquisition of IEL for the period from February&nbsp;14, 2014 (the acquisition date) to December&nbsp;31,
	2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Other Operating Income
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other operating income increased 6.4% from
	&euro;4.0 million for the year ended December&nbsp;31, 2013 to &euro;4.2 million for the year ended December&nbsp;31, 2014, primarily
	as a result of increased income from the CIR.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Depreciation and Amortization
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Depreciation and amortization increased
	25.6%, from &euro;9.5 million for the year ended December&nbsp;31, 2013 to &euro;12.0 million for the year ended December&nbsp;31,
	2014. Of the &euro;2.5 million total increase, &euro;1.2 million was due to additional impairment losses in Portugal, &euro;0.6
	million was due to the depreciation related to production sites in France, &euro;0.3 million was due to the acquisition of IEL
	in February&nbsp;2014 and &euro;0.2 million was due to the depreciation related to a production site in Germany.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Operating Loss
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a result of the above, we had an operating
	loss of&thinsp; &euro;8.6 million for the year ended December&nbsp;31, 2014, compared to an operating loss of&thinsp; &euro;1.9
	million for the year ended December&nbsp;31, 2013, or a loss increase of&thinsp; &euro;6.7 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Finance Income (Including Changes in
	Fair Value of Contingent Consideration)
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finance income remained stable at &euro;0.4
	million from the year ended December&nbsp;31, 2013 to the year ended December&nbsp;31, 2014. See &ldquo;&mdash;Factors Affecting
	Our Results of Operations&mdash;Changes in Fair Value of Contingent Consideration and Their Effects on Financial Results.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 114 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	107
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Finance Costs (Including Changes in Fair
	Value of Contingent Consideration)
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Finance costs decreased 78.4% from
	&euro;10.2 million for the year ended December&nbsp;31, 2013 to &euro;2.2 million for the year ended December&nbsp;31, 2014.
	The decrease of &euro;8.0 million is primarily due to a &euro;7.4 million charge for a change in value of the contingent
	consideration related to our acquisition of BioSynthema in the year ended December&nbsp;31, 2013. This charge has decreased
	to &euro;0.9 million for the year ended December&nbsp;31, 2014. Also, in the year ended December&nbsp;31, 2013, transactions
	in currencies other than the Euro resulted in a loss of&thinsp;&thinsp; &euro;0.9 million, while we had gains of income
	of&thinsp;&thinsp;&euro;0.2 million for the year ended December&nbsp;31, 2014. Other financial expenses decreased by
	&euro;0.5 million charge for the year ended December&nbsp;31, 2014 compared to the same period in fiscal year 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Interest expenses on loans and leases remained
	stable at &euro;1.0 million for the year ended December&nbsp;31, 2014 and December&nbsp;31, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Income Taxes
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Income taxes decreased by &euro;0.8 million
	from &euro;1.2 million for the year ended December&nbsp;31, 2013 to &euro;0.4 million for the year ended December&nbsp;31, 2014,
	primarily as a result of decreased pre-tax income of our subsidiaries located in France and Spain. The income tax rate in most
	of the countries in Europe in which we operate is between 20% and 35%, with the rate being approximately 26.6% in Switzerland and
	16.3% in Israel for the year ended December&nbsp;31, 2014. Our subsidiaries in the United States, France, and Canada did not generate
	taxable income for the year ended December&nbsp;31, 2014 or for the year ended December&nbsp;31, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period decreased 15.5%
	from &euro;12.8 million for the year ended December&nbsp;31, 2013 to &euro;10.8 million for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period Attributable
	to Owners of the Company
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period attributable to
	owners of the company decreased 21.8% from &euro;12.2 million for the year ended December&nbsp;31, 2013 to &euro;9.5 million for
	the year ended December&nbsp;31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Net Loss for the Period Attributable
	to Non-Controlling Interests
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net loss for the period attributable to
	non-controlling interests increased by 107.3%, or &euro;0.7 million, from &euro;0.6 million for the year ended December&nbsp;31,
	2013 to &euro;1.3 million for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 115 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	108
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_RESULTS_OF_OPERATIONS>
<!-- FIELD: /PAGE -->
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_LIQUIDITYANDCAPITALRESOURCES">
</A>
	B.
</TD>
<TD>
	Liquidity and Capital Resources
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Funding Requirements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We believe that our existing cash
	and cash equivalents, including the net initial public offering proceeds, will enable us to fund our operating expenses and capital expenditure requirements
	for at least the next 24&nbsp;months. We have based this estimate on assumptions that may prove to be wrong, and we could use our
	capital resources sooner than we currently expect. We expect that we may require additional capital to finance acquisitions, for
	a potential second Phase 3 trial for Lutathera for the treatment of pNETs, development of Somakit, Annexin V-128 and other therapeutic
	and diagnostic candidates, expansion of our commercialization network for Lutathera, construction or acquisition of at least one
	production site dedicated to the production of Lutathera in the United States and modification of our F-18 production site in Zaragoza,
	Spain to enable it to produce Lutathera, development of an increasing presence within the United States and, in developing our
	own U.S. sales force, the recruitment and training of a significant number of employees in the middle to end of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our future funding requirements will depend
	on many factors, including but not limited to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the scope, rate of progress, results and cost of our clinical trials, nonclinical testing and other related activities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the cost, timing and outcomes of regulatory approvals;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our potential decision to invest in the construction of additional plants dedicated to the production of Lutathera, as well
	as additional facilities for PET production in Europe, and the incurrence of significant cash outflows as a result;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in addition to enhancing our European sales force, additional sales, marketing and distribution set-up costs associated with
	establishing a U.S. sales force;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products
	that we may develop;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone
	and royalty payments thereunder;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the number and characteristics of product candidates that we pursue;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our acquisition of other businesses or assets, including the acquisition of minority interests in operators or intellectual
	property rights relating to existing or future product candidates; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	expansion of our PET and SPECT production network.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also expect to incur additional ongoing
	costs associated with operating as a public company, including implementation of the Sarbanes-Oxley Act controls.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Adequate funds may not be available on
	a timely basis, on acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement
	our business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product
	development programs or commercialization efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may raise additional capital through
	the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of
	these securities may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs and their
	underlying ordinary shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A change in the outcome of any of these
	variables with respect to the development of Lutathera or any other product candidate could mean a significant change in the costs
	and timing associated with the development of that product candidate. For example, if the EMA or the FDA or other regulatory authority
	were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of
	clinical development of Lutathera or any other product candidate, or if we experience significant delays in enrollment in any
	of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of
	clinical development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For more information as to the risks associated
	with our future funding needs, see &ldquo;Item 3. Key Information&mdash;D. Risk Factors.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 116 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	109
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Comparative Cash Flows
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table sets forth our cash
	flows for the periods indicated:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	US$(1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Euro
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(US Dollars and Euros in thousands)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net cash used in operating activities&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(4,122
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(3,796
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,363
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	7,367
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net cash used in investing activities&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,704
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(11,699
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,925
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net cash from financing activities&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97,873
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90,131
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,229
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net increase/(decrease) in cash and cash equivalents&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	81,047
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	74,636
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	31,363
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(329
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Effect of exchange rate changes on cash and cash equivalents&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(919
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(846
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Cash and cash equivalents at the end of the year&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	129,098
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Translated solely for convenience into dollars at the noon buying rate of&thinsp; &euro;1.00=US$1.0859 at December&nbsp;31,
	2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Operating Activities
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash used in operating activities
	was -&euro;3.8 million for the year ended December&nbsp;31, 2015 compared to &euro;2.4 million net cash generated for the
	year ended December&nbsp;31, 2014. The decrease was primarily due to a significant increase in working capital as well as the
	increased charges for our R&amp;D efforts, primarily in the development of Lutathera and the ongoing development of the
	Company and corresponding increased personnel costs, office rent and general administrative expenses, partially offset by our
	increase in sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash generated from operating activities
	decreased 67.9% from &euro;7.4 million for the year ended December&nbsp;31, 2013 to &euro;2.4 million for the year ended December&nbsp;31,
	2014, primarily due to our Lutathera development program, partially offset by our increase in sales. We also reduced working capital
	(defined as inventory plus trade receivables, minus trade payables) as a percentage of sales from 17.1% of sales in fiscal year
	2013 to 16.1% in fiscal year 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Investing Activities
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash used in investing activities increased
	38.7% from &euro;8.4 million for the year ended December&nbsp;31, 2014 to &euro;11.7 million for the year ended December&nbsp;31,
	2015. The increase is primarily due to an increase in cash used for acquisition of property, plants and equipment of&thinsp;&euro;2.4
	million, mainly for the new production site under construction in the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash used in investing activities decreased
	22.8% from &euro;10.9 million for the year ended December&nbsp;31, 2013 to &euro;8.4 million for the year ended December&nbsp;31,
	2014. The decrease is primarily due to (1) an increase of cash receipts from repayment on financial assets of&thinsp; &euro;1.1
	million, partially offset by an increase of acquisition of financial assets of&thinsp; &euro;0.6 million, (2) a decrease in cash
	used in acquisition of companies by &euro;0.8 million, (3) an increase in cash received from government grants of&thinsp; &euro;0.6
	million and (4) a decrease in cash used for acquisition of property, plants and equipment of&thinsp; &euro;0.4 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Financing Activities
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash provided by financing activities
	increased &euro;52.7 million from &euro;37.4 million for the year ended December&nbsp;31, 2014 to &euro;90.1 million for the year
	ended December&nbsp;31, 2015. The increase resulted primarily from our issuance of 15,327,170 ordinary shares (this figure includes
	the issue of 755,000 employee shares, which resulted in no cash inflow) as part of our share capital increases, including our initial public offering,
	for the period ended December 31, 2015 for total proceeds of&thinsp; &euro;97 million, versus proceeds of&thinsp; &euro;41.1 million
	in 2014 from the issuance of 8,212,295 ordinary shares as part of our share capital increase in February 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 117 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	110
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Net cash provided by financing activities
	increased &euro;34.2 million from &euro;3.2 million for the year ended December&nbsp;31, 2013 to &euro;37.4 million for the year
	ended December&nbsp;31, 2014. The increase resulted primarily from our issuance of 8,212,295 ordinary shares as part of our share
	capital increase in February&nbsp;2014 for proceeds of &euro;41.1 million in the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The remainder is explained
	by interest charges paid for loans and leases obtained from banks and other financial institutions, and by the repayment of
	existing borrowings net of proceeds from new borrowings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Financial Liabilities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, we had &euro;21.8
	million in financial current and non-current liabilities, including accrued interest, consisting of&thinsp; &euro;6.1 million of
	financial lease obligations and &euro;15.7 million of loans, a decrease of 28.2% and 14.9%, respectively, compared to the corresponding
	amounts at December&nbsp;31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2014, we had &euro;26.9
	million in financial current and non-current liabilities, including accrued interest, consisting of&thinsp;&thinsp; &euro;8.4 million
	of financial lease obligations and &euro;18.4 million of loans, an increase of 11.2% and 1.2%, respectively, compared to the corresponding
	amounts at December&nbsp;31, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2013, we had &euro;25.8
	million in financial current and non-current liabilities, including accrued interest, consisting of&thinsp; &euro;7.6 million in
	finance lease obligations and &euro;18.2 million in loans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We provided guarantees in the form of rights
	to trade receivables, inventory, equipment, land and by a mortgage for a building on &euro;8.9 million of loans as at December
	31, 2015, &euro;10.9 million as at December 31, 2014 and &euro;13.0 million as at December&nbsp;31, 2013. We benefited from the
	guarantee by OS&Eacute;O (now
<I>
	Banque Publique d&rsquo;Investissement
</I>
	, or the Public Investment Bank) for &euro;3.5 million
	of our loans at December&nbsp;31, 2015, &euro;4.5 million at December&nbsp;31, 2014 and &euro;5.0 million at December&nbsp;31,
	2013. The Public Investment Bank is a French public institution whose goal is to promote the development and financing of small
	and medium sized companies. We have used these loans and leases primarily for expanding our production footprint and acquiring
	property, plants and equipment. These loans and leases typically have a duration of five to ten years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, &euro;6.1 million
	of the total amount of financial liabilities was at a floating interest rate and &euro;15.6 million was at a fixed interest rate.
	These loans and leases range from &euro;156,000 to &euro;3,000,000 in size with typical maturities in the range of five to ten
	years. The average annual interest rate for loans and leases financed at variable interest rates was 1.94% while the average for
	loans or leases financed at fixed interest rates was 2.67%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December 31, 2014, &euro;6.9 million
	of the total amount of financial liabilities bore interest at a floating rate and &euro;20 million bore interest at a fixed rate.
	These loans and leases range from &euro;65,000 to &euro;3,000,000 in size with typical maturities in the range of five to ten years.
	The average annual interest rate for loans and leases financed at variable interest rates was 2.0% while the average for loans
	or leases financed at fixed interest rates was 2.7%
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December 31, 2013, &euro;8.2 million
	of the total amount of financial liabilities bore interest at a floating rate and &euro;17.6 million bore interest at a fixed rate.
	These loans and leases ranged from &euro;12,000 to &euro;3,000,000 in size with typical maturities in the range of five to ten
	years, at variable interest rates in low single-digit percentages or fixed rates ranging from 0.84% to 6.44% per annum.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table presents information
	relating to contractual obligations for our financial liabilities outstanding at December&nbsp;31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Contractual Obligations
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Less than 1 year
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Between 1 and 3 years
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Between 4 and 5 years
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	More than 5 years
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(amounts in thousands of Euros)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Finance lease obligations(1)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,913
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,189
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,711
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,020
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	6,833
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Other loans and financial liabilities(1)&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,084
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,521
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,504
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,814
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,923
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Total&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,997
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,710
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,215
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,834
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,756
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Includes interest payments.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 118 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	111
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other Non-Current Liabilities
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, our other non-current
	liabilities were &euro;39.4 million, consisting of&thinsp; &euro;38.2 million of contingent consideration and fixed milestone payments
	due to the former owners of the acquired companies BioSynthema, Atreus, Barnatron and Cadisa, and GE Healthcare S.r.L.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The principal contingent consideration
	relates to the acquisition of BioSynthema and consists of four fixed tranches of consideration, payable in cash and shares of the
	Company on reaching certain milestones as defined in the contract with BioSynthema. For a description of these arrangement, see
	&ldquo;&mdash;A. Operating Results&mdash;Factors Affecting Our Results of Operations&mdash;Changes in Fair Value of Contingent
	Consideration and Their Effects on Financial Results.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have potential obligations and commitments
	under various agreements and contracts that may result in additional cash and share payments to our counterparties under agreements
	and contracts described below. The commitments and potential obligations are not recorded in our IFRS financial statements as they
	do not meet the definition of a liability or a provision. The principal obligations are described below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	We are obligated to make one future milestone payment for the year 2016, with 50% paid in cash and 50% paid in our ordinary
	shares if Marshall, comprising our enriched water operations, achieves certain EBIT targets during the employment of a certain
	Marshall manager. The results for the year 2015 were below the earn-out target and as consequence there was no obligation for AAA
	to make any milestone payment for the year 2015.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Under a license agreement with IASON relating to IASOcholine, IASOflu and IASOdopa, we are obligated to pay IASON royalties
	for every batch of such products that we produce. In fiscal years 2013, 2014 and 2015, we recognized aggregate royalties of&thinsp;
	&euro;0.4 million, &euro;0.4 million and &euro;0.5 million, respectively, to IASON.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Under a license agreement relating to products that are labeled with somatostatin analogues, we are obligated to pay a low
	single-digit royalty on net sales of Lutathera, for the longer of&thinsp; (i) the period that the use or sale of Lutathera is covered
	by a valid patent licensed under the agreement, or (ii) ten years from first commercial sale, in each case on a country-by-country
	basis.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, in the course of normal business
	operations, we have agreements with contract service providers, such as Pierrel (now part of Therametrics holding AG) and CROs
	to assist in the performance of our R&amp;D, clinical trial and manufacturing activities. Expenditures on services from CROs represent
	a significant cost in clinical development. We could also enter into additional collaborative research, contract research, manufacturing,
	and supplier agreements in the future, which may require upfront payments and even long-term cash commitments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In connection with the preparation for
	our initial public offering and the 2015 annual financial statements, we identified material weaknesses in our internal controls
	related to our financial reporting and consolidation, as well as in our treasury functions. The specific weaknesses in our internal
	controls related to financial reporting and consolidation included, among other things, a lack of formal or written policies and
	procedures relating to various aspects of our financial reporting and consolidation process the lack of a Company-wide accounting
	manual and standard reporting package model, as well as a lack of procedures for subsequent events reporting, reconciliation between
	local accounts and Company reporting, provisions for risks and charges and capitalization of R&amp;D expenditure. The specific
	weaknesses in our internal controls related to our treasury function included, among other things, a lack of formal or written
	procedures related to bank transactions and payment functions, and a failure to properly segregate duties (including access right
	segregation of duties in the newly implemented system) relating to these transactions and functions. We also identified a larger
	number of significant deficiencies in our internal controls.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We cannot assure you that we have identified
	all of our existing material weaknesses, or that we will not in the future have additional material weaknesses. Undetected material
	weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 119 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	112
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have not yet remediated the material
	weaknesses described above. However, we have taken and continue to take actions to remediate these issues. We have strengthened
	our financial control and our accounting teams at the consolidated level over the past 12 months by hiring additional experienced
	professionals and we also have reinforced the finance and accounting capabilities in several of our subsidiaries during the same
	period. In July 2015 we hired an internal auditor who is also responsible for managing our SOX compliance project that we commenced
	in May 2015. This project is supported by a team of external professionals experienced in SOX compliance matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have also initiated a company-wide project
	to transfer all of our accounting to a single accounting software platform. Four AAA subsidiaries have been using this software
	for the closure of the 2015 financial statements, encountering difficulties and inefficiencies compared to the application of the
	previously used software packages. We intend to take further steps to remediate the foregoing weaknesses, but the remediation measures
	that we are implementing may be insufficient to address our existing material weaknesses or to identify or prevent additional material
	weaknesses. See &ldquo;Item 3. Key Information&mdash;D. Risk Factors&thinsp;&mdash;Risks Related to our Business, Growth and Employees&mdash;In
	the past, we had identified material weaknesses in our internal control over financial reporting. If the since-implemented internal
	controls fail to be effective, such failure could result in material misstatements in our financial statements, cause investors
	to lose confidence in our reported financial and other public information and have a negative effect on the trading price of our
	shares.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Critical Accounting Estimates and Judgments
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our management&rsquo;s discussion and analysis
	of our financial condition and results of operations is based on our financial statements, which we have prepared in conformity
	with IFRS. The preparation of the consolidated financial statements in conformity with IFRS requires use of estimates and assumptions,
	which have an impact on the amounts reported in our financial statements. These estimates may be revised if circumstances change
	or if new information becomes available. The actual results may therefore differ from the initial estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	While our significant accounting policies
	are more fully described in the notes to our consolidated financial statements appearing elsewhere in this annual report on Form
	20-F, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating
	our financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Revenue Recognition
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Sales are recognized when the following
	conditions are satisfied:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	there is an agreement between the parties;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the goods have been delivered or the services rendered (i.e. the transfer of risks and benefits of ownership has taken place);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the price is fixed or can be reliably measured; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	it is probable that future economic benefits from the transaction will flow to the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Rebates and discounts granted to customers
	are deducted from the corresponding sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Certain of the products and product candidates
	that we sell have a very short shelf life, in particular our PET products, which have a useful shelf life of approximately ten
	hours. These PET products and product candidates are manufactured in batch processes overnight and delivered to customers, generally
	located close to the production site, in the morning. The transfer of ownership occurs when the product is delivered to the customer,
	which is also the date on which the sales are recognized in the consolidated statement of income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We may enter into supply agreements with
	certain large pharmaceutical groups for the production of PET products. Such agreements define the sale and invoicing of doses
	during the distribution phase. Sales are recognized on product delivery, similar to other products that we manufacture and sell.
	Such agreements may also include transfer of assets from customers. The related revenue recognition is spread over the term of
	the contract under IFRIC18 as we consider such revenue transfer to be an integral part of the supply agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 120 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	113
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Internally Generated Intangible Assets
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Expenditure on research activities is expensed
	as incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Expenditure on development activities is
	capitalized as an internally generated intangible asset resulting from a development project if, and only if, all of the following
	criteria exist:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	there is technical feasibility to complete the development project;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we have the intention to complete the project and to use or sell it;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we have the ability to use the intangible asset;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	probability that the intangible asset is likely to generate future economic benefits;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	there is availability of adequate technical, financial and other resources to complete the development project;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	we have the ability to measure reliably the expenditures allocated to the development project.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A development project is initially recognized
	corresponding to the sum of all expenditure incurred after the date on which the development project met all of the above criteria.
	When all of the above criteria are not met, development expenditure is expensed as incurred. We have determined that the criteria
	for capitalization are considered not to have been met until a regulatory filing has been made in a major market and approval is
	considered highly probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In accordance with the above criteria,
	there has been no R&amp;D expenditure capitalized to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Business Combinations
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In a business combination, and in accordance
	with the revised IFRS 3, the consideration transferred, or acquisition cost, is measured at fair value, which is the sum of the
	acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners
	of the acquired assets and the equity interests issued by the acquirer. The identifiable assets acquired, and liabilities assumed
	of the company, are assessed at their acquisition-date fair values. The costs directly attributable to the acquisition are accounted
	for in &ldquo;Other operating expenses.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Goodwill represents the fair value of the
	consideration transferred (including the fair value of any interest previously held in the acquiree) plus the carrying amount of
	any non-controlling interest, less the amount recognized (in general at fair value) of the identifiable assets acquired and liabilities
	assumed. For each business combination, we may elect to measure any non-controlling interest in the acquiree either at the non-controlling
	interest&rsquo;s proportionate share of the acquiree&rsquo;s identifiable net assets or at fair value. Under the latter method
	(called the full goodwill method), goodwill is recognized on the full amount of the identifiable assets acquired and liabilities
	assumed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the case of a business combination achieved
	in stages, the equity interest previously held by us is remeasured at its fair value at the acquisition date. Any resulting gain
	or loss is recognized directly in profit or loss (&ldquo;Other finance income&rdquo; or &ldquo;Other finance costs&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The provisional amounts recognized at the
	acquisition date may be adjusted retrospectively during a 12-month measurement period if new information is obtained about facts
	and circumstances that existed as of the acquisition date. Goodwill cannot be adjusted after the measurement period. The subsequent
	acquisition of non-controlling interests does not give rise to the recognition of additional goodwill.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Furthermore, any contingent consideration
	is included in the cost of the acquisition at its acquisition-date fair value, even if it is not probable that an outflow of resources
	reflecting economic benefits will be required to settle the obligation. Subsequent changes in the fair value of contingent consideration
	due to facts and circumstances that existed as of the acquisition date are recorded by adjusting goodwill if they occur during
	the measurement period or directly in profit or loss for the period (&ldquo;Other finance income&rdquo; or &ldquo;Other finance
	expenses&rdquo;) if they arise after the measurement period, unless the obligation is settled in equity instruments, in which
	case the contingent consideration is not remeasured.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If, after reassessment, the fair value
	of the acquiree&rsquo;s identifiable net assets exceeds the sum of the consideration transferred measured at fair value and the
	amount of any non-controlling interest in the acquiree, the excess is recognized immediately in profit or loss as a bargain.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 121 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	114
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Contingent Consideration in the Context
	of Completed Acquisitions
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are committed to paying contingent consideration
	to certain former owners of certain acquired companies, as set forth in each acquisition agreement. As indicated above under &ldquo;&mdash;&thinsp;Business
	Combinations,&rdquo; any contingent consideration is included in the acquisition cost at fair value at the acquisition date. Subsequent
	changes in the fair value of contingent consideration occurring during the measurement period due to new information obtained about
	facts and circumstances that existed as of the acquisition date are recorded by adjusting goodwill. Such subsequent changes are
	recorded directly in the income statement (&ldquo;Net finance costs&rdquo;) if they arise after the measurement period, unless
	the contingent consideration obligation is settled in equity instruments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our primary contingent consideration liability
	relates to payments owed to the BI Shareholders. The payments consist of three fixed milestone payments in cash and ordinary shares
	of the Company, in addition to the initial consideration of cash and shares paid. These milestones are based on reaching certain
	targets in the development of Lutathera. At December&nbsp;31, 2015, we had paid the initial consideration and the first milestone
	payment. The contingent consideration also includes a variable royalty amount calculated at a low single-digit percentage of future
	annual net sales of Lutathera, assuming that our gross profit margin with respect to Lutathera, as defined in the BioSynthema sale
	and purchase agreement, exceeds 30% for the relevant year. At December&nbsp;31, 2015, 2014 and 2013, the main assumptions used
	in calculating the amount of this fixed and variable contingent consideration involved:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	our sales forecasts for Lutathera, using our most recent respective business plans;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a 80% at December 31, 2015 and 67% at December 31, 2014 and 2013, probability of successfully commercializing Lutathera and
	obtaining reimbursement, estimated by us based on the stage of Lutathera&rsquo;s development at the end of the reporting period;
	and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a discount rate of 10% to the expected cash outflows to reflect the time value of money and the estimated risks to realizing
	the future cash flows.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On this basis, the contingent
	consideration liability amounted to &euro;33.8 million and &euro;29.8 million at December&nbsp;31, 2015 and 2014,
	respectively, and to &euro;28.9 million and at December&nbsp;31, 2013. The resulting finance charge of&thinsp; &euro;3.9
	million over the year ended December&nbsp;31, 2015 is mainly due the increase in the liability resulting from the increase of
	the probability of occurrence from 67% to 80% as the Company had substantially completed Lutathera phase 3 development at
	December 31, 2015, the exchange rate fluctuations between the U.S. dollar and the euro, and the unwinding of the discount.
	Those impacts are partially offset by the updating of the business plan on future sales of Lutathera. The Company revised the
	business plan of future sales of Lutathera to take into account some modified assumptions. These consist primarily of a
	revised sales launch schedule for some countries in Europe compared to the previously assumed single launch date for major
	European countries. If the probability of occurrence was to be increased to 100%, the contingent consideration would have
	amounted to &euro;42.2 million at December&nbsp;31, 2015. An increase or decrease of 1 percentage point in the discount rate
	would respectively lead to a decrease of &euro;1.9 million or an increase of &euro;2 million, in the contingent consideration
	liability. An increase or decrease of 5 percentage point in exchange rate used in the calculation would respectively lead to
	a decrease of &euro;1.1 million or an increase of &euro;1.2 million in the contingent consideration liability. Other
	items could have an impact on the contingent consideration such as the timing of market authorization in the various
	jurisdictions or the future selling prices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The finance costs recorded in the
	consolidated statement of income in connection with the increase in this contingent consideration amounted to &euro;15.6
	million for the year ended December&nbsp;31, 2012, &euro;7.4 million for the year ended December&nbsp;31, 2013 and &euro;0.9
	million for the year ended December&nbsp;31, 2014. The increase in the liability was primarily the result of updating our
	business plan and forecasts of future sales of Lutathera and, to a lesser extent, the unwinding of the discounting of the
	contingent liability due to the passage of time. The 2013 increase described above was partially offset by a
	&euro;2.3 million payment upon reaching the second milestone specified in the purchase agreement with BioSynthema (there were
	no such payments for the year ended December&nbsp;31, 2012).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 122 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	115
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On December&nbsp;18, 2014, we acquired
	the remaining 49.9% non-controlling interest in Atreus. As a result of this acquisition, we currently own 100% of Atreus. The consideration
	to be paid for this acquisition is composed of fixed anniversary and milestone payments prior to having obtained marketing authorization
	for Annexin V-128 and of contingent consideration based on a low single-digit percentage royalty on sales of Annexin V-128 for
	a duration of 10 years following the receipt of marketing authorization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, the main assumptions
	used in calculating the amount of this fixed and variable contingent consideration were the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Regulatory approval obtained in 2019 (assumed 2018 in the prior year);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Future sales of Annexin V-128 based on our most recent business plan;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Probability of occurrence: 100% for 2016 anniversary payments and milestones payments, 60% for 2017 and 2018 anniversary payments
	and milestones payments, and then 30% for further anniversary payments and milestone payments and for royalty payments, all of
	which require regulatory approval and/or commercial sales of Annexin V-128, estimated by us based on the stage of product development
	at the end of the reporting period; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Discount rate of 10% to reflect the time value of money and the estimated risk of not realizing future cash flows.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On this basis, the
	contingent consideration amounted to &euro;6.3 million and &euro;6 million at December 31, 2015 and 2014, respectively. The
	increase in the contingent consideration is driven by a finance charge of&thinsp; &euro;0.6 million for the period ended at
	December 31, 2015 mainly due to the updating of the business plan on future sales of Annexin, updating the probability of
	occurrence of payments of anniversary and milestone payment and the exchange rate variation of the Canadian dollar to the
	euro, partially offset by a payment of &euro;0.3 million made to former Atreus owners. The Company revised the business
	plan on future sales of Annexin. The changes are primarily due to the fact that a first potential indication for Annexin was
	replaced with a different, more promising indication. This results in a delayed start of sales with a Marketing Authorization
	and a higher amount of royalties to pay over the contractually relevant period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If the probability of occurrence were
	to be increased to 100% for all payments, the contingent consideration would have amounted to &euro;19.7 million at
	December&nbsp;31, 2015. An increase or decrease of 1 percentage point in the discount rate would lead to a decrease of
	&euro;0.5 million or an increase of&thinsp; &euro;0.6 million of the contingent consideration liability respectively. An
	increase or decrease of 5 percentage point in the Canadian dollar against the euro would lead to a decrease or an increase
	of &euro;0.3 million in the contingent consideration liability, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Impairment Testing
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In accordance with IAS 36, the carrying
	amount of goodwill and intangible assets not subject to amortization is tested at least once a year or whenever events or changes
	in the internal or external environment indicate a risk of loss of value. For property, plants and equipment or intangible assets
	subject to amortization, such tests are carried out only when new events or circumstances indicate that their carrying amounts
	may not be recoverable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For the purposes of these tests, the carrying
	amounts of assets are allocated to cash-generating units, or CGUs, or to groups of CGUs. Under IAS 36, an impairment loss is recognized
	when the carrying amount exceeds the recoverable amount. The recoverable amount of an asset or CGU is the higher of fair value
	less costs to sell and value in use.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Fair value less costs to sell is the amount
	obtainable from the sale of an asset or the price paid to transfer a liability in an orderly transaction between market participants
	at the measurement date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 123 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	116
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Value in use is the present value of estimated
	future cash flows expected to be derived from the continuing use of the asset or CGU. It is determined from the estimated cash
	flows based on budgets and business plans over periods ranging from five to ten years. Subsequent cash flows are estimated by applying
	a constant rate of positive or negative growth. The discount rate reflects current market conditions, the time value of money and
	the specific risks associated with the asset or CGU.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Key assumptions underlying the impairment
	testing are the estimated future cash flows and the discount rates. Sensitivity analysis on changes in these assumptions are described
	in note 5.3.2 to the consolidated financial statements as of and for the years ended December&nbsp;31, 2015, 2014 and 2013 included
	elsewhere in this annual report on Form 20-F. We have done new impairment tests for the consolidated financial statements as of,
	and for the year ended, December&nbsp;31, 2015. Those tests lead to an additional impairment of &euro;0.5 million for the Portugal
	CGU for the year ended December 31, 2015 (this after impairment of &euro;1 million and &euro;2.1 million had already been accounted
	for in 2013 and 2014 respectively). The decrease in the Portugal CGU enterprise value is driven by a reduction in EBITDA projections
	compared to the projections made for the test in 2014. While gross profit has improved vs. prior year projections, operating expenses
	and salaries have significantly increased starting 2017 mostly due to Lutathera (5 additional headcount in 2017).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Share-Based Payments
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have implemented Free Share Plans in
	which certain of our employees participate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	These plans provide for the grant of equity-settled
	share-based payments that are measured at fair value on the grant date in accordance with IFRS 2. The cumulative expense recognized
	is based on the fair value at the grant date. It is recognized over the vesting period in net operating income directly through
	equity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Compensation expense is recognized in the
	consolidated statement of income based on the estimated fair value of the awards on the date of grant. The fair value of the share
	price at the date of the grant was determined, prior to the initial public offering, by reference to the subscription price paid in the most recent
	share capital increase that occurred prior to the date of the grant. As of the completion of the initial public offering the fair value of the share
	price is the closing share price at the end of the day the share grant is made. For a summary of our capital increases, see &ldquo;Item
	10. Additional Information&mdash;B. Articles of Association&mdash;History of Securities Issuances.&rdquo; There are only service-based
	vesting conditions for the free shares granted pursuant to our Free Share Plans. Based on historical trends, we have assumed that
	95% of the free shares allocated will eventually be acquired by our employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On November 10, 2015, the day of the initial public offering
	pricing, the board of directors made use of a new Stock Option Plan which was authorized by shareholders in June 2015. A total
	of 3,947,625 stock options were granted in a first allocation round to employees. These stock options have an exercise price of
	$8.00 (&euro;7.45 at the exchange rate at grant date). The vesting period is 3 years and one option entitles to buy one ordinary
	share. The residual contractual life of these options was 9.86 years at December 31, 2015. No options were exercisable at December
	31, 2015. The fair value of options granted in this first allocation round was estimated by using the Black-Scholes option pricing
	model with assumptions as described in note 4.3.2 to the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Provision for the Decommissioning of PET Production Sites
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The manufacture of certain products in
	the field of MNM generates radiation and causes the contamination of production site facilities (in particular the cyclotron).
	Our subsidiaries producing PET products have a legal obligation to dismantle and decontaminate their site and production equipment
	at the end of their useful lives. The provision is initially recognized through an additional cost of the related asset which is
	then amortized over its useful life. The provision is updated at each reporting date; unwinding of the discounting of the provision
	is recognized as a finance cost and any changes in the estimated ultimate costs of decommissioning are recognized within the cost
	of the related asset.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, these provisions
	amounted to &euro;7.2 million. The increase of approximately &euro;0.3 million between December&nbsp;31, 2014 and December&nbsp;31,
	2015 relates to the unwinding of the discounting of the obligation. At December&nbsp;31, 2014, these provisions amounted to &euro;6.9
	million compared with &euro;5.1 million at December 31, 2013. The increase of approximately &euro;1.8 million between 2013 and
	2014 is due to the unwinding of the discounting of the obligation for &euro;0.3 million and the installation of three new cyclotrons
	in Germany and France in 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 124 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	117
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Decommissioning costs for a typical site
	have been estimated by an independent expert. From this base cost and with annual inflation assumed to be 2%, we have estimated
	the expected decommissioning costs at the forecast date for each site concerned. These costs are then discounted to the reporting
	date. The discount rate applied is 4.57% (the same as at December 31, 2014 and 2013). A change (decrease or increase) of 1 percentage
	point in this rate would lead to a respective increase or decrease in the provision of &euro;0.2 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Recent Accounting Pronouncements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See note 3.3 to the consolidated financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_RESEARCHANDDEVELOPMENT">
</A>
	C.
</TD>
<TD>
	Research and Development, Patents and Licenses, etc.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 4. Information on the Company&mdash;B.
	Business Overview&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_TRENDINFORMATION">
</A>
	D.
</TD>
<TD>
	Trend Information
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have not provided any trend information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_OFF-BALANCESHEET">
</A>
	E.
</TD>
<TD>
	Off-balance Sheet Arrangements
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We currently have no off-balance sheet
	arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_TABULARDISCLOSURE">
</A>
	F.
</TD>
<TD>
	Tabular Disclosure of Contractual Obligations
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 5. Operating and
	Financial Review and Prospects&mdash;B. Liquidity and Capital Resources&mdash;Financial Liabilities.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Company has other obligations in connection
	with retirement obligation which are described in note&nbsp;5.12 to the Consolidated Financial Statements. As these obligations
	are not contractually fixed as to timing and amount, they have not been included in this disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SAFEHARBOR">
</A>
	G.
</TD>
<TD>
	Safe Harbor
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Forward-Looking Statements.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 125 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	118
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_LIQUIDITY_CAPITAL>
</EFX_OPERATING_AND_FINANCIAL_REVIEW>
<!-- FIELD: /PAGE -->
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM6">
</A>
	ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DIRECTORSANDSENIOR">
</A>
	A.
</TD>
<TD>
	Directors and Senior Management
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table sets forth information
	regarding our executive officers, key employees and directors. Ages are as of December&nbsp;31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 8PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Name
</P>
</TD>
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 8PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Age
</P>
</TD>
<TD STYLE="WIDTH: 30%; PADDING-RIGHT: 8PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Position
</P>
</TD>
<TD STYLE="WIDTH: 15%; PADDING-RIGHT: 8PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Initial
	Year of Appointment
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-DECORATION: UNDERLINE; PADDING-RIGHT: 8PT">
<B>
<U>
	Executive Officers and Key Employees
</U>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	Stefano Buono&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	49
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Chief Executive Officer
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2002
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 8PT">
	Heinz M&auml;usli&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	53
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Chief Financial Officer
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2008
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	G&eacute;rard Ber&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	57
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Chief Operating Officer
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2002
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 8PT">
	Claude Hariton&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	61
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Global Head of R&amp;D
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: UNDERLINE; PADDING-RIGHT: 8PT">
<B>
<U>
	Board of Directors
</U>
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	Claudio Costamagna&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	59
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Chairman
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2010
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 8PT">
	Stefano Buono&#9;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	49
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 8PT">
	Director and Chief Executive Officer
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2002
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	Muriel de Szilbereky&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	62
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 8PT">
	Kapil Dhingra&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	56
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	Steve Gannon&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	54
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 8PT">
	Yvonne Greenstreet&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	53
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-RIGHT: 8PT">
	Christian Merle&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	62
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 8PT">
	Leopoldo Zambeletti&#9;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	47
</TD>
<TD STYLE="PADDING-RIGHT: 8PT">
	Director
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN; PADDING-RIGHT: 8PT">
	2014
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following is a brief summary of the
	business experience of our executive officers, key employees and directors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Stefano Buono
</B>
	is the Chief Executive
	Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002, Mr. Buono worked as a physicist
	at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4, Mr. Buono headed a team
	of engineers working on different international research projects in the field of energy production and nuclear waste transmutation.
	For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world&rsquo;s largest research laboratory
	for particle physics. He actively participated in the development of CERN&rsquo;s Adiabatic Resonance Crossing method. He is the
	author of numerous scientific papers. Mr. Buono received his master&rsquo;s degree in physics from the Universita degli Studi di
	Torino in Turin, Italy in 1991.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Heinz M&auml;usli
</B>
	is the Chief Financial
	Officer and a former member of our board of directors from 2008 to 2014. Mr. M&auml;usli joined AAA in 2003. He also serves as
	a member of the boards of directors of several of AAA&rsquo;s subsidiaries. Prior to joining AAA, Mr. M&auml;usli was a management
	consultant for Accenture from 1996 to 2001 and Gemini Consulting from 1995 to 1996. Mr. M&auml;usli received a master&rsquo;s degree
	from the University of St. Gallen in St. Gallen, Switzerland in 1988 and a master&rsquo;s degree in business administration from
	Columbia Business School in New York City, New York in 1994.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	G&eacute;rard Ber
</B>
	is the Chief Operating
	Officer and a former member of our board of directors from 2002 to 2014. Mr. Ber joined AAA in 2002. Prior to joining AAA, Mr.
	Ber served as the Director of OM Pharma&rsquo;s Western European group from 2000 to 2002, the Director General and Director of
	Marketing and Commerce for CIS Medipro from 1994 to 2000, and in various management roles at CIS Bio International from 1984 to
	1994. He is also a member of the boards of directors of several of AAA&rsquo;s subsidiaries. Mr. Ber received a PhD in pharmacy
	and a master&rsquo;s degree in advanced studies in food science from the Universit&eacute; Scientifique et M&eacute;dicale de Grenoble
	in Grenoble, France in 1983 and 1984, respectively, and a degree in marketing and international commerce from the Institut de Pharmacie
	Industrielle de Paris in Paris, France in 1984.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 126 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	119
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage127"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0.25IN">
<B>
	Claude
	Hariton
</B>
	joined AAA in February&nbsp;2014 as Head of Clinical Development. He was appointed Global Head of Research and Development
	in January 2016. Over the last 25 years, he has held senior positions in biotechnology and pharmaceutical companies in Switzerland,
	Canada, Australia, Germany, Spain and the United Kingdom, with his most recent positions including Vice President, Global Head
	of Regulatory Affairs at Mayne Pharma, Vice President, Clinical and Regulatory Affairs and Chief Medical Officer at Aeterna-Zentaris,
	Vice President, Scientific Affairs at Fresenius and Vice President, Global Head of R&amp;D at ISDIN. Dr. Hariton received his
	PhD in neuroscience from the University of Sciences in Marseille, France in 1984 and conducted postdoctoral research at INSERM
	U278 also in Marseille, France. He received his DSc in Pharmacology from the University of Medicine in Marseille, France in 1988while
	leading drug development at Ciba Geigy and Novartis in Switzerland, and was appointed Associate Professor at the School of Medicine
	in Marseille, France in 1998.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Claudio Costamagna
</B>
	is the Chairman
	of our board of directors and was appointed to our board in January&nbsp;2010. He is the founder and Chairman of the financial
	advisory boutique CC&amp;Co. and Chairman of Cassa Depositi e Prestiti S.p.A. (CDP). He also sits on the Board and is the Chair
	of the Compensation Committee of FTI Consulting Inc. a company listed on the NYSE. He previously held senior positions at Citigroup,
	Montedison, and most recently, Goldman Sachs, where he served until 2006 as Chairman of the Investment Banking division for Europe
	and the Middle East. He has served as Independent Board Member of several public companies including, among others, Luxottica Group,
	Bulgari S.p.A. and Virgin Group Holding. Mr. Costamagna holds a degree in Business Administration from Universit&agrave; Bocconi
	in Milan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Muriel de Szilbereky
</B>
	became a member
	of our board of directors in June&nbsp;2013. Prior to joining AAA, Ms. de Szilbereky served in several audit firms. She was a partner
	of and the head of the Regulatory Activities Department at Deloitte France from 2001 to 2012 and the head of French corporate finance
	activities at PricewaterhouseCoopers from 1992 to 1997. Previously she served as the head of mergers and acquisitions activities
	at the Banque Industrielle et Mobili&egrave;re Priv&eacute;e from 1989 to 1992. In addition, she spent ten years serving in the
	French Government, including three years as an adviser to the Minister of Industry. While in government, she was responsible for
	regulatory issues in the sector of Energy and Telecommunications. She received a degree from the Institut de Sciences Politiques
	and a master&rsquo;s degree in public law from the Universit&eacute; de Paris I-Panth&eacute;on Sorbonne, both in Paris, France.
	She also earned a degree from the French National School of Administration (ENA) in Strasbourg, France in 1978 and is a certified
	statutory accountant in Paris, France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Kapil Dhingra
</B>
	became a member of
	our board of directors in March&nbsp;2014. Dr. Dhingra founded and is the head of KAPital Consulting, a healthcare consulting firm.
	Prior to joining AAA, Dr. Dhingra worked for over 25 years in oncology clinical research and drug development. His experience includes
	nine years at Hoffman-La Roche, where he served in various positions, including Vice President, Head of the Oncology Disease Biology
	Leadership Team and Head of Oncology Clinical Development. Prior to that, he worked as a Senior Clinical Research Physician at
	Eli Lilly and Company. Dr. Dhingra specialized in internal medicine and medical oncology. He holds an MD (MBBS) degree from the
	All India Institute of Medical Sciences in New Delhi, India, with subsequent residency in internal medicine at Lincoln Medical
	and Mental Health Center in New York City, New York and New York Medical College in Valhalla, New York, and was a Fellow in hematology/oncology
	at Emory University School of Medicine in Atlanta, Georgia. He has served as independent Board member of several public companies,
	including Micromet, Algeta and, Five Prime (NASDAQ &ndash; FPRX).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Steven Gannon
</B>
	became a member of
	our board of directors in June&nbsp;2014. He was a Senior Vice President and the Chief Financial Officer and Treasurer at Aptalis
	Pharma Inc. until February&nbsp;2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis Pharma Inc. in 2006,
	Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies, Inc. from 1999 to 2006, as the Director of Finance
	and Administration of the Research Division of Astrazeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of
	Mallinckrodt Medical Inc.&rsquo;s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business
	systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of
	Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a chartered accountant since 1985.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Yvonne Greenstreet
</B>
	became a member
	of our board of directors in June&nbsp;2014. Dr. Greenstreet was a senior vice president and the Head of Medicines Development
	at Pfizer from 2010 to 2013. Prior to joining Pfizer, Dr. Greenstreet served in various roles at GlaxoSmithKline from 1992 to 2010,
	including Chief Medical Officer for Europe and Chief of Strategy. Dr. Greenstreet serves on the Advisory Board of the Bill&nbsp;and
	Melinda Gates Foundation and as a member of the board of directors of Pacira, Moelis and Company and Indivior. She completed her
	medical training at the University of London Hospitals in London, United Kingdom in 1990, and received her MBChB from the University
	of Leeds in Leeds, United Kingdom in 1985. She subsequently completed a master&rsquo;s degree in business administration at INSEAD
	in Fontainebleau, France in 1991.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 127 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	120
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Christian Merle
</B>
	became a member
	of our board of directors in June&nbsp;2014. Mr. Merle is the Managing Partner of Merle &amp; Partners. Prior to founding Merle
	&amp; Partners in 2014, Mr. Merle was the Chief Executive Officer of Banque Espirito Santo from 2007 to 2013, the Managing Partner
	of Gimar &amp; Cie from 2003 to 2007 and the Chief Executive Officer of Banca Intesa from 1998 to 2003. Prior to joining Banca
	Intesa, he served in various roles at Credit Agricole, including as the Executive Vice President of Credit Agricole Indosuez. He
	also served in various roles in the French Treasury, including the Chief Representative in the United States from 1987 to 1990.
	He received his undergraduate degree from the Institut d&rsquo;Etudes Politiques de Paris in 1974 and a master&rsquo;s degree in
	economics from the Universit&eacute; de Paris I-Panth&eacute;on Sorbonne in 1975, both in Paris, France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	Leopoldo Zambeletti
</B>
	became a member
	of our board of directors in June&nbsp;2014. Mr. Zambeletti is an independent financial advisor in the Life Science sector. In
	this capacity he has advised various companies on corporate finance matters including advising Nogra Pharma in the largest ever
	out licensing to Celgene for a compound in development. Prior to becoming an advisor, Mr. Zambeletti was a managing director and
	Head of European, India and MENA Healthcare Investment Banking at Credit Suisse and a managing director and the Head of the Ultra
	High Net Worth group at Credit Suisse&rsquo;s investment bank from 2007 to 2012. From 1994 to 2007, he held various positions at
	J.P. Morgan, including as Head of Healthcare Investment Banking. He received a bachelor&rsquo;s degree in business administration
	from the Universit&agrave; Commerciale Luigi Bocconi in Milan, Italy in 1992. Mr. Zambeletti serves as a member of the board of
	directors of Nogra Pharma, Summit Therapeutics Qardio, Dignity Biosciences and Faron Pharmaceuticals. He is also a trustee of Saint
	Barts and the London Charity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_COMPENSATION">
</A>
	B.
</TD>
<TD>
	Compensation
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Compensation of Senior Management and the Board of Directors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The aggregate compensation paid
	and benefits in kind granted by us to our senior management (consisting of CEO, COO and CFO), including annual performance
	bonus, IPO Bonus and social and pension benefits for the year ended December&nbsp;31, 2015 was &euro;2.8 million (US$3
	million). In addition, these three senior managers received in the financial year 2015 a total of 515,000 stock options. No
	employee shares were awarded to these three individuals in 2015. See below the tables with details on share and options
	grants under &ldquo;Equity Awards to Senior Management&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our non-employee directors were paid as
	a group a total of &euro;525,000 (US$570,000) for services rendered in board and audit, R&amp;D and compensation committee meetings
	(this excludes travel costs and a special IPO bonus for the Chairman of the board) in the year 2015. The fees members of the board
	were entitled to in 2015 are:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Attendance fees: &euro;60,000 (US$65,154) for all board meetings; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Attendance fees for board committee: &euro;15,000 (US$16,288) for members and &euro;20,000 (US$21,718) for the Chairperson.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition to the above, in connection
	with services relating to our initial public offering, and subject to certain conditions, we agreed to pay the chairman of
	our board, Claudio Costamagna, a cash payment equivalent to 0.2% of the number of our ordinary shares issued and outstanding prior
	to the offering, multiplied by the public offering price per ordinary share upon the listing of our shares on a public stock exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On August 19, 2015, the Board implemented
	a warrants plan to allow for non-executive members of our Board, excluding Mr. Costamagna, the Chairman of the Board, to subscribe
	to an aggregate of 225,000 warrants (with a maximum of 37,500 warrants per director) at a price of&thinsp; &euro;0.8 per warrant
	between August 20, 2015 and September 4, 2015, and to exercise such warrants to obtain ordinary shares within 18 months after September
	4, 2015 at a fixed price of&thinsp; &euro;6.10 per ordinary share. As of September&nbsp;4, 2015, the participants in the warrant
	plan had subscribed to all the 225,000 warrants and made payment for them. The warrants can now be exchanged into shares before
	March&nbsp;4, 2017, against a payment price of &euro;6.1 per ordinary share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 128 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	121
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Equity Awards to Senior Management
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have granted rights to acquire free
	shares to our senior management since January&nbsp;1, 2013 as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total including per year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares Granted
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	issuances
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stefano Buono (CEO)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	G&eacute;rard Ber (COO)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Heinz M&auml;usli (CFO)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total Shares Granted to Senior Management&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	70,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	70,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have also granted stock-options to our
	senior management in the year 2015:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total including per year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Shares Granted
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	issuances
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Stefano Buono (CEO)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	G&eacute;rard Ber (COO)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	165,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	165,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Heinz M&auml;usli (CFO)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	150,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	150,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total Shares Granted to Senior Management&#9;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	515,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	515,000
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN">
<B>
	Free
	share plans
</B>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In 2006, we established the first plan
	for the allocation of free shares, the 2006 Free Share Plan. In 2010, we established the second plan for the allocation of free
	shares, the 2010 Free Share Plan. In 2013, we established the third plan for the allocation of free shares, the 2013 Free Share
	Plan, and together with the 2010 Free Share Plan and the 2006 Free Share Plan, the Free Share Plans. Each of the Free Share Plans
	was approved by our shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The right to acquire free shares is
	a contractual right to receive ordinary shares in the future if certain vesting conditions are met. Following vesting,
	ordinary shares (the free shares) are issued in respect of such acquisition rights but generally remain subject to a holding
	period during which transfer of the free shares is restricted. During the holding period, free shares carry dividend,
	information and voting rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Prior Plans
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The 2006 Free Share Plan and the 2010 Free
	Share Plan are no longer used to make new grants of free shares. As of December 31, 2015, under the 2010 Free Share Plan, there
	were 547,500 rights to acquire free shares that are not yet issued. The terms of the 2006 Free Share Plan and the 2010 Free Share
	Plan are substantially similar to those of the 2013 Free Share Plan described below (except for the duration of the vesting and
	holding periods for certain beneficiaries who are non-French tax residents).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 129 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	122
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	2013 Plan
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Administration
</I>
	. Our board of directors
	has the authority to administer the 2013 Free Share Plan, subject to the provisions that fall within the exclusive competence of
	an extraordinary general meeting of our shareholders. Subject to the terms of the 2013 Free Share Plan, our board of directors
	determines recipients, dates of grant, the number of free shares to be granted and the terms and conditions of the free shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Eligibility
</I>
	. Our employees, corporate
	officers, directors and those of our affiliated companies are eligible to be granted free shares under the 2013 Free Share Plan.
	However no free share may be granted to a person holding more than 10% of our share capital or who would hold more than 10% of
	our share capital as a result of such grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Share Reserve
</I>
	. The maximum number
	of our ordinary shares that may be issued under the 2013 Free Share Plan is 500,000. In addition, under French law, the number
	of free shares issued may not exceed 10% of the outstanding share capital on a non-diluted basis as at the date of grant. As of
	December 31, 2015, 303,500 rights to acquire free shares have been awarded under the 2013 Plan. An additional maximum 196,500 shares
	may therefore be allocated in 2016 by the board of directors to designated employees. No shares acquisitions from this plan have
	so far been registered.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Vesting and Holding Periods
</I>
	. Awards
	granted under the 2013 Free Share Plan must have a vesting period of at least two years from the date of grant of the right to
	acquire free shares and a holding period of at least two years from the effective date of the acquisition of the free shares (which
	is generally expected to be concurrent with vesting), except for certain beneficiaries who are non-French tax residents, who are
	subject to a vesting period of at least four years and no holding period. Rights to acquire free shares will not vest during any
	notice period following a resignation. During the vesting period, if an award recipient (i) experiences certain specified disabilities,
	such recipient&rsquo;s rights to acquire free shares will immediately vest but will remain subject to restrictions during the applicable
	holding period, or (ii) dies, the recipient&rsquo;s heirs have six months from the date of death to request that the recipient&rsquo;s
	free shares be issued to them; otherwise, the rights to acquire free shares will be cancelled. During the holding period, if a
	free share recipient experiences a qualifying retirement, the restrictions on such recipient&rsquo;s free shares will lapse.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Restructuring Impact
</I>
	. Vesting and
	holding periods do not fall away in the event of an initial public offering or a merger transaction;
<I>
	provided
</I>
	,
<I>
	however
</I>
	,
	that if a merger agreement does not provide for the assumption of awards under the 2013 Free Share Plan, the vesting of outstanding
	awards will be accelerated upon approval of the merger by our board of directors and, further, at least 30 days in advance of the
	general meeting to approve the merger, we will notify award recipients of the opportunity to be issued the free shares in advance
	of such vesting event. Following an initial public offering, otherwise unrestricted free shares may not be sold either ten days
	before or after consolidated or annual accounts are made public or during a period when the company has material nonpublic information
	or for ten days thereafter. During the vesting period, award recipients benefit from anti-dilution protection. In the case of certain
	recapitalization events, the Company shall either allow recipients to participate, immediately or upon vesting, in such events,
	or adjust the number of free shares that such recipients are entitled to receive in order to cancel the dilutive effect of such
	events.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Amendment and Termination
</I>
	. Our board
	of directors has the authority to amend, alter, suspend, or terminate our 2013 Free Share Plan, as long as no grants have been
	made under the plan, subject to shareholder approval of any amendment to the extent necessary and desirable to comply with applicable
	laws. After grants have been made under the plan, the 2013 Free Share Plan cannot be amended, altered, suspended or terminated
	without the consent of each award recipient.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Term
</I>
	. Rights to acquire free shares
	may be granted under the 2013 Plan until December&nbsp;17, 2016, unless the plan is terminated earlier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Tax Considerations
</I>
	. Noncompliance
	with reporting requirements by us, our affiliates or award recipients may result in the forfeiture of favorable tax treatment and
	fines.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 130 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	123
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN">
<B>
	Option
	Plan
</B>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We entered into a stock option plan pursuant
	to shareholder authorization granted on June 29, 2015, under which we expect to issue options to purchase up to 13 million newly-issued
	ordinary shares to officers and employees of the Company and its subsidiaries. Pursuant to the shareholders authorization, the
	Board is empowered, during a maximum period of 38 months from June 29, 2015, to grant options on an annual basis, subject to a
	limit of 3% of the total number of outstanding shares per year, in 2016, 2017 and 2018. The options are to be issued at a subscription
	price to be determined at the date of issuance and in accordance with a fair market value based on the market price of the Company&rsquo;s
	share price at such date and applicable provisions of French law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Eligibility
</I>
	. Our employees and those
	of our affiliated companies (i.e. AAA S.A. owns at least 10% directly or indirectly) are eligible to be beneficiaries of the stock
	option plan. However no options may be granted to a person holding more than 10% of our share capital or who would hold more than
	10% of our share capital as a result of such grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Vesting and Exercise Periods.
</I>
	Awards
	granted under the 2015 Stock Option Plan have a vesting period of three years from the date of grant of the right to acquire options
	and the beneficiary has to be an employee of AAA or one of our affiliated companies at the third anniversary of the grant date.
	The vesting period can be reduced in exceptional circumstances such as disability, death with transfer to heirs within 6 months
	of date of death or voluntary/compulsory retirement or having reached age limit for holding corporate office; in these cases the
	beneficiary has the right to the full number of awarded options; in the cases of disability or death the exercise period would
	be accelerated so that the options may be exercised before the exercise date. The exercise period cannot exceed 10 years as of
	grant date. It can however be reduced by the board to comply with local laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A first option allocation was approved
	by the Board on November 10, 2015 i.e. the day of pricing our initial public offering at Nasdaq. A total of 4 million options (a higher total than
	possible in future allocation rounds due to the having completed the initial public offering and as per the relevant shareholder resolution) were allocated
	to the employees of the company at an exercise price of US$8 per share or the equivalent of US$16 per ADS (Note: 1 ADS equals two
	ordinary shares). 336 employees eventually accepted the option grant and the total number of options granted in this allocation
	round amounts to 3,947,625. If all beneficiaries would comply with the service condition and chose to exercise their rights, this
	option grant could result in the issue of 3,947,625 newly issued shares as of November 10, 2018.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	After this first option allocation in November
	2015, the Board could allocate an additional maximum of 9,052,375 options from the 2015 stock option plan by August 28, 2018.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Employment Agreements and Incentive Plans
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We intend to enter into employment agreements
	with certain of our named executive officers. We have not yet determined the specific provisions of such employment agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We also intend to enter into a new warrant
	plan for our non-executive Board Members. Such a plan will require approval from our shareholders. We have not yet determined the
	specific provisions of such a new plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Limitations on Liability and Indemnification Matters
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under French law, provisions of by-laws
	that limit the liability of directors are prohibited. However, French law allows
<I>
	soci&eacute;t&eacute;s anonymes
</I>
	to contract
	for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party
	action, provided that they acted in good faith and within their capacities as directors or officers of the company. Criminal liability
	cannot be indemnified under French law, whether directly by the company or through liability insurance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We expect to maintain liability insurance
	for our directors and officers, including insurance against liability under the Securities Act of 1933, as amended, and we may
	enter into agreements with our directors and executive officers to provide contractual indemnification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	With certain exceptions and subject to
	limitations on indemnification under French law, these agreements will provide for indemnification for damages and expenses including,
	among other things, attorneys&rsquo; fees, judgments, fines and settlement amounts incurred by any of these individuals in any
	action or proceeding arising out of his or her actions in that capacity. We believe that this insurance and these agreements are
	necessary to attract and maintain qualified directors and executive officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	These agreements may discourage shareholders
	from bringing a lawsuit against our directors and executive officers for breach of their fiduciary duty. These provisions also
	may have the effect of reducing the likelihood of derivative litigation against directors and executive officers, even though such
	an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&rsquo;s investment may be
	adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these
	insurance agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Certain of our non-employee directors may,
	through their relationships with their employers or partnerships, be insured against certain liabilities in their capacity as members
	of our board of directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 131 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	124
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_BOARDPRACTICES">
</A>
	C.
</TD>
<TD>
	Board Practices
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Board of Directors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our board of directors is composed
	of eight members, one of whom is an executive director. The Chairman of the board is Claudio Costamagna. Under French law and
	our by-laws, our board of directors must be composed of between three and 18 members. Within this limit, the number of
	directors is determined by our shareholders. Directors are elected, re-elected and may be removed at a shareholders&rsquo;
	general meeting with a simple majority vote of our shareholders. Pursuant to our by-laws, our directors are elected for
	one-year terms. In accordance with French law, our by-laws also provide that our directors may be removed with or without
	cause by the affirmative vote of the holders of at least a majority of the votes of the shareholders present, represented by
	a proxy or voting by mail at the relevant ordinary shareholders&rsquo; meeting, and that any vacancy on our board of
	directors resulting from the death or resignation of a director, provided there are at least three directors remaining, may
	be filled by vote of a majority of our directors then in office provided that there has been no shareholders meeting since
	such death or resignation. Directors chosen or appointed to fill a vacancy shall be elected by the board of directors for the
	remaining duration of the current term of the replaced director. The appointment must then be ratified at the next
	shareholders&rsquo; general meeting. In the event the board of directors would be composed of less than three directors as a
	result of a vacancy, the remaining directors shall immediately convene a shareholders&rsquo; general meeting to elect one or
	several new directors so there are at least three directors serving on the board of directors, in accordance with French
	law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, French law requires that companies
	having at least 50 employees for a period of 12 months over the last three years set up a
<I>
	Comit&eacute; d&rsquo;Entreprise
</I>
	,
	or Works&rsquo; Council, composed of representatives elected from among the employees. Our Works&rsquo; Council was formed in July&nbsp;2011.
	Two of these representatives are entitled to attend all meetings of the board of directors and the shareholders, in an observer
	capacity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Director Independence
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our board of directors determined that
	each of Yvonne Greenstreet, Muriel De Szilbereky, Kapil Dhingra, Steven Gannon, Christian Merle and Leopoldo Zambeletti is an &ldquo;independent
	director&rdquo; as that term is defined under the applicable rules and regulations of the SEC, and the listing requirements and
	rules of Nasdaq that are generally applicable to a U.S. company. In making such determination, our board of directors considered
	the relationships that each non-employee director has with us and all other facts and circumstances our board of directors deemed
	relevant in determining the director&rsquo;s independence, including the number of ordinary shares beneficially owned by the director
	and his or her affiliated entities (if any).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Corporate Governance Practices
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a French
<I>
	soci&eacute;t&eacute; anonyme
</I>
	,
	we are subject to various corporate governance requirements under French law. In addition, as a FPI listed on Nasdaq, we will be
	subject to the Nasdaq corporate governance listing standards. However, Nasdaq&rsquo;s listing standards provide that FPIs are permitted
	to follow home country corporate governance practices in lieu of Nasdaq rules, with certain exceptions. As a FPI, we are required
	to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides
	that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as
	control over the performance of their duties, management of complaints made, and selection of consultants. However, if the laws
	of an FPI&rsquo;s home country require that any such matter be approved by the board of directors or the shareholders, the audit
	committee&rsquo;s responsibilities or powers with respect to such matter may instead be advisory. Under French law, the audit committee
	may only have an advisory role and appointment of our statutory auditors, in particular, must be decided by the shareholders at
	our annual meeting. Consistent with French Law, our by-laws provide that a quorum requires the presence of shareholders having
	at least (1) 20% of the shares entitled to vote in the case of an ordinary shareholders&rsquo; general meeting or at an extraordinary
	shareholders&rsquo; general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits
	or share premium or (2)&nbsp;25% of the shares entitled to vote in the case of any other extraordinary shareholders&rsquo; general
	meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement when an ordinary general meeting
	is reconvened, but the reconvened meeting may consider only questions which were on the agenda of the adjourned meeting. When an
	extraordinary general meeting is reconvened, the quorum required is 20% of the shares entitled to vote, except where the reconvened
	meeting is considering capital increases through capitalization of reserves, profits or share premium. For these matters, no quorum
	is required at the reconvened meeting. If a quorum is not present at a reconvened meeting requiring a quorum, then the meeting
	may be adjourned for a maximum of two months. See &ldquo;Item 10. Additional Information&mdash;B. Articles of Association.&rdquo;
	In addition, neither the corporate laws of France nor our by-laws require a majority of our directors to be independent and our
	independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present.
	Currently, we intend to voluntarily adopt the corporate governance listing standards of Nasdaq relating to a majority independent
	board to the extent possible under French law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 132 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	125
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Board Committees
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are a foreign private issuer. As a result,
	in accordance with the Nasdaq stock exchange listing requirements, we will rely on home country governance requirements and certain
	exemptions thereunder rather than relying on the stock exchange corporate governance requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The board of directors has established
	an audit committee, which operates pursuant to a separate charter adopted by our board of directors. The composition and functioning
	of the committee complies with all applicable requirements of the French commercial code, the Exchange Act, the exchange on which
	our ADSs, as are listed, and SEC rules and regulations. In accordance with French law, the audit committee and all other committees
	of our board of directors only have an advisory role and can only make recommendations to our board of directors. As a result,
	decisions are made by our board of directors taking into account nonbinding recommendations of such committees, including the audit
	committee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Audit Committee
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The audit committee is chaired by
	Christian Merle and includes Muriel de Szilbereky and Steve Gannon, who are non-executive board members. The audit committee
	reviews our internal accounting procedures, consults with and reviews the services provided by our independent registered
	public accountants and assists our board of directors in its oversight of our corporate accounting and financial reporting.
	Our board has determined that each member of our audit committee is independent within the meaning of the independence
	requirements contemplated by Rule 10A-3 under the Exchange Act and Nasdaq and SEC rules applicable to foreign private
	issuers. Our board of directors has further determined that each member of our audit committee is an &ldquo;audit committee
	financial expert&rdquo; as defined by SEC rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Compensation Committee
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The compensation committee is chaired by
	Yvonne Greenstreet and includes Kapil Dhingra and Leopoldo Zambeletti. The committee will assist our board of directors in overseeing
	our cash compensation and equity award recommendations for our directors, executive officers and employees along with the rationale
	for such recommendations. In accordance with Nasdaq Listing Rule 5615(a)(3), we will follow home country requirements with respect
	to our compensation committee. As a result, our practice will vary from the requirements of Nasdaq Listing Rule 5605(d), which
	sets forth certain requirements as to the responsibilities, composition and independence of compensation committees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	R&amp;D Steering Committee
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The R&amp;D Steering Committee consists
	of Stefano Buono, Kapil Dhingra and Yvonne Greenstreet, and oversees our R&amp;D strategies and activities and in pursuing new
	R&amp;D opportunities, as well as providing the rationale for recommendations related to R&amp;D oversight and coordination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_EMPLOYEES">
</A>
	D.
</TD>
<TD>
	Employees
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	At December&nbsp;31, 2015, we had 403 employees:
	124 in Italy, 111 in France, 45 in Spain, 27 in the United Kingdom, 15 in Portugal, 15 in Israel, 25 in the United States, 13 in
	Germany, 14 in Poland and 14 in Switzerland. Since that date, we have continued to expand the number of employees supporting our
	production, marketing and sales infrastructure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SHAREOWNERSHIP">
</A>
	E.
</TD>
<TD>
	Share Ownership
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 7. Major Shareholders
	and Related Party Transactions&mdash;A. Major Shareholders.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 133 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	126
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_DIRECTORS_AND_OFFICERS>
<!-- FIELD: /PAGE -->
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM7">
</A>
	ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MAJORSHAREHOLDERS">
</A>
	A.
</TD>
<TD>
	Major Shareholders
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our authorized share capital is &euro;7.9
	million (US$8.6 million), consisting of 78,556,211 ordinary shares, nominal value &euro;0.10 per share. Each of our ordinary shares
	entitles its holder to one vote.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table presents the beneficial
	ownership of our ordinary shares as of the date of this annual report, referred to in the table below as the &ldquo;Beneficial
	Ownership Date,&rdquo; by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each of our directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	each of our senior management; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	all directors and senior management as a group.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Beneficial ownership is determined in accordance
	with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under
	such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power
	as well as any shares that the individual has the right to acquire within 60 days of the Beneficial Ownership Date through the
	exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws,
	the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The percentage of ordinary shares beneficially
	owned is based on 78,556,211 ordinary shares outstanding as of December 31, 2015 and assumes the exercise of warrants issued to
	members of our board in September 2015, which are exercisable from the date of issue and until March 3, 2017 at a price of&thinsp;
	&euro;6.10 per ordinary share. Ordinary shares that a person has the right to acquire within 60 days of the Beneficial Ownership
	Date are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed
	outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership
	of all directors and senior management as a group. Unless otherwise indicated below, the address for each beneficial owner listed
	is c/o 20 Rue Rudolf Diesel, 01630 Saint-Genis-Pouilly, France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Ordinary Shares Beneficially&nbsp;Owned
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name of Beneficial Owner
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Percent
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-STYLE: ITALIC">
	Directors and Senior Management
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 78%">
	Claudio Costamagna(1)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,050,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1.3
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Christian Merle(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	Kapil Dhingra(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Leopoldo Zambeletti(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	81,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Muriel de Szilbereky(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stefano Buono (3)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,897,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	Steve Gannon(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Yvonne Greenstreet(2)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	G&eacute;rard Ber&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,460,600
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Heinz M&auml;usli&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	771,050
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Claude Hariton&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	All directors and senior management as a group (11 persons)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,499,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.82
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-STYLE: ITALIC">
	5% Shareholders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Andrea Ruben Osvaldo Levi(4)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,376,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fin Posillipo S.p.A.(5)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,316,219
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	HBM Healthcare Investments (Cayman) Ltd.(6)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,975,222
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Sergio Domp&eacute; S.r.l.(7)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,625,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	*
</TD>
<TD>
	Indicates ownership of less than 1% of the total outstanding ordinary shares.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 134 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	127
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Consists of&thinsp; (i) 650,000 ordinary shares directly held by Mr. Costamagna and (ii) 400,000 ordinary shares held by CC
	&amp; Soci S.r.l. Because Mr. Costamagna is the chairman of the board of, and owns 90% of, CC &amp; Soci S.r.l., Mr. Costamagna
	may be deemed to individually beneficially own the 400,000 ordinary shares held by CC &amp; Soci S.r.l.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Consists for all these persons of 37,500 ordinary shares issuable upon the exercise of warrants that are exercisable within
	60 days after September 28, 2015 at an exercise price per ordinary share of&thinsp;&euro;6.10 and of ADSs acquired in the initial public offering.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Consists of (i) 4,850,800 ordinary shares directly held by Mr. Buono and (ii) 47,000 ordinary shares held by Mr. Buono&rsquo;s
	spouse, which may be deemed to be beneficially owned by Mr. Buono
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD>
	Consists of&thinsp; (i) 3,426,000 ordinary shares directly held by Mr. Levi; (ii) 1,000,000 ordinary shares held by Parabensa
	S.r.l.; and (iii) 950.000 ordinary shares held by Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.r.l. Mr. Levi is the
	sole director of Parabensa S.r.l. and has sole voting and disposition power with respect to the shares held by Parabensa S.r.l.
	The address of Parabensa S.r.l.&rsquo;s headquarters is Corso D&rsquo;Azeglio 21, Torino 10126, Italy. Mr. Levi is a member of
	the board of directors of Dal 1802 Educazione Cultura Salute Ambiente Tecnologia S.r.l., which consists of Mr. Levi, Paola Chiari
	and Pietro Sighicelli, and has shared voting and disposition power with respect to the 950,000 shares held by Dal 1802 Educazione
	Cultura Salute Ambiente Tecnologia S.r.l. None of the members of the board of directors of Dal 1802 Educazione Cultura Salute Ambiente
	Tecnologia S.r.l. has individual voting or disposition power with respect to the 950,000 shares and each disclaims beneficial ownership
	of such shares except to the extent of any pecuniary interest therein. The address of Dal 1802 Educazione Cultura Salute Ambiente
	Tecnologia S.r.l.&rsquo;s headquarters is Via Principe Amedeo 11, Torino 10123, Italy.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(5)
</TD>
<TD>
	Consists of (i) 6,115,189 ordinary shares directly held by Fin Posillipo S.p.A. and (ii) 201,030 ordinary shares indirectly
	held by Fin Posillipo S.p.A. through its 68.4% ownership of Life Sciences Capital S.p.A.(LSC). The board of directors of Fin Posillipo
	S.p.A. has sole voting and disposition power with respect to the shares held by such entity. The board of directors of Fin Posillipo
	S.p.A. is comprised of Massimo Petrone, Raffaele Petrone, Pierluigi Petrone and Alberto D&rsquo;Alessandro, none of whom has individual
	voting or disposition power with respect to these shares and each of whom disclaim beneficial ownership of the shares held by Fin
	Posillipo S.p.A., except to the extent of any pecuniary interest therein. Raffaele Petrone, Massimo Petrone and Pierluigi Petrone
	each hold approximately 33.3% of the equity of Fin Posillipo S.p.A. Fin Posillipo S.p.A. owns 68.4% of LSC and therefore indirectly
	owns approximately 68.4% of the ordinary shares held directly by LSC.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(6)
</TD>
<TD>
	Consists of 6,975,222 ordinary shares held by HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare
	Investments (Cayman) Ltd. has sole voting and disposition power with respect to the shares held by such entity. The board of directors
	of HBM Healthcare Investments (Cayman) Ltd. is comprised of Jean-Marc Lesieur, Richard Coles, Sophia Harris, Dr. Andreas Wicki,
	Prof. John Urquhart and Paul Woodhouse, none of whom has individual voting or disposition power with respect to such shares and
	each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address of HBM Healthcare
	Investments (Cayman) Ltd.&rsquo;s headquarters is Governor&rsquo;s Square, Suite No: 4-212-2, 213 Lime Tree Bay Avenue, West Bay,
	Grand Cayman, Cayman Islands.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(6)
</TD>
<TD>
	Consists of 5,625,000 ordinary shares held by Sergio Domp&eacute; S.r.l. The board of directors of Sergio Domp&eacute; S.r.l
	has sole voting and disposition power with respect to the shares held by such entity. The sole director of Sergio Domp&eacute;
	S.r.l., Mr. Sergio Domp&eacute;, disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
	Due to Mr. Domp&eacute;'s 100% ownership interest in Sergio Domp&eacute; S.r.l., Mr. Domp&eacute; may be deemed to individually
	beneficially own 5,625,000 ordinary shares held by Sergio Domp&eacute; S.r.l. The address of Sergio Domp&eacute; is Via Santa Lucia
	6, I-20122 Milan, Italy.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_RELATEDPARTYTRANSACTIONS">
</A>
	B.
</TD>
<TD>
	Related Party Transactions
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Transactions with our Principal Shareholders, our Board
	Members and Senior Managers in 2015
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The group of our board of directors, senior
	managers and 5%+ shareholders purchased a total of 352,830 ADSs (equivalent to 705,660 ordinary shares) in the initial public offering in November
	2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 135 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	128
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Shareholders&rsquo; Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We entered into a second amended and restated
	shareholders&rsquo; agreement with certain shareholders. The shareholders&rsquo; agreement, among other things:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	contains certain restrictions on disposal and transfer of our ordinary shares and other securities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	grants certain shareholders a right to tag along to another shareholder&rsquo;s proposed transfer of our ordinary shares;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	grants certain shareholders, in connection with such shareholders&rsquo; proposed sale of our ordinary shares, a right to drag
	the other shareholders along with such proposed sale; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	limits the ability of shareholder directors to compete with AAA or to hold interests exceeding 2% of the share capital of any
	third party that competes with AAA, subject to exemption by a majority vote of the board.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The shareholders&rsquo; agreement will,
	by its terms, terminate upon the earlier of February&nbsp;28, 2019 or the listing of our ordinary shares or other securities on
	any stock exchange. As a result, the shareholders&rsquo; agreement terminated upon the listing of our ADSs in November 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Stock Option Plan
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In connection with our initial public offering,
	we entered into an option plan for the benefit of certain of our officers and employees and a New Free Share Plan, as described
	in &ldquo;Item 6. Directors, Senior Management and Employees&mdash;B. Compensation&mdash;Option Plan&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Warrants
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of December 31, 2015, we had issued
	an aggregate of 225,000 warrants to certain members of our Board pursuant to a shareholder authorization granted in June 2015.
	Each warrant is exercisable from the date of issue until March 3, 2017, and may be exercised in exchange for one ordinary share
	at a price of &euro;6.10 per share. See &ldquo;Item 6. Directors, Senior Management and Employees&mdash;B. Compensation&mdash;Compensation
	of Senior Management and the Board of Directors.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other Transactions
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are also a party to service agreements
	with Pierrel, of which our former director Raffaele Petrone is president, for contract services related to our Phase 3 trial for
	Lutathera. See &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Other Contracts.&rdquo; The foregoing
	agreements were entered into and, to the extent applicable, provided compensation to such former directors or their affiliated
	entities on terms negotiated on an arm&rsquo;s-length basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In connection with services relating to
	our initial public offering, and subject to certain conditions, we have agreed to pay the chairman of our board, Claudio Costamagna,
	a cash payment equivalent to 0.2% of the number of our ordinary shares issued and outstanding prior to the offering, multiplied
	by the public offering price per ordinary share upon the listing of our shares on a public stock exchange. In addition to the above,
	we agreed to pay certain members of our management and certain of our employees a one-time bonus upon the completion of our initial
	public offering, in an aggregate amount of about &euro;1.2 million (US$ 1.3 million).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have in the past entered into agreements
	with certain of our former directors or officers relating to services provided by such officers or directors or entities with which
	such officers or directors were affiliated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, certain of our existing shareholders
	have purchased our ordinary shares during the course of the private placements that we completed in May and June 2015 in arm&rsquo;s
	length transactions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_INTERESTSOFEXPERTS">
</A>
	C.
</TD>
<TD>
	Interests of Experts and Counsel
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 136 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	129
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SECURITY_OWNERS>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM8">
</A>
	ITEM 8. FINANCIAL INFORMATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTS">
</A>
	A.
</TD>
<TD>
	Consolidated Statements and Other Financial Information
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Financial statements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 18. Financial Statements,&rdquo;
	which contains our financial statements prepared in accordance with IFRS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SIGNIFICANTCHANGES">
</A>
	B.
</TD>
<TD>
	Significant Changes
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A discussion of the significant changes
	in our business can be found under &ldquo;Item 4. Information on the Company&mdash;A. History and development of the company.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 137 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	130
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<!-- FIELD: /PAGE -->
<EFX_LISTING>
<A NAME="FIS_LISTING"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM9">
</A>
	ITEM 9. THE OFFER AND LISTING
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_OFFERING">
</A>
	A.
</TD>
<TD>
	Offering and Listing Details
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;&mdash;C. Markets&rdquo; below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_PLANOFDISTRIBUTION">
</A>
	B.
</TD>
<TD>
	Plan of Distribution
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MARKETS">
</A>
	C.
</TD>
<TD>
	Markets
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In November, 2015 we completed our initial
	public offering and listed our ADSs on the NASDAQ Global Select Market, or the NASDAQ, under the symbol &ldquo;AAAP.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The table below presents, for the periods
	indicated, the annual, quarterly and monthly high and low closing prices (in US$) of our ADSs on the NASDAQ.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Period
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	Year Ended
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 78%">
	2015 (from November 11, 2015)&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	31.96
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	24.50
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Quarter Ended
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	Fourth Quarter 2015 (from November 11, 2015)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD">
	Month Ended
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	November 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	December 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	January 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30.88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	February 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33.47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24.06
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	March 2016&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	April 2016 (through April 14, 2016)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36.81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SELLINGSHAREHOLDERS">
</A>
	D.
</TD>
<TD>
	Selling Shareholders
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DILUTION">
</A>
	E.
</TD>
<TD>
	Dilution
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_EXPENSESOFTHEISSUE">
</A>
	F.
</TD>
<TD>
	Expenses of the Issue
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 138 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	131
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_LISTING>
<!-- FIELD: /PAGE -->
<EFX_ADDITIONAL_INFORMATION>
<A NAME="FIS_ADDITIONAL_INFORMATION"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM10">
</A>
	ITEM 10. ADDITIONAL INFORMATION
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SHARECAPITAL">
</A>
	A.
</TD>
<TD>
	Share Capital
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<A NAME="DP65110_20F_HTM_ARTICLESOFASSOCIATION">
</A>
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
	B.
</TD>
<TD>
	Articles of Association
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following description of our share
	capital summarizes certain provisions of our By-laws. Such summaries do not purport to be complete and are subject to, and are
	qualified in their entirety by reference to, all of the provisions of our By-laws a copy of which have been filed as an exhibit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	General
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of the date of this annual report, our
	outstanding share capital consisted of a total of 78,556,211 ordinary shares, nominal value &euro;0.10 per ordinary share, all
	issued and outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of date of this annual report, approximately
	9,342,444 shares, representing 11.89% of our outstanding shares were held of record by 23 residents of the United States.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under French law, our By-laws set forth
	only our issued and outstanding share capital as of the date of the By-laws on a non-diluted basis. Our fully diluted share capital
	currently represents the amount of all issued and outstanding shares, plus the amount of the shares already granted to our directors
	and employees under previous plans that are not issued yet.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	History of Securities Issuances
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	From January&nbsp;1, 2011 through the date
	of this annual report, the following events have changed the number of our issued and outstanding shares:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On May&nbsp;20, 2011, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated May&nbsp;11, 2011,
	the board of directors decided to issue 2,000,000 ordinary shares, increasing the share capital by &euro;200,000;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On June&nbsp;28, 2011, pursuant to decisions at the Extraordinary General Meeting of the shareholders dated February&nbsp;16,
	2011, May&nbsp;11, 2011 and June&nbsp;19, 2006, the board of directors decided to issue a total of 8,507,417 ordinary shares covering,
	in aggregate, the decisions at these three meetings, increasing the share capital by &euro;850,741.70;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On February&nbsp;23, 2012, pursuant to a decision at the Extraordinary General Meeting of the shareholders of the same day,
	the board of directors decided to issue 120,000 ordinary shares, increasing the share capital by &euro;12,000;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On December&nbsp;14, 2012, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated January&nbsp;29,
	2010, the board of directors decided to issue 19,377 ordinary shares, increasing the share capital by &euro;1,937.70. On the same
	day and pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;22, 2010, the board of
	directors decided to issue an additional 190,000 ordinary shares, increasing the share capital by &euro;19,000;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On April&nbsp;11, 2013, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated March&nbsp;8,
	2013, the board of directors decided to issue 535,994 ordinary shares, increasing the share capital by &euro;53,599.40. On the
	same day and pursuant to another decision at the same Extraordinary General Meeting of the shareholders dated March&nbsp;8, 2013,
	the board of directors decided to issue an additional 427,092 ordinary shares, increasing the share capital by &euro;42,709.20;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On June&nbsp;19, 2013, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;20,
	2012, the board of directors decided to issue 575,000 ordinary shares, increasing the share capital by &euro;57,500;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 139 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	132
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On November&nbsp;29, 2013, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;22,
	2010, the board of directors decided to issue 177,500 ordinary shares, increasing the share capital by &euro;17,750;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On February&nbsp;14, 2014, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;22,
	2010, the board of directors decided to issue 40,000 ordinary shares, increasing the share capital by &euro;4,000. On the same
	day and pursuant to two decisions at the Extraordinary General Meeting of the shareholders dated March&nbsp;8, 2013, the board
	of directors decided to issue an additional 8,507,038 ordinary shares, increasing the share capital by &euro;850,703.80;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On March&nbsp;27, 2014, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated October&nbsp;18,
	2013, the board of directors decided to issue 241,114 ordinary shares, increasing the share capital by &euro;24,111.40;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On October 16, 2014, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June 22, 2010, the
	board of directors decided to issue 295,000 ordinary shares, increasing the share capital by &euro;29,500;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On May 28, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated December 16, 2014, the
	board of directors decided to issue 1,459,660 ordinary shares, increasing the share capital by &euro;145,966;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On June 17, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated December 16, 2014,
	the board of directors decided to issue 2,330,110 ordinary shares, increasing the share capital by &euro;233,011;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On August 19, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June 22, 2010, the
	board of directors decided to issue 352,500 ordinary shares, increasing the share capital by &euro;35,250;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On September&nbsp;6, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;19,
	2006, the board of directors decided to issue 235,000 ordinary shares, increasing the share capital by &euro;23,500;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On September&nbsp;28, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated June&nbsp;22,
	2010, the board of directors decided to issue 167,500 ordinary shares, increasing the share capital by &euro;16,750; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	On November 10, 2015, pursuant to a decision at the Extraordinary General Meeting of the shareholders dated December 16, 2014,
	the board of directors decided to issue 10,782,400 ordinary shares, increasing the share capital by &euro;1,078,240.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Each share is entitled to one vote on all
	matters submitted to our shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of December 31, 2015, the Company had
	issued 225,000 warrants to purchase ordinary shares to certain members of our board of directors. Such warrants are exercisable
	from the date of issuance until March 3, 2017, for a price per ordinary share of&thinsp; &euro;6.10. As of December 31, 2015, we
	had not issued any ordinary shares pursuant to the exercise of such warrants. See &ldquo;Item 6. Directors, Senior Management and
	Employees&mdash;B. Compensation&mdash;Compensation of Senior Management and the Board of Directors.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Key Provisions of Our By-laws and French Law Affecting
	Our Ordinary Shares
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The description below reflects the terms
	of our By-laws and summarizes the material rights of holders of our ordinary shares under French law. Please note that this is
	only a summary and is not intended to be exhaustive. For further information, please refer to the full version of our By-laws which
	is included as an exhibit to this annual report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 140 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	133
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage141"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Corporate Purpose
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our corporate purpose in France and abroad
	includes:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	sale of products, services and studies in the sector of medicine and industry, of applications of particles accelerators, of
	pharmaceutical products, of chemical products, of artificial radio elements and of all other similar products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	production, trade, distribution, transportation, exportation, importation and sale of radioactive isotopes for industrial and
	medical applications;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	production, trade, distribution, transportation, exportation, importation and sale of chemical, pharmaceutical and medical
	products and of all similar products;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	production, trade, distribution, transportation, exportation, importation and sale of industrial and medical machines and consumables,
	and ancillary services;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	participation of the Company, by all means, directly or indirectly, to all operations that are related to its corporate purpose,
	through creation of new companies, contribution, subscription or acquisition of shares, merger or other similar means, through
	creation, acquisition, leasing, lease-management, of any business assets or business goodwill or facility and through creation,
	acquisition, use or transfer of all processes and patents related to the corporate purpose of the Company; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	and more generally, participation in any industrial, commercial, financial, civil, real estate operations that are related
	directly or indirectly to the corporate purpose of the Company or to any similar or attached activity.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Directors
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Quorum and Voting.
</I>
	The board of
	directors can only deliberate if at least half of the directors attend the meeting in the manners provided for in our By-laws.
	Our By-laws allow directors to attend meetings of the board of directors in person or, to the extent permitted by the internal
	rules that may be adopted by the board of directors and applicable law, by videoconference or other telecommunications arrangements.
	In addition, our By-laws allow a director to grant another director a proxy to represent him at a meeting of the board of directors,
	but no director can hold more than one proxy at any meeting. Decisions of the board of directors are taken by the majority of votes
	cast. In the event of a tied vote, the Chairman of the board of directors shall have a casting vote.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Directors&rsquo; Voting Powers on Proposal,
	Arrangement or Contract in which any Director is Materially Interested
</I>
	. Under French law, any agreement entered into (directly
	or through an intermediary) between us and any director that is not entered into (1) in the ordinary course of our business and
	(2) upon standard market terms is subject to the prior authorization of the board of directors (it being specified that the interested
	director cannot vote on such decision). The same provision applies to agreements between us and another company if one of our directors
	is the owner or a general partner, manager, director, general manager or member of the executive or supervisory board of the other
	company, as well as to agreements in which one of our directors has an indirect interest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Directors&rsquo; Compensation.
</I>
	The
	aggregate amount of attendance fees (
<I>
	jetons de presence
</I>
	) of the board of directors is determined at the shareholders&rsquo;
	annual ordinary general meeting. The board of directors then divides this aggregate amount among some or all of its members by
	a simple majority vote. In addition, the board of directors may grant exceptional compensation (
<I>
	remunerations exceptionnelles
</I>
	)
	to individual directors on a case-by-case basis for special and temporary assignments. The board of directors may also authorize
	the reimbursement of reasonable travel and accommodation expenses, as well as other expenses incurred by directors in the corporate
	interest. See &ldquo;Item 6. Directors, Senior Management and Employees&mdash;B. Compensation&rdquo; for a description of our compensation
	policy for our non-employee directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Board of Directors&rsquo; Borrowing
	Powers.
</I>
	There are currently no limits imposed on the amounts of loans or borrowings that the board of directors may approve.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Directors&rsquo; Age Limits.
</I>
	The
	Directors&rsquo; age limit is 75 years old.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 141 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	134
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage142"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Employee Director Limits.
</I>
	&nbsp;&nbsp;&nbsp;The
	number of directors who are also party to employment contracts with the Company may not exceed a third of the directors in office.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Directors&rsquo; Share Ownership Requirements
</I>
	.&nbsp;&nbsp;&nbsp;None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Directors Mandate Duration.
</I>
	&nbsp;&nbsp;&nbsp;Our
	By-laws provide that members of our board of directors are elected for a tenure of one year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Rights, Preferences and Restrictions
	Attaching to Ordinary Shares
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Dividends
</I>
	. We may only distribute
	dividends out of our &ldquo;distributable profits,&rdquo; plus any amounts held in our reserves that the shareholders decide to
	make available for distribution, other than those reserves that are specifically required by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&ldquo;Distributable profits&rdquo; consist
	of our unconsolidated net profit in each fiscal year, plus any distributable reserves and &ldquo;
<I>
	distributable premium
</I>
	&rdquo;
	that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law,
	as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts
	pursuant to French law (see below).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Legal Reserve.
</I>
	Pursuant to French
	law, we must allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before dividends may be paid
	with respect to that year. Funds must be allocated until the amount in the legal reserve is equal to 10% of the aggregate nominal
	value of the issued and outstanding share capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Approval of Dividends.
</I>
	Pursuant
	to French law, our board of directors may propose for a dividend to be distributed, or not distributed, to the shareholders at
	the annual ordinary general meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Upon recommendation of our board of directors,
	our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them
	forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may
	not be distributed when our net assets are or would become as a result of such distribution lower than the amount of the share
	capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders (the amount of our
	share capital plus the amount of our legal reserves which may not be distributed was equal to &euro;8.2 million (US$8.9 million)
	on December&nbsp;31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our board of directors may distribute interim
	dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when
	the interim consolidated statement of financial position, established during such year and certified by an auditor, reflects that
	we have earned distributable profits since the close of the last financial year, after recognizing the necessary depreciation and
	provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law, and including
	any retained earnings. The amount of such interim dividends may not exceed the amount of the profit so defined.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Pursuant to recently passed legislation,
	if a dividend is distributed we may be required to pay a dividend tax in an amount equal to 3% of the aggregate dividend paid by
	us in cash.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Distribution of Dividends.
</I>
	Dividends
	are distributed to shareholders
<I>
	pro rata
</I>
	according to their respective holdings of shares. The actual dividend payment date
	is decided by the shareholders at an ordinary general shareholders&rsquo; meeting or by our board of directors in the absence of
	such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Dividends may be paid in cash or, if the
	shareholders&rsquo; meeting so decides, in kind, provided that all shareholders receive a whole number of assets of the same nature
	paid in lieu of cash. French law provides that, subject to a decision of the shareholders&rsquo; meeting taken by ordinary resolution,
	each shareholder may be given the choice to receive his dividend in cash or in shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Timing of Payment.
</I>
	Pursuant to French
	law, dividends must be paid within a maximum of nine months after the close of the relevant fiscal year, unless extended by court
	order. Dividends not claimed within five years after the payment date shall be deemed to expire and revert to the French state.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 142 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	135
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage143"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Voting Rights.
</I>
	We only have ordinary
	shares outstanding. Each share shall entitle its holder to vote and be represented in the shareholders&rsquo; meetings in accordance
	with the provisions of French law and of our By-laws. Ownership of one share implies,
<I>
	ipso jure
</I>
	, adherence to our By-laws
	and the decisions of the shareholders&rsquo; meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In general, each shareholder is entitled
	to one vote per share at any general shareholders&rsquo; meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under French law, treasury shares or shares
	held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Rights to Share in Our Profit.
</I>
	Each
	share entitles its holder to a portion of the corporate profits and assets proportional to the amount of share capital represented
	thereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Rights to Share in the Surplus in the
	Event of Liquidation.
</I>
	If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of
	the remaining obligations will first be used to repay in full the nominal value of our shares. Any surplus will be distributed
<I>
	pro rata
</I>
	among shareholders in proportion to the number of shares respectively held by them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Repurchase and Redemption of Shares.
</I>
	Under French law, we may acquire our own shares for the following purposes only:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is made to all
	shareholders, with the approval of the shareholders at an extraordinary general meeting; following the purchase offer made to all
	shareholders, in case the number of shares presented for repurchase by shareholders who agree to sell their shares is higher than
	the number of shares to be purchased under the offer, the number of shares to be repurchased from each concerned shareholder will
	be reduced on a pro rata basis of its participation. If the number of shares presented for repurchase by shareholders is lower
	than the number of shares to be purchased under the offer, the board of directors shall confirm the repurchase of the concerned
	shares, and may proceed to a new purchase offer. In this case, the shares repurchased must be cancelled within one month from their
	repurchase date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to provide shares for distribution to employees, corporate officers and directors under a profit-sharing or equity compensation
	plan; in this case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be
	cancelled; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	to facilitate an issue of additional shares or securities convertible or exchangeable into shares, a merger or a spin-off approved
	by the shareholders at an ordinary general meeting; in this case, the shares repurchased cannot represent more than 0.25% of the
	share capital in any fiscal year and must be immediately cancelled.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	No such repurchase of shares may result
	in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital (5% in case of repurchase
	of shares to be used in payment or in exchange for assets acquired by us). Shares repurchased by us continue to be deemed &ldquo;issued&rdquo;
	under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Sinking Fund Provisions.
</I>
	Our by-laws
	do not provide for any sinking fund provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Liability to Further Capital Calls.
</I>
	Shareholders are liable for corporate liabilities only up to the nominal of the shares they hold; they are not liable to further
	capital calls.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Requirements for Holdings Exceeding
	Certain Percentages.
</I>
	None except as described under the section &ldquo;Form, Holding and Transfer of Shares&thinsp;&mdash;&thinsp;Ownership
	of Shares by Non-French Persons.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Actions Necessary to Modify Shareholders&rsquo;
	Rights
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Shareholders&rsquo; rights may be modified
	as allowed by French law. Only the extraordinary shareholders&rsquo; meeting is authorized to amend any and all provisions of our
	By-laws. It may not, however, increase shareholder commitments without the prior approval of each shareholder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 143 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	136
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage144"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Rules for Admission to and Calling Annual
	Shareholders&rsquo; Meetings and Extraordinary Shareholders&rsquo; Meetings
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Access
	to, Participation in and Voting Rights at Shareholders&rsquo; Meetings.
</I>
	Shareholders may in accordance with legal and regulatory
	requirements, send their vote or proxy either by hard copy or telecommunications means. Shareholders sending their vote within
	the applicable time limit, using the form provided to them by us for this purpose, are deemed present or represented at the meeting.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Notice of Annual Shareholders&rsquo;
	Meetings.
</I>
	Shareholders&rsquo; meetings are convened by our board of directors, or, failing that, by the statutory auditors,
	or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder following a public tender
	or exchange offer or following a change of control. Meetings are held at our registered offices or at any other location indicated
	in the convening notice. Subject to limited exceptions provided by French law, notices must be given at least 15 days before the
	date of the meeting. When the shareholders&rsquo; meeting cannot deliberate due to the lack of the required quorum, the second
	meeting must be called at least ten days in advance in the same manner as used for the first notice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Agenda and Conduct of Annual Shareholders&rsquo;
	Meetings.
</I>
	The agenda of the shareholders&rsquo; meeting shall appear in the notice to convene the meeting and is set by the
	author of the notice. The shareholders&rsquo; meeting may only deliberate on the items on the agenda except for the removal of
	directors and the appointment of their successors which may be put to vote by any shareholder during any shareholders&rsquo; meeting.
	One or more shareholders representing the percentage of share capital required by French law (currently 5%), and acting in accordance
	with legal requirements and within applicable time limits, may request the inclusion of items or proposed resolutions on the agenda.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the By-laws, shareholders&rsquo;
	meetings shall be chaired by the Chairman of the board of directors or, in his or her absence, by the director appointed for this
	purpose by the board of directors. Scrutinizing shall be performed by the two members of the meeting who are present and accept
	such duties, who represent, either on their own behalf or as proxies, the greatest number of votes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Ordinary Shareholders&rsquo; Meeting.
</I>
	Ordinary shareholders&rsquo; meetings are those meetings called to make any and all decisions that do not amend our By-laws.
	An ordinary meeting shall be convened at least once a year within six months of the end of each fiscal year in order to approve
	the annual and consolidated accounts for the relevant fiscal year or, in case of postponement, within the period established by
	court order. Upon first notice, the meeting may validly deliberate only if the shareholders present or represented by proxy or
	voting by mail represent at least one-fifth of the shares entitled to vote. Upon second notice, no quorum is required. Decisions
	are made by a majority of the votes held by the shareholders present, represented by proxy, or voting by mail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Extraordinary Shareholders&rsquo; Meeting.
</I>
	Only an extraordinary shareholders&rsquo; meeting is authorized to amend our By-laws. It may not, however, increase shareholder
	commitments without the approval of each shareholder. Subject to the legal provisions governing share capital increases from reserves,
	profits or share premiums, the resolutions of the extraordinary meeting shall be valid only if the shareholders present, represented
	by proxy or voting by mail represent at least one-fourth of all shares entitled to vote upon first notice, or one-fifth upon second
	notice. If the latter quorum is not reached, the second meeting may be postponed to a date no later than two months after the date
	for which it was initially called. Decisions are made by a two-thirds majority of the votes held by the shareholders present, represented
	by proxy, or voting by mail.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition to the right to obtain certain
	information regarding us at any time, any shareholder may, from the date on which a shareholders&rsquo; meeting is convened until
	the fourth business day preceding the date of the shareholders&rsquo; meeting, submit written questions relating to the agenda
	for the meeting to our board of directors. Our board of directors is required to respond to these questions during the meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 144 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	137
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage145"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Provisions Having the Effect of Delaying,
	Deferring or Preventing a Change in Control of the Company
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Provisions contained in our By-laws and
	the corporate laws of France, the country in which we are incorporated, could make it more difficult for a third-party to acquire
	us, even if doing so might be beneficial to our shareholders. These provisions include the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	provisions of French law allowing the owner of 95% of the share capital or voting rights of a public company to force out the
	minority shareholders following a tender offer made to all shareholders are only applicable to companies listed on a stock exchange
	of the European Union and will therefore not be applicable to us;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	under French law, a non-resident of France may have to file an administrative notice with French authorities in connection
	with a direct or indirect investment in us, as defined by administrative rulings; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	pursuant to French law, the sections of the By-laws relating to the number of directors and election and removal of a director
	from office may only be modified by a resolution adopted by two-third of the votes of our shareholders present, represented by
	a proxy or voting by mail at the meeting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Declaration of Crossing of Ownership
	Thresholds
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our By-laws provide that any natural person
	or legal entity, acting either alone or in concert, that comes to hold a number of shares representing a proportion of the share
	capital or voting rights that is equal to or greater than 1% of the share capital or voting rights, or any multiple of this percentage,
	including any in excess of the declaration thresholds provided for by the legislation and regulations in force, must inform the
	company of the total number of shares and voting rights that they own, and also inform it of the number of securities giving future
	access to the capital, and the number of any voting rights that may be attached to these, by means of a letter sent by recorded
	delivery with return receipt, within a timeframe of ten (10) days as from the time crossing the threshold in question.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This obligation to inform the company also
	applies whenever a shareholder&rsquo;s holding in the share capital or the voting rights falls below one of the thresholds mentioned
	in the preceding paragraph.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If not declared in accordance with the
	provisions of the By-laws, shares exceeding the portion which should have been declared will be deprived of their voting right
	at shareholder&rsquo;s meetings, in accordance with the provisions of the Commercial Code, if, at a meeting, the failure to have
	made a declaration is noted and one or more shareholders that together hold at least 5% of the share capital request this at this
	meeting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	There are no other declarations of crossing
	of ownership thresholds except as described under the section &ldquo;Form, Holding and Transfer of Shares&thinsp;&mdash;&thinsp;Ownership
	of Shares by Non-French Persons.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Changes in Share Capital
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Increases in Share Capital.
</I>
	Pursuant
	to French law, our share capital may be increased only with shareholders&rsquo; approval at an extraordinary general shareholders&rsquo;
	meeting following the recommendation of our board of directors. The shareholders may delegate to our board of directors either
	the authority
<I>
	(d&eacute;l&eacute;gation de comp&eacute;tence)
</I>
	or the power
<I>
	(d&eacute;l&eacute;gation de pouvoir)
</I>
	to carry out any increase in share capital.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Increases in our share capital may be effected
	by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	issuing additional shares;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	increasing the nominal value of existing shares;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	creating a new class of equity securities (preference shares); and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	exercising the rights attached to securities giving access to the share capital.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 145 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	138
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage146"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Increases in share capital by issuing additional
	securities may be effected through one or a combination of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in consideration for cash;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	in consideration for assets contributed in kind;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	through an exchange offer or merger;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	by conversion of previously issued debt instruments;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	by exercise of the rights attached to securities giving access to the share capital;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	by capitalization of profits, reserves or share premium; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	subject to certain conditions, by way of offset against debt incurred by us.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Decisions to increase the share capital
	through the capitalization of reserves, profits and/or share premium require shareholders&rsquo; approval at an extraordinary general
	shareholders&rsquo; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&rsquo; meetings.
	Increases effected by an increase in the nominal value of shares require unanimous approval of the shareholders, unless effected
	by capitalization of reserves, profits or share premium. All other capital increases require shareholders&rsquo; approval at an
	extraordinary general shareholders&rsquo; meeting acting under the regular quorum and majority requirements for such meetings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Reduction in Share Capital.
</I>
	Pursuant
	to French law, any reduction in our share capital requires shareholders&rsquo; approval at an extraordinary general shareholders&rsquo;
	meeting following the recommendation of our board of directors. The extraordinary general meeting may delegate to the board of
	directors, as applicable, all powers required to implement it. The share capital may be reduced either by decreasing the nominal
	value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced
	by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder
	agrees otherwise, depending on the contemplated operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Preferential Subscription Right.
</I>
	According
	to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights to these
	securities on a
<I>
	pro
</I>
	rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe
<I>
	pro rata
</I>
	based on the number of shares held by them to the issuance of any securities increasing, or that may result in
	an increase of, our share capital by means of a cash payment or a set-off of cash debts. The preferential subscription rights are
	transferable during the subscription period relating to a particular offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The preferential subscription rights with
	respect to any particular offering may be waived at an extraordinary general meeting by a two-thirds vote of our shareholders or
	individually by each shareholder. Our board of directors and our independent auditors are required by French law to present reports
	to the shareholders&rsquo; meeting that specifically address any proposal to waive the preferential subscription rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our current shareholders waived their preferential
	subscription rights with respect to this offering at an extraordinary general shareholders&rsquo; general meeting held on December&nbsp;16,
	2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Form, Holding and Transfer of Shares
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Form of Shares.
</I>
	Our By-laws provide
	that our shares are registered or bearer shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Holding of Shares.
</I>
	In accordance
	with French law concerning the &ldquo;dematerialization&rdquo; of securities, the ownership rights of shareholders are represented
	by book entries instead of share certificates. Registered shares are entered into an account maintained by us or by a representative
	appointed by us. We maintain accounts in the name of each shareholder either directly or, at a shareholder&rsquo;s request, through
	such shareholder&rsquo;s accredited intermediary. Each shareholder&rsquo;s account shows the name of the relevant shareholder and
	number of shares held.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 146 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	139
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage147"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Ownership of Shares by Non-French Persons.
</I>
	Neither French law nor our By-laws limit the right of non-residents of France or non-French persons to own or, where applicable,
	to vote our securities. Non-residents of France must file an administrative notice with the French authorities in connection with
	a direct or indirect investment in us, including through ownership of ADSs, on the date a binding purchase agreement is executed
	or a tender offer is made public. Under existing administrative rulings the following transactions would require the filing of
	an administrative notice:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	any transaction carried out on our capital by a non-French resident provided that after the transaction the cumulative amount
	of the capital or the voting rights held by non-French residents exceeds 33.33% of our capital or voting rights;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	any transaction mentioned above by a corporation incorporated under French law, more than 33.33% of whose capital or voting
	rights are held by non-French residents;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	any transaction carried out abroad resulting in a change of the controlling shareholder of a corporation incorporated under
	a foreign law that holds a shareholding or voting rights in us if more than 33.3% of our capital or voting rights are held by non-French
	residents;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	significant loans and guarantees granted or the purchase of patents or licenses, the conclusion of commercial contracts or
	the provision of technical assistance, which confer to our counterparty a
<I>
	de facto
</I>
	controlling position.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Violation of this administrative notice
	requirement is sanctioned by a fine of not more than &euro;750. This amount may be multiplied by five if the violation is made
	by a legal entity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	Assignment and Transfer of Shares.
</I>
	They are registered in a share account and transferred by means of a transfer from account to account. We must receive notice of
	any transfer for it to be validly registered in our accounts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Limitations Affecting Shareholders of a French Company
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Many limitations affect shareholders of
	a French company, the rights of such shareholders being subject to the provisions of French company law. The below list highlights
	certain of the principal limitations, but is not an exhaustive list.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Availability of Preferential Subscription
	Rights
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	While our current shareholders waived their
	preferential subscription rights with respect to this offering at a shareholders&rsquo; general meeting held on December 16, 2014,
	in the future our shareholders will have the preferential subscription rights described under &ldquo;Description of Share Capital&thinsp;&mdash;&thinsp;Key
	Provisions of Our By-laws and French Law Affecting Our Ordinary Shares&thinsp;&mdash;&thinsp;Changes in Share Capital&mdash;Preferential
	Subscription Rights.&rdquo; Under French law, shareholders have preferential rights to subscribe for cash issues of new shares
	or other securities giving rights to acquire additional shares on a pro rata basis. Holders of our securities in the United States
	(which may be in the form of shares or ADSs) may not be able to exercise preferential subscription rights for their securities
	unless a registration statement under the Securities Act is effective with respect to such rights or an exemption from the registration
	requirements imposed by the Securities Act is available. We may, from time to time, issue new shares or other securities giving
	rights to acquire additional shares (such as warrants) at a time when no registration statement is in effect and no Securities
	Act exemption is available. If so, holders of our securities in the United States will be unable to exercise any preferential subscription
	rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any
	issuance of new shares or other securities. We intend to evaluate at the time of any rights offering the costs and potential liabilities
	associated with registering the rights, as well as the indirect benefits to us of enabling the exercise by holders of shares and
	holders of ADSs in the United States of the subscription rights, and any other factors we consider appropriate at the time, and
	then to make a decision as to whether to register the rights. We cannot assure you that we will file a registration statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For holders of our shares in the form of
	ADSs, the Depositary may make these rights or other distributions available to ADS holders. If the depositary does not make the
	rights available to ADS holders and determines that it is impractical to sell the rights, it may allow these rights to lapse. In
	that case the holders will receive no value for them. See &ldquo;Item 12. Description of Securities Other than Equity Securities&mdash;D.
	American Depositary Shares&rdquo; for a detailed explanation of the Depositary&rsquo;s responsibility in connection with a rights
	offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 147 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	140
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage148"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Differences in Corporate Law
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The laws applicable to French
<I>
	soci&eacute;t&eacute;s
	anonymes
</I>
	differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences
	between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&rsquo;
	rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in
	its entirety by reference to Delaware law and French law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	France
	&nbsp;
</B>
</P>
</TD>
<TD STYLE="WIDTH: 38%; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 0.5PT SOLID">
<B>
	Delaware
	&nbsp;
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #DBE5F1">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Number of Directors
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under French law, a
<I>
	soci&eacute;t&eacute; anonyme
</I>
	must have at least 3 and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the by-laws.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the by-laws.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Director Qualifications
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under French law, a corporation may prescribe qualifications for directors under its by-laws, subject to applicable regulations.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or by-laws.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #DBE5F1">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Removal of Directors
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under French law, directors may be removed from office, with or without cause, at any shareholders&rsquo; meeting without notice or justification, by a simple majority vote.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority shareholder vote, though in the case of a corporation whose board is classified, shareholders may effect such removal only for cause.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Vacancies on the board of directors
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under French law, vacancies on the board of directors resulting from death or a resignation, provided that at least 3 directors remain in office, may be filled by a majority of the remaining directors pending ratification by the next shareholders&rsquo; meeting.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under Delaware law, vacancies on a corporation&rsquo;s board of directors, including those caused by an increase in the number of directors, may be filled by a majority of the remaining directors.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #DBE5F1">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Annual General Meeting
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual meeting, within 6 months after the close of the relevant fiscal year unless such period is extended by court order.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT; BACKGROUND-COLOR: WHITE">
	Under Delaware law, the annual meeting of shareholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the by-laws.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 148 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	141
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage149"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	General Meeting
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, general meetings of the shareholders may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, special meetings of the shareholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the by-laws.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Notice of General Meetings
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, for corporations all the shares of which are in registered form, written notice of any meeting of the shareholders must be given at least 15 calendar days before the date of the meeting. When the shareholders&rsquo; meeting cannot deliberate due to the lack of the required quorum, the second meeting must be called at least ten calendar days in advance in the same manner as used for the first notice. The notice shall specify the name of the company, its legal form, share capital, registered office address, registration number with the French Registry of commerce and companies, the place, date, hour and agenda of the meeting and its nature (ordinary or extraordinary meeting).
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, unless otherwise provided in the certificate of incorporation or by-laws, written notice of any meeting of the shareholders must be given to each shareholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Proxy
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, any shareholder may vote by mail or grant a proxy to his/her spouse, his/her partner with whom he/she has entered into a civil union or another shareholder for physical persons or to any person for legal entities. General proxies are not valid and a separate proxy must be provided for each shareholders&rsquo; meeting, unless it concerns an ordinary and an extraordinary meeting held the same day or within the next 15 days, or a consecutive general meeting with the same agenda (in the event the quorum has not been reached).
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, at any meeting of shareholders, a shareholder may designate another person to act for such shareholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 149 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	142
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage150"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
	Shareholder action by written consent
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Under French law, shareholders&rsquo; action by written consent is not permitted in a
<I>
	soci&eacute;t&eacute; anonyme
</I>
	.
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, a corporation&rsquo;s certificate of incorporation (1) may permit shareholders to act by written consent if such action is signed by all shareholders, (2) may permit shareholders to act by written consent signed by shareholders having the minimum number of votes that would be necessary to take such action at a meeting or (3) may prohibit actions by written consent.
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
	Preemptive Rights
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Under French law, in case of issuance of additional shares or other securities for cash or set-off against cash debts, the existing shareholders have preferential subscription rights to these securities on a
<I>
	pro rata
</I>
	basis unless such rights are waived by a two-thirds majority of the votes held by the shareholders present, at&nbsp;the extraordinary meeting deciding or authorizing the capital increase, represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential rights.
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, unless otherwise provided in a corporation&rsquo;s certificate of incorporation, a shareholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the corporation&rsquo;s stock.
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Sources of Dividends
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Under French law, dividends may only be paid by a
	French
<I>
	soci&eacute;t&eacute; anonyme
</I>
	out of&thinsp; &ldquo;
<I>
	distributable profits
</I>
	,&rdquo; plus any distributable reserves
	and &ldquo;
<I>
	distributable premium
</I>
	&rdquo; that the shareholders decide to make available for distribution, other than those
	reserves that are specifically required by law. &ldquo;
<I>
	Distributable profits
</I>
	&rdquo; consist of the unconsolidated net profits
	of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&ldquo;
<I>
	Distributable premium
</I>
	&rdquo; refers
	to the contribution paid by the shareholders in addition to the nominal value of their shares for their subscription that the shareholders
	decide to make available for distribution. Except in case of a share capital reduction, no distribution can be made to the shareholders
	when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed
	in accordance with the law.
</P>
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, dividends may be paid by a Delaware corporation either out of&thinsp; (1) surplus or (2) in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 150 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	143
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage151"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Repurchase of Shares
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Under French law, a private corporation (being specified
	that the company will not qualify as a public corporation for French law purposes for so long as it shall be listed in the United
	States only) may acquire its own shares for the following purposes only:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
	decrease its share capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders
	on a
<I>
	pro rata
</I>
	basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
	a view to distributing within one year of their repurchase the relevant shares to employees, corporate officers and directors under
	a profit-sharing or equity incentive plan;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
</P>
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
	sell the relevant shares to any shareholders willing to purchase them as part of a process organized by the corporation within
	five years of their repurchase; or
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;within
	the limit of 5% of its issued share capital, in payment or in exchange for assets acquired by the corporation within two years
	of their repurchase.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	No such repurchase of shares may result in the company holding,
	directly or through a person acting on its behalf, more than 10% of its issued share capital.
</P>
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 151 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	144
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage152"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Liability of Directors and Officers
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, the by-laws may not include any provisions limiting the liability of directors.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Under Delaware law, a corporation&rsquo;s certificate
	of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its
	shareholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of
	a director for: any breach of the director&rsquo;s duty of loyalty to the corporation or its shareholders;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acts
	or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;intentional
	or negligent payment of unlawful dividends or stock purchases or redemptions; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
	transaction from which the director derives an improper personal benefit.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Voting Rights
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	French law provides that, unless otherwise provided in the by-laws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Delaware law provides that, unless otherwise provided in the certificate of incorporation, each shareholder is entitled to one vote for each share of capital stock held by such shareholder.
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Shareholder Vote on Certain Transactions
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Generally, under French law, completion of a merger,
	dissolution, sale, lease or exchange of all or substantially all of a corporation&rsquo;s assets requires:
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;completion
	of a merger requires the approval of the board of directors and the approval by a two-third majority of the votes held by the shareholders
	present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a non-EU company, approval
	of all shareholders of the corporation may be required, depending on the nationality of the concerned companies and therefore the
	applicable laws;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dissolution
	requires the approval by a two-third majority of the votes held by the shareholders present, represented by proxy or voting by
	mail at the relevant meeting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sale,
	lease or exchange of all or substantially all of a corporation&rsquo;s assets requires the approval by a two-third majority of
	the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting if such operation modifies
	the corporate purpose set forth in the By-laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Generally, under Delaware law, unless the certificate
	of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or
	exchange of all or substantially all of a corporation&rsquo;s assets or dissolution requires:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	approval of the board of directors; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;approval
	by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or
	less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0.25IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
</TD>
</EFX_UNIDENTIFIED_TABLE>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 152 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	145
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage153"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 39%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Dissent or Dissenters&rsquo; Appraisal Rights
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	French law does not provide for any such right but provides that a merger is subject to shareholders&rsquo; approval by a two-thirds majority vote as stated above.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Under Delaware law, a holder of shares of any class
	or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for
	the shareholder&rsquo;s shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action
	timely brought by the corporation or a dissenting shareholder. Delaware law grants these appraisal rights only in the case of mergers
	or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock. Further, no appraisal
	rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more
	than 2,000 shareholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything
	other than:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
	of stock of the surviving corporation;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
	of stock of another corporation that are either listed on a national securities exchange or held of record by more than 2,000 shareholders;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cash
	in lieu of fractional shares of the stock described in the two preceding bullet points; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
	combination of the above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	In addition, appraisal rights are not available to
	holders of shares of the surviving corporation in specified mergers that do not require the vote of the shareholders of the surviving
	corporation.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 153 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	146
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage154"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 22%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Standard of Conduct for Directors
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a corporation&rsquo;s corporate interest (
<I>
	int&eacute;r&ecirc;t social
</I>
	).
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the shareholders.
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
	Shareholder Suits
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	French law provides that a shareholder, or a group of shareholders,
	may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&rsquo;s interest if
	it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees
	relating to such action are borne by the relevant shareholder or the group of shareholders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The plaintiff must remain a shareholder through the duration
	of the legal action.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	A shareholder may alternatively or cumulatively bring individual
	legal action against the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case,
	any damages awarded by the court are paid to the relevant shareholder.
</P>
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Under Delaware law, a shareholder may initiate a derivative
	action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;state
	that the plaintiff was a shareholder at the time of the transaction of which the plaintiff complains or that the plaintiff&rsquo;s
	shares thereafter devolved on the plaintiff by operation of law; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;allege
	with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons
	for the plaintiff&rsquo;s failure to obtain the action; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;state
	the reasons for not making the effort.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Additionally, the plaintiff must remain a shareholder through
	the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court
	of Chancery.
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 22%; BORDER-BOTTOM: WHITE 1PT SOLID; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	France
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Delaware
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Amendment of Certificate of Incorporation
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, there is no certificate of incorporation
<I>
	per se
</I>
	. The equivalent of the certificate of incorporation is called &ldquo;
<I>
	extrait K-bis
</I>
	&rdquo; and reflects all the significant information with regards to a French company, such as its name, date of registration, identification number, form, share capital, registered office, governance and administration,
<I>
	etc
</I>
	. Any changes of the By-laws, or in the situation of the company as reflected in the extrait K-bis, shall be registered with the competent Registry of Commerce and Companies on the French territory.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	Under Delaware law, generally a corporation may amend
	its certificate of incorporation if:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its
	board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.2IN 0PT 20PT; TEXT-INDENT: -19PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;&#9;
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
	amendment is adopted by the affirmative votes of a majority (or greater percentage as may be specified by the corporation) of
	the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation)
	of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series.&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Amendment of By-laws
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under French law, by-laws may only be adopted or amended at extraordinary shareholders&rsquo; meetings.
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-RIGHT: 10PT; PADDING-BOTTOM: 6PT">
	Under Delaware law, the shareholders entitled to vote have the power to adopt, amend or repeal by-laws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 154 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	147
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage155"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MATERIALCONTRACTS">
</A>
	C.
</TD>
<TD>
	Material Contracts
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 4. Information on the Company&mdash;B.
	Business Overview&mdash;Licensing&rdquo; and &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Other Contracts.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_EXCHANGECONTROLS">
</A>
	D.
</TD>
<TD>
	Exchange Controls
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under current French foreign exchange control
	regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and
	regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French
	resident to a non-resident such as dividend payments be handled by an accredited intermediary. All registered banks and substantially
	all credit institutions in France are accredited intermediaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_TAXATION">
</A>
	E.
</TD>
<TD>
	Taxation
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<I>
	The following summary contains a description
	of the material French and U.S. federal income tax consequences of the acquisition, ownership and disposition of ADSs, but it does
	not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to own ADSs. The
	summary is based upon the tax laws of France and regulations thereunder and on the tax laws of the United States and regulations
	thereunder as of the date hereof, which are subject to change.
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	French Tax Consequences
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following describes the material French
	income tax consequences to U.S. Holders (as defined below) of purchasing, owning and disposing of our ADSs and ordinary shares,
	or the Securities and, unless otherwise noted, this discussion is the opinion of Orrick, Herrington &amp; Sutcliffe (Europe) LLP,
	our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect to those matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This discussion does not purport to be
	a complete analysis or listing of all potential tax effects of the acquisition, ownership or disposition of our securities to any
	particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally
	assumed to be known by investors. All of the following is subject to change. Such changes could apply retroactively and could affect
	the consequences described below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	France has introduced a comprehensive set
	of new tax rules applicable to French assets that are held by or in foreign trusts. These rules provide, inter alia, for the inclusion
	of trust assets in the settlor&rsquo;s net assets for purpose of applying the French wealth tax, for the application of French
	gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of trusts not already
	subject to the French wealth tax and not declared to the French tax authorities, and for a number of French tax reporting and disclosure
	obligations. The following discussion does not address the French tax consequences applicable to securities held in trusts. If
	securities are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax adviser regarding the specific
	tax consequences of acquiring, owning and disposing of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The description of the French income tax
	and wealth tax consequences set forth below is based on the Convention Between the Government of the United States of America and
	the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to
	Taxes on Income and Capital of August&nbsp;31, 1994, or the Treaty, which came into force on December&nbsp;30, 1995 (as amended
	by any subsequent protocols, including the protocol of January&nbsp;13, 2009) (the &ldquo;U.S. Treaty&rdquo;), and the tax guidelines
	issued by the French tax authorities in force as of the date of this annual report on Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For the purposes of this discussion, the
	term &ldquo;U.S. Holder&rdquo; means a beneficial owner of securities that is (1) an individual who is a U.S. citizen or resident
	for U.S. federal income tax purposes, (2) a U.S. domestic corporation or certain other entities treated as a corporation for U.S.
	federal income tax purposes, created or organized in or under the laws of the United States or any state thereof, including the
	District of Colombia, or (3) otherwise subject to U.S. federal income taxation on a net income basis in respect of our securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If a partnership holds securities, the
	tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. If a U.S.
	Holder is a partner in a partnership that holds securities, such holder is urged to consult its own tax adviser
	regarding the specific tax consequences of acquiring, owning and disposing of securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 155 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	148
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage156"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This discussion applies only to U.S. Holders
	who meet the following conditions:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they own, directly or indirectly, less than 10% of the capital and dividend rights of the Company;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they hold their ADSs as capital assets that have the U.S. dollar as their functional currency;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they are entitled to U.S. Treaty benefits under the &ldquo;Limitation on Benefits&rdquo; provision contained in the U.S. Treaty;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	the ownership of their ADSs is not effectively connected to a permanent establishment or a fixed base they have in France;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they are not multi resident;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they do not hold their ADSs through a non-U.S.-based pass-through entity; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	they do not receive dividends, capital gains or other payments on their ADSs in an account opened in a Non-Cooperative State,
	as defined under Article 238-0 A of the French Tax Code, or the FTC, and as mentioned in the list updated and published by the
	French tax authorities on January&nbsp;1 of each year
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A U.S. Holder who meets all the above conditions
	is hereafter defined as an &ldquo;Eligible U.S. Holder&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For the purpose of the U.S. Treaty, an
	Eligible U.S. Holder of ADSs will be treated as the owner of the Company&rsquo;s ordinary shares represented by such ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The description below is relevant only
	to U.S. holders who are Eligible U.S. Holders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Certain U.S. Holders (including, but not
	limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks,
	insurance companies, regulated investment companies, tax-exempt organizations, financial institutions, persons subject to the alternative
	minimum tax, persons who acquired the securities pursuant to the exercise of employee share options or otherwise as compensation,
	persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share
	capital, dealers in securities or currencies, persons that elect to mark their securities to market for U.S. federal income tax
	purposes and persons holding securities as a position in a synthetic security, straddle or conversion transaction) may be subject
	to special rules not discussed below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	U.S. Holders of our ADSs are urged to consult
	their own tax advisers regarding the tax consequences of the purchase, ownership and disposition of our ADSs in light of their
	particular circumstances, especially with regard to the &ldquo;Limitations on Benefits&rdquo; provision.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Estate and Gift Taxes and Transfer Taxes
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In general, a transfer of securities by
	gift or by reason of death of a U.S. Holder that would otherwise be subject to French gift or inheritance tax, respectively, will
	not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government
	of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates,
	Inheritances and Gifts, dated November&nbsp;24, 1978, unless the donor or the transferor is domiciled in France at the time of
	making the gift or at the time of his or her death, or the securities were used in, or held for use in, the conduct of a business
	through a permanent establishment or a fixed base in France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Pursuant to Article 235 ter ZD of the FTC,
	purchases of shares or ADSs of a French company listed on a regulated market of the European Union or an exchange formally acknowledged
	by the French Financial Market Authority (AMF) are subject to a 0.2% French tax on financial transactions provided that the issuer&rsquo;s
	market capitalization exceeds 1 billion Euros as of December&nbsp;1 of the year preceding the taxation year. Nasdaq is not currently
	acknowledged by the French AMF but this may change in the future. French companies whose market capitalization exceeds 1 billion
	Euros are included on a list published by the French State.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 156 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	149
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage157"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Following our initial public offering,
	purchases of AAA&rsquo;s securities may be subject to such tax provided that its market capitalization exceeds 1 billion Euros
	and that Nasdaq is acknowledged by the French AMF.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the case where Article 235 ter ZD of
	the FTC is not applicable, transfers of shares issued by a listed French company will be subject to uncapped registration duties
	at the rate of 0.1% if the transfer is evidenced by a written statement (
<I>
	acte
</I>
	) executed either in France or outside France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Wealth Tax
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The French wealth tax (
<I>
	imp&ocirc;t de
	solidarit&eacute; sur la fortune
</I>
	) applies only to individuals and does not generally apply to securities held by a U.S. resident,
	as defined pursuant to the provisions of the Treaty, provided that such U.S. Holder does not own directly or indirectly more than
	25% of the issuer&rsquo;s financial rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Taxation of Dividends
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under French domestic law, dividends paid
	by a French corporation to non-residents of France are generally subject to French withholding tax at a rate of 30%. Dividends
	paid by a French corporation in a Non-Cooperative State or Territory, as defined in Article 238-0 A of the FTC, will generally
	be subject to French withholding tax at a rate of 75%, irrespective of the tax residence of the beneficiary of the dividends. Subject
	to certain conditions and filing requirements, such withholding tax rates may generally be reduced under applicable double income
	tax treaties entered into by France.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Eligible U.S. Holders will not be subject
	to this 30% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the U.S. Treaty, the rate of French
	withholding tax on dividends paid to an Eligible U.S. Holder is generally reduced to 15% and such U.S. Holder may claim a refund
	from the French tax authorities of the amount withheld in excess of the Treaty rates of 15%, if any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For Eligible U.S. Holders that are not
	individuals but are U.S. residents, as defined in the U.S. Treaty, the requirements for eligibility for Treaty benefits, including
	the reduced 15% withholding tax rate, contained in the &ldquo;Limitation on Benefits&rdquo; provision of the U.S. Treaty, are complicated,
	and certain technical changes were made to these requirements by the protocol of January&nbsp;13, 2009. These Eligible U.S. Holders
	are advised to consult their own tax advisers regarding their eligibility for U.S. Treaty benefits in light of their own particular
	circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Dividends paid to an Eligible U.S. Holder
	may immediately be subject to the reduced rate of 15% provided that such holder establishes before the date of payment that it
	is a U.S. resident under the U.S. Treaty by completing and providing the depositary with a treaty form (Form 5000) in accordance
	with French guidelines (BOI-INT-DG-20-20-20-20). Dividends paid to an Eligible U.S. Holder that has not filed the Form 5000 before
	the dividend payment date will be subject to French withholding tax at the rate of 30%, if paid in a Non-Cooperative State or Territory
	(as defined in Article 238-0 A of the FTC), and then reduced at a later date to 15%, provided that such holder duly completes and
	provides the French tax authorities with the treaty forms Form 5000 and Form 5001 before December&nbsp;31 of the second calendar
	year following the year during which the dividend is paid. Certain qualifying pension funds and certain other tax-exempt entities
	are subject to the same general filing requirements as other U.S. Holders except that they may have to supply additional documentation
	evidencing their entitlement to these benefits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Form 5000 and Form 5001, together with
	instructions, will be provided by the depositary to all U.S. Holders registered with the depositary. The depositary will arrange
	for the filing with the French tax authorities of all such forms properly completed and executed by U.S. Holders of ordinary shares
	or ADSs and returned to the depositary in sufficient time so that they may be filed with the French tax authorities before the
	distribution in order to obtain immediately a reduced withholding tax rate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Tax on Sale or Other Disposition
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In general, under the Treaty, an Eligible
	U.S. Holder will not be subject to French tax on any capital gain from the redemption (other than redemption proceeds characterized
	as dividends under French domestic tax law or administrative guidelines), sale or exchange of ordinary shares or ADSs. Special
	rules apply to U.S. Holders who are residents of more than one country.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 157 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	150
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage158"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	U.S. Federal Income Tax Considerations for U.S. Holders
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Following is a description of the material
	U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of ordinary shares or ADSs. It
	is not a comprehensive description of all tax considerations that may be relevant to a particular person&rsquo;s decision to hold
	ordinary shares or ADSs. This discussion applies only to a U.S. Holder that holds ordinary shares or ADSs as capital assets for
	U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of
	a U.S. Holder&rsquo;s particular circumstances, including alternative minimum tax consequences, the potential application of the
	provisions of the Code known as the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special
	rules, such as:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	certain financial institutions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	dealers or traders in securities who use a mark-to-market method of tax accounting;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	persons holding ordinary shares or ADSs as part of a hedging transaction, &ldquo;straddle,&rdquo; wash sale, conversion transaction
	or integrated transaction or persons entering into a constructive sale with respect to the ordinary shares or ADSs;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	persons whose &ldquo;functional currency&rdquo; for U.S. federal income tax purposes is not the U.S. dollar;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	tax exempt entities, including &ldquo;individual retirement accounts&rdquo; and &ldquo;Roth IRAs&rdquo;;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	entities classified as partnerships for U.S. federal income tax purposes;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	persons who acquired our ordinary shares or ADSs pursuant to the exercise of an employee stock option or otherwise as compensation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	persons that own or are deemed to own ten percent or more of our voting shares; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	persons holding ordinary shares or ADSs in connection with a trade or business conducted outside the United States.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If an entity that is classified as a partnership
	for U.S. federal income tax purposes holds ordinary shares or ADSs, the U.S. federal income tax treatment of a partner will generally
	depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary shares or ADSs and partners
	in such partnerships are encouraged to consult their own tax advisers as to the particular U.S. federal income tax consequences
	of holding and disposing of ordinary shares or ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The discussion is based on the Code, administrative
	pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between France
	and the United States (the &ldquo;Treaty&rdquo;) all as of the date hereof, changes to any of which may affect the tax consequences
	described herein&mdash;possibly with retroactive effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A &ldquo;U.S. Holder&rdquo; is a holder
	who is, for U.S. federal income tax purposes, a beneficial owner of ordinary shares or ADSs, eligible for the benefits of the Treaty
	and is:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a citizen or individual resident of the United States;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any
	state therein or the District of Columbia; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In general, a U.S. Holder who owns ADSs
	will be treated as the owner of the underlying shares represented by those ADSs for U.S. federal income tax purposes. Accordingly,
	no gain or loss will be recognized if a U.S. Holder exchanges ADSs for the underlying shares represented by those ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 158 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	151
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage159"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The U.S. Treasury has expressed concerns
	that parties to whom ADSs are released before shares are delivered to the depositary (&ldquo;pre-release&rdquo;), or intermediaries
	in the chain of ownership between holders and the issuer of the security underlying the ADSs, may be taking actions that are inconsistent
	with the claiming of foreign tax credits by holders of ADSs. These actions would also be inconsistent with the claiming of the
	reduced rate of tax, described below, applicable to dividends received by certain non-corporate holders. Accordingly, the creditability
	of French taxes, and the availability of the reduced tax rate for dividends received by certain non-corporate U.S. Holders, each
	described below, could be affected by actions taken by such parties or intermediaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	U.S. Holders are encouraged to consult
	their own tax advisers concerning the U.S. federal, state, local and foreign tax consequences of owning and disposing of ordinary
	shares or ADSs in their particular circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Taxation of distributions
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Subject to the PFIC rules described below,
	distributions paid on ordinary shares or ADSs, other than certain pro rata distributions of ordinary shares, will generally be
	treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal
	income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles,
	we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations and the
	discussion above regarding concerns expressed by the U.S. Treasury, dividends paid to certain non-corporate U.S. Holders may be
	taxable at preferential rates applicable to long-term capital gain. The amount of a dividend will include any amounts withheld
	by us in respect of French withholding taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S.
	Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code.
	Dividends will be included in a U.S. Holder&rsquo;s income on the date of the U.S. Holder&rsquo;s, or in the case of ADSs, the
	Depositary&rsquo;s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated
	by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is
	in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should
	not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency
	gain or loss if the dividend is converted into U.S. dollars after the date of receipt.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Subject to applicable limitations, some
	of which vary depending upon the U.S. Holder&rsquo;s particular circumstances and subject to the discussion above regarding concerns
	expressed by the U.S. Treasury, French income taxes withheld from dividends on ordinary shares or ADSs at a rate not exceeding
	the rate provided by the Treaty will be creditable against the U.S. Holder&rsquo;s U.S. federal income tax liability. The rules
	governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign
	taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct
	foreign taxes, including any French income tax, in computing their taxable income, subject to generally applicable limitations
	under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or
	accrued in the taxable year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Sale or other taxable disposition of
	ordinary shares or ADSs
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Subject to the PFIC rules described below,
	gain or loss realized on the sale or other taxable disposition of ordinary shares or ADSs will be capital gain or loss, and will
	be long-term capital gain or loss if the U.S. Holder held the ordinary shares or ADSs for more than one year. The amount of the
	gain or loss will equal the difference between the U.S. Holder&rsquo;s adjusted tax basis in the ordinary shares or ADSs disposed
	of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be
	U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Passive foreign investment company rules
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Under the Code, we will be a PFIC for any
	taxable year in which, after the application of certain &ldquo;look-through&rdquo; rules with respect to subsidiaries, either (i)
	75% or more of our gross income consists of &ldquo;passive income,&rdquo; or (ii) 50% or more of the average quarterly value of
	our assets consist of assets that produce, or are held for the production of, &ldquo;passive income.&rdquo; Passive income generally
	includes interest, dividends, rents, certain non-active royalties and gains from the disposition of assets that produce passive
	income. If a foreign corporation owns at least 25% by value of the stock of another corporation, the foreign corporation is treated
	for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation, and as receiving directly
	its proportionate share
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 159 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	152
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage160"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	of the other corporation&rsquo;s income. Based
	upon the nature of our business and estimates of the valuation of our assets, including goodwill, which is based, in part, on the
	trading price of our ADSs, we do not believe that we were a PFIC for the year ended at December 31, 2015. However, because PFIC
	status depends on the composition of our income and assets and the relative fair market value of our assets from time to time,
	there can be no assurance that we will not be a PFIC for any taxable year. If we are a PFIC for any year during which a U.S. Holder
	holds ordinary shares or ADSs, we generally would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding
	years during which the U.S. Holder holds ordinary shares or ADSs, even if we ceased to meet the threshold requirements for PFIC
	status.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If we are a PFIC for any taxable year during
	which a U.S. Holder holds ordinary shares or ADSs, the U.S. Holder may be subject to adverse tax consequences. Generally, gain
	recognized upon a disposition (including, under certain circumstances, a pledge) of ordinary shares or ADSs by the U.S. Holder
	would be allocated ratably over the U.S. Holder&rsquo;s holding period for such ordinary shares or ADSs. The amounts allocated
	to the taxable year of disposition and to years before we became a PFIC would be taxed as ordinary income. The amount allocated
	to each other taxable year would be subject to tax at the highest rate in effect for that taxable year for individuals or corporations,
	as appropriate, and would be increased by an additional tax equal to interest on the resulting tax deemed deferred with respect
	to each such other taxable year. Further, to the extent that any distribution received by a U.S. Holder on its ordinary shares
	or ADSs exceeds 125% of the average of the annual distributions on such ordinary shares or ADSs received during the preceding three
	years or the U.S. Holder&rsquo;s holding period, whichever is shorter, that distribution would be subject to taxation in the same
	manner described immediately above with respect to gain on disposition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Alternatively, if we are a PFIC and if
	our ordinary shares or ADSs are &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange,&rdquo; a U.S. Holder could make
	a mark-to-market election that would result in tax treatment different from the general tax treatment described in the preceding
	paragraph. Our ordinary shares or ADSs would be treated as &ldquo;regularly traded&rdquo; in any calendar year in which more than
	a
<I>
	de minimis
</I>
	quantity of the ordinary shares or ADSs, as the case may be, are traded on a qualified exchange on at least
	15 days during each calendar quarter. The Nasdaq market on which the ADSs are listed is a qualified exchange for this purpose.
	However, as our ordinary shares are not expected to be listed on an exchange, holders of ordinary shares will not be able to make
	a mark-to-market election. U.S. Holders should consult their tax advisers regarding the availability and advisability of making
	a mark-to-market election in their particular circumstances. If a U.S. Holder makes the mark-to-market election, the U.S. Holder
	generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over
	their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over
	their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included
	as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&rsquo;s tax basis in the ADSs
	will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year
	when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent
	of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election will be
	effective for the taxable year for which the election is made and all subsequent taxable years, unless our ADSs cease to be marketable
	stock or the IRS consents to the revocation of the election.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A timely election to treat a PFIC as a
	qualified electing fund under Section 1295 of the Code would result in alternative treatment. U.S. Holders should be aware, however,
	that we do not intend to satisfy the record-keeping and other requirements that would permit U.S. Holders to make qualified electing
	fund elections if we were a PFIC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In addition, if we are a PFIC or, with
	respect to particular U.S. Holders, are treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable
	year, the preferential rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	If a U.S. Holder owns ordinary shares or
	ADSs during any year in which we are a PFIC, the holder generally must file an IRS Form 8621, generally with the holder&rsquo;s
	federal income tax return for that year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	U.S. Holders should consult their tax advisers
	regarding whether we are or may become a PFIC and the potential application of the PFIC rules.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 160 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	153
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage161"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Information reporting and backup withholding
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Payments of dividends and sales proceeds
	that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information
	reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii)
	in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not
	subject to backup withholding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The amount of any backup withholding from
	a payment to a U.S. Holder will be allowed as a credit against the holder&rsquo;s U.S. federal income tax liability and may entitle
	it to a refund, provided that the required information is timely furnished to the IRS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Foreign Financial Asset Reporting
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Certain U.S. Holders
	may be required to report information relating to their ownership of an interest in certain foreign financial assets, including
	stock of a non-U.S. person, generally on Form 8938, subject to exceptions (including an exception for stock held through a U.S.
	financial institution). U.S. Holders should consult their tax advisers regarding their reporting obligations with respect to ordinary
	shares or ADSs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DIVIDENDS">
</A>
	F.
</TD>
<TD>
	Dividends and Paying Agents
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_STATEMENTBYEXPERTS">
</A>
	G.
</TD>
<TD>
	Statement by Experts
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DOCUMENTSONDISPLAY">
</A>
	H.
</TD>
<TD>
	Documents on Display
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We are subject to the informational requirements
	of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Accordingly, we are required to submit reports and other
	information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other
	information filed with the SEC at the Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation
	of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website
	that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that
	website is www.sec.gov.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As a FPI, we are exempt under the Exchange
	Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers,
	directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section
	16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements
	with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we
	will file with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an
	annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and may
	submit to the SEC, on Form 6-K, unaudited quarterly financial information for the first three quarters of each fiscal year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_SUBSIDIARYINFORMATION">
</A>
	I.
</TD>
<TD>
	Subsidiary Information
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 161 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	154
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage162"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ADDITIONAL_INFORMATION>
<!-- FIELD: /PAGE -->
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM11">
</A>
	ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
	MARKET RISK
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Risk Management
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In the ordinary course of our business
	activities, we are exposed to various market risks that are beyond our control, including fluctuations in foreign exchange rates
	and the price of our primary supplies, and which may have an adverse effect on the value of our financial assets and liabilities,
	future cash flows and profit. As a result of these market risks, we could suffer a loss due to adverse changes in foreign exchange
	rates and the price of commodities in the international markets. Our policy with respect to these market risks is to assess the
	potential of experiencing losses and the consolidated impact thereof, and to mitigate these market risks. We are not currently
	exposed to significant interest rate risk because most of our long-term debt is at fixed interest rates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Foreign Currency Exchange Rate Risk
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Exchange rate variations could affect our
	consolidated statement of income. For the year ended December&nbsp;31, 2015 we realized 74% of our sales in the euro zone compared
	to 77% for the same period in 2014. In fiscal year 2014 we generated 77% of our sales in the euro zone as compared to 88% in fiscal
	year 2013. However, we operate internationally and are exposed to foreign exchange risk arising from various exposures, primarily
	with respect to the Israeli Shekel, Japanese Yen, Swiss Franc, UK Pound Sterling and U.S. Dollar due to our operations in those
	countries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Foreign exchange risk arises from future
	commercial transactions, recognized assets and liabilities and net investments in foreign operations. At December&nbsp;31, 2015
	and December&nbsp;31, 2014, a 5% increase or decrease in these exchange rates with all other variables held constant would not
	have resulted in a significant change to our results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have hedged about 50% of the US$ initial public offering
	proceeds against variations in the US$/&euro; exchange rate. Other than that we do not have any hedging policies in place to manage
	these exposures but may consider putting them in place going forward.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	Interest Rate Risk
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 9.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We do not consider our exposure to changes
	in interest rates to be significant. Some of our lease contracts are partially linked to indices such as Euribor and INSEE. Variations
	in these indices could entail increased interest payments. A variation of 1% in these indices would increase (decrease) our interest
	rate expenditure by approximately &euro;0.1 million. At December&nbsp;31, 2015, 2014 and 2013, we had &euro;6.1 million, &euro;6.9
	million and &euro;8.2 million, respectively, in financial liabilities that bore interest at a floating rate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 162 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	155
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage163"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET_RISK>
<!-- FIELD: /PAGE -->
<EFX_OTHER_SECURITIES>
<A NAME="FIS_OTHER_SECURITIES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM12">
</A>
	ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DEBTSECURITIES">
</A>
	A.
</TD>
<TD>
	Debt Securities
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_WARRANTSANDRIGHTS">
</A>
	B.
</TD>
<TD>
	Warrants and Rights
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_OTHERSECURITIES">
</A>
	C.
</TD>
<TD>
	Other Securities
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_AMERICANDEPOSITARYSHARES">
</A>
	D.
</TD>
<TD>
	American Depositary Shares
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Bank of New York Mellon, as depositary,
	registers and delivers American Depositary Shares, also referred to as ADSs. Each ADS represents two ordinary shares (or a right
	to receive two ordinary shares) deposited with the principal Paris office of BNP Paribas Securities Services or any successor,
	as custodian for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by
	the depositary in respect of the depositary facility. The depositary&rsquo;s corporate trust office at which the ADSs will be administered
	is located at 101 Barclay Street, New York, New York 10286. The principal executive office is located at One Wall Street, New York,
	New York 10286.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	A deposit agreement among us, the depositary
	and the ADS holders sets out the ADS holder rights as well as the rights and obligations of the depositary. New York law governs
	the deposit agreement and the ADRs. A copy of the Agreement is incorporated by reference as an exhibit to this Annual Report on
	Form 20-F.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	Fees and Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Pursuant to the terms of the deposit agreement,
	the holders of ADSs will be required to pay the following fees:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 51%; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Persons depositing
	or withdrawing shares or ADS holders must&nbsp;pay:
</B>
</P>
</TD>
<TD STYLE="WIDTH: 49%; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	For:
</B>
</P>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
	$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Issuance of ADSs, including issuances resulting from a distribution
	of shares or rights or other property
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Cancellation of ADSs for the purpose of withdrawal, including
	if the deposit agreement terminates
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	$.05 (or less) per ADS
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Any cash distribution to ADS holders
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	$.05 (or less) per ADS per calendar year
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Depositary services
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	Registration or transfer fees
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 163 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	156
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage164"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 51%; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Persons depositing
	or withdrawing shares or ADS holders must&nbsp;pay: &nbsp;
</B>
</P>
</TD>
<TD STYLE="WIDTH: 49%; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	For: &nbsp;
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	Expenses of the depositary
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement) converting foreign currency to U.S. dollars
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	As necessary
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-RIGHT: 10PT">
	Any charges incurred by the depositary or its agents for servicing the deposited securities
</TD>
<TD STYLE="PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	As necessary
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The depositary collects its fees for delivery
	and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
	acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
	or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services
	by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants
	acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that
	are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those
	services are paid.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	From time to time, the depositary may make
	payments to us to reimburse and/or share revenue from the fees collected from ADS holders, or waive fees and expenses for services
	provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing
	its duties under the deposit agreement, the depositary may use brokers, dealers or other service providers that are affiliates
	of the depositary and that may earn or share fees or commissions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Bank of New York Mellon has also agreed
	to reimburse us annually for certain expenses (subject to certain limitations) in connection with the ADR facility and to pay us
	annually a further amount which is a function of the issuance and cancellation fees and depositary service fees charged by the
	depositary to our ADS holders.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	In this context, and for the fiscal year
	ended December 31, 2015, the Company did not receive any reimbursement from The Bank of New York Mellon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	Payment of Taxes
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	You will be responsible for any taxes or
	other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary
	may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until
	such taxes or other charges are paid. It may apply any dividends or other distributions owed to you or sell deposited securities
	represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited
	securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send
	to ADS holders any property, remaining after it has paid the taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 164 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	157
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage165"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_SECURITIES>
</EFX_PART_I>
<!-- FIELD: /PAGE -->
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_PARTII">
</A>
	PART II
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_DEFAULTS>
<A NAME="FIS_DEFAULTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM13">
</A>
	ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DEFAULTS">
</A>
	A.
</TD>
<TD>
	Defaults
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	No matters to report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_ARREARSANDDELINQUENCIES">
</A>
	B.
</TD>
<TD>
	Arrears and Delinquencies
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	No matters to report.
</P>
</EFX_DEFAULTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_MATERIAL_MODIFICATIONS>
<A NAME="FIS_MATERIAL_MODIFICATIONS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM14">
</A>
	ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY
	HOLDERS AND USE OF PROCEEDS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MATERIALMODIFICATIONS">
</A>
	A.
</TD>
<TD>
	Material modifications to instruments
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MATERIALMODIFICATIONSTORIGHTS">
</A>
	B.
</TD>
<TD>
	Material modifications to rights
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_WITHDRAWALORSUBSTITUTIONOFASSETS">
</A>
	C.
</TD>
<TD>
	Withdrawal or substitution of assets
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CHANGEINTRUSTEES">
</A>
	D.
</TD>
<TD>
	Change in trustees or paying agents
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_USEOFPROCEEDS">
</A>
	E.
</TD>
<TD>
	Use of proceeds
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	On November 10, 2015, our registration
	statement on Form F-1 (File No. 333-207223), as amended, was declared effective by the SEC for our initial public offering of our
	ADS, pursuant to which we offered and sold a total of 5,391,200 ADSs, each representing 2 of our ordinary shares, &euro;0.10 nominal
	value per share, at a public offering price of $16.00 per ADS. Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running
	managers for the offering. The offering began on November 2, 2015 and was completed on November 10, 2015. All securities registered
	in the registration statement have been sold pursuant to the underwriting agreement for the initial public offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We sold 5,391,200 ADSs, including 703,200
	ADSs purchased by the underwriters pursuant to their option to purchase additional ADSs for an aggregate price of $86.3 million.
	We received net proceeds of approximately $80.4 million, after deducting underwriting discounts and commissions of approximately
	$5.8 million and other expenses of approximately $0.05 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Our expenses in connection with our initial
	public offering from November 10, 2015 through December&nbsp;31, 2015, other than underwriting discounts and commissions, were
	the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expenses
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Amount (US$)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT">
	SEC registration fee&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9,230
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	FINRA filing fee&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	NASDAQ listing fee&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	150,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Printing and engraving expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	202,111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Legal fees and expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	560,768
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounting fees and expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	386,628
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Road show expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,470
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Miscellaneous costs (IPO Bonus)*&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,457,599
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 0.125IN">
	Total&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,821,556
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	*
</TD>
<TD>
	IPO Bonus costs paid in cash or accrued for in 2015 for the Chairman of the Board, senior
	management and
	certain employees of the company
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 165 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	158
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage166"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	None of the underwriting discounts and
	commissions or other expenses were paid directly or indirectly to any director, officer or general partner of ours or to their
	associates, persons owning ten percent or more of any class of our equity securities, or to any of our affiliates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For the period up until December 31, 2015
	AAA made the following uses of the net proceeds from the initial public offering:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Investments for the construction of our new production sites in Murcia (Spain) and in Millburn (USA) of &euro;1.6M approximately;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Bonus payments made for the completion of the initial public offering at Nasdaq to the Chairman and senior managers and employees
	of the company of approximately &euro;1.6 million;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Payment of a contingent liability to former owners of the acquired companies Barnatron and Cadisa or &euro;1 million;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Payment of legal fees related to the work on the initial public offering and also board fees of a combined &euro;0.8 million;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
	Payments made on R&amp;D projects, notably Somakit, Lutathera, Annexin and some other operating expenses of &euro;0.7 million.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The investments and expenses described
	above amounted to approximately &euro;5.7 million (US$6.2 million)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Other than as described above, there has
	been no significant change in the planned use of proceeds from our initial public offering as described in our final prospectus
	dated November 10, 2015 filed with the SEC on November 12, 2015.
</P>
</EFX_MATERIAL_MODIFICATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM15">
</A>
	ITEM 15. CONTROLS AND PROCEDURES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_DISCLOSURECONTROLS">
</A>
	A.
</TD>
<TD>
	Disclosure Controls and Procedures
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	As of December 31, 2015, under the supervision
	and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we performed an
	evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)
	under the Exchange Act). There are inherent limitations to the effectiveness of any disclosure controls and procedures system,
	including the possibility of human error and circumventing or overriding them. Even if effective, disclosure controls and procedures
	can provide only reasonable assurance of achieving their control objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Based on such evaluation, our Chief Executive
	Officer and Chief Financial Officer concluded that our disclosure controls and procedures are not effective due to the material
	weaknesses in our internal control over financial reporting identified during our preparation for our initial public offering and
	2015 annual financial statements as more fully described in &ldquo;Item 5. Operating and Financial Review and Prospects&mdash;A.
	Operating Results&mdash;Internal Control Over Financial Reporting.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_MANAGEMENTSANNUALREPORT">
</A>
	B.
</TD>
<TD>
	Management&rsquo;s Annual Report on Internal Control
	over Financial Reporting
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This annual report does not include a report
	of management's assessment regarding internal control over financial reporting due to a transition period established by rules
	of the Securities and Exchange Commission for newly public companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_ATTESTATIONREPORT">
</A>
	C.
</TD>
<TD>
	Attestation Report of the Registered Public Accounting
	Firm
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	This Annual Report does not include an
	attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for emerging
	growth companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CHANGESININTERNALCONTROL">
</A>
	D.
</TD>
<TD>
	Changes in Internal Control over Financial Reporting
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	See &ldquo;Item 5. Operating and Financial
	Review and Prospects&mdash;B. Liquidity and Capital Resources&mdash;Internal Control Over Financial Reporting&rdquo; for changes
	in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the
	period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, internal control
	over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 166 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	159
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage167"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16">
</A>
	ITEM 16. [RESERVED]
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_AUDIT_COMMITTEE_EXPERT>
<A NAME="FIS_AUDIT_COMMITTEE_EXPERT"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16A">
</A>
	ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The audit committee is chaired by Christian
	Merle and includes Muriel de Szilbereky and Steve Gannon, who are non-executive board members. The audit committee reviews our
	internal accounting procedures, consults with and reviews the services provided by our independent registered public accountants
	and assists our board of directors in its oversight of our corporate accounting and financial reporting. Our board has determined
	that each member of our audit committee is independent within the meaning of the independence requirements contemplated by Rule
	10A-3 under the Exchange Act and Nasdaq and SEC rules applicable to foreign private issuers. Our board of directors has further
	determined that the members of our audit committee members have the professional experience and knowledge to qualify as &ldquo;audit
	committee financial experts&rdquo; as defined by SEC rules.
</P>
</EFX_AUDIT_COMMITTEE_EXPERT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_CODE_OF_ETHICS>
<A NAME="FIS_CODE_OF_ETHICS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16B">
</A>
	ITEM 16B. CODE OF ETHICS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have adopted a code of conduct
	applicable to the board of directors and all employees. Since its effective date on September 17, 2015, we have not waived
	compliance with or amended the code of conduct. We have posted a copy of our code of conduct on our website.
</P>
</EFX_CODE_OF_ETHICS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16C">
</A>
	ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The following table describes the amounts
	billed to us by KPMG S.A., independent registered public accounting firm, for audit and other services performed in fiscal years
	2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands of Euros)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 78%; TEXT-ALIGN: LEFT">
	Audit fees&#9;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,006
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,266
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Audit-related fees&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax fees&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	All other fees&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The Audit Committee is responsible for
	the appointment, replacement, compensation, evaluation and oversight of the work of the independent auditors. As part of this responsibility,
	the Audit Committee pre- approves all audit and non-audit services performed by the independent auditors in order to assure that
	they do not impair the auditor's independence from the Company. The above audit fees in 2014 include also costs incurred in the
	preparation of our first and eventually not successful initial public offering attempt at the beginning of 2015.
</P>
</EFX_ACCOUNTANT_FEES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="FIS_EXEMPTIONS_FROM_LISTING"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16D">
</A>
	ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT
	COMMITTEES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_EXEMPTIONS_FROM_LISTING>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_PURCHASES_OF_EQUITY>
<A NAME="FIS_PURCHASES_OF_EQUITY"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16E">
</A>
	ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER
	AND AFFILIATED PURCHASERS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	None.
</P>
</EFX_PURCHASES_OF_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="FIS_CHANGE_IN_ACCOUNTANT"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16F">
</A>
	ITEM 16F. CHANGE IN REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
</EFX_CHANGE_IN_ACCOUNTANT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_CORPORATE_GOVERNANCE>
<A NAME="FIS_CORPORATE_GOVERNANCE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16G">
</A>
	ITEM 16G. CORPORATE GOVERNANCE
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	For a description of the significant ways
	in which our corporate governance practices differ from those required for U.S. companies listed on Nasdaq, see &ldquo;Item 6.
	Directors, Senior Management and Employees&mdash;C. Board Practices&mdash;Corporate Governance Practices.&rdquo;
</P>
</EFX_CORPORATE_GOVERNANCE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM16H">
</A>
	ITEM 16H. MINE SAFETY DISCLOSURE
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 167 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	160
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage168"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_II>
<!-- FIELD: /PAGE -->
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_PARTIII">
</A>
	PART III
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM17">
</A>
	ITEM 17. FINANCIAL STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	We have responded to Item 18 in lieu of
	this item.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_2"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM18">
</A>
	ITEM 18. FINANCIAL STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Financial Statements are filed as part
	of this annual report. See page F-1.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="DP65110_20F_HTM_ITEM19">
</A>
	ITEM 19. EXHIBITS
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; PADDING-RIGHT: 10PT; TEXT-ALIGN: CENTER; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; BORDER-BOTTOM: BLACK 0.5PT SOLID; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	Exhibit
	No.
</P>
</TD>
<TD STYLE="WIDTH: 92%; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
<P STYLE="FONT: BOLD 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 0.5PT SOLID">
	Description
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	1.1
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	English Translation of Articles of Association.*
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.1
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Form of Deposit Agreement among Advanced Accelerator Applications S.A., The Bank of New York Mellon, as depositary, and owners and holders of American Depositary Shares (incorporated by reference to our Registration Statement on Form F-6 (File No. 333-201502) filed with the SEC on January 14, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.3
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Form of American Depositary Receipt (included in Exhibit 4.1).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.4
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Form of Shareholders&rsquo; Agreement (incorporated herein by reference to Exhibit 4.3 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.5
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Share Purchase Agreement, dated February 14, 2014, among Advanced Accelerator Applications S.A., Imaging Equipment (Holdings) Limited, Nicholas Stevens, Helen Ruth Stevens, Prabhjeevan Singh Virk, Victor Griffin and Richard Huggins (incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.6
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Advanced Accelerator Applications S.A. Stock Option Plan (incorporated herein by reference to Exhibit 10.11 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	2.7
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Form of Warrant Subscription (incorporated herein by reference to Exhibit 10.12 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.1
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Sale and Purchase Agreement, dated May 20, 2010, by and among Advanced Accelerator Applications S.A., BioSynthema Inc., and certain shareholders of BioSynthema Inc. listed in Schedule 1 thereto (incorporated herein by reference to Exhibit 10.2 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.2
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	License Agreement, dated October 10, 2007, by and between Mallinckrodt Inc. and BioSynthema Inc. (incorporated herein by reference to Exhibit 10.3 to the Company&rsquo;s Registration Statement on Form F 1 (File No. 333-207223) filed with the SEC on October 1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.3
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Know How and Trademark License Agreement, dated January 14, 2009, between Advanced Accelerator Applications S.A. and IASON GmbH (incorporated herein by reference to Exhibit 10.4 to the Company&rsquo;s Registration Statement on Form F 1 (File No. 333-207223) filed with the SEC on October 1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.4
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	License Agreement, dated June 12, 2007 (incorporated herein by reference to Exhibit 10.5 to the Company&rsquo;s Registration Statement on Form F 1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.5
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Service Agreement, dated April 3, 2012, between Advanced Accelerator Applications S.A. and Pierrel Research Italy S.p.A (incorporated herein by reference to Exhibit 10.6 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	4.6
</TD>
<TD STYLE="PADDING-RIGHT: 10PT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	Unanimous Shareholders Agreement dated March 27, 2014, among Advanced Accelerator Applications Canada Inc., 4549694 Canada Inc., 7329563 Canada Inc. and Atreus Pharmaceuticals Corporation (incorporated herein by reference to Exhibit 10.7 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).&dagger;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 168 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	161
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage169"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
	4.7
</TD>
<TD STYLE="WIDTH: 92%">
	Share Purchase Agreement dated December 18, 2014 between 7329563 Canada Inc. and Advanced Accelerator Applications S.A. (incorporated herein by reference to Exhibit 10.8 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	4.8
</TD>
<TD>
	Agreement on Special Compensation Allowance by and between Advanced Accelerator Applications S.A. and Claudio Costamagna dated January 19, 2015 (incorporated herein by reference to Exhibit 1.1 to the Company&rsquo;s Amendment No. 1 to Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on November 2, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	4.9
</TD>
<TD>
	License Agreement, dated June 16, 2015 between Advanced Accelerator Applications International and Fujifilm RI Pharma Co., Ltd (incorporated herein by reference to Exhibit 10.10 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).&dagger;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	8.1
</TD>
<TD>
	List of subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company&rsquo;s Registration Statement on Form F-1 (File No. 333-207223) filed with the SEC on October&nbsp;1, 2015).
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	12.1
</TD>
<TD>
	Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.*
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	12.2
</TD>
<TD>
	Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.*
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	13.1
</TD>
<TD>
	Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	13.2
</TD>
<TD>
	Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*
</TD>
</TR>
</TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	*
</TD>
<TD>
	Filed with this Annual Report on Form 20-F.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&dagger;
</TD>
<TD>
	Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the
	Securities and Exchange Commission.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 169 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	162
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage170"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_III>
<!-- FIELD: /PAGE -->
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	SIGNATURES
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The registrant hereby certifies that it
	meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual
	report on its behalf.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3">
<B>
	ADVANCED ACCELERATOR APPLICATIONS S.A.
</B>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	By:
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Stefano Buono
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 48%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
	Name:
</TD>
<TD STYLE="WIDTH: 33%">
	Stefano Buono
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
	Chief Executive Officer
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;&nbsp;
</TD>
<TD>
	(Principal Executive Officer)
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	Date: April 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 170 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	163
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage171"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_TOC">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS">
</A>
	Index to
	Financial Statements
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 91%">
<B>
	Audited Consolidated Financial Statements&thinsp;&mdash;&thinsp;Advanced Accelerator Applications S.A.
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 9%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<A HREF="#DP65110_20F_HTM_REPORTOFINDEPENDENT">
	Report of Independent Registered Public Accounting Firm&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFINCOME">
	Consolidated Statements of Income for the years ended December&nbsp;31, 2015, 2014 and 2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
	Consolidated Statements of Comprehensive Income for the years ended December&nbsp;31, 2015, 2014 and&nbsp;2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
	Consolidated Statements of Financial Position at December&nbsp;31, 2015, 2014 and 2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCHANGES">
	Consolidated Statements of Changes in Equity for the years ended December&nbsp;31, 2015, 2014 and 2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-7
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<A HREF="#DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
	Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2015, 2014 and 2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-10
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<A HREF="#DP65110_20F_HTM_NOTES">
	Notes to the Consolidated Financial Statements for the years ended December&nbsp;31, 2015, 2014 and 2013&#9;
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	F-13
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 171; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage172"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%">
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	Advanced
	Accelerator Applications S.A.
</B>
</FONT>
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	20
	rue Rudolf Diesel
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	01630
	Saint Genis Pouilly
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	____________________________
</B>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	IFRS CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Years ended December 31, 2015, 2014 and
	2013
</B>
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 172; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage173"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS">
	Table of Contents
</A>
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Advanced Accelerator Applications S.A.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<I>
	&nbsp;
</I>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_KPMG.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
	&nbsp;
</I>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="WIDTH: 75%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 59%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
<B>
	KPMG Audit
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 26%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	T&eacute;l&eacute;phone&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	+33 (0)4 37 64 76 00
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	51 rue de Saint Cyr
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	T&eacute;l&eacute;copie&nbsp;:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	+33 (0)4 37 64 76 09
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	CS 60409
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	Site internet&nbsp;:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	www.kpmg.fr
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	69338 Lyon Cedex 9
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	France
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
</EFX_SIGNATURES>
<BR STYLE="CLEAR: BOTH">
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
</I>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<I>
</I>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: BOLD 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="DP65110_20F_HTM_REPORTOFINDEPENDENT">
</A>
<FONT STYLE="FONT-SIZE: 10PT">
	Report
	of Independent Registered Public Accounting Firm
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board of Directors and Stockholders
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Advanced Accelerator Applications
	S.A.
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	We have
	audited the accompanying consolidated statements of financial position of Advanced Accelerator Applications S.A. and&nbsp;subsidiaries
	(&ldquo;the Company&rdquo;) as of December&nbsp;31, 2015, 2014 and 2013, and the related consolidated statements of income, comprehensive
	income, changes in equity, and cash flows for each of the years in the three-year period ended December&nbsp;31, 2015. These consolidated
	financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
	these consolidated financial statements based on our audits.
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	We conducted
	our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
	require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
	misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.
	An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating
	the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In our opinion,
	the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Advanced
	Accelerator Applications S.A. and&nbsp;subsidiaries as of December&nbsp;31, 2015, 2014 and 2013, and the results of their operations
	and their cash flows for each of the years in the three-year period ended December&nbsp;31, 2015, in conformity with International
	Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board.
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Lyon, France
<BR>
	April 28, 2016
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	KPMG Audit
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	A division
	of KPMG S.A.
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ St&eacute;phane
	Devin
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	St&eacute;phane
	Devin
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Partner
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 173 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage174"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
</EFX_AUDITORS_OPINION>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_4"></A>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFINCOME">
</A>
<B>
	CONSOLIDATED STATEMENTS OF INCOME
</B>
</P>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	for
	the years ended December 31, 2015, 2014 and 2013
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Notes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Sales
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
	4.1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Raw materials and consumables used
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18,335
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,185
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Personnel costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.2
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(29,520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16,265
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other operating expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.4
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(44,447
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(35,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(24,644
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other operating income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.5
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,474
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,230
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,977
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation and amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.7
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(11,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(11,993
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,545
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,534
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,599
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,856
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finance income (including changes in fair value of contingent consideration)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.8
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	387
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finance costs (including changes in fair value of contingent consideration)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.8
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,852
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,196
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net finance loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,696
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,800
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,768
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss before income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(16,230
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,399
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,624
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.9
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,157
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Attributable to:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Owners of the Company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-controlling interests
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.11
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(629
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Basic (&euro; per share)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Diluted (&euro; per share)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(0.25
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(0.15
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(0.22
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 174 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage175"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
</A>
<B>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE
	INCOME
</B>
</P>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	year
	ended December 31, 2015, 2014 and 2013
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss for the year
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Other comprehensive income / (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Items that may be reclassified subsequently to profit or loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;Exchange differences on translating foreign operations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,239
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,053
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(125
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Items that will never be reclassified subsequently to profit or loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;Remeasurement of defined benefit liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(559
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other comprehensive income / (expense) net of tax (1)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,680
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,992
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(108
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total comprehensive loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(14,321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,811
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,889
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total comprehensive loss attributable to:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;Owners of the Company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,776
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,061
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;Non-controlling interests
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,035
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(828
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tax effect of &euro; 176 thousand at December 31, 2015, &euro; 31 thousand at December 31, 2014
	and &euro; (5) thousand at December 31, 2013.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 175 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage176"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_2"></A>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
</A>
<B>
	CONSOLIDATED STATEMENTS OF FINANCIAL
	POSITION
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	at
	December 31, 2015, 2014 and 2013
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	ASSETS (In &euro; thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Notes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Non-current assets
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	112,687
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	107,842
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	103,449
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Goodwill
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.3
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,377
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,252
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.3
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31,884
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,410
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.4
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	56,332
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	51,779
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.5
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,512
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,959
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deferred tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.9
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	297
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	317
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	161,416
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	78,672
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	40,028
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.7
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,363
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.6
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.8
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.9
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL ASSETS
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	274,103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	186,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	EQUITY AND LIABILITIES (In &euro; thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Notes
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	12.31.2015
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	12.31.2014
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	12.31.2013
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Equity attributable to owners of the Company
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	169,754
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	55,723
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,415
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share premium
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	213,982
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118,421
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	76,594
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reserves and retained earnings
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(35,083
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(30,058
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Non-controlling interests
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.11
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,360
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.10
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	169,754
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	57,083
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Non-current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	68,341
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	70,709
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	62,052
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-current provisions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.12
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,968
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,029
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-current financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.13
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,205
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,971
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,359
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.9
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,804
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,460
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,187
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other non-current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.14
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	39,364
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	37,267
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	31,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,008
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	30,618
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	24,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current provisions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.12
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.13
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,560
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,915
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,458
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5.14
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,738
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,419
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,551
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	104,349
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	101,327
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	86,394
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	TOTAL EQUITY AND LIABILITIES
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	274,103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	186,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 176 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
</EFX_CASH_FLOW>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage177"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCHANGES">
</A>
<B>
	CONSOLIDATED STATEMENT OF CHANGES
	IN EQUITY
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: SMALL-CAPS 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	Year
	ended December 31, 2015
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="23" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Attributable to the Company
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share premium
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Translation reserve
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net Income / (loss)&nbsp;&nbsp;for the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Group reserves
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 34%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At January 1, 2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,323
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	118,421
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,620
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(31,678
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,187
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Comprehensive income for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other comprehensive income / (loss) for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,239
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(559
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,680
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total comprehensive income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,239
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(559
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(14,321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Transactions with owners of the Company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issue of ordinary shares (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,533
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	103,742
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share issue costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Appropriation of 2014 net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Equity-settled share-based payments (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total transactions with owners of the Company
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,533
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	95,561
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,499
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,705
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	98,888
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,856
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	213,982
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,859
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(39,942
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	169,754
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<BR CLEAR="ALL">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See note 5.10
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See Note 4.3
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 177 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage178"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	CONSOLIDATED
	STATEMENT OF CHANGES IN EQUITY
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	Year
	ended December 31, 2014
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="27" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Attributable to the Company
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share premium
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Translation reserve
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Group share of net Income / (loss)&nbsp;&nbsp;for the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Group reserves
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total Attributable to owners of the Company
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Non-controlling interests
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 26%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,415
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	76,594
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(433
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(13,701
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	55,723
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,360
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	57,083
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Comprehensive income for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other comprehensive income / (loss) for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,784
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(61
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,723
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,992
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total comprehensive income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,784
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(61
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,776
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,811
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Transactions with owners of the Company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issue of ordinary shares (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	908
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,827
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(603
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Appropriation of 2013 net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Purchases of non controlling interest (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	269
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,422
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,153
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(325
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,478
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Equity-settled share-based payments (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other transactions with owners of the company
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total transactions with owners of the Company
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	908
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	41,827
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,916
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,240
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(325
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,915
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,323
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	118,421
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,620
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,499
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(31,678
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	85,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See note 5.10
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See note 5.11
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See Note 4.3
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 178 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage179"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	CONSOLIDATED
	STATEMENT OF CHANGES IN EQUITY
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Year ended December 31, 2013
</B>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="27" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Attributable to the Company
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share capital
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share premium
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Translation reserve
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Group share of net Income / (loss) for the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Group reserves
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total Attributable to owners of the Company
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Non-controlling interests
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 26%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At January 1, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,244
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	69,650
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(507
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(20,047
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,049
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	58,389
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,188
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	60,577
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Comprehensive income /(loss) for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(629
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other comprehensive income / (loss) for the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	91
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(199
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(108
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total comprehensive income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,061
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(828
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,889
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Transactions with owners of the Company
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issue of ordinary shares (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,944
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Appropriation of 2012 net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(20,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Equity-settled share-based payments (2)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,280
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,280
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,280
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total transactions with owners of the Company
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	171
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,944
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,047
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,767
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,395
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,395
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At December 31, 2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,415
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	76,594
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(433
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(13,701
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	55,723
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,360
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	57,083
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See note 5.10
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	See note 4.3
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 179 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage180"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_INDEXTOFINANCIALSTATEMENTS" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW_3"></A>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<A NAME="DP65110_20F_HTM_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
</A>
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	CONSOLIDATED
	STATEMENTS OF CASH FLOWS
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
<B>
	years
	ended December 31, 2015, 2014 and 2013
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from operating activities
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT">
	Net loss for the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT">
	Adjustments:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation, amortization and impairment of non-current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,993
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,545
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share based payment expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,281
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loss / (Gain) on disposal of property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	367
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial result
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,696
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,768
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Income tax expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	771
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,158
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Negative Goodwill recognized in other operating income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Subtotal
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,948
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,776
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,909
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(742
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,085
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(445
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in trade receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,572
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,910
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(606
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase / (decrease) in trade payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(639
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Change in other receivables and payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,436
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(58
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(442
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in provisions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	752
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	153
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	253
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in working capital
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,842
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,962
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,879
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Income tax paid
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,902
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,451
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(663
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3,796
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,363
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,367
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Acquisition of property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(11,286
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,289
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Acquisition of intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(910
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(394
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Acquisition of financial assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(745
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(116
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest received
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	265
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Repayment on financial assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from disposal of property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	118
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	130
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from government grants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	623
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Acquisition of subsidiaries, net of cash acquired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(561
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,395
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,699
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,437
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,925
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net cash from financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Payment of deferred and contingent liabilities to former owners of acquired subsidiaries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,494
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,884
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Issuance of share capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97,094
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,666
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,820
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transactions with shareholders (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from borrowings
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,041
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,496
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Repayment of borrowings
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,852
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,058
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Interests paid
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(827
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(906
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,029
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash from financing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	90,131
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,437
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,229
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net increase / (decrease) in cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	74,636
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	31,363
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(329
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash and cash equivalents at the beginning of the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,611
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,947
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Effect of exchange rate changes on cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(846
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	122
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents at the end of the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,611
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Transactions with shareholders are related to the acquisition of non-controlling interest during
	the period. See note 5.10
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 180 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage181"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	TABLE
	OF CONTENTS
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.25IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE">
<A NAME="DP65110_20F_HTM_NOTES">
</A>
	NOTES TO THE CONSOLIDATED FINANCIAL
	STATEMENTS
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
	TABLE OF CONTENTS
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-11
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F1">
	1.&nbsp;&nbsp;&nbsp;Description of the group&rsquo;s business
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F2">
	2.&nbsp;&nbsp;&nbsp;Major events for the year
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-1">
	2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisitions
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-1-1">
	2.1.1.&nbsp;&nbsp;&nbsp;Acquisitions for the year 2015
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-1-2">
	2.1.2.&nbsp;&nbsp;&nbsp;Acquisitions for the year 2014
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-1-3">
	2.1.3.&nbsp;&nbsp;&nbsp;Acquisitions for the year 2013
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-2">
	2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other significant events
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-2-1">
	2.2.1.&nbsp;&nbsp;&nbsp;Other significant events of the year 2015
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-2-2">
	2.2.2.&nbsp;&nbsp;&nbsp;Other significant events of the years 2014 and 2013
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-16
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F2-3">
	2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Events after the reporting date
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-17
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F3">
	3.&nbsp;&nbsp;&nbsp;Significant accounting policies
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-18
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-1">
	3.1.&nbsp;&nbsp;&nbsp; Statement of Compliance
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-18
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-2">
	3.2.&nbsp;&nbsp;&nbsp; Basis of preparation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-18
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-3">
	3.3.&nbsp;&nbsp;&nbsp;&nbsp;IFRS standards
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-19
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-4">
	3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting date
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-21
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-5">
	3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scope and method of consolidation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-21
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-6">
	3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in scoping and method of consolidation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-21
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-7">
	3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-22
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-8">
	3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of judgements and estimates
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-22
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-9">
	3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-23
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-10">
	3.10&nbsp;&nbsp;&nbsp;Business combinations
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-23
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-11">
	3.11&nbsp;&nbsp;&nbsp;Other intangible assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-24
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-12">
	3.12&nbsp;&nbsp;&nbsp;Government subsidies
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-25
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-13">
	3.13&nbsp;&nbsp;&nbsp;Property, plant and equipment
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-25
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-14">
	3.14&nbsp;&nbsp;&nbsp;Impairment
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-26
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-15">
	3.15&nbsp;&nbsp;&nbsp;Other non-current financial assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-26
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-16">
	3.16&nbsp;&nbsp;&nbsp;Inventories
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-17">
	3.17&nbsp;&nbsp;&nbsp;Trade and other receivables
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-18">
	3.18&nbsp;&nbsp;&nbsp;Leases
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-19">
	3.19&nbsp;&nbsp;&nbsp;Cash and cash equivalents
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-20">
	3.20&nbsp;&nbsp;&nbsp;Derivatives
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-21">
	3.21&nbsp;&nbsp;&nbsp;Share-based payments
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-27
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-22">
	3.22&nbsp;&nbsp;&nbsp;Provisions
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-28
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-23">
	3.23&nbsp;&nbsp;&nbsp;Defined benefit retirement plans
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-28
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-24">
	3.24&nbsp;&nbsp;&nbsp;Sales
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-29
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-25">
	3.25&nbsp;&nbsp;&nbsp;Raw materials and other consumables used
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-29
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-26">
	3.26&nbsp;&nbsp;&nbsp;Research and development expenditure
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-29
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-27">
	3.27&nbsp;&nbsp;&nbsp;Operating Result
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-29
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-28">
	3.28&nbsp;&nbsp;&nbsp;Finance income and costs
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-30
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-29">
	3.29&nbsp;&nbsp;&nbsp;Income taxes
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-30
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-30">
	3.30&nbsp;&nbsp;&nbsp;Statement of cash flows
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-31
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F3-31">
	3.31&nbsp;&nbsp;&nbsp;Earnings per share
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-31
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F4">
	4.&nbsp;&nbsp;&nbsp;Notes to the consolidated statement of income
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-31
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-1">
	4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Operating segments and entity-wide disclosures
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-31
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-2">
	4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel costs
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-32
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-3">
	4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Share-based payments
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-33
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-3-1">
	4.3.1&nbsp;&nbsp;&nbsp;Restricted (free) share plans
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-33
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-3-2">
	4.3.2&nbsp;&nbsp;&nbsp;Options
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-34
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-3-3">
	4.3.3&nbsp;&nbsp;&nbsp;Warrants
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-35
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-4">
	4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other operating expenses
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-35
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 181 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<A NAME="eolPage182"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Advanced Accelerator Applications S.A.
</FONT>
</P>
<P STYLE="MARGIN: 0PT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT; WIDTH: 90%">
<A HREF="#DP65110_20F_HTM_F4-5">
	4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other operating income
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; WIDTH: 10%">
	F-36
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-6">
	4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Research and development expenditures
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-36
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-7">
	4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depreciation and amortization
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-36
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-8">
	4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Finance income and finance costs
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-36
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-9">
	4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Income taxes
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-37
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-9-1">
	4.9.1&nbsp;&nbsp;&nbsp;Income tax expense
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-37
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-9-2">
	4.9.2&nbsp;&nbsp;&nbsp;Explanation of effective tax expense
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-37
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F4-9-3">
	4.9.3&nbsp;&nbsp;&nbsp;Deferred tax assets and liabilities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-37
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F5">
	5.&nbsp;&nbsp;&nbsp;Notes to the consolidated statement of financial position
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-38
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-1">
	5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition of business
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-38
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-2">
	5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acquisition of business for the year 2014
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-38
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-3">
	5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Goodwill and Other intangible assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-40
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-4">
	5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Property, plant and equipment
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-44
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-5">
	5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-current financial assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-46
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-6">
	5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trade and other receivables
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-46
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-7">
	5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventories
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-46
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-8">
	5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other current assets
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-47
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-9">
	5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-47
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-10">
	5.10&nbsp;&nbsp;&nbsp; Equity
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-47
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-11">
	5.11&nbsp;&nbsp;&nbsp; Non-controlling interests
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-50
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-12">
	5.12&nbsp;&nbsp;&nbsp; Current and non-current provisions
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-51
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-13">
	5.13&nbsp;&nbsp;&nbsp; Current and non-current financial liabilities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-53
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-14">
	5.14&nbsp;&nbsp;&nbsp; Other current and non-current liabilities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-54
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F5-15">
	5.15&nbsp;&nbsp;&nbsp; Financial assets and liabilities
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-57
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F6">
	6&nbsp;&nbsp;&nbsp;RISK MANAGEMENT
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-59
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F6-1">
	6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Business risks
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-59
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F6-2">
	6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Legal risks
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-60
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT; PADDING-LEFT: 12PT">
<A HREF="#DP65110_20F_HTM_F6-3">
	6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Market risks
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 0IN; PADDING-BOTTOM: 0PT">
	F-60
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F7">
	7&nbsp;&nbsp;&nbsp;Consolidation scope
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-64
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT; PADDING-LEFT: 0IN">
<A HREF="#DP65110_20F_HTM_F8">
	8&nbsp;&nbsp;&nbsp;Related party disclosures
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-TOP: 6PT; PADDING-BOTTOM: 6PT">
	F-64
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 182 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage183"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; BACKGROUND-COLOR: #D9D9D9; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; BORDER: BLACK 1PT SOLID">
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Advanced Accelerator Applications
	S.A.
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Notes to the Consolidated
	Financial Statements
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	years ended December 31,
	2015, 2014 and 2013
</P>
<P STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&#9;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Advanced Accelerator Applications S.A. (&ldquo;AAA&rdquo;
	or the &ldquo;Company&rdquo;) is incorporated in France. Its registered office is at 20 rue Rudolf Diesel, 01630 Saint Genis Pouilly,
	France. The consolidated financial statements include those of the Company and its subsidiaries (&ldquo;the Group&rdquo;. Each
	company is referred to as a &ldquo;Group entity&rdquo;). The consolidated financial statements were authorized for issue by the
	Board of Directors on
<BR>
	April 27, 2016.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<A NAME="DP65110_20F_HTM_F1">
</A>
	1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Description of the group&rsquo;s business
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA is a radiopharmaceutical company founded
	in 2002 that develops, produces and commercializes molecular nuclear medicine (&ldquo;MNM&rdquo;) diagnostic and therapeutic products.
	MNM is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and
	to treat diseases such as cancer. The Company has a portfolio of six diagnostic positron emission tomography (&ldquo;PET&rdquo;)
	and single-photon emission computed tomography (&ldquo;SPECT&rdquo;) products. PET and SPECT are imaging techniques in molecular
	nuclear diagnostics (&ldquo;MND&rdquo;) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious
	diseases. AAA&rsquo;s leading diagnostic product is Gluscan, our branded 18-fluorodeoxyglucose (&ldquo;FDG&rdquo;) PET imaging
	agent. Gluscan assists in the diagnosis of serious medical conditions, primarily in oncology, by assessing glucose metabolism.
	AAA&rsquo;s primary development focus is on product candidates in the field of molecular nuclear therapy (&ldquo;MNT&rdquo;). AAA&rsquo;s
	lead therapeutic candidate, Lutathera, is a novel compound that it is currently developing for the treatment of Neuro Endocrine
	Tumors (&ldquo;NETs&rdquo;), a significant unmet medical need. Lutathera is a Lu-177 labeled somatostatin analogue peptide that
	has received orphan drug designation from the European Medicines Agency (&ldquo;EMA&rdquo;) and the US Food and Drug Administration
	(&ldquo;FDA&rdquo;). Lutathera was granted Fast-Track designation by the FDA for the treatment of inoperable progressive midgut
	NETs. It is also currently administered on a compassionate use and named patient basis for the treatment of NETs in ten European
	countries.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA is also building on its diagnostics
	foundation by developing additional MND product candidates to further strengthen our existing portfolio, which include key product
	candidates Somakit, the companion PET diagnostic candidate for Lutathera and Annexin V-128, a SPECT product candidate for the imaging
	of apoptotic and necrotic lesions with potential applications in a broad range of indications.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to its own portfolio of PET,
	SPECT and therapy products and product candidates, AAA manufactures several diagnostic products and product candidates for third
	parties, including GE Healthcare and Eli Lilly in Europe. AAA also manufactures and distributes IASOflu (bone metastases), IASOdopa
	(Parkinson&rsquo;s disease), and IASOcholine (prostate cancer) under license from IASON.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA manufactures a majority of its own products
	and product candidates, as well as those that it manufactures for third parties at the 16 production sites. To improve the efficiency
	of the supply chain for the U.S. market, AAA acquired a Milburn, NY facility, currently retrofitting to produce Lutathera. AAA
	has a direct sales and marketing presence in eight countries and generates sales in 19 countries.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<A NAME="DP65110_20F_HTM_F2">
</A>
	2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Major events for the year
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F2-1">
</A>
	2.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisitions
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.35IN">
<A NAME="DP65110_20F_HTM_F2-1-1">
</A>
	2.1.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisitions for the year 2015
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no acquisitions in 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 183 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage184"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.35IN">
<A NAME="DP65110_20F_HTM_F2-1-2">
</A>
	2.1.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisitions for the year 2014
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of Imaging Equipment Limited
	(IEL)
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On February 14, 2014, AAA entered into an
	agreement to acquire 100% of the shares of Imaging Equipment Ltd (IEL), a privately-owned distributor of nuclear medicine products,
	based in England.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to note 5.2 for details on
	the acquired entity.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of the Steripet business
	in Italy
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 15, 2014, AAA Italy acquired
	from GE Healthcare S.r.L. its FDG-PET business. This acquisition includes the SteriPET&reg; (FDG) Marketing Licence. The acquisition,
	consisting of certain assets, liabilities and legal relationships, primarily customer relationships, allows AAA Italy to strengthen
	its commercial operations and to become the leader in this business in Italy. The transaction consists of cash payments of up to
	&euro;697 thousand within 12 months of execution of the contract and of royalty payments on sales to former SteriPET&reg; customers
	of GE Healthcare Italy. The royalties will be due on sales between September 2015 and September 2017.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to note 5.2 for details on
	the acquired entity.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of non-controlling interest
	in AAA Germany GmbH
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 10, 2014, the Group acquired
	the remaining 49.9% non-controlling interest in AAA Germany GmbH (the former Umbra AG). As a result of this acquisition, AAA now
	owns 100% of AAA Germany GmbH. The consideration paid for this acquisition was &euro;1.2 million in cash.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to note 5.11 for detail of
	the impact of the operation on the equity attributable to the shareholders.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of non-controlling interest
	in Atreus Pharmaceuticals Corporation
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 18, 2014, the Group acquired
	the remaining 49.9% non-controlling interest in Atreus Pharmaceuticals Corporation (Atreus). As a result of this acquisition, AAA
	now has 100% ownership of Atreus. The complete ownership facilitates the Group&rsquo;s R&amp;D work and, if the Group is successful
	in obtaining marketing authorization for Annexin, would support a more effective exploitation of the commercial potential of the
	product.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consideration to be paid for this acquisition
	is composed of fixed anniversary and milestone payments prior to having obtained marketing authorization for Annexin and of a contingent
	consideration of a low single-digit percentage royalty on sales of Annexin for a period of 10 years from marketing authorization.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to note 5.11 for detail of
	the impact of the operation on the equity attributable to the shareholders.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Please refer to note 5.14 for the estimate
	of the contingent consideration to be paid.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.35IN">
<A NAME="DP65110_20F_HTM_F2-1-3">
</A>
	2.1.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisitions for the year 2013
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There were no acquisitions in 2013.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F2-2">
</A>
	2.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other significant events
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.35IN">
<A NAME="DP65110_20F_HTM_F2-2-1">
</A>
	2.2.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other significant events of the year 2015
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Financing
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In January 2015, AAA filed for a listing
	on NASDAQ and subsequently conducted an extensive roadshow in both Europe and the USA. As a result of market feedback regarding
	the valuation environment for Biotech IPO&rsquo;s from thought leading institutional investors, it was decided to not go ahead
	with the Initial Public Offering (IPO) at this time. The application with the Securities and Exchange Commission (SEC) was withdrawn
	on February 18, 2015. The costs incurred for legal, accounting and audit services have been expensed in the fourth quarter of 2014
	(refer to the annual consolidated financial statements for the year ended December 31, 2014).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 184 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage185"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In two separate capital increases in May
	and June 2015, three US-based investment funds acquired 3.789.770 newly issued AAA shares for a total amount of &euro;23.1 million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA completed an IPO of 4,688,000
	American Depositary Shares (&ldquo;ADS&rdquo;) representing 9,376,000 ordinary shares at a price of $16.00 per ADS (each ADS
	represents 2 ordinary shares). The ADS have been listed on the Nasdaq Global Select Market on and started trading on November
	11, 2015 under the ticker &ldquo;AAAP&rdquo;. The overallotment option (Greenshoe) of 15% was also used immediately by the
	Underwriters and an additional 1,406,400 shares or 703,200 ADS were issued at the same price of US$16.00 per ADS. The
	total number of shares issued after the IPO is therefore 78,556,211 (equals 39,278,105.5 ADS). Net proceeds is &euro;.73,796
	thousands.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Group structure
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The three Canadian entities AAA Canada Inc.,
	4549694 Canada Inc. and Atreus Pharmaceuticals Corporation merged into one single entity AAA Canada Inc.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA Iberica started the construction of
	the Murcia Site, Spain in February.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA USA&rsquo;s plans for a production site
	in Millburn, New Jersey, USA have been approved in April by the township&rsquo;s planning board and the purchase of the related
	building has been completed.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Lutathera development
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA finalized recruitment for NETTER-1,
	its pivotal Phase III trial for key drug candidate Lutathera.&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In April 2015, the FDA has granted Fast Track designation to Lutathera for the treatment of patients with inoperable, progressive,
	well-differentiated, Octreoscan-positive carcinoid tumors of the midgut.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In May 2015, the French National Agency
	for Medicines and Health Products Safety (ANSM) has granted an &quot;Autorisation Temporaire d'Utilisation de Cohorte&rdquo; (ATU
	de Cohorte) or Cohort Temporary Authorization for Use, for Lutathera for the treatment of midgut NETs.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In June 2015, AAA entered into a distribution
	agreement for Lutathera in Japan with Fujifilm RI Pharma.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA filed a New Drug Application (NDA) for
	Somakit with the FDA (Food and Drug Administration in the USA) on the first of July 2015. Somakit is Lutathera&rsquo;s companion
	diagnostic. The FDA approved the application for a substantive review on August 28, 2015 and granted Priority classification.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2015, the AAA substantially
	completed Lutathera phase III clinical trial and presented the results of the analysis on an Oral Presentation at the Presidential
	Session on September 27, 2015 at the ESMO conference. In addition, on the basis in part, of positive initial safety and efficacy
	results in earlier trials for both midgut NET&rsquo;s and pNET&rsquo;s, another subset of NET&rsquo;s arising in the gastro-entero-pancreatic
	tract, physicians treating NET patients have sought and have received authorizations to use Lutathera on a compassionate use and
	named patient basis in the European countries.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Other products development
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2015, AAA has deposited the request
	for the Marketing Authorization for Cardiogen in France.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA enrolled its first patient in a Phase
	I/II clinical trial for its key diagnostic candidate Annexin V-128 in rheumatoid arthritis and ankylosing spondylitis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA obtained two Marketing Authorizations
	in France for FCholine and FDopa on September 16, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Share based payment
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	352,500 free shares were issued to Managers
	of the Group on August 19, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In June 2015, the shareholders approved
	a warrant plan for the non-executive Board members (excluding the Chairman of the Board). This plan was implemented by the Board
	of Directors on August 19, 2015 and 225,000 warrants could be issued at a &euro;0.8 subscription price. This price is based on
	an independent expert report. In September 2015, the non-executive Board members have subscribed this plan and paid for the warrants.
	As a consequence, 225&nbsp;000 warrants were issued on September 28, 2015. Each warrant is exercisable from the date of issue until
	March 3, 2017 and may be exercised in exchange for one ordinary share at a price of &euro;6.10 per share within the 18 coming months.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 185 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage186"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An additional 235,000 free shares were issued
	on September 6, 2015 and another 167,500 new shares were issued on September 28, 2015 to Managers of the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 10, 2015. the day of the IPO
	pricing, the Board of Directors decided to grant 4 million stock options to AAA employees. It was authorized to do so by a shareholder
	resolution taken at June 29, 2015. The regular vesting period is 3 years and one option entitles to acquire one share. The exercise
	price of the option is US$8 which translates to US$16 per ADS. This is the first use of the stock option plan. A maximum of an
	additional 9 million options can be granted to AAA employees before the end of August 2018. Please refer to note 4.3.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.35IN">
<A NAME="DP65110_20F_HTM_F2-2-2">
</A>
	2.2.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other significant events of the years 2014 and 2013
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Financing
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	AAA completed a capital increase of &euro;41
	million in February 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Governance
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Dr. Kapil Dhingra, former head of Roche&rsquo;s
	oncology division, joined the AAA Board of Directors as an independent non-executive Director in April 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	A new Board of Directors was elected in the
	course of the annual shareholder meeting on June 27, 2014. Newly elected independent directors are Yvonne Greenstreet, Steven Gannon,
	Christian Merle and Leopoldo Zambeletti. The mandates of Claudio Costamagna (Chairman), Stefano Buono, Kapil Dhingra and Muriel
	de Szilbereky were renewed in this meeting. The mandates of Eugenio Aringhieri, G&eacute;rard Ber, Andrea Ruben Levi, Heinz M&auml;usli
	and Raffaele Petrone arrived at their expiration and were not renewed.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Product development
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	AAA received orphan drug designation from the FDA and the EMA in March 2014 for Gallium-68 DOTATATE. The Ga-68
	kit, also known as Somakit, helps diagnose NETs with PET imaging.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA signed an exclusive license agreement
	with Johns Hopkins University to develop PSMA receptor ligand in prostate cancer. This agreement enables AAA to broaden its pipeline
	with PSMA-SR6, which could be used to treat, image, monitor and stage prostate cancer utilizing a clinical development strategy
	similar to Lutathera and Somakit.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Operations
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	A capital increase of &euro;4.8 million was
	completed in April 2013. AAA strengthened its Board of Directors with the appointment of Muriel de Szilbereky as an independent
	non-executive Director in June 2013. Giorgio Chieregatti and William Cavendish both resigned from the Board during 2013.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The clinical Phase 3 trial for Lutathera is
	a multi-center, randomized, comparator-controlled, parallel-group study evaluating the efficacy and safety of Lutathera (using
	total cumulative administered radioactivity of 29.6 GBq) compared to Novartis&rsquo;s Sandostatin&reg; LAR 60mg for the treatment
	of midgut metastatic NETs. Lutathera is the first ever MNT product candidate to enter Phase 3 clinical trials for the treatment
	of midgut metastatic NETs. Lutathera was authorized for compassionate use in 2013, in Estonia and France. Lutathera is currently
	authorized to be administered on a compassionate use and/or named patient basis in nine European countries.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	AAA continued the expansion of its European
	MNM network with the creation of AAA Polska and the signing of an agreement with the University of Warsaw to operate its production
	site in 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Umbra Medical AG was renamed Advanced Accelerator
	Applications Germany GmbH in March 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	BioSynthema Inc. was renamed Advanced Accelerator
	Applications USA, Inc. and is now incorporated in Delaware. AAA also opened a new office in New York, NY in the United States in
	April 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Advanced Accelerator Applications International
	S.A. was created in May 2014 in Geneva, Switzerland.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	AAA completed the construction of its facility
	in Marseille, France. The Marseille site opened for commercial radiopharmaceutical production on May 12, 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The production sites in Warsaw, Poland, and
	in Bonn, Germany, each obtained GMP authorization in July 2014 and both started commercial operations on September 15, 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Advanced Accelerator Applications International
	S.A. and Advanced Accelerator Applications Switzerland S.A. opened their new office in Geneva in October 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 186 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage187"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F2-3">
</A>
	2.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Events after the reporting date
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Group structure
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA acquired 100% shares in IDB Group incorporated
	in The Netherlands in January 2016. This transaction contributes to AAA&rsquo;s international expansion and expands AAA&rsquo;s
	global supply chain in preparation for the commercial launch of Lutathera.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On January 6, 2016, AAA acquired 100% shares
	in IDB Group cs. (hereafter IDB Group) incorporated in Netherlands.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IDB Group is a group of six entities incorporated
	in Netherlands and one entity located in Belgium, active in the development, production and wholesale of medical products and more
	specifically radiopharmaceutical products and medical and industrial radioactive substances.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Acquiring the IDB Group will enable AAA
	to own one of its two providers of Lu-177 for Lutathera and build its own Lu-177 manufacturing business. This acquisition strengthens
	AAA&rsquo;s leadership position in European MNM and is in-line with the Company&rsquo;s vertical integration strategy. Owning the
	IDB Group will help AAA maintain a reliable supply of Lu-177 for the production of Lutathera and AAA&rsquo;s future product candidates.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 65%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: JUSTIFY">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Recognized amounts of identifiable assets acquired and liabilities assumed (in thousands)
</B>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&euro;
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 85%; TEXT-ALIGN: LEFT">
	Intangible assets
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	14,292
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,406
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Inventory
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	490
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	905
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	340
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash and cash equivalent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(449
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total net assets acquired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17,495
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Goodwill
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,839
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total consideration
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	28,334
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Satisfied by:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;&nbsp;&nbsp;Cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,720
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Contingent consideration arrangement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,614
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total consideration transferred
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	28,334
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net cash outflow arising on acquisition
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;&nbsp;&nbsp;Cash consideration*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,720
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Less: cash and cash equivalents acquired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,461
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,259
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
<BR CLEAR="ALL">
<FONT STYLE="FONT-SIZE: 8PT">
	* of which &euro; 0.3 million is expected to be paid at the end of April 2016
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Intangible assets acquired consist of customer
	relationships valued at &euro; 6 million and trademarks and licenses valued at &euro; 8.3 million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the contingent consideration arrangement,
	AAA is obligated to pay the sellers an additional earn-out. A first payment of &euro; 1.7 million was paid at the
	end of April 2016. On the basis of the 2016 business plan for IDB AAA considers it likely that the remaining earn-out payment will
	amount to &euro;3 million. This represents an estimated fair value of &euro;2.9 million at the acquisition date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have accounted for Goodwill in the acquisition
	of the IDB Group because the consideration paid included expectations regarding future revenue growth, ease of market development
	and increased control of distribution channels. These benefits are not recognized separately from Goodwill because they do not
	meet the recognition criteria for identifiable intangible assets. Goodwill resulting from this acquisition is not expected to be
	deductible for tax purposes.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 187 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage188"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the acquisition had occurred on January
	1, 2015, management estimates that consolidated revenues would have been &euro; 95.9 million, and consolidated net loss for the
	year would have been &euro; 17.4 million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In determining these amounts, management
	have assumed that the fair value adjustments, determined provisionally, that arose on the acquisition date would have been the
	same if the acquisition had occurred on January 1, 2015. The increase of the consolidated net loss of the year is due to the additional
	depreciation and amortization on the fair value assessment of newly identified assets.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our initial accounting for this acquisition
	may be revised within one year following the acquisition date should new information on facts and circumstances that existed at
	the date of acquisition suggest doing so.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Lutathera and Somakit development
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In January 2016 AAA entered into a non-exclusive
	agreement with Zevacor for the preparation and delivery of SomaKit-TATE in the US.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additional Lutathera NETTER-1 Phase III
	data was presented both on January 22, 2016 at the 2016 Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, California
	and on March 11, 2016 at the 13th Annual European Neuroendocrine Tumor Society (ENETS) conference in Barcelona, Spain.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The FDA extended the Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the NDA for
	Somakit-TATE, AAA&rsquo;s investigational kit for neuroendocrine tumor diagnosis and follow-up. The PDUFA date has been extended
	to June 1, 2016.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2016 AAA opened an expanded access
	program (EAP) in the U.S. for Lutathera. Through the program, Lutathera is being made available for eligible patients suffering
	from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In March 2016 AAA announced its NDA filing
	plan for Lutathera, following the pre-NDA meeting held on March 14, 2016. AAA announced it would be filing a rolling submission
	with the FDA, given that this is possible under the Fast-Track program granted for Lutathera. All parts of the Lutathera NDA are
	to be filed by end of March except for the ISS and ISE (Integrated Summaries of Safety and Efficacy Databases), which will be submitted
	within thirty days after the bulk of the submission. The ISS and ISE databases required an additional amount of time because they
	merge Phase 3 Data from the NETTER-1 study with the Phase 2 data from an investigator sponsored single arm clinical study conducted
	at the Erasmus Clinical Center in Rotterdam, The Netherlands, between January 2000 and December 2012. This study enrolled a total
	of 1214 patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors, and the results
	of this study are to serve as a basis for assessing the efficacy and safety of Lutathera in all inoperable, metastatic NETs over-expressing
	somatostatin receptors. The review clock for the NDA will not begin until AAA informs the FDA that a complete NDA has been submitted,
	including the ISS and ISE. The rolling submission will, however, allow the FDA to immediately start the review of the most relevant
	parts of the application, including the separate Clinical Reports of both NETTER-1 and the Phase 2 study. Given the fact that rolling
	submissions are not permitted at the EMA, a complete submission to the EMA will be completed by the
	end of April.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<A NAME="DP65110_20F_HTM_F3">
</A>
	3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Significant accounting policies
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F3-1">
</A>
	3.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Statement of Compliance
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidated financial statements have
	been prepared in accordance with International Financial Reporting Standards (&ldquo;IFRS&rdquo;) as issued by the International
	Accounting Standard Board (&ldquo;IASB&rdquo;).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F3-2">
</A>
	3.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basis of preparation
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidated financial statements for
	the year ended December 31, 2015 are presented in Euro, the functional currency of the Company, rounded to the nearest thousand
	unless otherwise stated.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidated statement of income is
	presented on the basis of a classification of income and expenses by nature.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidated statement of cash flows
	has been prepared according to the indirect method.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 188 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage189"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 21.3PT">
</TD>
<TD STYLE="WIDTH: 21.6PT">
<A NAME="DP65110_20F_HTM_F3-3">
</A>
	3.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	IFRS standards
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	New currently effective requirements
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The 2015 financial statements comprise all
	information required under IFRS.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accounting policies are consistent with
	those of the annual financial statements for the year ended December 31, 2014, as described in the consolidated financial statements
	for the year ended December 31, 2014, with the exception of the adoption as of January 1, 2015 of the standards and interpretations
	described below:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Amendments to IAS 19&nbsp;: Defined Benefit Plans&nbsp;: contributions;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Annual Improvements to IFRSs 2010-2012 Cycle and Annual improvements to IFRSs 2011-2013 Cycle;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The adoption of the above standards did
	not result in any significant impact in these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The nature and effects of the changes are
	explained below.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	(a) Amendments to IAS 19: Defined Benefit
	Plans, Employee Contributions
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The amendments to IAS 19 clarify the accounting
	treatment for contributions from employees or third parties to a defined benefit plan.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The application of the amendments did not
	have material impact on the 2015 financial statements.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	(b) Amendments to IFRS 2, IFRS 3, IFRS 8,
	IFRS 13, IAS 16, IAS 24 and IAS 38 issued in the Annual improvements to IFRSs 2010-2012 Cycle and Amendments to IFRS 1, IFRS 3,
	IFRS 13 and IAS 40 issued in the Annual improvements to IFRSs 2011-2013 Cycle
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The annual improvements include amendments
	to a number of IFRSs. The application of these amendments has had no material impact on the disclosures or on the amounts recognized
	in the 2015 financial statements.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Forthcoming requirements
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group has not applied the following
	new and revised IFRSs that have been issued but are not yet effective.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	IFRS 9
</FONT>
</TD>
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Financial Instruments (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	IFRS 15
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Revenue from contract with customers (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	IFRS 14
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Regulatory Deferral Accounts (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Annual Improvements to IFRSs:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Annual Improvements to IFRSs: 2012-2014 Cycle (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 189 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage190"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Amendments to IAS 1
</FONT>
</TD>
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Disclosure Initiative (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Amendments to IFRS 10 and IAS 28
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Amendments to IAS 16 and IAS 38
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Clarification of Acceptable Methods of Depreciation and Amortisation (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Amendments to IFRS 11
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Accounting for Acquisitions of Interests in Joint Operations (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Effective for annual period beginning on or after 1 January 2016, with earlier application permitted.
	The Company does not anticipate that the application of these amendments will have a material impact on its financial statements
	in 2016
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Effective for annual period beginning on or after 1 January 2018, with earlier application permitted.
	These standards are further detailed below
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Effective date of this amendment has been postponed indefinitively
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 9, published in July 2014, replaces
	the existing guidance in IAS 39
<I>
	Financial Instruments: Recognition and Measurement
</I>
	. IFRS 9 includes revised guidance on
	the classification and measurement of financial instruments, a new expected credit loss model for calculating impairment on financial
	assets, and new general hedge accounting requirements. It also carries forward the guidance and recognition and derecognition of
	financial instruments from IAS 39.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 9 is effective for annual reporting
	periods beginning on or after 1 January 2018, with early adoption permitted.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 15 provides a single, principles based
	five-step model to be applied to all contracts with customers.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The five steps in the model are:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Step 1: Identify the contract with the
	customer;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Step 2: Identify the performance obligations
	in the contract;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Step 3: Determine the transaction price;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Step 4: Allocate the transaction price
	to the performance obligations in the contracts;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Step 5: Recognize revenue when (or as)
	the entity satisfies a performance obligation.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under IFRS 15, an entity recognizes revenue
	when (or as) a performance obligation is satisfied.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 15 will supersede the current revenue
	recognition guidance including IAS 18 Revenue, IAS 11 Construction Contracts and the related Interpretations when it becomes effective.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Guidance is provided on topics such as the
	point in which revenue is recognized, accounting for variable consideration, costs of fulfilling and obtaining a contract and various
	related matters. New disclosures about revenue are also introduced.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IFRS 15 will become effective for annual
	periods beginning on or after January 1, 2018 with early adoption permitted.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The potential impact of the application
	of these standards is currently under review by the Group. Most of the Group&rsquo;s revenue is derived from the sales of diagnostic
	products. For such products, the transfer of ownership occurs when the batch is delivered to the customer, which is also the date
	on which the sales revenue is recognized in the statement of income. The application of IFRS 15 is not expected to have any significant
	impact on the revenue recognition for these products.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 190 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage191"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-4">
</A>
	3.4
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Reporting date
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The reporting date for all Group companies
	is December 31.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-5">
</A>
	3.5
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Scope and method of consolidation
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group financial statements include the
	financial statements of Advanced Accelerator Applications SA and those of the entities over which it exercises control (its subsidiaries).
	The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and
	has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on
	which control is obtained to the date when control ceases. The financial statements of subsidiaries are prepared for the same period
	as that of the Group&rsquo;s financial statements using consistent accounting policies. All assets and liabilities, unrealized
	gains and losses, income and expenses, dividends, and other transactions arising from intra-group transactions are eliminated when
	preparing the Group&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	A change in the ownership interest
	of a subsidiary, without loss of control, is accounted for as an equity transaction. &#9;The carrying amounts of the Group&rsquo;s
	interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries.
	Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid
	or received is recognized directly in equity and attributed to the owners of the Company.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the event that the Group loses
	control of a subsidiary, the Group:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Derecognizes the assets (including goodwill)
	and liabilities of the subsidiary;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Derecognizes the carrying amount of any
	non-controlling interests;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Recognizes the fair value of any interest
	retained;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Recognizes any gain or loss in the statement
	of income;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidation scope is presented
	in note 7.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-6">
</A>
	3.6
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Changes in scoping and method of consolidation
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The scoping and method of consolidation
	are consistent with previous periods.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 191 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage192"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-7">
</A>
	3.7
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Foreign currency translation
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In preparing the financial statements of
	the Group, the financial statements of subsidiaries, which report in a currency other than the Euro, the translation to Euros is
	done as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Assets and liabilities, including goodwill
	and fair value adjustments arising on a business combination, are translated into Euros at the foreign exchange rates at the reporting
	date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Income statement items are translated into
	Euros at the exchange rate, which represents the average exchange rate for the period.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	All resulting translation differences are
	recognized directly in other comprehensive income.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The table below shows the exchange rates used
	by the Group:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;&nbsp;2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	USD&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	CAD&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	ILS&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	CHF&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	GBP&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Closing Rate
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	0.9185
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	0.6616
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	0.2354
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	0.9229
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	1.3625
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Average Rate
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.9016
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.7059
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.2320
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.9369
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1.3782
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2014
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	USD
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	CAD
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	ILS
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	CHF
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	GBP
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Closing Rate
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.8227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.7076
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.2107
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.8315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.2780
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Average Rate
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.7535
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.6821
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.2106
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.8232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1.2449
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	2013
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	USD
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	CAD
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	ILS
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	CHF
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	GBP
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Closing Rate
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.7251
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.6816
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.2089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.8146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Average Rate
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.7529
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.7308
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.2085
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.8124
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Transactions in foreign currencies are translated
	to the respective functional currencies of the Group entities at exchange rates at the dates of the transactions. Monetary assets
	and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency using the exchange
	rate of that date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Exchange differences on monetary assets
	and liabilities denominated in foreign currencies are recognized in operating income or financial result according to the nature
	of the underlying transaction.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Non-monetary items denominated in foreign
	currencies that are measured at historical cost are translated using the exchange rate at the date of the transaction.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Non-monetary items denominated in foreign
	currencies that are measured at fair value are translated using the exchange rate at the date when the fair value was determined.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-8">
</A>
	3.8
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Use of judgements and estimates
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The preparation of financial statements
	in conformity with IFRS requires making judgements, estimates and assumptions, which affect amounts reported in the financial statements.
	These estimates may be revised if circumstances require so or if new information is available. The actual results may differ from
	the initial estimates.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Significant estimates, judgments and assumptions
	made on the basis of information available at the reporting date mainly concern:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	The measurement and impairment of goodwill,
	intangible assets acquired or generated as part of a business combination, and their estimated useful life;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the measurement of contingent consideration
	(&ldquo;earn outs&rdquo;) agreed during a business combination;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the measurement of decommissioning provisions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 192 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage193"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-9">
</A>
	3.9
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A number of accounting policies and disclosures
	require the determination of fair value for both financial and non-financial assets and liabilities. Fair values have been determined
	for measurement or disclosure purposes based on the following methods (additional information on the assumptions used to determine
	fair values are given, if applicable, in the notes specific to the asset or liability):
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Intangible assets: Intangible assets that
	are typically acquired by the Group in a business combination are in process Research and Development (R&amp;D) projects and/or
	customer relationships. The fair value of these assets is calculated using the excess profits method. This method is based on discounting
	excess profits generated by these assets over their estimated useful lives. Excess profits are determined from the operating margin
	attributable to customer relationships or estimated sales of products resulting from ongoing projects, less a capital charge for
	the assets necessary for their operation.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Loans and receivables are measured at amortized
	cost. Due to their short-term nature, the carrying amount of trade receivables and other receivables and of cash approximates fair
	value.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Non-derivative financial liabilities are
	measured at amortized cost. Due to their short-term nature, the carrying value of bank overdrafts and advances, trade payables
	and other payables approximates fair value.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	The fair value of borrowings and financial
	liabilities other than contingent consideration agreed during a business combination is based on the fair value of future cash
	flows generated by the principal and interest repayments, discounted at market interest rates at the reporting date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Contingent consideration agreed during
	a business combination is measured at fair value under the terms of the contract. It is generally based on the present value of
	cash flows as defined in the contract, with a weighting for the probability of occurrence of the factors governing their payment.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Decommissioning provisions are measured
	on the basis of estimated future decommissioning costs discounted to the reporting date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-10">
</A>
	3.10&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Business combinations
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	IFRS 3 revised (2009)
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In compliance with IFRS 3 revised, the consideration
	transferred in a business combination (i.e. the acquisition cost) is measured at the fair value of the assets transferred, equity
	instruments issued and liabilities assumed at the transfer date. The identifiable assets and liabilities of the acquiree are generally
	measured at their fair values at the acquisition date. Transaction costs directly attributable to the acquisition are recognized
	in &ldquo;Other operating expenses.&rdquo;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Goodwill represents the fair value of the
	consideration transferred (including the fair value of any interest previously held in the acquiree) plus the carrying amount of
	any non-controlling interest, less the amount recognized (in general at fair value) of the identifiable assets acquired and liabilities
	assumed. For each business combination, at the date when control is acquired, the Group may elect to measure any non-controlling
	interest in the acquiree either at its proportionate share of the acquiree&rsquo;s identifiable net assets or using the &ldquo;full
	goodwill method.&rdquo; Under the latter method, the non-controlling interests are measured at fair value and goodwill is recognized
	on the full amount of the identifiable assets and liabilities.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the case of a business combination achieved
	in stages, the equity interest previously held by the Group is remeasured at its fair value at the acquisition date. Any resulting
	gain or loss is recognized directly in profit or loss (&ldquo;Other finance income&rdquo; or &ldquo;Other finance costs&rdquo;)
	and related items of other comprehensive income will be reclassified to profit or loss.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The amounts recognized at the acquisition
	date may be adjusted retrospectively if new information is obtained about facts and circumstances that existed as of the acquisition
	date. Goodwill may not be adjusted after the measurement period. The measurement period is of a maximum length of twelve months
	from the acquisition date. The subsequent acquisition of non-controlling interests does not give rise to the recognition of additional
	goodwill. See below.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 193 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage194"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any contingent consideration is included
	in the acquisition cost at fair value at the acquisition date irrespective of the probability of its ultimate occurrence. Subsequent
	changes in the fair value of contingent consideration due to facts and circumstances that existed as of the acquisition date are
	recorded by adjusting goodwill if they occur during the measurement period or directly in the income statement (&ldquo;Financial
	result&rdquo;) if they arise subsequently, unless the obligation is settled in equity instruments.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any excess of the fair value of the acquiree&rsquo;s
	identifiable net assets over the fair value of the consideration transferred plus the amount of any non-controlling interest in
	the acquiree (&ldquo;gain on bargain purchase&rdquo;) is recognized immediately in the income statement.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The valuation techniques used for measuring
	the fair value of material assets acquired is as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 26%; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
<B>
	Assets acquired
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 74%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
<B>
	Valuation technique
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: WHITE">
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Property,
<BR>
	plant and
<BR>
	equipment
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Given the nature of the assets acquired, the valuation model considers mainly the depreciated replacement cost.&nbsp;&nbsp;Depreciated replacement cost reflects adjustments for physical deterioration as well as functional and economic obsolescence.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; BACKGROUND-COLOR: WHITE">
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Intangible
<BR>
	assets
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Multi-period excess earnings method: The multi-period excess earnings method considers the present value of net cash flows expected to be generated by the intangible asset recognized, by excluding any cash flows related to contributory assets.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Goodwill
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The goodwill of consolidated companies is
	recognized as an asset under the heading &ldquo;Goodwill.&rdquo; In conformity with IFRS 3 revised - Business combinations, goodwill
	is not amortized but is subject to an impairment test done at least once a year. For the purpose of impairment testing, goodwill
	is allocated to one or more of the Group&rsquo;s Cash-Generating Units (CGUs) or groups of CGUs that are expected to benefit from
	the synergies of the business combination. In the Group, each country generally represents a CGU. More details on impairment testing
	of CGUs and its accounting are disclosed in note 3.14.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	When the recoverable value of a CGU is less
	than its carrying amount, the corresponding impairment loss is first allocated to goodwill and recognized in net operating income
	as &ldquo;Depreciation and amortization&rdquo; (see note 4.7).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-11">
</A>
	3.11.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other intangible assets
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Internally-generated intangible assets &ndash;
	Research &amp; development expenditure
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditure on research activities is expensed
	as incurred.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditure on development activities is
	capitalized as an internally-generated intangible asset resulting from a development project if, and only if, all of the following
	criteria exist:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Technical feasibility to complete the development
	project;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	intention of the Group to complete the
	project and to use or sell it;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	ability of the Group to use the intangible
	asset;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	probability that the intangible asset is
	likely to generate future economic benefits;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	availability of adequate technical, financial
	and other resources to complete the development project;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the ability to measure reliably the expenditures
	allocated to the development project.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A development project is initially recognized
	corresponding to the sum of all expenditure incurred after the date on which the development project met all of the above criteria.
	When all of the above criteria are not met, development expenditure is expensed as incurred. The Group has determined that the
	criteria for capitalization are considered not to have been met until a regulatory filing has been made in a major market and approval
	is considered highly probable.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 194 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage195"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Capitalized development expenditure comprises
	all directly attributable costs necessary to create, manufacture, and prepare the asset for use as intended by management.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Subsequent to initial recognition, capitalized
	development expenditure is measured at cost less accumulated amortization and impairment losses, similarly to an intangible asset
	acquired separately.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The amortization of capitalized development
	assets commences when the asset is available for use, which is generally the date on which it receives regulatory market approval.
	Capitalized development assets are amortized on a straight-line basis over their estimated useful lives.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Other intangible assets
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other intangible assets are recognized at
	cost or at fair value at the date of acquisition of control for those acquired through business combinations, less accumulated
	amortization and impairment losses, if any. Amortization is calculated on the straight-line basis over the useful lives of the
	assets. The useful lives and amortization methods are reviewed at each reporting date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The principal useful lives are shown below:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Patent / License: Over the term of the
	contract (10 years for the main license);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Customer relationship: 5 to 10 years.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Significant changes in the useful life of
	an asset are accounted for on a prospective basis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An impairment loss is recognized when the
	carrying amount of the asset exceeds its recoverable amount. Any impairment losses on intangible assets are presented under &ldquo;Depreciation
	and amortization&rdquo; in the consolidated statement of income (see note 4.7).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-12">
</A>
	3.12.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Government subsidies
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Government grants are recognized in income
	statement on a systematic basis when the entity recognizes as expenses the related costs that the grants are intended to compensate.
	Government grants mainly related to R&amp;D projects. When deferred, government subsidies are presented in &ldquo;Other liabilities&rdquo;
	in the consolidated statement of financial position.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-13">
</A>
	3.13.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Property, plant and equipment
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Property, plant and equipment is recognized
	in the consolidated statement of financial position at acquisition cost, comprising purchase price and any costs directly attributable
	in bringing the asset to the location and working condition for its use as intended by management.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Depreciation is calculated on a straight-line
	basis over the useful lives of the assets.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The principal useful lives are shown below:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Buildings (offices and laboratories): 20
	years;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Laboratory equipment: 5 - 10 years;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Cyclotrons: 10 years;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	IT equipment: 3 - 5 years;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 17.85PT">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Office equipment: 5 years.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Items of property, plant and equipment are
	depreciated from the date on which they are ready for use.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The useful lives, residual values and depreciation
	methods are reviewed at each reporting date and adjusted if appropriate on a prospective basis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In accordance with IAS 16
<I>
	Property, plant
	and equipment
</I>
	, components of an item of property, plant and equipment with a different useful life or producing economic benefits
	for the enterprise at a different rhythm are accounted for as separate items.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 195 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage196"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In compliance with IAS 23
<I>
	Borrowing costs,
</I>
	interest expenses directly attributable to the acquisition of items of property, plant and equipment are capitalized.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any impairment losses on property, plant
	and equipment are presented under &ldquo;Depreciation, amortization and provisions&rdquo; in the consolidated statement of income
	(see note 4.7).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-14">
</A>
	3.14.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impairment
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Goodwill and intangible assets not yet
	available for use
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In accordance with IAS 36
<I>
	Impairment
	of assets
</I>
	, the carrying amount of goodwill and intangible assets not subject to amortization are tested at least once a year
	or whenever events or changes in the internal or external environment indicate a risk of loss of value. For the purposes of this
	test, the carrying amounts &#8203;&#8203;of assets are allocated to Cash-Generating Units (CGU) or groups of CGUs.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under IAS 36, an impairment loss is recognized
	when the carrying amount exceeds the recoverable amount. The recoverable amount of an asset or CGU is the higher of fair value
	less costs to sell and value in use.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fair value is the price that would be received
	to sell an asset or the price paid to transfer a liability in an orderly transaction between market participants at the measurement
	date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Value in use is the present value of estimated
	future cash flows expected to be derived from the continuing use of the asset or CGU. It is determined from the estimated cash
	flows based on budgets and business plans over periods ranging from 5 to 10 years. Subsequent cash flows are estimated by applying
	a constant rate of positive or negative growth. The discount rate reflects current market conditions, the time value of money and
	the specific risks associated with the asset (or CGU). The Group calculates the value in use by applying a post-tax discount rate
	to discount the post-tax cash-flows. The value in use calculated by discounting pre-tax cash flows and applying a pre-tax discount
	rate would not be materially different.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Property, plant and equipment and intangible
	assets subject to amortization
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	When new events or circumstances indicate
	that the carrying amount of an item of property, plant and equipment or of an intangible asset may not be recoverable, this amount,
	or the amount of the Cash Generating Unit (CGU) the asset belongs to, is compared to its recoverable amount, which is the higher
	of its value in use or its fair value less cost of disposal. If the recoverable amount of the asset (or CGU) is less than its carrying
	amount, this latter is reduced to the recoverable amount and the impairment charge is recognized in &ldquo;Depreciation, amortization
	and provisions.&rdquo; The revised carrying value of the asset (or CGU) is subsequently depreciated or amortized on a prospective
	basis over the new residual useful life of the asset.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Reversal of Impairment losses
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Impairment losses assessed on goodwill may
	not be reversed.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	With respect to other assets, an impairment
	loss is reversed if there has been a change in the estimates used to determine the recoverable amount.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An impairment loss is reversed only to the
	extent that the asset&rsquo;s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation
	or amortization, if no impairment loss had been recognized.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-15">
</A>
	3.15.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other non-current financial assets
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Non-current financial assets principally
	include shareholdings in non consolidated entities and other investments, guarantee deposits made in the normal course of business
	and loans.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Shareholdings in non consolidated entities
	and other investments are classified as available-for-sale financial assets and initially measured at fair value.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These shareholdings are subsequently remeasured
	at fair value or at acquisition cost when no reliable fair value measurement is possible, under the terms of IAS 32 and IAS 39
	in respect to financial instruments.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Changes in fair value are recognized in
	other comprehensive income and reclassified through the income statement on disposal of the related asset or when the decline in
	its fair value below its cost is significant or prolonged.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 196 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage197"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-16">
</A>
	3.16.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Inventories
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In accordance with IAS 2
<I>
	Inventories
</I>
	,
	inventories are measured at the lower of cost or net realizable value. Raw materials and supplies are measured at acquisition cost
	using the First In First Out (FIFO) method, including transport costs and after deducting supplier discounts and rebates. Net realizable
	value is the estimated sale price at the reporting date, less the estimated costs of completion and selling expenses, and after
	taking account of technical or commercial obsolescence and risks from low inventory turn.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-17">
</A>
	3.17.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Trade and other receivables
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Trade and other receivables are measured
	at fair value on initial recognition, and subsequently at amortized cost using the effective interest rate method, less impairment
	losses. Provisions for impairment of trade receivables are determined on the basis of the age of the receivables and identified
	risks of recovery.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-18">
</A>
	3.18.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Leases
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Leases are classified as finance leases
	when the terms of the lease contract transfer substantially all the risks and rewards of ownership to the lessee. All other leases
	are classified as operating leases.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An asset held under a finance lease contract
	is recognized at fair value with a corresponding liability in the consolidated statement of financial position at the inception
	of the lease contract or, if lower, at the present value of the minimum lease payments under the contract. The asset is subsequently
	depreciated over its expected useful life.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Construction in progress financed using
	a finance lease is classified as property, plant and equipment in progress. The corresponding financial liability is recognized
	as a liability once the building is available for use.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-19">
</A>
	3.19.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents in the consolidated
	statement of financial position includes bank balances and short-term liquid investments with an initial maturity of less than
	three months and virtually no risk of change in fair value.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-20">
</A>
	3.20.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Derivatives
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group uses derivative financial instruments
	to hedge its exposure to foreign exchange risks arising from operational, financing and investment activities.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Derivative financial instruments are initially
	recognised at fair value at the date the derivative contract are entered into and are subsequently re-measured at fair value at
	each reporting date. The gains and losses resulting from the fair value re-measurement are recognised in profit or loss.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-21">
</A>
	3.21.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share-based payments
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group has implemented restricted (free)
	share plans and stock option plans for designated categories of employees.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These plans represent equity-settled share-based
	payments and are measured at fair value on the grant date under IFRS 2. The cumulative expense recognized is based on the fair
	value at the grant date. It is recognized over the vesting period in net operating income directly through equity.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 197 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage198"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-22">
</A>
	3.22.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Provisions
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In accordance with IAS 37, a provision is
	recognized when the Group has a present legal or constructive obligation as a result of a past event, when it is probable that
	an outflow of resources embodying economic benefits will be required to settle the obligation and when a reliable estimate of the
	amount of the obligation can be made. The part of a provision that becomes due in less than one year is recorded as a current liability,
	the remainder as non-current. The Group measures provisions for present obligations using facts and circumstances available at
	the reporting date, on the basis of its experience and best knowledge when the financial statements are approved for issue.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Where the effect of the time value of money
	is material, the amount of the provision is the present value of the future cash flows expected to be required to settle the obligation,
	using a discount rate that reflects current market rates and any specific risks of the obligation.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Provision for the decommissioning of
	PET production sites
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The manufacture of certain products in the
	field of molecular nuclear medicine generates radiation and causes the contamination of parts of the production site (in particular
	the cyclotron). AAA Group entities producing PET products have a legal obligation to dismantle and decontaminate their site and
	production equipment at the end of their useful lives. The provision is initially recognized through an additional cost of the
	related asset which is then amortized over its useful life. The provision is updated at each reporting date. Unwinding of the discounting
	of the provision is recognized as a finance cost and any changes in the estimated ultimate costs of decommissioning are recognized
	within the cost of the related asset.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-23">
</A>
	3.23.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Defined benefit retirement plans
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In accordance with IAS 19
<I>
	Employee benefits,
</I>
	with regard to defined benefit plans, post-employment and other long-term benefits are subject to annual actuarial measurement,
	using the projected credit unit method. Under this method, each period of service gives rise to an additional unit of benefit entitlement,
	each of which is measured separately to obtain the final obligation. This final obligation is then discounted to present value.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These calculations include essentially:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	An assumption regarding the date of payment
	of the benefits;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	a discount rate specific to the currency
	of the country where the post-employment benefit obligations arise;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	a rate of inflation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	assumptions covering the estimated rates
	of future salary increases, employee turnover and mortality.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The main actuarial assumptions chosen at
	December 31, 2015 are described in note 5.12.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Positive or negative actuarial differences
	include the effects on the obligation of changes in the underlying assumptions and experience adjustments. In conformity with IAS
	19 revised
<I>
	Employee Benefits
</I>
	, the Group recognizes these actuarial gains and losses directly in other comprehensive income,
	classified as remeasurement of defined benefit obligations.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The liability presented in the consolidated
	statement of financial position represents the total obligation at the reporting date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 198 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage199"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-24">
</A>
	3.24.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Sales
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Sales are recognized when the following
	conditions are satisfied:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	There is an agreement between the parties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the goods have been delivered or the services
	rendered (i.e. the transfer of risks and benefits of ownership has taken place);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the price is fixed or can be reliably measured;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	it is probable that future economic benefits
	from the transaction will flow to the Group as required under IAS 18.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Rebates and discounts granted to customers
	are deducted from the corresponding sales revenues.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Certain products and product candidates
	sold by AAA have a very short shelf life. In particular, the shelf life of F18 PET products and product candidates does not exceed
	10 hours. As a result, these products and product candidates are manufactured in batch processes overnight and delivered to customers,
	generally located close to the production site, in the morning. The transfer of ownership occurs when the batch is delivered to
	the customer, which is also the date on which the sales revenue is recognized in the statement of income.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group entered into an agreement for
	the production of AV-45 with the Eli Lilly group in 2013.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For each site where AV-45 is produced, AAA
	is committed under the agreement to purchase the specialized production equipment (from Eli Lilly for certain designated sites
	or from a third party supplier for other sites) and to manage its installation and commissioning. The cost of all associated equipment
	and expenses are charged back under the contract to Eli Lilly when the site is commissioned. The related revenue recognition is
	spread over the term of the contract under IFRIC18 as the Group considers that it represents a transfer of assets from a customer
	and that the related revenue transfer is an integral part of the AV-45 supply agreement.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The agreement also defines the sale and
	invoicing of trial batches as well as the sale and invoicing of doses during the distribution phase. These latter sales are recognized
	on product delivery similarly to other products manufactured and sold by the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-25">
</A>
	3.25.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Raw materials and other consumables used
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This line item includes raw materials consumed,
	transport, sales royalties and licensing fees, and purchases of pharmaceutical products.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-26">
</A>
	3.26.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and development expenditure
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditure incurred during research is
	expensed as incurred (see note 4.6).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Expenditure incurred during development
	is capitalized as intangible assets under the conditions described in note 3.11.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-27">
</A>
	3.27.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Operating Result
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Net operating income consists of sales less
	the cost of raw materials and other consumables used and other operating expenses. Operating expenses mainly include personnel
	costs, other operating income and expenses, depreciation and amortization expense and impairment charges.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Net operating income includes the impact
	of:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	gains and losses on disposal of non-current
	assets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	impairment of goodwill;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	transaction costs incurred in connection
	with business combinations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	litigation or non-recurring events.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 199 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage200"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-28">
</A>
	3.28.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Finance income and costs
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Finance costs consist of:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	interest expenses (gross finance cost,
	which includes financial expenses, issuance costs and foreign exchange losses on financial liabilities) on Group financial debt
	consisting of loans and other financial liabilities (in particular overdrafts and finance lease liabilities);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	unwinding of the discounting of provisions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	impact on loss from shareholdings in non-consolidated
	investments (impairment, loss on disposal);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the loss in the fair value of liabilities
	to former owners of subsidiaries (contingent consideration);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	exchange rate losses.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Finance income consists of:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	other financial income;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	impact on profit from shareholdings in
	non-consolidated investments (dividends, profit on disposal) and income from short-term investments;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	exchange rate gains;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	the gain in the fair value of liabilities
	to former owners of subsidiaries (contingent consideration);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	exchange gains on financial liabilities
	on Group financial debt consisting of loans and other financial liabilities (in particular overdrafts and finance lease liabilities).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-29">
</A>
	3.29.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	Income taxes consist of current
	and deferred tax. Income tax is recognized in the statement of income except when it relates to items recognized directly in other
	comprehensive income or in equity, in which case it is recognized in other comprehensive income or in equity, respectively.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	Current tax is the expected tax
	payable on the taxable income of a period, using tax rates enacted or substantively enacted at the reporting date, and any adjustment
	to tax payable from previous years.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	Deferred tax is determined using
	the liability method, for temporary differences between the carrying amounts of assets and liabilities for financial reporting
	purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: (i) goodwill not
	deductible for tax purposes, (ii) differences relating to investments in subsidiaries to the extent that it is probable that they
	will not reverse in the foreseeable future and (iii) the initial recognition of assets or liabilities in a transaction that is
	not a business combination and that affects neither accounting nor taxable profit. The measurement of deferred tax assets and liabilities
	is based on the judgment of the Group as to how it will recover the carrying amount of assets and liabilities, using tax rates
	enacted or substantively enacted at the reporting date. Deferred tax is measured at the tax rates that are expected to be applied
	to temporary differences when they reverse or are offset.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	Deferred tax assets and liabilities
	are offset when there is a legally enforceable right to offset current tax assets and liabilities and when they relate to income
	tax levied by the same tax jurisdiction and the Group intends to settle its current tax assets and liabilities on a net basis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	A deferred tax asset net of any
	deferred tax liabilities that may be offset is recognized only to the extent that it is probable that the Group will have sufficient
	future taxable profits to recover it. A deferred tax asset is reduced to the extent that it is no longer probable that sufficient
	future taxable profits will be available.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.05IN 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 200 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage201"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-30">
</A>
	3.30.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Statement of cash flows
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The consolidated statement of cash flows
	is prepared using the indirect method. It distinguishes between cash flows from operating, investing and financing activities.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Operating activities are the principal activities
	that generate the income of the entity and all other activities that do not meet the definition as investing or financing activities.
	Cash flows from operating activities are obtained by adjusting net income for changes in working capital, items that do not affect
	cash (depreciation and amortization, impairment charges etc.), gains and losses on disposal of non-current assets, calculated expenses,
	etc.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Cash flows from investing activities are
	the cash flows from the acquisition and disposal of non-current assets and other investments.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Financing activities are operations that
	result from changes in the volume and composition of capital contributions and from changes in borrowings. Increases in share capital,
	payments of deferred and contingent liabilities to former owner of acquired subsidiaries, transaction with NCI, new borrowings
	and related repayments are financing activities.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Increases and decreases in assets and liabilities
	without effect on cash are eliminated. It follows that lease payments for assets being financed with a finance lease are not included
	in investing activities while the reduction in liabilities under finance leases is included in the loan repayments for the period.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F3-31">
</A>
	3.31.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Earnings per share
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group presents basic earnings per share
	and diluted earnings per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Basic and diluted earnings per share are
	calculated under IAS 33.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Basic earnings per share are calculated
	by dividing the Group share of net income by the average weighted number of shares outstanding during the year.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Diluted earnings per share are calculated
	by dividing the adjusted Group share of net income for the year by the average weighted number of ordinary shares outstanding adjusted
	for the effect of all dilutive potential ordinary shares.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<A NAME="DP65110_20F_HTM_F4">
</A>
	4.&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notes to the consolidated statement of income
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F4-1">
</A>
	4.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Operating segments and entity-wide disclosures
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Operating segment
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In compliance with IFRS 8
<I>
	Operating Segments
</I>
	,
	the segment information is based on internal management reports used by the Board of Directors (the chief operating decision maker
	of the Group) to review the performance of the business. There is only one operating segment in the Group and its performance is
	shown in the consolidated statement of income.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Entity-wide disclosures
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other required entity-wide disclosures in
	accordance with IFRS 8 are presented below.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Sales by product category
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_57"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT; TEXT-INDENT: 8PT">
	PET
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	59,831
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	48,882
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	41,437
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 8PT">
	Therapy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,049
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,472
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,262
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 8PT">
	Other products
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,163
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,138
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 8PT">
	SPECT
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,431
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,348
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,969
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	TOTAL
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 201 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage202"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Geographical information
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The two tables that follow show the Group&rsquo;s
	sales and non-current assets by country. In presenting the following information, sales disclosures are based on the location of
	customers and asset disclosures on the location of the sites of Group entities.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Sales by country&#9;
</I>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_58"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	France
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	28,152
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	25,003
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	23,263
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Italy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,640
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,775
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,821
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	United Kingdom
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,577
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,692
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,926
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,281
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Switzerland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,017
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,729
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,967
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,413
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,159
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,823
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,056
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	979
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Poland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	452
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 5.2PT">
	United States
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	TOTAL
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	88,615
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	69,865
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53,806
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The table of non-current assets by geographic
	location excludes financial and deferred tax assets.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Non-current assets by country
</I>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_59"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	France
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	24,836
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	27,939
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	26,893
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	United States
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,036
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,525
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,365
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,671
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,661
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,962
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Italy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,237
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,002
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17,169
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,899
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,923
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,504
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,026
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,648
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,467
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,848
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,485
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	United Kingdom
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,295
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Switzerland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	785
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	192
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.2PT">
	Poland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	181
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	181
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: 5.2PT">
	Portugal
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	689
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,181
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	TOTAL
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	110,878
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	105,566
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	101,113
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F4-2">
</A>
	4.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Personnel costs
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Personnel costs are analyzed as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_60"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT">
	Wages and salaries
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(20,280
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(14,246
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(10,214
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Social charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,846
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,496
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,770
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,281
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other personnel expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,600
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(69
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(29,520
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(21,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(16,265
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Personnel costs include in 2015, the one-time
	bonus paid to certain members of the management for an amount of &euro;1.2 million (see note 8).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 202 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage203"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_61"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The table below shows AAA personnel by country
	as of December 31, 2015, 2014 and 2013.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT">
	Italy
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	124
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	114
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	France
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	United States
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	United Kingdom
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Switzerland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Poland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Germany
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	403
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	332
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	274
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	In
	the years ended December 31, 2015, 2014 and 2013, the total remuneration of the Group&rsquo;s senior executives was as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_62"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 67%; TEXT-ALIGN: LEFT">
	Short-term benefits
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,457
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,357
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,121
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	322
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Post employment defined benefits
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	329
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	71
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,865
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,672
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The expense recognized for share-based payments
	amounted to &euro;1.8 million for the year ended December&nbsp;31, 2015. The expenses for the years 2014 and 2013 were &euro;2.3
	million and &euro;2.3 million respectively.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-3">
</A>
	4.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share-based payments
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<A NAME="DP65110_20F_HTM_F4-3-1">
</A>
	4.3.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Restricted (free) share plans
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Share-based payments include restricted
	(free) share plans for Group management. The fair value of the share grants was determined by reference to the subscription price
	of share capital increases carried out closest to the dates of these free share grants.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are no vesting conditions, except
	for a service condition.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_63"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="WIDTH: 29%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Grant date
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 11%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	09/2010
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 11%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	11/2011
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	01/2012
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	12/2012
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	08/2013
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	11/2014
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	05/2015
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Number of shares granted
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	370,000
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	370,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	15,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	562,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	477,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	155,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	160,000
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Fair value at grant date (&euro;)
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2.5
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	4.0
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	4.0
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	4.0
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5.0
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5.0
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	6.1
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Total fair value (&euro;)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	925,000
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1,480,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	60,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2,250,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2,387,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	775,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	976,000
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Vesting period (in years)*
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*except for Italian employees for whom the
	vesting period has been extended to 4 or 5 years for tax purposes in accordance with the shareholders meeting decision of December
	16, 2014 and the Board of Directors&rsquo; decision of February 26, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 203 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage204"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<A NAME="DP65110_20F_HTM_F4-3-2">
</A>
	4.3.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Options
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 10, 2015. the day of the IPO
	pricing, the Group adopted a new Stock Option Plan, under which equity-settled stock options have been granted to employees. Movements
	in stock options over ordinary shares in the Company were as follows
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_64"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted average exercise price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	As at 1 January
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: JUSTIFY">
	Options granted in the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,947,625
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options exercised in the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options lapsed in the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Options forfeited in the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	As at 31 December
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,947,625
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The options outstanding at December 31,
	2015 had an exercise price of $8.00 (&euro;7.45 based on an exchange rate at the grant date) and a weighted average remaining contractual
	life of 9.86 years. No options were exercisable at December 31, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair value of options granted during
	the year was estimated using the Black-Scholes option pricing model with the following significant assumptions:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_65"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 40%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 77%; TEXT-ALIGN: JUSTIFY">
	Expected life (years)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
	4.5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Expected dividend
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Weighted average fair value per option
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Weighted average exercise price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Weighted average share price at grant date
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Volatility was determined by considering
	the volatility of a group of comparable listed companies over the period commensurate with the expected term.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The options are not subject to any performance
	conditions and normally vest following the third anniversary of the date of grant provided that the option holder remains a Director
	or employee of the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair value of the Stock Option plan
	was estimated at &euro;13.7 million. This expense will be recorded gradually over the 3-year vesting period in accordance with
	IFRS 2. An expense of &euro;603 thousand was recognized in the consolidated statement of income (loss) for the year ended December
	31, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 204 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage205"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<A NAME="DP65110_20F_HTM_F4-3-3">
</A>
	4.3.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Warrants
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the year, the Company granted 225,000
	warrants to six Board members for consideration of &euro;0.80 per warrant (&euro;180,000 in aggregate). The warrants are exercisable
	immediately following the grant date and lapse after a period of 18 months.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Movements in equity-settled warrants over
	ordinary shares in the Company in the year were as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_66"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted average exercise price
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	As at 1 January
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 54%; TEXT-ALIGN: JUSTIFY">
	Warrants granted in the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: LEFT">
	225,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: LEFT">
	6.10
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Warrants lapsed in the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Warrants exercised in the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	As at 31 December
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	225,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&euro;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	6.10
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	225,000 warrants were exercisable at year
	end.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair value of the warrants were valued
	at &euro;0.8 per warrant by a third party using the Black-Scholes pricing model with the following significant assumptions:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_67"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 77%; TEXT-ALIGN: LEFT">
	Term of option (years)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
	1.5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.633
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As the consideration paid by the grantees
	represented the fair value of the warrants at the grant date, no related expense has been recognized in the consolidated statement
	of income (loss) for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-4">
</A>
	4.4.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other operating expenses
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other operating expenses principally concern
	non-inventoried purchases, consumable equipment &amp; supplies, travelling expenses, communication costs, consulting and other
	external services relating to R&amp;D, and other professional services:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_68"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	External R&amp;D Services
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(10,274
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(7,114
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(5,008
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transport
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,087
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,731
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Consulting and other professional services
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,825
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5,802
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,195
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Lease and other administrative expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,981
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,736
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Repairs and maintenance
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,420
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,962
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,346
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Travel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,097
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,560
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(843
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Communications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,836
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(650
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(538
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Royalties and Licensing fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,439
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,121
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(621
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Energy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,373
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,235
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(986
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(719
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(582
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Allowance for doubtful accounts
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(193
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(149
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Subcontractors
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(89
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(488
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,580
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,725
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,421
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(44,447
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(35,015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(24,644
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Consulting and other professional services
	costs include the one-time compensation to the Chairman of the Board for &euro;1 million (refer to note 8).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 205 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage206"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-5">
</A>
	4.5.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other operating income
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other operating income amounted to &euro;5.47
	million for the year ended December 31, 2015. The respective figures for the years 2014 and 2013 were &euro;4.23 million and &euro;3.98
	million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_69"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Government subsidies
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,871
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,701
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,462
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net gain / (loss) on disposal of non-current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(367
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other operating income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	539
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	453
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,474
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,230
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,977
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Government subsidies consist for the most
	part of the French research tax credit (CIR).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-6">
</A>
	4.6.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and development expenditures
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_70"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Personnel costs (including share-based payments for R&amp;D personnel)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,238
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,390
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,380
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other operating costs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,060
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,900
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total expenditure on R&amp;D projects
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(14,714
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,450
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,280
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Total expenditures on R&amp;D projects mainly
	include external fees, personnel costs, depreciation on fixed assets, transport and consumables costs.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-7">
</A>
	4.7.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Depreciation and amortization
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_71"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Impairment of goodwill
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(840
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment of Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,322
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Depreciation and amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10,860
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,831
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,530
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,993
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,545
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Impairment of goodwill and of property plant
	and equipment concerns operations in Portugal - see note 5.3.2.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-8">
</A>
	4.8.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Finance income and finance costs
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Change in fair value of contingent consideration
	is mainly attributed to the change in the fair value of the contingent consideration payable to the former owners of Advanced Accelerator
	Applications USA, Inc. Refer to note 5.14 for further details.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_72"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Gain on derivatives at fair value (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	259
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	387
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total finance income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,156
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	387
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(5,323
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(1,092
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(7,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net foreign exchange gain / (loss)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,252
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(862
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Interest expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(809
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(951
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,029
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(468
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(339
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(846
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total finance costs
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,852
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The &euro;897 thousand gain on derivatives at fair value correspond to the change in fair value
	of the foreign exchange contracts concluded by the Group to hedge its currency risk exposure. Please see note 5.8.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 206 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage207"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9PT">
</TD>
<TD STYLE="WIDTH: 24PT">
<A NAME="DP65110_20F_HTM_F4-9">
</A>
	4.9.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A NAME="DP65110_20F_HTM_F4-9-1">
</A>
	4.9.1
</FONT>
	.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<U>
	Income tax expense
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_73"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Current tax
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,533
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(1,692
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,072
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deferred tax
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,762
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,288
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	915
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,157
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<A NAME="DP65110_20F_HTM_F4-9-2">
</A>
	4.9.2
</FONT>
	.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<U>
	Explanation of effective tax expense
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_74"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Net profit / (loss) after tax
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(17,001
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,803
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(12,781
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income tax
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(771
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Net profit / (loss) before tax
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(16,230
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(10,399
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,624
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Theoretical tax rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Expected tax (charge) / income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,409
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,466
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,873
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impact of unrecognized deferred tax asset on tax loss for the year
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,095
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,068
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impact of tax rate differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(504
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	531
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Impact of unrecognized deferred tax asset on temporary differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,458
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	impact of permanent differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,260
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(445
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,668
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	impact of income tax prior year recovery
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Income tax expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(431
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(102
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(790
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	CVAE &amp; IRAP (1)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(340
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(302
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(367
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Group tax charge
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(404
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,157
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Contribution sur la Valeur Ajout&eacute;e des Entreprises (&ldquo;CVAE&rdquo;) and the Imposta
	Regionale sulle Attivita Produttive (&ldquo;IRAP&rdquo;) are French and Italian local taxes, respectively. They are determined
	using defined elements of revenues and expenses and are considered to be income taxes in accordance with IAS 12.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<A NAME="DP65110_20F_HTM_F4-9-3">
</A>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	4.9.3
</FONT>
	.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<U>
	Deferred tax assets and liabilities
</U>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Changes in net deferred tax assets and liabilities
	during the year are explained as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_75"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net deferred tax at the beginning of the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(4,143
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(4,187
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(5,386
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,762
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,288
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	915
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other comprehensive income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	176
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Change in consolidation scope
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(715
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Translation differences
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(374
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other changes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	72
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(245
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net deferred tax at the end of the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,143
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Deferred tax liabilities recognized mainly
	concern the remeasurement of assets due to business combinations.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_76"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Intangible assets
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(7,061
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(7,655
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(6,742
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Carry forward losses (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,852
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,060
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(825
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(822
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(868
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other temporary differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,487
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,482
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,363
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: 8.05PT">
	Deferred liabilities, net
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,507
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,143
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 8.05PT">
	Net deferred tax liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: RIGHT">
	of which deferred tax assets (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,080
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,608
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	of which deferred tax liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,587
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8,751
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,435
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Deferred tax assets on carry forward losses
	have been recognised only to the extent of the available taxable temporary differences for each taxable entity.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	Deferred tax assets and tax liabilities
	are offset when they concern the same taxable entity (or group of entities) and the entity has a legally enforceable right to settle
	current tax assets and liabilities in the consolidated statement of financial position
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 207 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage208"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of 31 December 2015, the Group had available
	tax loss carry forwards for which no deferred tax asset was recognized due to the early stage of development of the entities in
	these countries, and because these entities are not likely to have taxable income in the foreseeable future:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Carry forward tax loss
</B>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_77"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	France
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	23,034
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	15,127
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,879
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,404
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,661
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,545
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	917
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	749
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,545
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Poland
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,171
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,316
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	353
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Switzerland
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,053
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	490
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,346
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,173
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,805
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<A NAME="DP65110_20F_HTM_F5">
</A>
	5.&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notes to the consolidated statement of financial position
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-1">
</A>
	5.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisition of business
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	None in 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-2">
</A>
	5.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquisition of business for the year 2014
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of Imaging Equipment Ltd.
	(IEL)
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On February 14, 2014, the Group obtained
	control of Imaging Equipment Limited (IEL) by acquiring 100% of its issued share capital. IEL is a privately-held UK distributor
	of nuclear medicine products. This acquisition contributes to AAA&rsquo;s international expansion by providing a direct distribution
	presence in the UK and Ireland as well as an established sales and marketing platform.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_78"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Recognized amounts of identifiable assets acquired and liabilities assumed (in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&pound;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&euro;&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Customer relationships
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,424
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,742
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Investments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Inventory
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	406
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	497
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash and cash equivalent
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	296
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	362
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Loans
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(26
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,961
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deferred tax liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(299
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(366
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Total net assets acquired
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,632
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,996
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Negative Goodwill
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(77
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(94
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total consideration
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,555
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,902
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Satisfied by:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;&nbsp;Cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Equity instruments (294,743 ordinary shares at &euro; 5)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,205
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,474
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total consideration transferred
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,555
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,902
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Net cash outflow arising on acquisition
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;&nbsp;&nbsp;Cash consideration
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;&nbsp;&nbsp;&nbsp;Less: cash and cash equivalents acquired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(296
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(362
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The valuation technique used for measuring
	the acquired customer relationship was the multi-period excess earnings method. There was no other significant tangible or intangible
	asset.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Following this acquisition, negative Goodwill
	of &euro; 94 thousand was recognized in other operating income in the consolidated income statement of the Group at December 31,
	2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 208 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage209"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair value of the 294,743 ordinary shares
	issued as part of the consideration paid for IEL (&euro; 1,474 thousand) was assessed on the basis of a capital increase of new
	shares that were issued on the same day as the IEL acquisition. Shareholders and new investors paid a total of &euro; 41 million
	for these shares i.e. a price of &euro;5 per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IEL contributed &euro; 9.6 million to the
	Group&rsquo;s revenue and &euro; 0.4 million to the Group&rsquo;s income for the period between the date of acquisition and the
	December 31, 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the acquisition of IEL had been completed
	on the first day of the financial year 2014, group revenues for the year ended December 31, 2014 would have been &euro; 71.9 million
	(instead of &euro;69.9 million) and the contribution to the Group&rsquo;s income would have been &euro; (0.6) million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Acquisition of the SteriPet business
	of GE Healthcare S.r.L in Italy
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 15, 2014, AAA Italy acquired
	from GE Healthcare S.r.L. its FDG-PET business. This acquisition includes the SteriPET&reg; (FDG) Marketing Licence. This acquisition,
	consisting of certain assets, liabilities and legal relationships, for the most part customer relationships, allows AAA Italy to
	strengthen its commercial operations and to become the leader in this business in Italy. The transaction consists of cash payments
	of up to &euro;697 thousand within 12 months of execution of the contract and royalty payments on sales to former SteriPET&reg;
	customers of GE Healthcare Italy. The royalties will be due on sales between September 2015 and September 2017. The costs related
	to this acquisition are not significant and were expensed as incurred.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_79"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="5" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Recognized amounts of identifiable assets acquired and liabilities assumed (in thousands)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&euro;&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Customer relationships
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,089
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	License
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Inventory
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	142
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(342
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Goodwill
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total consideration
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,255
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Satisfied by:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	495
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Contingent consideration
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
	(1)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	760
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total consideration transferred
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,255
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	(1)
	Contingent consideration
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; COLOR: #4F81BD">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group has agreed to pay the selling
	shareholders a contingent consideration in cash. The amount has been estimated at acquisition date as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&euro;200 thousand paid on September 15,
	2015 provided that one of the suppliers is still regularly supplying. The contribution to the contingent consideration transferred
	is &euro; 196 thousand which corresponds to the present value of &euro;200 thousand discounted at 3% from the payment date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	&euro;564 thousand of estimated royalties
	to be paid on future net sales to existing customers between September 15, 2015 and September 15, 2017.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The valuation technique used for measuring
	the acquired customer relationship was the multi-period excess earnings method. There was no other significant tangible or intangible
	asset.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Following this acquisition, Goodwill of
	&euro;200 thousand was recognized at December 31, 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The goodwill is entirely attributable to
	AAA Italy, which is considered as a separate CGU (cash generating unit) within the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	This acquisition had no significant impact
	on the Group&rsquo;s revenues and income for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 209 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage210"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-3">
</A>
	5.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Goodwill and Other intangible assets
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36.45PT">
</TD>
<TD STYLE="WIDTH: 37.35PT">
<A NAME="DP65110_20F_HTM_F5-3-1">
</A>
	5.3.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Change in the year
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_80"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquisition Cost In &euro; thousands
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Goodwill
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquired In Process R&amp;D
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Patents, Licenses and other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Customer relationships
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 1 January 2013
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,285
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,667
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11,834
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,417
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	60,203
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	634
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,048
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(131
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	131
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,066
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,267
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,619
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,337
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,548
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	59,771
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Business combinations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2'831
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,131
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	765
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,499
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	69
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,450
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	23,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	16,118
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,900
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,496
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	65,746
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,535
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,535
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(458
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(458
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassification
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	134
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,285
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	922
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	85
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	646
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,938
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	24,517
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,040
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,142
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	69,895
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Accumulated amortization and impairment losses In &euro; thousands
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 1 January 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,342
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,731
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,073
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Amortization expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,878
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reversal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(32
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,028
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,894
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,937
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Amortization expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,712
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,442
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3,154
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(840
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(840
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(10
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,750
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,354
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,959
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Amortization expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,788
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(3,309
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassification
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(204
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(213
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,165
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,329
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(15,349
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;Carrying amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	At 31 December 2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,252
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,619
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,309
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,654
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	51,833
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	At 31 December 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,377
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16,118
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,150
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,142
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53,787
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	22,662
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,040
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,813
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54,546
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Patents/Licenses primarily consist of intellectual
	property relating to the therapy product candidate FabOvar which was acquired in 2011 for an amount of &euro;8 million with a carrying
	amount of &euro;4.8 million at December 31, 2015 (&euro;5.6 million at December 31, 2014 and &euro;6.4million at December 31, 2013).
	The purchase agreement also provides for a variable payment based on a percentage of future sales until the legal protection of
	the patent expires in 2028. Acquired IPR&amp;D for &euro;17.1 million as at December 31, 2015 (&euro;16.1 million as at December
	31, 2014 and &euro;14.7 million as at December 31, 2013) results from the acquisitions of Atreus Pharmaceuticals Corporation and
	Advanced Accelerator Applications USA, Inc. in 2010.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 210 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage211"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Allocation of goodwill and Other intangible assets to Cash-Generating Units (CGUs)
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group has allocated goodwill and other
	intangible assets to its CGUs. The CGUs correspond to each of the countries in which the Group operates. The carrying amount of
	goodwill and other intangible assets allocated is as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_81"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Goodwill
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquired IPR&amp;D
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated impairment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Gipharma
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Italy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	551
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,916
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,467
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	USA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,154
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,278
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,484
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,484
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other countries
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	24,517
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,040
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,702
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_82"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Goodwill
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquired IPR&amp;D
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated impairment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Gipharma
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Italy
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	589
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,258
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,847
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	USA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,720
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,860
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,595
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,595
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other countries
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,232
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16,118
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,855
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,495
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_83"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Goodwill
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquired IPR&amp;D
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated impairment
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Italy (Gipharma)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,947
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	416
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,064
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,480
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	USA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,223
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,555
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,778
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,027
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,261
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Portugal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,855
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	840
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other countries
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	22,267
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,619
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	35,871
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Goodwill is stable with a total amount of
	&euro; 22.6 million at December 2015 compared to &euro; 21.3 million at December 31, 2014 and &euro; 21.2 million at December 31,
	2013. The variation in 2015 results from an increase of goodwill due to the translation differences on the USD / ILS denominated
	goodwill for &euro; 1.3 million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2014, the stability resulted from an
	increase of goodwill due to the acquisition of the SteriPet business of GE Healthcare and to the translation differences on the
	USD / CAD denominated goodwill compensated by the &euro; 0.8 million additional impairment loss recognized on the Portugal goodwill.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The recoverable amount of CGUs was
	calculated on the basis of their value in use. The value in use is the present value of the estimated future cash flows from
	the continued use of the asset. The value in use is determined on the basis of estimated cash flows using budgets and
	business plans over periods from 5 to 10 years; subsequent cash flows are extrapolated by applying a constant rate of
	positive or negative growth, and discounted to present value. The discount
	rate used reflects current market assessments of the time value of money and the risks specific to the asset (or CGU).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 211 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage212"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Principal assumptions used in impairment testing:
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_84"></A>
	CGU
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Budgeted EBITDA average increase per year (of forecast period)&nbsp;
<B>
	(1)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Post tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pre tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Terminal growth rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Forecast period in years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Italy
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	11.9
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	13.6
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	0.4
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Gipharma
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Canada (2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	68.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-1.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	USA
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	173.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Germany
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Spain
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Israel
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	UK
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Portugal
<B>
	(3)
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-2.3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13.9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
<A NAME="FIS_UNIDENTIFIED_TABLE_85"></A>
	CGU
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Budgeted EBITDA average increase per year (of forecast period)
<B>
	(1)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Post tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pre tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Terminal growth rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Forecast period in years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Italy
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	17.7
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	12.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	16.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	1.6
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Gipharma
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Canada (2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	111.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	USA
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Germany
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	79.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Spain
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Israel
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	UK
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Portugal
<B>
	(3)
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	105.3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17.2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_86"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	CGU
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Budgeted EBITDA average increase per year (of forecast period) (1)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Post tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Pre tax discount rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Terminal growth rate
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Forecast period in years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: LEFT">
	Gipharma (Italy)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	12.1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	13.8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Canada
<B>
	(2)
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	73.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	USA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	341.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Portugal
<B>
	(3)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7.1
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17.4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	The budgeted EBITDA increase
	mainly results from the forecasted sales of Lutathera, which is expected to obtain FDA approval and EMA marketing authorization
	in 2017. This product candidate is currently in Phase 3 development and as a result an extended forecast period of 8 to 10 years
	has been retained. For the U.S. CGU, the forecasted sales are based entirely on Lutathera.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 212 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage213"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Concerning Canada, the
	future EBITDA growth is also based on the sale of Annexin V-128, a product candidate currently under development and currently
	in Phase 1/2 trials.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Following these tests,
	an impairment loss of &euro;1.0 million was recognized on the goodwill of Portugal CGU in 2013, and of &euro;0.8 million in 2014.
	An additional impairment loss of &euro; 1.3 million has been attributed to tangible assets of Portugal in 2014, and of &euro;0.46
	million in 2015. The loss mainly results from the downward revision of forecasted sales and EBITDA as a result of a new competitor
	who entered the market.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36.45PT">
</TD>
<TD STYLE="WIDTH: 37.35PT">
<A NAME="DP65110_20F_HTM_F5-3-2">
</A>
	5.3.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Sensitivity analysis of the goodwill impairment tests at December 31, 2015:
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_87"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.13.2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.13.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Change required for carrying amount to equal recoverable amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Change required for carrying amount to equal recoverable amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Change required for carrying amount to equal recoverable amount
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	CGU
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Increase in Discount rate (in basis point)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Decrease in Budgeted EBITDA per year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Increase in Discount rate
<BR>
	(in basis point)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Decrease in Budgeted EBITDA per year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Increase in Discount rate
<BR>
	(in basis point)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Decrease in Budgeted EBITDA per year
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT">
	Italy
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(67
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(55
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N/A&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NA&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Gipharma
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(59
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(26
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Canada
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	USA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Germany
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Spain
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(58
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Israel
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(53
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	United Kingdom
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(80
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(67
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Portugal (1)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	(1)
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	The recoverable amount of Portugal CGUs
	is equal to its carrying amount after recognition of impairment loss. Therefore any adverse movement in a key assumption would
	lead to further
</FONT>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	impairment.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 213 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage214"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_88"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-4">
</A>
	5.4.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Property, plant and equipment
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Acquisition cost In &euro; thousands
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Land
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Construction and
<BR>
	development
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equipment and laboratory material
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Sub total financed under lease
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Land
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Construction &amp; equipment in progress
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equipment and laboratory material
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other tangible assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Sub total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	TOTAL
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 1 January 2013
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,001
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,498
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,699
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,320
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,097
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	36,709
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,849
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53,975
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	71,674
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,717
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,717
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,866
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,321
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,038
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(204
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,950
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,161
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,161
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassifications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,002
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,874
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	92
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,215
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	19,416
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,320
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17,889
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	39,719
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,310
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	61,238
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	80,654
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,435
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,435
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,385
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	251
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,910
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,345
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Business combinations
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	76
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(111
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(111
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassifications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,355
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(493
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	570
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(493
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	147
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	21
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	182
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	182
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	152
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,201
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17,032
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	22,385
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	750
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,858
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,117
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,570
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	68,295
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	90,680
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,247
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,599
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,146
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,146
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(700
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(745
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(548
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,293
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassifications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	253
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(547
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(134
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(134
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	138
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	416
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	83
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	637
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	639
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	107
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,501
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	17,034
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,642
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	795
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	30,491
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	47,082
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,028
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	81,396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	103,038
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 214 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage215"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_89"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Accumulated depreciation and impairment losses in In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Land
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Construction and
<BR>
	development
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equipment and laboratory material
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Sub total financed under lease
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Land
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Construction
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Equipment and laboratory material
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other tangible assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Sub total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	TOTAL
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 1 January 2013
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,303
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,893
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,196
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,627
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,471
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(618
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(19,716
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(25,912
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation expense
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(410
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,164
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,574
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(556
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,130
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,086
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,660
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	423
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	467
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	467
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(266
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	At 31 December 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,713
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,057
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,770
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,159
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(16,444
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,001
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(23,604
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(31,374
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(341
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,612
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,953
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(319
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,724
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,677
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,321
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,321
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other Changes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	430
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	478
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	493
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(59
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(68
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(68
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,624
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,621
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,245
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,497
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(21,848
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,311
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(29,656
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(38,901
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,816
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,042
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(866
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,287
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(356
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,509
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,551
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Impairment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(382
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(461
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(461
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposals
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	306
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reclassifications
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(15
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(309
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(318
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(318
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,631
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(9,422
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(11,053
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,431
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(26,567
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,655
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(35,653
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(46,706
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Carrying amount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	At 31 December 2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,288
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,158
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,646
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,320
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,730
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,275
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,309
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,634
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	49,280
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	At 31 December 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	152
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,577
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,411
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,140
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	750
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,361
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,269
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,259
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,639
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	51,779
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	At 31 December 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	107
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,870
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,612
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,589
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	795
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,060
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,515
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,373
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	45,743
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	56,332
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 215 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage216"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-5">
</A>
	5.5.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Non-current financial assets
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Non-current financial assets correspond
	mainly to guarantee deposits related to the remaining liabilities due on the acquisition of Cadisa and Barnatron in December 2012
	and to a tender won in Spain.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-6">
</A>
	5.6.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Trade and other receivables
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Trade and other receivables are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_90"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Gross value
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	24,397
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	20,557
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	16,524
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Allowance for doubtful accounts
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(772
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(504
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(381
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Change in allowance for doubtful accounts
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_91"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Allowance for doubtful accounts, beginning of the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	504
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	381
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	240
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	313
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	139
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	149
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Utilized
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Reversed
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Translation adjustment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Allowance for doubtful accounts, end of the year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	772
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	504
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	381
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Aging of trade
</B>
<B>
	and other receivables
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_92"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Not overdue
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	15,631
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	12,941
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8,647
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Past due up to 30 days
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,041
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,457
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Past due for 30-60 days
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,219
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,492
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,462
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Past due for 60-90 days
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,108
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	290
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	890
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Past due for 90-180 days
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,575
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,593
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,204
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Past due for more than 180 days
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,823
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,864
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Allowance for doubtful accounts
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(772
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(504
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(381
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA is not significantly exposed to credit
	risk. A large portion of the customers are public hospitals which represent a relatively low risk.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-7">
</A>
	5.7.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Inventories
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_93"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Raw materials
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,266
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,959
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,652
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Finished goods
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	872
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	436
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	967
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,320
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	199
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total gross value
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,105
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,379
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,287
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Write-downs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(16
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,105
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,363
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,278
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 216 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage217"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-8">
</A>
	5.8.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other current assets
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other current assets are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_94"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	R&amp;D tax credit receivable
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7,513
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,328
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,562
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax receivables (incl. VAT) and other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,994
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,476
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,712
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Derivative assets (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,356
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	723
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other current assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,800
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	10,160
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,997
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Derivative assets primarily correspond to the fair value of the foreign exchange contracts concluded
	by the Group to hedge its exposure to foreign exchange risks arising from the cash received in dollars following the IPO. These
	derivatives assets are measured at fair value subsequent to their initial recognition and any change in the fair value is recorded
	through the income statement.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-9">
</A>
	5.9.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Cash and cash equivalents are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_95"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Term saving deposits (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	951
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	21,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,600
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	117,935
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	24,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,010
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Term savings deposits include very insignificant risk of a negative change in value and have maturity
	dates of typically less than 3 months.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-10">
</A>
	5.10.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Equity
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group&rsquo;s policy is to manage its
	capital to ensure to be able to continue as a going concern while maximizing the return to shareholders through the optimization
	of the debt and equity balance. The capital structure consists of financial liabilities as detailed in Notes 5.13 offset by cash
	and bank balances and equity (comprising issued capital, reserves and retained earnings). The Group is not subject to any externally
	imposed capital requirements.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, the share capital
	consists of 78,556,211 fully paid-up ordinary shares, with a nominal value of &euro;0.10 per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Increase of share capital
</U>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increases in share capital which occurred
	from January 1, 2015 through December 31, 2015 are described follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_96"></A>
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 11%; BORDER: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Date
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 34%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nature of operation
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Note
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Number of shares
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Price per share / warrant
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Raised capital (in K&euro;)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nominal value
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Share capital (in K&euro;)
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Dec 31, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Outstanding shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	63,229,041
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	6,323
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	May 28, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1,459,660
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	6.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	8,904
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	146
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	June 17, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(2)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2,330,110
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	6.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	14,214
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	233
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Aug 19, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	352,500
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	35
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 217 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage218"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_97"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 11%; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Sept 6, 2015
</FONT>
</TD>
<TD STYLE="WIDTH: 34%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-TOP: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	235,000
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	24
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Sept 28, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	167,500
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	17
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Sept 28, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of 225,000 warrants at a &euro;0.8 price
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.80
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	180
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Nov 11, 2015
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(3)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	10,782,400
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	7.5
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	80,444
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1,078
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Share issuance costs
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(6,648)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Total
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	78,556,211
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	97,094
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	0.10
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	7,856
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.7PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On May 28, 2015, 1,459,660 shares have been issued at a price of &euro;6.10 per share following
	the extraordinary general meeting held on December 16, 2014;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.7PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 17, 2015, 2,330,110 shares have been issued at a price of &euro;6.10 per share following
	the extraordinary general meeting held on December 16, 2014.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 38.7PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(3)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<U>
	Initial Public Offering (IPO)
</U>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA completed an IPO of 4,688,000
	American Depositary Shares (&ldquo;ADS&rdquo;) representing 9,376,000 ordinary shares at a price of $16.00 (&euro;14.9) per
	ADS (each ADS represents 2 ordinary shares). The ADS have been listed on the Nasdaq Global Select Market on and started
	trading on November 11, 2015 under the ticker &ldquo;AAAP&rdquo;. The overallotment option (Greenshoe) of 15% was also used
	immediately by the Underwriters and an additional 1,406,400 shares or 703,200 ADS were issued at the same price of US$16.00
	(&euro;14.9) per ADS.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2014, the share capital
	consisted of 63,229,041 fully paid-up ordinary shares, with a nominal value of &euro;0.10 per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increases in share capital which occurred
	from January 1, 2014 through December 31, 2014 are described follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_98"></A>
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 11%; BORDER: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Date
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 34%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nature of operation
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Note
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Number of shares
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Price per share
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Raised capital (in K&euro;)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nominal value
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Share capital (in K&euro;)
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Dec 31, 2013
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Outstanding shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	54,145,889
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5,415
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Feb 14, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	8,212,295
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	41,061
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	821
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Feb 14, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Share issuance costs
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(395)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Feb 14, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	294,743
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	29
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Feb 14, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	40,000
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	4
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	March 27, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(2)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	241,114
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	24
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Oct 16, 2014
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	295,000
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	30
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Total
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	63,229,041
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	40,666
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	0.10
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	6,323
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 46.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On February 14, 2014, 8,212,295 shares have been issued at a price of &euro;5 per share following
	the extraordinary general meeting held on April 11, 2013 and 294,743 shares were issued in relation with the acquisition of IEL;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 46.35PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On March 27, 2014, the Board of Directors decided to issue 241,114 ordinary shares, were issued
	in relation with the acquisition of Atreus.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2013, the share capital
	consisted of 54,145,889 fully paid-up ordinary shares, with a nominal value of &euro;0.10 per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 218 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage219"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_99"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The increases in share capital which occurred
	from January 1, 2013 through December 31, 2013 are described follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 11%; BORDER: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Date
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 34%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nature of operation
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Note
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Number of shares
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Price per share
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Raised capital (in K&euro;)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Nominal value
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Share capital (in K&euro;)
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Jan 1st, 2013
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Outstanding shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	52,430,303
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5,243
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Jan 1st, 2013
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(1)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	575,000
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	58
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	April 11, 2013
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(2)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	963,086
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	5.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	4,815
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	96
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Nov 29, 2013
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Issuance of common shares (free shares allocated to employees)
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	177,500
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.00
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	0.10
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	18
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; BORDER-LEFT: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Total
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	54,145,889
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	4,815
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	0.1
</B>
</FONT>
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	5,415
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	At the beginning of 2013, 575,000 new shares were issued in partial settlement of the contingent
	consideration due to the former owners of Advanced Accelerator Applications USA, Inc.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On April 11, 2013, the general meeting of shareholders approved the issue of 963,086 ordinary shares
	at a price of &euro;5 per share.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Basic and diluted earnings per share
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_100"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD NOWRAP STYLE="WIDTH: 39%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 17%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Net profit&nbsp;&nbsp;(loss)
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(thousands of Euros)
</FONT>
</TD>
<TD STYLE="WIDTH: 22%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Average number
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	of shares
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	outstanding
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</TD>
<TD STYLE="WIDTH: 22%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Earnings per
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	share (EUR)
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Year ended December 31, 2015
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17,001)
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Basic earnings per share
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;66,943,481
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;(0.25)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Diluted earnings per share
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	&nbsp;&nbsp;&nbsp;&nbsp;66,943,481
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
	(0.25)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Year ended December 31, 2014
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;&nbsp;&nbsp;(9,499)
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Basic earnings per share
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	61,884,911
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(0.15)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Diluted earnings per share
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	61,884,911
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(0.15)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Year ended December 31, 2013
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(12,152)
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Basic earnings per share
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	54,156,067
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(0.22)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(213,234,234)">
<TD NOWRAP STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Diluted earnings per share
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	54,156,067
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	(0.22)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the year ended December 31, 2015, and
	2014 there are no free shares vested but not yet issued included in the average number of shares outstanding.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For the year ended December 31, 2013, the
	average number of shares outstanding includes 241,114 shares related to the contingent consideration for the acquisition of Atreus
	Pharmaceuticals Corporation in 2010 (as all conditions were met at December 31, 2013) and 197,500 shares vested but not yet issued
	by the Company:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	As at December 31, 2013, the contingent
	consideration recognized as an equity instrument provides for the issuance in 2014 of 241,114 shares to the former owners of Atreus
	Pharmaceuticals Corporation. The fair value of the contingent consideration was estimated at the acquisition of Atreus Pharmaceuticals
	Corporation in 2010 based on the fair value of AAA shares at the acquisition date, i.e., &euro;2.50 per share, representing contingent
	consideration at December 31, 2013 of &euro;603,000 and a fixed number of shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 28.35PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF">
	A total of 197,500 free shares granted
	to employees in November 2011 were fully vested at December 31, 2013 but had not yet been issued, at the request of the employees.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 219 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage220"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Free shares and options granted to employees
	and warrants to six Board members but not yet vested and/or exercised at December 31, 2015, December 31, 2014 and December 31,
	2013 are not considered for diluted earnings per share calculation as they would reduce loss per share.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-11">
</A>
	5.11.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Non-controlling interests
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015 and 2014, the Group
	has no non-controlling interest at the end of the periods as a result of the following transactions.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 10, 2014, the Group acquired
	the remaining 49.9% non-controlling interest in AAA Germany GmbH (the former Umbra Medical AG) as explained in notes 2.1.2. The
	method of consolidation remains unchanged for this shareholding.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 18, 2014, the Group acquired
	the remaining 49.9% non-controlling interest in Atreus Pharmaceuticals Corporation as explained in notes 2.1.2. The method of consolidation
	remains unchanged for these shareholding.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table summarizes the effect
	of these acquisitions on the Group Equity in 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_101"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Atreus Pharmaceuticals Corporation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Umbra
<BR>
	Medical AG
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Non-Controlling interest at January 1, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	49.90
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	49.90
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Consideration :
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	264
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,200
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,464
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Contingent consideration:
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,013
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;6,013
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Total Consideration
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,277
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,200
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,477
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Summary of the effects of increase in ownership :
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Decrease in Group reserves (consideration paid)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,277
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Transfer of the Non-controlling interest Reserves at January 1, 2014 attributable to the Group reserve at January 1, 2014:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,548
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(188
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,360
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Transfer of the loss for the year until change of Ownership date from Non-controlling Interest to Group Shareholders
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(536
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(768
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Transfer of other comprehensive income of the year until change of Ownership date from Non-controlling Interest to Group Shareholders
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	269
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Total of Non-controlling interest transferred
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,281
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(956
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	325
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
	Total impact on Equity attributable to owners of the Company in 2014:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(4,996
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,156
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,153
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2013, Non-controlling interests
	concerned Atreus Pharmaceuticals Corporation and Umbra Medical AG, where the Group was holding 50.1% of the share capital in each
	case.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 220 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage221"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The following table summarizes the information
	relating to each of the Group&rsquo;s subsidiaries that has material Non-Controlling Interest, before any intra-group elimination
	as of and for the year ended December 31, 2013.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_102"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	In KEUR
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Atreus Pharmaceuticals Corporation
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Umbra Medical AG
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 70%">
	NCI percentage
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 12%">
	49.9
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	%
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 12%">
	49.9
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 1%">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,768
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,361
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	472
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	409
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,783
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,035
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Current liabilities
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(2,356
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(1,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Net assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	3,101
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(374
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Carrying amount of NCI
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,547
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(187
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Revenue
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total comprehensive income
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(1,204
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(459
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Comprehensive income allocated to NCI
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(601
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(229
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-12">
</A>
	5.12.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Current and non-current provisions
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The provisions are analyzed as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_103"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Decommissioning obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7,170
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,871
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	5,127
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Retirement indemnities and other employee benefits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,370
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,046
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	843
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Total non-current provisions
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,968
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,011
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,029
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Others
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total current provisions
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	128
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,968
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,139
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,144
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Provisions for decommissioning PET production
	sites
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, these provisions amounted
	to &euro;7.2 million compared with &euro;6.9 million at December 31, 2014 and &euro;5.1 million in 2013. The increase of approximately
	&euro;0.3 million between 2015 and 2014 relates to the unwinding of the discounting of the obligation. The increase of approximately
	&euro;1.8 million between 2013 and 2014 is due to the unwinding of the discounting of the obligation for &euro; 0.3 million and
	the installation of three new Cyclotrons in Germany and France in 2014.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Decommissioning costs for a typical site
	have been estimated by an independent expert. From this base cost and with annual inflation assumed to be 2%, the Group has estimated
	the expected decommissioning costs at the forecast date for each site concerned. These costs are then discounted to the reporting
	date. The discount rate applied is 4.57% (same as at December 31, 2014 and 2013). A change (decrease or increase) of 1 percentage
	point in this rate would lead to a respective increase or decrease in the provision of &euro; 0.2 million.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 221 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage222"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Retirement Indemnities and other employee
	benefits
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	The
	Group has three main employee defined benefit obligations in France, Italy and Switzerland which
</FONT>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	are
	subject to annual actuarial measurement, using the projected credit unit method. The assets and liabilities recognised in the balance
	sheet at 31 December for these defined benefit obligations are as follows:
</FONT>
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_104"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fair value of plan assets
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,962
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,273
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	684
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Post-employment benefit plans
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Defined benefit obligation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,332
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,319
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,527
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net Liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,370
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,046
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(843
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The plan assets concern only the Swiss defined
	benefit plan. The plan assets are primarily held within instruments with quoted market prices in an active market such as Equity
	securities and Debt securities, with the exception of the property that includes some direct investment in real estate.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Movements in the net asset/(liability) during
	the period:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Net asset / (liability) at the beginning of the year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(1,046
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(843
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(678
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expense recognised in the income statement (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(764
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(111
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Remeasurements recognised in other comprehensive income (2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(736
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contributions paid by the Group
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Exchange differences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net asset / (liability) at the end of the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,370
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,046
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(843
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	This mainly includes service costs for the period
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	This mainly results from actuarial gain / (loss) due to experience and change in financial assumptions
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
<I>
	In France
</I>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	AAA France employees receive, on retirement,
	severance pay as defined under the pharmaceutical industry collective wage agreement.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The principal assumptions underlying the measurement
	of the provision concerning the French employees are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 29%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<A NAME="FIS_UNIDENTIFIED_TABLE_105"></A>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2015
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2014
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2013
</I>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Discount rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1.70%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1.57%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	3.17%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Future increase in remuneration
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Rate of social charges
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	43%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	47%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	47%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Retirement age
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Managers: 65 years
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Other staff: 62 years
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Managers: 65 years
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Other staff: 62 years
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Managers: 65 years
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Other staff: 62 years
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Mortality table
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	INSEE 2011-2013
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	INSEE 2010-2012
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	INSEE 2008-2010
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
<I>
	In Italy
</I>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Employees of AAA Italy and Gipharma receive
	indemnity payments (TFR) when leaving the company.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The principal assumptions underlying the measurement
	of the provision concerning the Italian employees are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 29%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<A NAME="FIS_UNIDENTIFIED_TABLE_106"></A>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2015
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2014
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
<I>
	12.31.2013
</I>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Discount rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1.50%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1.50%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1.93%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Future increase in remuneration
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2.50%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2.48%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	2.48%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Rate of social charges
</B>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	39.35%: other staff
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	39.35%: other staff
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	39.35%: other staff
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Retirement age
</B>
</FONT>
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	44.45%:managers
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Man 66 years+7 months
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Woman 65 years+7 months
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	44.45%:managers
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Man 66 years+3 months
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Woman 63years+9 months
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	44.45%:managers
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Man 66 years+3 months
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Woman 62years+3 months
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Mortality
	table
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Istat
	2014
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Istat
	2013
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Istat
	2012
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 222 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage223"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
<I>
	In Switzerland
</I>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Group jointly operates with the employees
	a retirement foundation in Switzerland. The assets and liabilities of the retirement foundation are held separately from the Group.
	This foundation covers all the employees in Switzerland and provides benefits on a defined contribution basis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Each employee has a retirement account to which
	the employee and the Group contribute at a rate set out in the foundation rules based on a percentage of salary. Every year, the
	foundation decides the level of interest, if any, to apply to retirement accounts based on the agreed policy. At retirement, employees
	can elect to withdraw all or part of their balances of their retirement account, failing which the retirement account is converted
	into annuities at pre-defined conversion rates.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Because the foundation Board is expected to
	eventually pay out all of the foundation&rsquo;s assets as benefits to employees and former employees, no surplus is deemed to
	be recoverable by the Group. Similarly, unless the assets are insufficient to cover minimum benefits, the Group does not expect
	to make any deficit contribution to the foundation.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	However, according to IFRS, the foundation
	has to be classified as a defined benefit plan due to underlying benefit guarantees and has to be accounted for on this basis.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The weighted average duration of the expected
	benefit payment is approximately 16.99 years.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Group expects to contribute CHF 139 thousand
	to this plan in 2016.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The principal assumptions underlying the measurement
	of the provision concerning the Swiss employees are as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_107"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 29%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
<I>
	12.31.2015
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
<I>
	12.31.2014
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 23%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
<I>
	12.31.2013
</I>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Discount rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	0.8%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.10%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2.40%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Inflation rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Future increase in remuneration
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	2%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Pension increase rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Interest credited on pension savings
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.25%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.75%&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	1.75%&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Conversion rate
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.8%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.8%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	6.8%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Proportion opting for withdrawal Benefit
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	25%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	25%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	25%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Retirement age
</B>
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Men: 65 years
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Women: 64 years
</P>
</TD>
<TD>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Men: 65 years
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Women: 64 years
</P>
</TD>
<TD>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Men: 65 years
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Women: 64 years
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="BORDER-TOP: GRAY 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	Mortality table
</B>
</FONT>
</TD>
<TD STYLE="BORDER-TOP: GRAY 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	LPP2015gen
</B>
</FONT>
</TD>
<TD STYLE="BORDER-TOP: GRAY 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	LPP2010gen
</B>
</FONT>
</TD>
<TD STYLE="BORDER-TOP: GRAY 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
<B>
	LPP2010gen
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	There are no reimbursement rights included
	in plan assets. The actual return on plan assets was a gain of &euro;57 thousand (CHF 61 thousand).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-13">
</A>
	5.13.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Current and non-current financial liabilities
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Financial liabilities by category
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_108"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,062
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8,440
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7,591
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loans
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,703
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18,446
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18,226
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total (1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,765
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	25,817
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Including as at December 31, 2015, &euro;8.9 million guaranteed by equipment, business goodwill
	or land, and by a mortgage for a building (&euro;10.9 million as at December 31, 2014 and &euro;13 million as at December 31, 2013);
	the loans amounting to &euro;3.5 million have an OSEO-issued guarantee (&euro;4.5 million as at December 31, 2014 and &euro;5 million
	as at December 31, 2013. OSEO is now part of the Banque Publique d&rsquo;Investissement (BPI).&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 223 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage224"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_109"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Financial liabilities by date of maturity
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&lt;1 year
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	1-5 years
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&gt;5 years
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,705
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,475
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	882
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,062
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loans
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,854
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	7,527
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,322
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,703
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,559
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	11,002
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,204
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,765
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&lt; 1 year&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1-5 years&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&gt; 5 years&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,941
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,927
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,572
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8,440
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loans
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,967
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,678
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,801
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18,446
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,908
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	14,605
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	6,373
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&lt; 1 year&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1-5 years&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&gt; 5 years&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,585
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	4,281
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,725
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7,591
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loans
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,873
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,993
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,360
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	18,226
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,458
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	15,274
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,085
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	25,817
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Financial liabilities by type of interest
	rate
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_110"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	average interest
<BR>
	rate 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT">
	Fixed rates
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2.67
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	15,618
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	19,943
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	17,603
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Floating rates
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1.94
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,147
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,943
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,214
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,765
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	25,817
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F5-14">
</A>
	5.14.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other current and non-current liabilities
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_111"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In thousands of euros
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2015&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014&nbsp;&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Due to former owners of acquired companies (1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	38,155
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	36,125
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	29,786
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Government subsidies
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,209
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,142
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,691
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other non-current liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,364
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,267
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	31,477
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Due to former owners of acquired companies (1)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,223
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,425
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,793
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax, personnel and social charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other (2)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,577
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,770
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,872
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other current liabilities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	15,738
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	12,419
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	9,551
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Group is obligated to pay contingent considerations to the former owners of acquired companies,
	as defined under each acquisition agreement.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The other current liabilities include mainly deferred income.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 224 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage225"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Debt due to former owners of acquired
	companies
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The principal contingent consideration concerns
	Advanced Accelerator Applications USA, Inc. Contingent consideration included 4 fixed tranches payable in cash and shares of the
	Company on reaching certain milestones defined in the contract. These milestones are based on different stages of the development
	of Lutathera. As of December 31, 2015, the first two milestones defined in the contract have been met and paid.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The contingent consideration also includes
	a variable tranche based on a percentage of future Lutathera worldwide sales. At December 31, 2015, 2014 and 2013, the main assumptions
	used in calculating the amount of this fixed and variable contingent consideration are the following:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Future sales of Lutathera:
	determined using the most recent Group business plans; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Probability of occurrence:
	80% at December 31, 2015 (67 % at December 31, 2014 and 2013) for tranches subject to milestones that have not yet been reached.
	This percentage was reestimated in September 2015 by the Company based on the current stage of the product development; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Discount rate of 10%:
	this reflects the time value of money and the estimated risks of not realizing the future cash flows.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On this basis, contingent consideration
	amounted to &euro;33.8 million, &euro;29.8 million, &euro;28.9 million at December 31, 2015, 2014 and 2013 respectively. The resulting
	finance charge of &euro;3.9 million over the year ended December 31, 2015 is mainly due to the unwinding of the discounting and
	the exchange rate variation of the US$ to the &euro;; the increase in the liability resulting from the increase of the probability
	of occurrence from 67% to 80% as the Company has substantially completed Lutathera phase III development at December 31, 2015,
	was partially offset by the updating of the business plan on future sales of Lutathera. The Company revised the business plan of
	future sales of Lutathera to take into account some modified assumptions. These consist primarily of a revised sales launch schedule
	for some countries in Europe compared to the previously assumed one single launch date for all these European countries.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the probability of occurrence was to
	be increased to 100%, the contingent consideration would have amounted to &euro;42.2 million at December 31, 2015.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An increase or decrease of 1 percentage
	point in the discount rate would respectively lead to a decrease of &euro;1.9 million or an increase of &euro;2 million in the
	contingent consideration liability. An increase or decrease of 5 percentage point in exchange rate used in the calculation would
	respectively lead to a decrease of &euro;1.1 million or an increase of &euro;1.2 million of the contingent consideration liability.
	Other items could have an impact on the contingent consideration such as the timing of market authorization in the various jurisdictions
	or the future selling prices.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 18, 2014, the group acquired
	the remaining 49.9% non-controlling interest in Atreus Pharmaceuticals Corporation. As a result of this acquisition, AAA holds
	100% of Atreus Pharmaceuticals Corporation. The consideration to be paid for this acquisition is composed of fixed anniversary
	and milestone payments prior to having obtained marketing authorization for Annexin and of a contingent consideration based on
	a low single-digit percentage royalties on sales of Annexin for a duration of 10 years following marketing authorization.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 225 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage226"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	At December 31, 2015, the main assumptions
	used in calculating the amount of this fixed and variable contingent consideration are the following:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Regulatory approval obtained
	in 2019, (assumed in 2018 in the prior years);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Future sales of Annexin
	based on the most recent business plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Probability of occurrence:
	100% for 2016 payments of anniversary and milestone payments, 60% for 2017 and 2018 payments of anniversary and milestone payments
	and then 30% for further payments of anniversary and milestone payments and of 30% for royalty payments; These percentages were
	estimated by the Company based on the current stage of product development; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Discount rate of 10% to
	reflect the time value of money and the estimated risk of not realizing future cash flows.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On this basis, contingent consideration
	amounted to &euro;6.3 million and &euro;6 million at December 31, 2015 and 2014 respectively. Payment made during the year is &euro;0.3
	million. The resulting finance charge of &euro;0.6 million over the year is mainly due to the updating of the business plan on
	future sales of Annexin, updating the probability of occurrence of payments of anniversary and milestone payment and the exchange
	rate variation of the CA$ to the &euro;. The Company revised the business plan on future sales of Annexin. The changes are primarily
	due to the fact that a first potential indication for Annexin was replaced with a different, more promising indication. This results
	in a delayed start of sales with a Marketing Authorization and a higher amount of royalties to pay over the contractually relevant
	period.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	If the probability of
	occurrence was to be increased to 100%, the contingent consideration would have amounted to &euro;19.7 million at December 31,
	2015. An increase or decrease of 1 percentage point in the discount rate would lead to a decrease of &euro;0.5 million or an increase
	of &euro;0.6 million in the contingent consideration liability, respectively. An increase or decrease of 5 percentage point in
	the CA$ against the &euro; would lead to a decrease or an increase of &euro;0.3 million in the contingent consideration liability,
	respectively. Other items could have an impact on the contingent consideration such as the timing of market authorization in the
	various jurisdictions or the future selling prices.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The remaining debt to
	former owners of acquired companies of &euro;2,3 million as at December 31, 2015 (&euro;2.7 million as at December 31, 2014 and
	&euro;3.6 million as at December 31, 2013) comprises &euro;1 million (&euro;2 million as at December 31, 2014) for the acquisition
	of Cadisa and Barnatron in 2012 and &euro;1.3 million (&euro;0.7 million as at December 31, 2014) for the acquisition of the Steripet
	business of GE Healthcare S.r.L in Italy in 2014. Payments made during the year is &euro;1 million to former shareholders of Cadisa
	and Barnatron and &euro;0.2 million for Steripet business of GE Healthcare S.r.L in Italy.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The resulting finance
	charge is &euro;0.8 million ;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&euro;0.8 million related
	to Steripet business of GE Healthcare S.r.L in Italy mainly due to the updating of the future sales.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18.45PT">
</TD>
<TD STYLE="WIDTH: 17PT">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 11PT">
	&middot;
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	&euro;0.05 million charge
	for Cadisa and Barnatron due to unwinding of discounting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 226 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage227"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 39.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -21.75PT">
<A NAME="DP65110_20F_HTM_F5-15">
</A>
	5.15&#9;&#9;Financial
	assets and liabilities
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 39.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -21.75PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The fair values and the carrying amounts
	of financial assets and liabilities are summarized as follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_112"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="29" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	12.31.2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="23" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Level
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Designated at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Loans and receivables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Available-for-sale
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Available-for-sale financial assets
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Derivatives assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	950
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	950
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Trade receivables and other
<BR>
	Receivables
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,625
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Guarantee deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	118,886
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	897
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	143,970
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	53
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	144,920
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	144,920
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of
<BR>
	acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,765
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,765
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Trade payables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,475
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,475
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	37,031
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	36,475
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	78,853
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	79,409
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities
	that the entity can access at the measurement date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 2 inputs are inputs, other than quoted prices included within level 1, that are observable
	for the asset or liability, either directly or indirectly; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 3 inputs are unobservable inputs for the asset or liability.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 227 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage228"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_113"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="29" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="23" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Level
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Designated
<BR>
	at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Loans and receivables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Available-for-sale
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Available-for-sale financial assets
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Trade receivables and other
<BR>
	receivables
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,053
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Guarantee deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,861
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,861
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,861
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,096
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,010
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,010
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,010
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,010
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,108
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,108
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of&nbsp;
<BR>
	acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,595
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Trade payables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,042
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,042
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,751
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	38,550
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	39,042
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	77,592
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	78,301
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities
	that the entity can access at the measurement date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 2 inputs are inputs, other than quoted prices included within level 1, that are observable
	for the asset or liability, either directly or indirectly; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 3 inputs are unobservable inputs for the asset or liability.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 228 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage229"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_114"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="29" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	12.31.2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	In &euro; thousands
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="23" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair value
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Level
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Designated
<BR>
	at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Loans and receivables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Available-for-sale
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Other financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Available-for-sale financial assets
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Trade receivables and other
<BR>
	&nbsp;receivables
<BR>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Guarantee deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,282
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,282
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,282
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,610
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	54
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of
<BR>
	&nbsp;acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Not measured at fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,817
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,817
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,445
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Trade payables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total not measured at fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	35,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	35,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	35,663
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total financial liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	35,035
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	67,614
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	68,242
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities
	that the entity can access at the measurement date;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 2 inputs are inputs, other than quoted prices included within level 1, that are observable
	for the asset or liability, either directly or indirectly; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Level 3 inputs are unobservable inputs for the asset or liability.&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F6">
</A>
	6.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	RISK MANAGEMENT
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group&rsquo;s organization allows for
	risks to be identified, assessed and managed at the level of responsibility (subsidiaries, parent company) that best reflects the
	magnitude of the risk.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Information on the principal risks and their
	management is communicated to Group management under Group procedures.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Group management has reviewed all risks
	that could have a significant negative impact on its business, its financial situation and its results, or on its ability to meet
	its objectives. No specific significant risks were identified other than those outlined below.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group is however operating in a rapidly
	developing environment that gives rise to many risks for the Group, not all of which it can control. The risks and uncertainties
	outlined below are not all that the Group may face. Other risks and uncertainties of which the Group is currently unaware or which
	it currently considers negligible, or which could be of a nature to affect all economic players, might also have a negative impact
	on its business, its financial situation, or its ability to meet its objectives.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F6-1">
</A>
	6.1.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Business risks
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risk of unsuccessful R&amp;D projects
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group may be unable to benefit from
	its R&amp;D expenditure in the event of technical or industrial failure, if developed products do not receive regulatory authorizations,
	or if the expected commercial success is not achieved. The Group invests heavily in product R&amp;D. Any technical, industrial,
	regulatory, or commercial difficulties encountered by these products could affect the Group&rsquo;s growth and profitability. The
	Group therefore takes great care in choosing and implementing its R&amp;D projects.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 229 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage230"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risk of emerging competitive technologies
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group may also be confronted by the
	emergence of new diagnostic techniques, possibly impacting the continued use of certain of its products.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks from competition
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group may not face up to competition
	effectively. It therefore pays particular attention to market trends, to its knowledge of its competitors, and to the expressed
	needs of its customers.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks from international operations
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group operates in a number of countries.
	Many of the risks which the Group faces are specific to the international business environment. These include risks related to
	unexpected changes or to different legal regimes and regulations in different countries, including commercial, environmental and
	tax laws and regulations.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Risks from dependence on key personnel
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group&rsquo;s success depends to a large
	extent on contributions from certain key personnel, especially executives and scientific managers. The loss of their services could
	harm the Group&rsquo;s competitiveness. The Group therefore attaches special importance to the recruitment, retention and motivation
	of its personnel.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F6-2">
</A>
	6.2.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Legal risks
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Product liability risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In general, the manufacture and distribution
	of diagnostic products presents product liability risks for the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Intellectual property risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Should the Group be unable to protect its
	industrial property rights, it could find itself in an uncompetitive position and be unable to maintain its profitability.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F6-3">
</A>
	6.3.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Market risks
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 11PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Foreign exchange risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Changes in exchange rates may affect cash
	and cash equivalents, sales, results and the Group&rsquo;s equity.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Its business is generated principally in
	the &quot;Euro zone&rdquo; (74.2% of 2015 sales and 77.2% of 2014 sales). Each Group entity&rsquo;s market is local in nature,
	which means that revenues and costs are generally in the same currency. The Group&rsquo;s most significant foreign currency exposures
	are to the US Dollar, the British Pound Sterling, the Swiss Franc and the Israeli Shekel.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Loans and other financial liabilities are
	almost exclusively denominated in Euros and are not subject to foreign exchange risk except for debt to former shareholders of
	acquired companies (accounted for as contingent consideration).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 230 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage231"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the successfully completed IPO in November
	2015, AAA raised US$86.3 million in cash (about US$80,4 million after payment of the Underwriters&rsquo; fees). We hedged our near
	term exposure to variations in the US$/&euro; exchange rate with two forward contract over a periods of 3 months and 6 months and
	amounting to US$20 million and US$25 million respectively. The principal objective was to be in a position to protect about 50%
	of the cash raised (US$45 million of the about US$80 million net IPO proceeds) against an appreciation of the Euro against the
	US$ and to be able to exchange this amount at the exchange rate at the date of having closed the capital increase related to the
	IPO. These forward contracts carry no fees and are easy to understand and execute. For the chosen durations and exercise dates
	AAA has covered completely the downside risk, i.e. the value of the US$ depreciating against the Euro and it also has the option
	to participate in an appreciation of the US$ of up to about 5%. In these situations AAA is free to either cash in the profit on
	its position by exchanging US$ against &euro; or do nothing and keep its US$ and possibly close on a new forward contract. If however
	the US$ appreciates to more than the agreed triggering level it would be for the benefit of the bank and AAA would be obliged to
	sell its US$ at the exchange rate of the IPO. AAA would thus not have lost money but it had foregone the profit. At December 31,
	2015 the two forward contracts had not yet arrived at their exercise dates but their value was positive and AAA accordingly accounted
	for the upside.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to these two forward contracts
	the Group also entered into a similar but much smaller contract in its UK subsidiary. This contract also has an exercise period
	of less than one year.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_115"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015 (in&nbsp;&nbsp;thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Notional Amount in Currency
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Notional amount in Euros
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Book value in Euros
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fair value in Euros
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Over-the-Counter currency options :
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="3">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	British Pound Sterling (GBP)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	467
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	640
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	US Dollar (USD)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	45,000
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	41,967
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	888
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	888
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total Over-the-Counter currency options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,607
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	895
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	895
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total derivative financial instruments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	42,607
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	895
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	895
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The maturity dates of the derivative instruments
	held by the Group is less than one year for all the contracts.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These activities are carried out in accordance
	with the Group&rsquo;s risk management policies and objectives in areas such as counter-party exposure and hedging practices. Counter
	parties to these agreements are major international financial institutions with high credit ratings and positions are monitored
	using market value and sensitivity analyses. The associated credit risk is therefore limited. These agreements generally include
	the exchange of one currency for a second currency at a future date.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The above table summarises foreign exchange
	contracts outstanding at year-end. The notional amount of derivatives summarised above represents the gross amount of the contracts
	and includes transactions which have not yet matured. Therefore the figures do not reflect the Group&rsquo;s net exposure at year-end.
	The fair value approximates the costs to settle the outstanding contracts.
<FONT STYLE="BACKGROUND-COLOR: YELLOW">
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Interest rate risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA&rsquo;s exposure to changes in interest
	rates is not considered significant. A number of the finance lease contracts are linked to indices such as Euribor and INSEE. Variations
	in these indices could increase finance costs. T
<FONT STYLE="COLOR: #0B0B0B">
	he
</FONT>
	Group's
<FONT STYLE="COLOR: #0B0B0B">
	ex
</FONT>
<FONT STYLE="COLOR: #131313">
	pos
</FONT>
<FONT STYLE="COLOR: #1B1B1B">
	ure
</FONT>
<FONT STYLE="COLOR: #131313">
	to
</FONT>
<FONT STYLE="COLOR: #1B1B1B">
	in
</FONT>
<FONT STYLE="COLOR: #131313">
	ter
</FONT>
<FONT STYLE="COLOR: #0B0B0B">
	est
</FONT>
	rate risks is presented in 5.13.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Liquidity risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	After comparing its available cash resources
	at December 31, 2015 to its estimated cash requirements, the Group believes that there is currently no liquidity risk.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The table below presents the undiscounted
	repayments (principal and interest) of financial liabilities (which exclude current and non-current provisions and deferred tax
	liabilities) based on outstanding contractual maturities:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 231 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage232"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_116"></A>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015 (in&nbsp;&nbsp;thousands of Euros)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Outstanding contractual outflows
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Less than 1 year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	From 1 to 5 years
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	More than 5 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	6,062
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	6,833
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,913
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	3,900
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,020
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other loans and financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,703
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	16 923
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,084
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,025
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,814
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,710
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax, personnel and social charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,938
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of
<BR>
	acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	42,378
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	83,716
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,341
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,946
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	65,429
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	87,791
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	131,120
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	33,986
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	25,871
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	71,263
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014&nbsp;&nbsp;(in&nbsp;&nbsp;thousands of Euros)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Outstanding contractual outflows
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Less than 1 year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	From 1 to 5 years
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	More than 5 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT">
	Finance lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	8,440
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	9,585
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,254
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	5,579
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,752
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other loans and financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,446
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,108
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,365
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,539
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,204
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,156
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax, personnel and social charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of
<BR>
	acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38,548
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	78,183
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,490
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,514
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	63,179
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	84,814
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	127,256
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	27,489
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	29,632
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	70,135
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013&nbsp;&nbsp;(in&nbsp;&nbsp;thousands of Euros)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Carrying amount
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Outstanding contractual outflows
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	Less than 1 year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	From 1 to 5 years
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 6PT">
	More than 5 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: LEFT">
	Financial lease obligations
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	7,591
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	8,672
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	1,810
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	4,770
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	2,092
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other loans and financial liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,972
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,402
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,093
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,477
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Trade and other payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,218
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Tax, personnel and social charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,886
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Debt due to former owners of
<BR>
	acquired companies
<BR>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	32,579
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	68,055
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,884
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,665
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	57,506
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	71,500
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; BORDER-RIGHT: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	109,803
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	21,200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	25,528
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	63,075
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group does not expect that the cash
	flows included in the maturity analysis will take place significantly earlier or for significantly different amounts (excluding
	contingent consideration liabilities, see section 5.14 above).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Credit risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA is not significantly exposed to credit
	risk. A significant part of AAA&rsquo;s sales are to public hospitals, which represent a very low risk.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Definition of credit risk
</I>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Credit risk is the risk of financial loss
	to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally
	from the Group&rsquo;s trade receivables from customers and short-term investments of its surplus cash.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Trade receivables
</I>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group&rsquo;s exposure to credit risk
	is influenced mainly by the individual characteristics of each customer. The Group&rsquo;s customer portfolio consists mainly of
	major international enterprises with significant financial resources. The Group&rsquo;s customer portfolio consists primarily of
	several hundred public hospitals and private clinics and some few major international companies in the health care sector. Given
	this large total number of customer none of our customers individually exposes us to a significant credit risk.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Customer credit risk is managed by each
	Group entity&rsquo;s finance department. The Group&rsquo;s finance department examines overdue trade receivables when reviewing
	the monthly results. Each significant payment delay is monitored and, if necessary, an action plan is developed.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 232 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage233"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A credit review is performed for every new
	customer depending on its size.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group assesses its credit risk at each
	reporting date. This assessment is based on an individual analysis of each receivable with a risk of non-collection and a provision
	is recognized representing the best estimate of the probable loss which will be suffered by the Group.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Due to the continuing difficult economic
	conditions, the Group maintains rigorous monitoring of its trade receivables. However, due to the quality of its customer portfolio,
	the Group has found no significant increase in overdue receivables.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<I>
	Investment of surplus cash
</I>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group limits its exposure to credit
	risk by investing its funds solely in bank deposits with guaranteed capital repayment and with first-rate banking counterparties.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Given the high quality of its counterparties,
	the Group does not expect that any counterparty will be unable to meet its obligations.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Equity risk
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group&rsquo;s capital management objectives
	are to maintain the Group&rsquo;s ability to ensure the continuity of its operations in order to provide returns to shareholders
	and to maintain an optimal capital structure to minimize the cost of capital.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Group has always encouraged its employees
	to invest in the company, in particular within the framework of free share grants and as from 2015 of the stock option plan. As
	of December 31, 2015, employees, former employees and directors hold 16.49% of the share capital (i.e. 12,955,673) shares out of
	the total issued share capital of 78,556,211 shares at the reporting date). The total potential dilution from new shares issues
	as of December 31, 2015 is 6.59% of the share capital, of which 5.94% relates to employees, 0.27% to the Board members and 0.38
	% to former owners of acquired companies.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 233 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage234"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<A HREF="#DP65110_20F_HTM_NOTES" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Table of Contents
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 10PT">
	Advanced Accelerator Applications S.A.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT">
</P>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F7">
</A>
	7.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Consolidation scope
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fully consolidated Group companies are as
	follows:
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_117"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 47%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Entity
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	Registered office in
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 14%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	% Interest 2015
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 12%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	% Interest 2014
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 14%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
<B>
	% Interest 2013
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications SA
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	France
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Parent Company
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Parent Company
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Parent Company
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications Unipessoal
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;Lda
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Portugal
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications Polska sp zoo
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Poland
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications (Italy) Srl
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Italy
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	G.I. Pharma Srl
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Italy
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications International SA
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Switzerland
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications (Switzerland) SA
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Switzerland
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications GmbH (Ex -
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;Umbra Medical AG)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Germany
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	50.1%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications Ib&eacute;rica S.L.
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Spain
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications USA, Inc. (Ex -
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;Biosynthema Inc.)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	USA
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Marshall Isotopes Ltd
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Israel
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Marshel (R.R) Investments Ltd
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Israel
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Catalana De Dispensacion
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Spain
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Barnatron SA
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Spain
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Advanced Accelerator Applications Canada Inc.
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Canada
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Atreus Pharmaceuticals Corporation (Merged with
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	&nbsp;&nbsp;Advanced Accelerator Applications Canada Inc.)
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Canada
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	50.1%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(213,234,234)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Eifel Property GmbH
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Germany
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	Imaging Equipment Ltd
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	UK
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	100%
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 8PT">
	N/A
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: SMALL-CAPS BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 21.75PT">
<A NAME="DP65110_20F_HTM_F8">
</A>
	8.&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Related party disclosures
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In conformity with IAS 24, the total remuneration
	of Group senior executives is disclosed in note 4.2.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Board of Directors decided to increase
	the salaries of the three most senior managers of the company as of January 2015 to align them to comparable companies.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	AAA have agreed to pay to the Chairman of
	the Board a &euro;1.0 million cash payment equivalent to 0.2% of the number of the ordinary shares issued and outstanding prior
	to the offering, multiplied by the public offering price per ordinary share upon the listing of our shares on a public stock exchange.
	In addition, the Board of Directors in its meeting at September 17, 2015 decided to pay certain members of the management a one-time
	bonus upon the successful completion of the offering in an amount of &euro;1.2 million (note 4.2).
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015 no other transaction
	has been entered into with a member of the Group&rsquo;s executive bodies or with any of the principal shareholders.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 234; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	December 31, 2015, 2014 and 2013
</P>
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
<P STYLE="MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage235"></A>
<A NAME="DP65110_EX0101_HTM"></A>
<EFX_EXHIBIT_1>
<A NAME="FIS_EXHIBIT_1"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	Exhibit 1.1
</B>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ADVANCED
	ACCELERATOR APPLICATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	A limited
	company with a capital of &euro;7,855,621,10
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Registered
	office: 20, rue Diesel, 01630 Saint Genis Pouilly
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	BOURG EN
	BRESSE Trade and Companies Register no. 441 417 110
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	ARTICLES
	OF ASSOCIATION
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Entry in
	Force on November 17
<SUP>
	th
</SUP>
	, 2015
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/04/29/0000950103-16-012995_IMAGE_006.JPG" ALT="ADVANCED ACCELERATOR APPLICATIONS" STYLE="HEIGHT: 185PX; WIDTH: 185PX">
</P>
<P STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage236"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: LEFT">
	SECTION I &ndash; LEGAL FORM, PURPOSE, CORPORATE NAME, REGISTERED OFFICE AND DURATION
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 1 - Legal form of the company
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 2 - Purpose
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 3 - Corporate name
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 4 - Registered office
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 5 - Duration
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION II &ndash; SHARE CAPITAL AND SHARES
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 6 - Share capital
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 7 - Increasing, reducing and redeeming the share capital
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 8 - Form of the shares
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 9 - Share transfers
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 10 - The rights and obligations attached to shares
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 11 - Paying for shares
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION III &ndash; ADMINISTRATION OF THE COMPANY
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 12 - Board of Directors
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 13 - Decisions taken by the Board of Directors
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 14 - The Board of Directors' powers
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 15 - Method of ensuring the general management of the company
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 16 - General Management
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION IV &ndash; GENERAL MEETINGS
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 17 - General Meetings
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION V &ndash; AUDITORS
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 18 - Auditors
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION VI &ndash; FINANCIAL YEAR
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 19 - Financial year
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT">
	SECTION VII &ndash; DISPUTES
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: BOLD 10PT CALIBRI, HELVETICA, SANS-SERIF; TEXT-TRANSFORM: UPPERCASE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; FONT: SMALL-CAPS 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Article 20 - Disputes
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage237"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	I &ndash; LEGAL FORM, PURPOSE, CORPORATE NAME, REGISTERED OFFICE AND DURATION
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	1 - Legal form of the company
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&quot;ADVANCED
	ACCELERATOR APPLICATIONS&quot; was incorporated in the form of a
<I>
	soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e
</I>
	(limited liability company) through a private agreement signed on 4 March 2002 in THOIRY, which was registered in BELLEGARDE
	on 7 March 2002, sheet 92 number 2, and has a capital of &euro;7500.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Its legal
	form was changed to that of a
<I>
	soci&eacute;t&eacute; anonyme
</I>
	(limited company) by an extraordinary general meeting held
	on 19 August 2002.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	It continues
	to exist, being owned by the owners of the existing shares and any that may come to be created in the future. It is governed by
	the laws and regulations in force, and by these Articles of Association.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	2 - Purpose
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The company's
	purpose, in France and abroad, is:
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	sale of products, services and studies in the medical and industrial fields, particle
	accelerator applications, pharmaceuticals, chemicals, artificial radio-elements and any
	other similar products.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	production, marketing, distribution, transportation, export, importation and sale of
	radioactive isotopes for industrial and medical applications.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	production, marketing, distribution, transportation, export, importation and sale of
	chemicals, pharmaceuticals and medical products and any other similar products.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	production, marketing, distribution, transportation, export, importation and sale of
	industrial and medical appliances, devices and consumables, and associated services.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	company's participation, by any means, directly or indirectly, in any operations that
	relate to its purpose, by means of the creation of new companies, contributions, subscriptions,
	the purchase of corporate securities or rights, mergers, or by other means, the creation,
	acquisition, leasing, or lease-management of any businesses or establishments; registering,
	acquiring, exploiting or transferring any processes or patents relating to these activities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 17.85PT">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	And,
	in general, any industrial, commercial, financial, non-commercial or real estate operations,
	or operations concerning movable assets, that directly or indirectly relate to the company's
	purpose or to any similar or related purpose.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage238"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	3 - Corporate name
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The company's
	corporate name is:
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&quot;
<B>
	ADVANCED
	ACCELERATOR APPLICATIONS
</B>
	&quot;.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Its acronym
	is:
<B>
	AAA
</B>
	.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In all deeds
	and documents issued by the company and intended for third parties, the corporate name must be stated, immediately preceded or
	followed by the words &quot;soci&eacute;t&eacute; anonyme&quot; or the letters &quot;S.A.&quot;, accompanied by mention of the
	amount of the share capital.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	4 - Registered office
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The registered
	office is established at:
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Saint
	Genis Pouilly (01630) &ndash; 20, rue Diesel.
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	It may be
	transferred to any other location in the same
<I>
	d&eacute;partement
</I>
	or an adjacent
<I>
	d&eacute;partement
</I>
	by a decision
	taken by the Board of Directors, subject to ratification of this decision by the next ordinary general meeting, and transferred
	anywhere else by a decision taken by a shareholders' extraordinary general meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If transfer
	of the location of the registered office is decided on by the Board of Directors, it is authorized to amend the Articles of Association
	and complete the resulting formalities relating to legal notices and filing, on condition that it is indicated that the transfer
	is subject to the ratification provided for above.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	5 - Duration
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The company's
	duration is set at ninety-nine (99) years as from its registration in the Trade and Companies Register, unless it is wound up
	early or its duration is extended by a decision taken by an extraordinary general meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage239"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	II &ndash; SHARE CAPITAL AND SHARES
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	6 - Share capital
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	The share
	capital is set at the sum of SEVEN MILLION EIGHT HUNDRED FIFTY FIVE THOUSAND SIX HUNDRED TWENTY-ONE EUROS AND TEN CENTIMES
<B>
</B>
	(&euro;7,855,621.10), divided into SEVENTY-EIGHT MILLION FIVE HUNDRED FIFTY SIX THOUSAND AND TWO HUNDRED ELEVEN (78&rsquo;556&rsquo;211)
	shares with a nominal value of &euro;0.10 each, all fully paid-up and all of the same class.
</I>
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	7 - Increasing, reducing and redeeming the share capital
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The share
	capital may be increased, reduced or redeemed in accordance with the provisions of the legislation in force.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The general
	meeting may, among other things, decide to reduce the share capital, either by reducing the nominal value of the shares, or by
	reducing the number of shares.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	8 - Form of the shares
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The company's
	shares are registered or bearer shares. The existence of shares results from their registration in the name of the holder(s) in
	accounts maintained for that purpose by an authorized intermediary duly empowered by the company, under the conditions and in
	accordance with the procedures provided for by the law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	At the request
	of any shareholder, a shareholding certificate will be issued to them via the authorized intermediary.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	9 - Share transfers
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1.
</B>
	All
	share transfers must take place in accordance with the provisions of the law. All expenses resulting from share transfers will
	be payable by the transferee. The transmission of shares shall take place by their being transferred from one account to another,
	in accordance with the procedures stipulated by the legislation and regulations in force.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2.
</B>
	The company's shares are freely transferable.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	10 - The rights and obligations attached to shares
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1.
</B>
	The rights and obligations attached to each share will remain attached to it regardless of who owns it, and the transfer of a
	share will include all dividends that are due for payment but have not yet been paid, and all future dividends and also, where
	applicable, the corresponding share of reserve funds and provisions.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage240"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The ownership
	of a share entails,
<I>
	ipso facto
</I>
	, approval by the holder of these Articles of Association and an obligation to be bound by
	decisions taken by shareholders' general meetings.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Except in
	cases where this conflicts with the provisions of the law, each shareholder has as many voting rights and will have as many votes
	at general meetings as the number of shares that they hold in respect of which all sums due for payment have been paid. At equal
	nominal value, each share entitles the holder to one vote.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Each share
	entitles the holder, in respect of the company's profits and assets and the liquidation profit, to a portion of these that is
	proportional to the number and nominal value of the shares in existence.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Whenever
	it is necessary to own several shares or securities in order to exercise any right whatsoever, the shareholders or holders of
	securities will be personally responsible for grouping together the necessary number of shares or securities.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2.
</B>
	Any
	natural person or legal entity, acting either alone or in concert, that comes to hold a number of shares representing a proportion
	of the share capital or voting rights that is equal to or greater than 1% of the share capital or voting rights, or any multiple
	of this percentage, including any in excess of the declaration thresholds provided for by the legislation and regulations in force,
	must inform the company of the total number of shares and voting rights that they own, and also inform it of the number of securities
	giving future access to the capital, and the number of any voting rights that may be attached to these, by means of a letter sent
	by recorded delivery with return receipt, within a timeframe of ten (10) days as from the time crossing the threshold in question.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	This obligation
	to inform the company also applies whenever a shareholder's holding in the share capital or the voting rights falls below one
	of the thresholds mentioned in the preceding paragraph.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If not declared
	in accordance with the provisions of the Articles of Association, shares exceeding the portion which should have been declared
	will be deprived of their voting right at shareholders' meetings, in accordance with the provisions of the Commercial Code, if,
	at a meeting, the failure to have made a declaration is noted and one or more shareholders that together hold at least 5% of the
	share capital request this at this meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	11 - Paying for shares
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sums to be
	paid in payment of cash shares subscribed for on the score of a capital increase will be payable in accordance with the terms
	decided on by the extraordinary general meeting concerned.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	On the occasion
	of a capital increase, the initial payment cannot be less than one-quarter of the nominal value of the shares plus, where applicable,
	the whole of the share premium.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage241"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Calls for
	payment of the balance shall be made by the Board of Directors in one or more stages within a timeframe of five (5) years as from
	the date of accomplishment of the capital increase.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Sums remaining
	due in respect of shares to be paid for in cash shall be the subject of calls for payment issued by the Board of Directors, which
	shall determine the dates and amounts of calls for funds.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Shareholders
	that do not pay sums due in respect of shares held by them by the due payment date will
<I>
	ipso jure
</I>
	owe the company interest
	for late payment, calculated daily as from the due payment date and charged at the official interest rate applicable in commercial
	matters increased by three percentage points, without prejudice to the compulsory enforcement measures provided for by the law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	III &ndash; ADMINISTRATION OF THE COMPANY
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	12 - Board of Directors
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1.
</B>
	The company shall be administered by a Board of Directors made up of natural persons or legal entities, which shall have between
	three and eighteen members, that shall be appointed by general meetings.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Legal entities
	must, at the time of their appointment, appoint a natural person as their permanent representative on the Board of Directors.
	The duration of the permanent representative's term of office shall be the same as that of the legal entity that they are representing.
	If a legal entity revokes its permanent representative's appointment, it must replace them immediately. The same provisions will
	apply in the case of the death or resignation of the permanent representative.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The duration
	of the term of office of Board members shall be one (1) year, a year being the period which separates two consecutive annual ordinary
	general meetings. A Board member's term of office will end at the end of the shareholders' ordinary general meeting called to
	approve the accounts for the previous financial year.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Board members
	shall always be eligible for reappointment; they may be removed from office at any time by a decision taken by a shareholders'
	general meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If one or
	more seats on the Board of Directors fall vacant as a result of death or resignation, the Board of Directors may, between two
	general meetings, make provisional appointments. Board members appointed in replacement of another Board member whose appointed
	term of office has not yet expired, will only remain in office for the remainder of their predecessor's appointed term of office.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Appointments
	made by the Board of Directors by virtue of the preceding paragraph will be subject to ratification by the next ordinary general
	meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage242"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If an appointment
	is not ratified, prior decisions and actions taken by the Board will nonetheless remain valid.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	When the
	number of Board members falls below the legal minimum, the remaining Board members must immediately convene an ordinary general
	meeting with a view to appointing new Board members.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	members must not have reached the age of seventy five (75). When a board member has reached this age, his mandate continues until
	his assigned term.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2.
</B>
	The Board of Directors shall elect a Chairman from among its members, whose remuneration it shall determine. The Chairman, who
	must be a natural person, shall be appointed for a duration which cannot extend beyond their term of office as a Board member.
	They shall be eligible for reappointment.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors may be removed from office at any time. Any conflicting provision will be deemed to have not been written.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Chairman
	must not have reached the age of seventy five (75). When they reach this age, they will automatically be deemed to have resigned.
	Their term of office will continue however until the next Board of Directors' meeting, during which their successor will be appointed.
	Subject to this provision, the Chairman of the Board shall always be eligible for reappointment.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall appoint from among its members a Board member to be responsible for standing in for the Chairman in the event
	of their absence, their being temporary unable to fulfil their duties, their resignation or death, or the non-renewal of their
	appointment. If the Chairman is temporary unable to fulfil their duties, they will stand in for them solely for the duration of
	this situation; in the other cases, they will stand in for the Chairman until the election of a new Chairman.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	3.
</B>
	The Chairman of the Board of Directors organizes and directs the Board's work, and gives an account thereof to general meetings.
	They ensure the satisfactory operation of the company's various bodies, and in particular ensure that the Board members are in
	a position to fulfil their mission.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	13 - Decisions taken by the Board of Directors
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall meet at Board meetings convened by the Chairman as often as the interests of the company renders this necessary.
	They will be held at the registered office or at the place indicated in the notice of meeting. Meetings shall be convened by any
	means, even verbally, three (3) days in advance; they may also take place without delay if all the Board members agree to this.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Meetings
	of the Board of Directors shall be chaired by the Chairman of the Board of Directors. If the Chairman is absent, the Board of
	Directors shall appoint, for each meeting, one of its members to chair the meeting; if the votes cast to appoint the chairman
	of the meeting are tied, the meeting shall be chaired by the oldest of the Board members voted for.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage243"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If no Board
	meeting has been held for over two (2) months, at least one-third (1/3) of the members of the Board of Directors may request the
	Chairman to convene a meeting with a predetermined agenda. The Managing Director may also request the Chairman to convene a Board
	of Directors' meeting with a predetermined agenda. The Chairman will be obliged to accede to such requests.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If a Works
	Council exists, its representatives, who shall be appointed in accordance with the provisions of the Labour Code, must be invited
	to attend all Board of Directors' meetings.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	An attendance
	register shall be kept, and minutes shall be drawn up after each meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Board meetings
	can only take valid decisions if at least half the members of the Board of Directors are present.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Decisions
	shall be taken by a majority vote of the members present or represented.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Internal
	rules adopted by the Board of Directors may, among other things, stipulate that when calculating the quorum and majority, Board
	members that attend Board meetings by video conferencing or telecommunication means that are compliant with the regulations in
	force will be deemed to be present.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Any Board
	member may, even by letter, telegram or fax, give a proxy to another Board member to represent them at a Board meeting, but no
	Board member may hold more than one proxy at a meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Copies of
	or excerpts from the minutes of Board of Directors' meetings shall be validly certified as being true copies by the Chairman of
	the Board of Directors, the Managing Director, the Deputy Managing Directors, the Managing Director temporarily assuming the duties
	of the Chairman, or a person who has been empowered for that purpose.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Board members,
	and anyone attending Board of Directors' meetings, will be obliged to maintain discretion vis-&agrave;-vis information of a confidential
	nature presented as such during a Board meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	14 - The Board of Directors' powers
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall determine the orientations of the company's activity and ensure their implementation. Subject to the powers
	expressly attributed by law to shareholders' meetings, and within the limits of the company's purpose, it shall deal with all
	questions concerning the satisfactory running of the company, and through its decisions rule on company matters.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In its relations
	with third parties, the company is bound by all actions taken by the Board of Directors, even if they do not come within the scope
	of the company's purpose, unless it can prove that the third party concerned knew that the action in question lay outwith this
	scope or could not be unaware of it under the
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage244"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	circumstances, mere publication of the Articles of Association being insufficient
	to constitute such proof.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall carry out the checks and verifications that it deems appropriate. Each Board member shall receive all the information
	necessary for them to fulfil their mission, and may have any documents that they deem of utility communicated to them.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In addition,
	the Board of Directors shall exercise the special powers granted to it by the law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	15 - Method of ensuring the general management of the company
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In accordance
	with the legislation in force, the general management of the company shall be assumed, under their responsibility, either by the
	Chairman of the Board of Directors, or by another natural person appointed by the Board of Directors, who shall have the title
	of Managing Director.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Changing
	the method of ensuring the company's general management will not lead to amendment of the Articles of Association.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	When the
	general management of the company is ensured by the Chairman, legislative and regulatory provisions and the provisions of the
	Article of Association relating to the Managing Director will be applicable to them. They shall have the title of Chairman and
	Managing Director.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	16 - General Management
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall appoint, either from among its members or outside of them, a Managing Director, who must be a natural person
	aged under sixty five (65). The Managing Director shall have the widest possible powers to act in all circumstances in the name
	of the company.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Managing
	Director shall exercise his or her powers within the limits of the company's purpose and subject to the powers that the law expressly
	attributes to shareholders' meetings and to the Board of Directors. He or she represents the company in its relations with third
	parties. The company will be bound even by actions taken by the Managing Director that lie outwith the scope of the company's
	purpose, unless the company can prove that the third party concerned knew that the action in question lay outwith this scope or
	could not be unaware of it under the circumstances, mere publication of the Articles of Association being insufficient to constitute
	such proof.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Decisions
	taken by the Board of Directors that limit the powers of the Managing Director will not be enforceable on third parties.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	At the suggestion
	of the Managing Director, the Board of Directors may appoint one or more natural persons to be responsible for assisting the Managing
	Director, who
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage245"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	shall have the title of Deputy Managing Director. The number of Deputy Managing Directors cannot exceed five.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Deputy
	Managing Directors must be aged under sixty five (65). In agreement with the Managing Director, the Board of Directors shall determine
	the scope and duration of the powers granted to the Deputy Managing Director(s). Vis-&agrave;-vis third parties, the Deputy Managing
	Directors shall have the same powers as the Managing Director.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Managing
	Director may be removed from office at any time by the Board of Directors. The same applies, at the proposal of the Managing Director,
	to Deputy Managing Directors. If removal from office is decided on without any valid reason(s) for this, this may result in damages
	being due, except when the Managing Director is also the Chairman of the Board of Directors.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If the Managing
	Director ceases to perform or is prevented from performing their duties, the Deputy Managing Directors shall retain their tasks,
	duties and responsibilities until the appointment of the new Managing Director, unless decided otherwise by the Board.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors shall determine the remuneration of the Managing Director and the Deputy Managing Directors.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	IV &ndash; GENERAL MEETINGS
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	17 - General Meetings
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1.
</B>
	Shareholders' meetings shall be convened by the Board of Directors under the conditions stipulated by law and in accordance with
	the timeframes stipulated by law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	They shall
	be held at the registered office or in any place designated by the convenor of the meeting, even outside the registered office
	or the
<I>
	d&eacute;partement
</I>
	in which the registered office is located.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2.
</B>
	Each shareholder has the right to participate in general meetings on presentation of proof of their identity and the registration
	in the company's accounts of their shares, either in their name or in the name of an intermediary registered on their behalf under
	the conditions and in accordance with the timeframes provided for by the law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage246"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	If not present
	in person at a meeting, shareholders may choose between one of the following three formulas:
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	they
	may give a proxy to another shareholder or their spouse, or partner with whom they have
	concluded a civil solidarity pact;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	they
	may vote by correspondence; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	they
	may send a proxy form to the company without indicating a proxy holder, in accordance
	with the provisions of the legislation and regulations in force.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Even if they
	have been deprived of their right to vote, bare owners of shares always have the right to be present at general meetings.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The Board
	of Directors may, in accordance with the provisions of the legislation and regulations in force, organize shareholders' attendance
	and voting at meetings by video conferencing or by another means of telecommunication enabling their identification.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Shareholders
	participating in meetings by video conferencing or any of the other means of telecommunication provided for above, as decided
	on by the Board of Directors, shall be considered to be present at meeting when calculating the quorum and the majority.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	3.
</B>
	An attendance sheet shall obligatorily be kept at each meeting. The proxies given to shareholders' representatives and, where
	applicable, postal voting forms, will be appended to this attendance sheet. Minutes shall be drawn up of the proceedings of each
	meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Meetings
	shall be chaired by the Chairman of the Board of Directors or, in their absence, by a Board member designated by the Board of
	Directors.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	The officers
	of each meeting shall comprise a Chairman and two scrutineers. The role of scrutineer shall be filled by the two shareholders
	present and accepting this role that both personally and as representatives hold the highest number of votes. The meeting's officers
	shall appoint a secretary to the meeting, who need not be a shareholder.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	4.
</B>
	The voting right attached to each share is proportional to the portion of the share capital that it represents.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	5.
</B>
	The competence of ordinary, extraordinary and special meetings is as stipulated by the law.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	6.
</B>
	Ordinary
	general meetings can only take valid decisions if the shareholders present, represented or that voted by correspondence own at
	least one-fifth of the shares with voting rights. If this is not the case a second meeting must be convened. No quorum will be
	required at this second meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage247"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Subject to
	the derogations provided for in the case of certain capital increases and changes to the company's legal form, extraordinary general
	meetings can only take valid decisions if the shareholders present, represented or that voted by correspondence own at least one-quarter
	of the shares with voting rights at the time of the meetings being first convened or, if a meeting has been convened for a second
	time, own one-fifth of the voting rights.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Special meetings
	can only take valid decisions if the shareholders present, represented or that voted by correspondence own at least at least one-quarter
	of the shares with voting rights at the time of the meeting's being first convened or, if a meeting has been convened for a second
	time, own one-fifth of the voting rights.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	7.
</B>
	Ordinary general meetings take decisions by a majority of the votes held by the shareholders present or represented or that voted
	by correspondence. Extraordinary general meetings and special meetings take decisions by a two-thirds majority of the votes held
	by the shareholders present or represented or that voted by correspondence.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	8.
</B>
	Copies of or excerpts from the minutes of meetings shall be validly certified by the Chairman of the Board of Directors, a Board
	member holding the post of Managing Director, or the secretary of the meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Ordinary
	and extraordinary general meetings will exercise their respective powers in accordance with the provisions of the legislation
	in force.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	V &ndash; AUDITORS
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	18 - Auditors
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	1.
</B>
	Auditing of the company shall be carried out, under the conditions set by the law, by one or more auditors that meet the legal
	conditions concerning eligibility. When the corresponding legal conditions are met, the company must appoint at least two auditors.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Each auditor
	shall be appointed by an ordinary general meeting.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	An ordinary
	general meeting shall appoint one or more deputy auditors, whose mission will be to replace the statutory auditors in the event
	of their refusing to perform their duties or being unable to so, or in the event of their resignation or death.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2.
</B>
	The auditors shall be appointed for a term of office of six (6) years.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage248"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 13PT">
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	VI &ndash; FINANCIAL YEAR
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	19 - Financial year
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Each of the
	company's financial years will have a duration of twelve months, which will commence on 1 January and end on 31 December each
	year.
</FONT>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 11PT">
	SECTION
	VII &ndash; DISPUTES
</FONT>
</P>
<P STYLE="FONT: BOLD 12PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Article
	20 - Disputes
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Any disputes
	that may arise during the company's lifetime or during its liquidation, either between the shareholders and the company, or between
	the shareholders themselves, relating to the interpretation or performance of these Articles of Association or, in general, concerning
	company matters, will be subject to the jurisdiction of the competent courts.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
	* *
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 13PT">
<B>
	*
</B>
</FONT>
</P>
<P STYLE="FONT: 14PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT ARIAL, HELVETICA, SANS-SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage249"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_1>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage250"></A>
<A NAME="DP65110_EX1201_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	Exhibit 12.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	CERTIFICATION BY THE
	PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	I, Stefano Buono, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	1.&#9;I have reviewed this annual report on
	Form 20-F of Advanced Accelerator Applications S.A.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD>
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known
	to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD>
	[Reserved]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	c.
</TD>
<TD>
	Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
	such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	d.
</TD>
<TD>
	Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the
	period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s
	internal control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or
	persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD>
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
	which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial
	information; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD>
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s
	internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Date: April 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	By:
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Stefano Buono
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	Name:
</TD>
<TD STYLE="WIDTH: 26%">
	Stefano Buono
</TD>
<TD STYLE="WIDTH: 66%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
	Chief Executive Officer
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	(Principal Executive Officer)
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage251"></A>
<A NAME="DP65110_EX1202_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	Exhibit 12.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	CERTIFICATION BY THE
	PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	I, Heinz M&auml;usli, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	1.&#9;I have reviewed this annual report on
	Form 20-F of Advanced Accelerator Applications S.A.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
	necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
	respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	3.
</TD>
<TD>
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
	all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
	presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	4.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD>
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
	supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known
	to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD>
	[Reserved]
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	c.
</TD>
<TD>
	Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
	such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	d.
</TD>
<TD>
	Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the
	period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s
	internal control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	5.
</TD>
<TD>
	The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or
	persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	a.
</TD>
<TD>
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
	which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial
	information; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	b.
</TD>
<TD>
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s
	internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Date: April 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	By:
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Heinz M&auml;usli
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	Name:
</TD>
<TD STYLE="WIDTH: 26%">
	Heinz M&auml;usli
</TD>
<TD STYLE="WIDTH: 66%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD>
	Chief Financial Officer
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage252"></A>
<A NAME="DP65110_EX1301_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	Exhibit 13.1
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	CERTIFICATION BY THE
	PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
	2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The certification set forth below is being
	submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the &ldquo;Company&rdquo;)
	for the fiscal year ended December 31, 2015 (the &ldquo;Report&rdquo;), I, Stefano Buono, certify pursuant to 18 U.S.C. Section
	1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Date: April 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	By:
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Stefano Buono
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	Name:
</TD>
<TD STYLE="WIDTH: 26%">
	&#9;Stefano Buono
</TD>
<TD STYLE="WIDTH: 66%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Title:&#9;
</TD>
<TD>
	Chief Executive Officer
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&#9;(Principal Executive Officer)
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage253"></A>
<A NAME="DP65110_EX1302_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
<B>
	Exhibit 13.2
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<B>
	CERTIFICATION BY THE
	PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
	2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	The certification set forth below is being
	submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the &ldquo;Company&rdquo;)
	for the fiscal year ended December 31, 2015 (the &ldquo;Report&rdquo;), I, Heinz M&auml;usli, certify pursuant to 18 U.S.C. Section
	1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	1.
</TD>
<TD>
	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	2.
</TD>
<TD>
	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	Date: April 29, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	By:
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	/s/ Heinz M&auml;usli
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Name:
</TD>
<TD>
	&#9;Heinz M&auml;usli
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	Title:&#9;
</TD>
<TD STYLE="WIDTH: 26%">
	Chief Financial Officer
</TD>
<TD STYLE="WIDTH: 66%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
</EFX_EXHIBIT_13>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
